ID Species ncRNA ncRNA type Environmental factor (EF) Phenotype Sample Condition of EF Evidence PubMed ID 1 Human 4631405K08Rik lncRNA enterovirus 71 (EV71) hand-foot-mouth disease (HFMD) human rhabdomyosarcoma (RD) cells Enterovirus 71 (EV71) treatment downregulated 30314355 2 Human A2M-AS1 lncRNA hypoxia/reoxygenation (H/R) myocardial ischemia/reperfusion (I/R) injury (MIRI) human neonatal cardiomyocytes hypoxia/reoxygenation (H/R) treatment LncRNA A2M-AS1 lessens the injury of cardiomyocytes caused by hypoxia and reoxygenation via regulating IL1R2. 33057899 3 Human AC003092.1 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87 cells; U251 cells temozolomide (TMZ) treatment lncRNA AC0030921 expression was significantly down- regulated in both U87TR and U251TR cells 30442884 4 Human AC005523.2-001 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 5 Human AC005550.3 lncRNA homocysteine (Hcy) homocysteine (HCY)-induced vascular endothelial injury human umbilical vein endothelial cells (HUVECs) homocysteine (HCY) treatment downregulated 30093949 6 Human AC006050.3-003 lncRNA cisplatin (DDP) lung squamous cell carcinoma (LSQCC) advanced lung squamous cell carcinoma patients cisplatin treatment downregulated 25250788 7 Human AC006262.5 lncRNA gemcitabine (GEM) ancreatic cancer (PC) SW1990 cells gemcitabine (GEM) treatment upregulated 30113217 8 Human AC007283.5 lncRNA influenza A virus (IAV) influenza A virus (IAV) infection human lung epithelial A549 cells influenza A/Puerto Rico/8/34 infection upregulated 30669933 9 Human AC007952.1.1-3:1 lncRNA nigericin pancreatic cancer (PC) PANC-4 cells nigericin treatment downregulated 32850392 10 Human AC013451.2 lncRNA N-retinylidene-N-retinylethanolamine (A2E) retinitis pigmentosa human retinal pigment epithelium cells N-retinylidene-N-retinylethanolamine (A2E) treatment upregulated 32326576 11 Human AC015849.2 lncRNA influenza A virus (IAV) influenza A virus (IAV) infection human lung epithelial A549 cells influenza A/Puerto Rico/8/34 infection upregulated 30669933 12 Human AC023115.3 lncRNA cisplatin (DDP) glioblastoma multiforme (GBM) human glioblastoma cells cisplatin treatment upregulated 28499919 13 Human AC026904.1 lncRNA TGF-¦Â breast cancer MCF-7 cells TGF-¦Â treatment "TGF-¦Â induced genome-wide changes in lncRNA levels in breast cancer cells, among which AC0269041 and UCA1 were highly expressed in metastatic breast cancer and closely associated with poor prognosis" 29774079 14 Human AC068039.4 lncRNA hypoxia hypoxic pulmonary hypertension (HPH) pulmonary artery smooth muscle cells (PASMCs) hypoxia treatment "Consistent with microarray analysis, quantitative PCR verified that AC068039.4 was obviously upregulated in hypoxia-induced PASMCs." 33026218 15 Human AC068580.3 lncRNA N-retinylidene-N-retinylethanolamine (A2E) retinitis pigmentosa human retinal pigment epithelium cells N-retinylidene-N-retinylethanolamine (A2E) treatment upregulated 32326576 16 Human AC078883.3 lncRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) "lung tissues, A549 and H460 cells" ?cisplatin treatment ?the low expression of lncRNA-AC0788833 contributed to the development of chemoresistance against cisplatin 31111480 17 Human AC092620.3 lncRNA hexavalent chromium [Cr(VI)] DNA damage Cr(VI)-treated 16HBE cells Cr(VI) exposure dysregulated 30476843 18 Human AC092620.3 lncRNA hexavalent chromium [Cr(VI)] DNA damage 16HBE cells hexavalent chromium [Cr(VI)] treatment upregulated 30476843 19 Human AC105052.4 lncRNA N-retinylidene-N-retinylethanolamine (A2E) retinitis pigmentosa human retinal pigment epithelium cells N-retinylidene-N-retinylethanolamine (A2E) treatment downregulated 32326576 20 Human AC133485 lncRNA "2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)" nonalcoholic fatty liver disease (NAFLD) L-02 cells "2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156) treatment" downregulated 31514003 21 Human AC145676.2.1-6 lncRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) whole blood samples Mycobacterium tuberculosis (MTB) infection downregulated 31028876 22 Human ADAMTS9-AS2 lncRNA tamoxifen (TAM) breast cancer Human MCF-7 cells Tamoxifen (TAM) treatment downregulated 30840279 23 Human ADAMTS9-AS2 lncRNA cisplatin (DDP) gastric cancer (GC) SGC7901 cells; BGC823C cells cisplatin treatment downregulated 32516127 24 Human ADAMTS9-AS2 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) "GBM cell lines (T98G, U118)" temozolomide (TMZ) treatment upregulated 31632968 25 Human AF085935 lncRNA chrysin hepatocellular carcinoma (HCC) HepG2 cells chrysin treatment chrysin against HCC through the suppression of the GPC3/SULF2 axis along with the downregulated of lncRNA-AF085935 expression. 33076548 26 Human AF085935 lncRNA epigallocatechin-3-gallate (EGCG) and metformin hepatocellular carcinoma (HCC) HepG2 cells epigallocatechin-3-gallate (EGCG) and metformin treatment downregulated 30710234 27 Human AF086415 lncRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) nasopharyngeal carcinoma (NPC) cells curcumin treatment dysregulated 24379026 28 Human AF086415 lncRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) nasopharyngeal carcinoma (NPC) cells curcumin treatment downregulated 24379026 29 Human AF131217.1 lncRNA laminar shear stress atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) Laminar shear stress induce upregulated 30905197 30 Human AF131217.1 lncRNA tumor necrosis factor alpha (TNF-¦Á) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 30905197 31 Human AF147447 lncRNA helicobacter pylori (H. pylori) gastric cancer (GC) tumor tissues H. pylori treatment downregulated 27835575 32 Human AFAP1-AS1 lncRNA trastuzumab breast cancer SKBR-3 cells; BT474 cells trastuzumab treatment upregulated 32020881 33 Human AFAP1-AS1 lncRNA oridonin epithelial-mesenchymal transition (EMT) ?BxPC-3 and PANC-1 cells oridonin treatment "the combination of oridonin and siAFAP1-AS1 inhibited pancreatic cancer cell proliferation, induced apoptosis, arrested cell cycle progression, prevented the migration, regulated EMT-related protein expression in BxPC-3 and PANC-1 cells, and inhibited pancreatic cancer cell tumorigenicity and EMT in nude mice." 31314060 34 Human AFAP1-AS1 lncRNA cucurbitacin B (CuB) pancreatic cancer (PC) BxPC-3 cells; HPAC cells cucurbitacin B (CuB) treatment CuB inhibits proliferation of PC cells by downregulating AFAP1-AS1 expression. 30206930 35 Human AFAP1-AS1 lncRNA cucurbitacin B (CuB) pancreatic cancer (PC) "Human PC cell lines, ASPC©\1, BxPC©\3, HPAC, MiaPaCa©\2" cucurbitacin B (CuB) treatment CuB-induced high miR-146b-5p expression and inhibited the expression of AFAP1-AS1. 30206930 36 Human AFAP1-AS1 lncRNA oridonin pancreatic cancer (PC) BxPC-3 and PANC-1 cells oridonin treatment "the combination of oridonin and siAFAP1-AS1 inhibited pancreatic cancer cell proliferation, induced apoptosis, arrested cell cycle progression, prevented the migration, regulated EMT-related protein expression in BxPC-3 and PANC-1 cells, and inhibited pancreatic cancer cell tumorigenicity and EMT in nude mice." 31314060 37 Human AGAP2-AS1 lncRNA trastuzumab breast cancer SKBR-3 cells; BT474 cells trastuzumab treatment upregulated 30157918 38 Human AIRN lncRNA gonadotropin-releasing hormone agonist (GnRHa; Buserelin) infertility Infertility patients testicular biopsies treat with GnRHa for 6 months upregulated 28505621 39 Human AK001796 lncRNA resveratrol lung cancer lung cancer tissues resveratrol (RS) treatment reduced lncRNA AK001796 level potentially impaired the inhibitory effect of resveratrol on cell proliferation 25888808 40 Human AK021021 lncRNA baicalin (BAI) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) baicalin (BAI) treatment upregulated 26885187 41 Human AK027294 lncRNA glycyrrhiza glabra nasopharyngeal carcinoma (NPC) C666-1 cells glycyrrhiza glabra treatment downregulated of AK027294 contributes to the anti-cancer function of G. glabra. 31589096 42 Human AK027294 lncRNA glycyrrhiza glabra nasopharyngeal carcinoma (NPC) C666-1 cells Glycyrrhiza glabra treatment AK027294 had a strongest downregulated upon G. glabra treatment. 31589096 43 Human AK056098 lncRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) nasopharyngeal carcinoma (NPC) cells curcumin treatment dysregulated 24379026 44 Human AK056098 lncRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) nasopharyngeal carcinoma (NPC) cells curcumin treatment upregulated 24379026 45 Human AK056155 lncRNA TGF-¦Â1 loeys-Dietz syndrome (LDS) peripheral blood circulating endothelial cells TGF-¦Â1 treatment upregulated 26617788 46 Human AK058003 lncRNA hypoxia gastric cancer (GC) GC cell lines hypoxia-induced GC treatment upregulated 25499222 47 Human AK077216 lncRNA high glucose (HG) diabetic retinopathy (DR) high glucose treatment AK077216 is downregulated in diabetic retinopathy and inhibited the apoptosis of ARPE-19 cells by downregulating miR-383. 31391356 48 Human AK092074 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cell differentiation human umbilical cord derived mesenchymal stem cells (hUCMSCs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 29633064 49 Human AK094457 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human aortic vascular smooth muscle cells (hVSMCs) oxidized low-density lipoprotein (ox-LDL) treatment "LncRNA AK094457 downregulated by shRNA-AK094457-1 have inhibiting effects on proliferation, migration, ROS level and inflammation level in OX-LDL induced vascular smooth muscle cells (VSMCs)." 31632534 50 Human AK094457 lncRNA angiotensin II (Ang II) hypertension human umbilical vein endothelial cells (HUVECs) angiotensin II (Ang II) treatment The expression of the lncRNA AK094457 in the angiotensin II (Ang II) treatment groups were higher than the control group. 32027625 51 Human AK094629 lncRNA IL-1¦Â temporomandibular joint osteoarthritis synovial-derived mesenchymal stem cells (SMSCs) IL-1¦Â treatment IL-1¦Â upregulated the expression of AK094629 in the SMSCs in vitro. 32468015 52 Human AK095147 lncRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) nasopharyngeal carcinoma (NPC) cells curcumin treatment dysregulated 24379026 53 Human AK095147 lncRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) nasopharyngeal carcinoma (NPC) cells curcumin treatment downregulated 24379026 54 Human AK294004 lncRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) nasopharyngeal carcinoma (NPC) cells curcumin treatment dysregulated 24379026 55 Human AK294004 lncRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) nasopharyngeal carcinoma (NPC) cells curcumin treatment upregulated 24379026 56 Human AK309872 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cell differentiation human umbilical cord derived mesenchymal stem cells (hUCMSCs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated 29633064 57 Human AL049437 lncRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) SH-SY5Y cells "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" upregulated 32057949 58 Human AL645940.1 lncRNA N-retinylidene-N-retinylethanolamine (A2E) retinitis pigmentosa human retinal pigment epithelium cells N-retinylidene-N-retinylethanolamine (A2E) treatment downregulated 32326576 59 Human ALT1 lncRNA hypoxia regulation of cell cycle human umbilical vein endothelial cells (HUVECs) hypoxia treatment upregulated 28977802 60 Human ANCR lncRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) "MCF10A,MDA-MB-231,MCF7,T47D,BT549,HEK293T" TGF-¦Â1 down-regulates ANCR treatment downregulated 28978036 61 Human ANPODRT lncRNA tert-butyl hydroperoxide (TBHP) intervertebral disc degeneration (IDD) nucleus pulposus (NP) cell ?tert-butyl hydroperoxide (TBHP) treatment We found that ANPODRT was downregulated in degenerative NP tissues and in NP cells treated with tert-butyl hydroperoxide 33603950 62 Human ANRIL lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK2 cells lipopolysaccharide (LPS) treatment The upregulation of ANRIL can reduce the expression of microRNA-199a and increases the number of apoptotic cells 32069473 63 Human ANRIL lncRNA human T-cell leukemia virus type 1 (HTLV-1) adult T-cell leukemia (ATL) ATL cells human T-cell leukemia virus type 1 (HTLV-1) infection The expression level of the lncRNA ANRIL was elevated in HTLV-1-infected cell lines and clinical ATL samples. 30258009 64 Human ANRIL lncRNA tanshinone IIA (Tan IIA) age-related nuclear cataract H2O2 treated human lens epithelial cell line SRA01/04 Tanshinone IIA treatment upregulated 30701534 65 Human ANRIL lncRNA IL-13 allergic rhinitis (AR) Human nasal epithelial cells (HNECs) IL-13 treatment "The expression levels of ANRIL and JAK2 were also upregulated in IL-13-induced HNECs, while the expression levels of miR-15a-5p were downregulated." 33325534 66 Human ANRIL lncRNA oxygen glucose deprivation (OGD) angiogenesis Human umbilical vein endothelial cells (HUVECs) oxygen glucose deprivation (OGD) treatment OGD remarkably decreased lncRNA-ANRIL expression level. 32400082 67 Human ANRIL lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human aorta vascular smooth muscle cells (HA-VSMCs); human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment ANRIL promoted AS progression by sponging miR-399-5p and regulating RAS/RAF/ERK signal pathway. 32141564 68 Human ANRIL lncRNA H2O2 cataract HLECs H2O2 treatment lncRNA ANRIL attenuated H2O2-induced cell injury in HELCs via up-regulating miR-21 via the activation of AMPK and ¦Â-catenin. 32310822 69 Human ANRIL lncRNA high glucose (HG) diabetic nephropathy (DN) kidney tissues high glucose (HG) treatment ANRIL and TXNIP were elevated in DN kidney tissues and HG-treated HK-2 cells while miR-497 was reduced.?miR-497 mimics inhibited caspase-1-dependent pyroptosis while co-overexpression of TXNIP blocked its effects in HG-treated HK-2 cells. 33160992 70 Human ANRIL lncRNA high glucose (HG) diabetic nephropathy (DN) human renal tubular epithelial cell cells (HK-2) high glucose (HG) treatment ANRIL promotes pyroptosis and kidney injury in DN via acting as miR-497 sponge to disinhibit TXNIP expression. 33160992 71 Human ANRIL lncRNA Rhein-8-O-¦Â-D-glucopyranoside (Rg) diabetic nephropathy (DN) human mesangial cells (HMCs) Rhein-8-O-¦Â-D-glucopyranoside (Rg) treatment Rg attenuated HG-induced apoptosis of HMCs by regulating the lincRNA ANRIL/let-7a/TGF-¦Â1/Smad signaling pathway 32256771 72 Human ANRIL lncRNA high glucose (HG) diabetic wound healing Human lymphatic endothelial cells (LECs) high glucose (HG) treatment downregulated 30565672 73 Human ANRIL lncRNA H2O2 glaucoma human trabecular meshwork (TM) cells "For the stimulation with H2 O2 , the cells were cultured in Trabecular Meshwork Cell Medium (TMCM) containing 50-400 ¦ÌM H2O2 (Sigma-Aldrich, St. Louis, MO, USA) for 24 h after they reached 80-85% confluence." H2O2-induced decrease of cell viability and the increases in apoptosis and ROS generation were significantly attenuated by lncRNA ANRIL overexpression 31081068 74 Human ANRIL lncRNA all-trans retinoic acid (ATRA) glioblastoma multiforme (GBM) U87 glioblastoma cells all-trans retinoic acid (ATRA) treatment downregulated 31186810 75 Human ANRIL lncRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells cisplatin treatment ANRIL knockdown inhibited the development of DDP resistance by upregulating miR-98. 32705261 76 Human ANRIL lncRNA cisplatin (DDP) osteosarcoma (OS) U2-OS and Saos-2 osteosarcoma cell lines cisplatin (DPP) treatment ANRIL-silenced cells were more sensitive to cisplatin: apoptotic ratio was increased and cleaved caspase-3 level was upregulated. 30777616 77 Human ANRIL lncRNA hypoxia osteosarcoma (OS) osteosarcoma cells (MNNG and U2OS) hypoxia treatment upregulated 28588425 78 Human ANRIL lncRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells cisplatin treatment upregulated 31189742 79 Human ANRIL lncRNA cisplatin (DDP) ovarian cancer (OC) ES2 cells cisplatin treatment upregulated 32901049 80 Human ANRIL lncRNA propofol (PPF) papillary thyroid cancer (PTC) Human PTC cell lines TPC-1 and IHH-4 Propofol treatment downregulated 30703346 81 Human ANRIL lncRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (HPASMCs) hypoxia induce downregulated 31974617 82 Human ANRIL lncRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (HPASMCs) hypoxia treatment downregulated 31974617 83 Human ANRIL lncRNA lipopolysaccharide (LPS) ulcerative colitis (UC) fetal human cells (FHCs) lipopolysaccharide (LPS) treatment upregulated 30477744 84 Human ANRIL lncRNA ursolic acid (UA) uric acid nephropathy (UAN) HK-2?cells uric acid treatment Uric acid increased the expression levels of ANRIL in HK-2 cells 30347231 85 Human ANRIL lncRNA high glucose (HG) wound healing human dermal lymphatic endothelial cells (LECs) high glucose (HG) treatment "ANRIL was downregulated, whereas miR-181a was upregulated in high glucose (HG)-induced LECs." 30565672 86 Human ANRIL lncRNA ionizing radiation (IR) colorectal cancer (CRC) SW480 cells irradiation treatment Irradiation significantly decreased cell viability and ANRIL expression in a dose-dependent manner. 33529508 87 Human AP000769.1-2:10 lncRNA celecoxib lung squamous cell carcinoma (LSQCC) The human LSQCC cell line SK-MES-1 celecoxib treatment downregulated 29512696 88 Human APAP2-AS1 lncRNA trastuzumab breast cancer HER2-positive SKBR-3 and BT474 cells Trastuzumab treatment upregulated 30910994 89 Human APPAT lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment APPAT showed significant reduction in ox-LDL treated human VSMCs in vitro. 29372117 90 Human ARAP1-AS2 lncRNA high glucose (HG) diabetic nephropathy (DN) HK2 cells high glucose (HG) treatment upregulated 32969198 91 Human ARAP1-AS2 lncRNA high glucose (HG) epithelial-mesenchymal transition (EMT) HK-2 cells high glucose (HG) treatment upregulated 31975379 92 Human Arid2-IR lncRNA advanced glycation end product (AGE) diabetic retinopathy (DR) human retinal endothelial cells (HRECs) advanced glycation end product (AGE) treatment upregulated 31912402 93 Human ARSR lncRNA oxaliplatin colorectal cancer (CRC) SW480 cells; SW620 cells oxaliplatin (OXA) treatment upregulated of lncARSR promoted OXA resistance in CRC. 32558022 94 Human ARSR lncRNA atorvastatin hypercholesterolemia peripheral blood samples atorvastatin treatment Atorvastatin increased the expression of lncRNAs ARSR after treatment. 33198086 95 Human ARSR lncRNA fatty acid nonalcoholic fatty liver disease (NAFLD) human hepatocarcinoma cell line (HepG2) fatty acid treatment upregulated 29555473 96 Human ARSR lncRNA high fatty acid nonalcoholic fatty liver disease (NAFLD) HepG2 cells high fatty acid treatment upregulated 32169080 97 Human AT102202 lncRNA epigallocatechin-3-gallate (EGCG) cholesterol metabolism "human hepatoblastoma cell line, HepG2" epigallocatechin-3-gallate (EGCG) treatment upregulated 25563320 98 Human ATB lncRNA TGF-¦Â1 atherosclerosis (AS) human umbilical vein endothelial cell (HUVEC) line TGF-¦Â1 treatment upregulated 30942415 99 Human ATB lncRNA angiotensin II (Ang II) endothelial cell injury human umbilical vein endothelial cell (HUVECs) angiotensin II (Ang II) treatment Ang II treatment downregulated the lncRNA-ATB level in HUVECs. 32581029 100 Human ATB lncRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) A549 cells TGF-¦Â1 induces EMT process and elevates treatment upregulated 29113749 101 Human ATB lncRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) A549 cells; Beas-2B cells TGF-¦Â1 treatment TGF-¦Â1 induces EMT process and elevates lncRNA-ATB levels in pulmonary epithelial cells 30010033 102 Human ATB lncRNA TGF-¦Â glioblastoma multiforme (GBM) LN-18 and U251 cells TGF-¦Â treatment upregulated 31140621 103 Human ATB lncRNA hepatitis B virus (HBV) HBV-associated hepatocellular carcinoma (HCC) HepG2 cell lines hepatitis B virus (HBV) infection upregulated 31746419 104 Human ATB lncRNA astragaloside IV (AS-IV) hepatocellular carcinoma (HCC) SMMC-7721 cells astragaloside (AS-IV) treatment downregulated 29331759 105 Human ATB lncRNA TGF-¦Â hepatocellular carcinoma (HCC) hepatoma cells SMMC-7721 continuously with TGF-¦Â for 21 days treatment different experssion 24768205 106 Human ATB lncRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HepG2 cells HBx treatment HBx-induced autophagy could upregulate the expression of TGF-¦Â and lncRNA-ATB. 31746419 107 Human ATB lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) human ATDC5 cells lipopolysaccharide (LPS) treatment "lncRNA-ATB expression was downregulated in LPS-injured cells, and lncRNA-ATB overexpression significantly alleviated LPS-induced inflammatory injury in ATDC5 cells." 30771739 108 Human ATB lncRNA TGF-¦Â1 renal fibrosis human kidney 2 (HK-2) cells TGF-?1 treatment LncRNA-ATB was highly expressed in TGF-?1 induced HK-2 cells 32447340 109 Human ATXN8OS lncRNA ginsenoside Rg3 breast cancer MCF-7 breast cancer cells ginsenoside Rg3 treatment "Here, a lncRNA (ATXN8OS) was found to be downregulated via Rg3-mediated promoter hypermethylation in MCF-7 breast cancer cells." 33477683 110 Human AU015836 lncRNA glyoxylate kidney damage and kidney stones HK-2 cells glyoxylate upregulated 29160413 111 Human AV310809 lncRNA TGF-¦Â1 peritoneal fibrosis human peritoneal mesothelial cells (HPMCs) TGF-¦Â1 treatment upregulated 30935692 112 Human AWPPH lncRNA bone morphogenetic protein 2 (BMP2) non-traumatic osteonecrosis of femoral head (ONFH) human MSCs from bone marrow (hMSC-BM) bone morphogenetic protein 2 (BMP2) treatment BMP-2 significantly upregulated the expression of lncRNA AWPPH in a dose-dependent manner. 31853285 113 Human AWPPH lncRNA bone morphogenetic protein 2 (BMP2) osteogenesis Human MSCs from bone marrow (hMSC-BM) bone morphogenetic protein 2 (BMP2) treatment "BMP-2 treatment significantly increased the expression level of AWPPH in human MSCs from bone marrow (hMSC-BM). AWPPH overexpression promoted, while AWPPH short hairpin RNA silencing inhibited the expression of Runx2 expression in hMSC-BM cells." 31853285 114 Human AWPPH lncRNA carboplatin (CBP) triple negative breast cancer (TNBC) o human TNBC cell lines MDA©\MB©\231 and BT©\ 20 carboplatin (CBP) treatment LncRNA AWPPH overexpression led to promoted cancer cells proliferation and improved cancer cell viability under carboplatin treatment. 31033015 115 Human AX747207 lncRNA doxorubicin (DOX) breast cancer MCF-7 cells doxorubicin treatment upregulated 29749447 116 Human AX800134 lncRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) blood; liver tissues hepatitis B virus (HBV) infection AX800134 was upregulated in HBV-positive HCC compared with HBV-negative HCC. 29789998 117 Human BACE1 lncRNA anisomycin ovarian cancer (OC) human ovarian cancer stem cells (OCSCs) anisomycin treatment upregulated 26783004 118 Human BACE1-AS lncRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) SH-SY5Y cells amyloid ¦Â1-42?(A¦Â) treatment "The BACE1-AS level was found to be upregulated in serum samples of AD patients, brain tissues of AD transgenic (Tg) mice and A¦Â1-42-treated SH-SY5Y cells." 33197504 119 Human BACE1-AS lncRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) SH-SY5Y cells amyloid ¦Â1-42?(A¦Â) treatment BACE1-AS Promotes Autophagy-Mediated Neuronal Damage Through The miR-214-3p/ATG5 Signalling Axis In Alzheimer's Disease. 33197504 120 Human BACE1-AS lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) HPN; SK-N-SH cells amyloid-¦Â (A¦Â) 25-35 treatment upregulated 31898085 121 Human BACE1-AS lncRNA berberine (BBR) Alzheimer's disease (AD) HPN; SK-N-SH cells berberine (BBR) treatment downregulated 31898085 122 Human BACE1-AS lncRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) senile plaque (SP) AD SH-SY5Y cell synthetic amyloid ¦Â-protein( A¦Â1-42) treatment up-regulate 24970022 123 Human BACE1-AS lncRNA HIV-1 transactivator of transcription (Tat) protein HIV-associated neurocognitive disorders (HAND) human primary astrocytes (HPAs) HIV-1 transactivator of transcription (Tat) protein treatment HIV-1 Tat-mediated astrocytic amyloidosis involves the HIF-1¦Á/lncRNA BACE1-AS axis. 32453744 124 Human BANCR lncRNA IFN-¦Ã age-related macular degeneration (AMD) ARPE-19 cells IFN-¦Ã treatment IFN-¦Ã by itself increases BANCR expression in RPE cells. 29054724 125 Human BANCR lncRNA high glucose (HG) diabetic retinopathy (DR) human retinal pigment epithelial cell line ARPE-19 high-glucose (HG) treatment "In vitro, high-glucose treatment failed to affect the expression of lncRNA BANCR in the human retinal pigment epithelial cell line ARPE-19. However, lncRNA BANCR overexpression inhibited the apoptosis of ARPE-19 cells under high-glucose conditions." 31007747 126 Human BANCR lncRNA IFN-¦Ã inflammation ARPE-19 cells IFN¦Ã treatment upregulated 29054724 127 Human BANCR lncRNA IFN-¦Â myocardial injury iPS cell-derived cardiomyocytes IFN-¦Â treatment BANCR promotes interferon-¦Â-induced cardiomyocyte apoptosis by targeting signal transducer and activator of transcription 1 in vitro. 33284897 128 Human BANCR lncRNA deoxyelephantopin (DOE) uterine leiomyoma (UL) UL cells deoxyelephantopin (DOE) treatment downregulated 33152917 129 Human BC005927 lncRNA hypoxia gastric cancer (GC) SGC7901 cells; MKN45 cells; MKN28 cells hypoxia treatment "BC005927 was strongly induced by hypoxia in SGC7901 cells, MKN45 cells and MKN28 cells in a time- dependent method." 29383777 130 Human BC064139 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cell differentiation human umbilical cord derived mesenchymal stem cells (hUCMSCs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 29633064 131 Human BC200 lncRNA aurora kinase inhibitor (CCT137690) breast cancer MDA-MB-231 cells aurora kinase inhibitor (CCT137690) treatment downregulated 31319040 132 Human BC200 lncRNA doxorubicin (DOX) cellular defense against genotoxic agents human glioma cell lines doxorubicin (DOX) treatment downregulated 25645334 133 Human BC200 lncRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) H1299/DDP cells cisplatin treatment the IC50 in H1299/DDP cells transfected with si-BC200 was lower than in those transfected with si-NC. 30779077 134 Human BC200 lncRNA carboplatin (CBP) ovarian cancer (OC) SKOV3 and A2780 ovarian cancer cells carboplatin (CBP) treatment "it was observed that carboplatin induced BC200 expression in the cell lines, and that the inhibition of BC200 decreased the sensitivity of the cells to the drug" 26893717 135 Human BCAR42 lncRNA Yes-associated protein (YAP) breast cancer "human breast cancer cell lines MDA©\MB©\231, MDA©\MB©\468, and human embryonic kidney cell line HEK293T" YAP treatment upregulated 28963395 136 Human BDLNR lncRNA baicalin (BAI) cervical cancer (CC) HeLa cells; SiHa cells baicalin (BAI) treatment BDLNR is downregulated by baicalein in a dose- and time-dependent manner in cervical cancer. 29175387 137 Human BDLNR lncRNA baicalin (BAI) cervical cancer (CC) "HeLa, SiHa, ME-180 cells" baicalin (BAI) treatment upregulated 291753872 138 Human BDNF-AS lncRNA high glucose (HG) diabetic retinopathy (DR) human retinal pigment epithelial (RPE) cells 50 mM D-glucose upregulated 28657668 139 Human BDNF-AS lncRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment "With treatment of 50?mM D-glucose, BDNF was markedly downregulated whereas BDNF-AS upregulated in ARPE-19 cells." 28657668 140 Human BDNF-AS lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment upregulated 32057951 141 Human BDNF-AS lncRNA lithium (Li) spinal cord injury (SCI) SH-SY5Y cells lithium treatment Lithium treatment rescued the upregulation of BDNF-AS expression and downregulated of miR-9-5p expression induced by H2O2 in SH-SY5Y cells. 33464390 142 Human BFAL1 lncRNA enterotoxigenic bacteroides fragilis (ETBF) colorectal cancer (CRC) HCT-116 and DLD-1 cells Enterotoxigenic Bacteroides fragilis (ETBF) infection upregulated 31515468 143 Human BLACAT1 lncRNA ketamine anesthesia-induced neural cytotoxicity human induced pluripotent stem cells (hiPSCs)-derived neurons "HiPSC-derived neurons were incubated with ketamine (MilliporeSigma, Shanghai, China) at various concentrations of 0, 0.001, 0.01, 0.1, 0.5, 1, 2 and 5 mM for 24 h." "ketamine induced neuronal apoptosis, neurite degeneration, and upregulated BLACAT1 gene expression. Inversely, lentiviral-induced BLACAT1 downregulated rescued ketamine-induced neural cytotoxicity in hiPSCs-derived neurons. In addition, BLACAT1 downregulated was demonstrated to prevent ketamine-induced mitochondrial dysregulations by suppressing ROS and caspase 3/7 activities in hiPSCs-derived neurons." 31622594 144 Human BLACAT1 lncRNA radiation head and neck squamous cell carcinoma (HNSCC) SCC25 cell; FaDu cells radiation treatment BLACAT1 knockdown enhanced radioresistance of HNSCC cells via regulating PSEN1 31944856 145 Human BLACAT1 lncRNA afatinib non-small cell lung cancer (NSCLC) NSCLC cell lines Calu3 and H1975 afatinib treatment BLACAT1 was upregulated in afatinib-resistant NSCLC cells. 31359792 146 Human Blnc1 lncRNA high glucose (HG) diabetic nephropathy (DN) HK2 cells high glucose (HG) treatment upregulated 31632538 147 Human BMP5 lncRNA oestrogen (E2) phallus development urethral epithelium of male phalluses oestrogen (E2) treatment Lnc-ZBTB16 was downregulated by oestrogen treatment in male phalluses at day 50 post-partum (pp). 30598023 148 Human C0100223 lncRNA estrogen (ES) epithelial ovarian cancer (EOC) E2 receptor (ER) ¦Á-positive EOC cells Estrogen (E2) treatment dysregulated 24481591 149 Human C2dat1 lncRNA platelet derived growth factor-BB (PDGF-BB) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) platelet-derived growth factor (PDGF)-BB treatment C2dat1 was higher in coronary artery disease (CAD) tissues than in normal arterial tissues and the C2dat1 expression level was upregulated in the proliferating VSMC after being treated with PDGF-bb 30474870 150 Human C2dat1 lncRNA tumor necrosis factor alpha (TNF-¦Á) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) tumor necrosis factor alpha (TNF-¦Á) treatment C2dat1 was higher in coronary artery disease (CAD) tissues than in normal arterial tissues and the C2dat1 expression level was upregulated in the proliferating VSMC after being treated with TNF-¦Á 30474870 151 Human C3orf67-AS1 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" breast cancer Ginsenoside Rh2-treated MCF-7 cancer cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 31645124 152 Human C3orf67-AS1 lncRNA ginsenoside Rh2 breast cancer MCF-7 cancer cells Ginsenoside Rh2 treatment downregulated 31645124 153 Human C5orf66-AS1 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) "gastric cardia adenocarcinoma (GCA) cell lines MGC-803, BGC-823, HGC-27, SGC-7901, NCI-N87" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 29566283 154 Human C7orf30-2 lncRNA IFN-¦Ã and TNF-¦Á atopic dermatitis (AD) human keratinocytes (HaCaT cells) IFN-¦Ã/TNF-¦Á treatment upregulated 31181406 155 Human C7orf30-2 lncRNA quercetin atopic dermatitis (AD) IFN-¦Ã/TNF-¦Á-treated human keratinocytes (HaCaT cells) Quercetin (Que) treatment downregulated 31181406 156 Human CA7-4 lncRNA high glucose (HG) autophagy human umbilical vein endothelial cells (HUVECs) high glucose treatment LncRNA CA7-4 that was induced by a high concentration of glucose. LncRNA CA7-4 facilitated endothelial autophagy and apoptosis as a competing endogenous RNA (ceRNA) by decoying miR877-3p and miR5680. 30957640 157 Human CA7-4 lncRNA 3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO) vascular endothelial cells (VECs) autophagy and apoptosis human vascular endothelial cells (VECs) 3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO) treatment 3BDO restrained the upregulation of CA7-4 induced by high glucose in VECs. 30957640 158 Human CAIF lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) human CHON-001 cells lipopolysaccharide (LPS) treatment "CAIF overexpression inhibited the apoptosis of CHON-001 cells under LPS treatment, while miR-1246 overexpression attenuated the effects of CAIF overexpression." 31653823 159 Human CASC15 lncRNA high glucose (HG) diabetic nephropathy (DN) CIHP-1 cells high glucose (HG) treatment CASC15 is upregulated in DCRF patients and promotes the apoptosis of podocytes by sponging miR-34c. 32053576 160 Human CASC15 lncRNA hypoxia non-small cell lung cancer (NSCLC) "NSCLC cell lines (A549, H1299, H1650, H1975, H520)" hypoxia treatment ?Further analysis showed that hypoxia-induced CASC15 transactivation was mainly dependent on hypoxia-inducible factor 1¦Á (HIF-1¦Á) and hypoxia response elements (HREs) located in CASC15 promoter. 33407675 161 Human CASC2 lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK-2 cells lipopolysaccharide (LPS) treatment downregulated 32323747 162 Human CASC2 lncRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment downregulated 29492259 163 Human CASC2 lncRNA paclitaxel (PTX) breast cancer MCF-7 cells and MDA-MB-231 cells paclitaxel (PTX) treatment upregulated 31352515 164 Human CASC2 lncRNA berberine (BBR) colorectal cancer (CRC) The human colorectal cancer cell lines HT29 and HCT116 berberine (BBR) treatment "LncRNA CASC2 was upregulated in cells treated with berberine, and knockdown of lncRNA CASC2 reversed the berberine-induced apoptosis." 30681073 165 Human CASC2 lncRNA berberine (BBR) colorectal cancer (CRC) "Five human CRC cell lines (HT-29, HCT116, SW480, SW620 and LoVo)" berberine (BBR) treatment lncRNA CASC2 was upregulated by berberine treatment 31173223 166 Human CASC2 lncRNA high glucose (HG) diabetic nephropathy (DN) human mesangial cells (HMCs) high glucose (HG) treatment "CASC2 upregulation suppressed HG-induced proliferation, ECM accumulation and oxidative stress of HMCs through miR-133b /FOXP1 regulatory axis." 32016985 167 Human CASC2 lncRNA high glucose (HG) diabetic nephropathy (DN) human renal mesangial cells (HRMCs) high glucose (HG) treatment "CASC2 could alleviate the degree and process of apoptosis, inflammation, and fibrosis in diabetic nephropathic models by regulating the miR-144/SOCS2 axis." 33227790 168 Human CASC2 lncRNA sanguinarine epithelial ovarian cancer (EOC) SKOV3 cells sanguinarine treatment upregulated 29571014 169 Human CASC2 lncRNA cisplatin (DDP) gastric cancer (GC) BGC823 cells; SGC7901 cells cisplatin treatment downregulated 30372881 170 Human CASC2 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U257 cells; U87 cells temozolomide (TMZ) treatment downregulated 29136760 171 Human CASC2 lncRNA iodine-131 (131I) papillary thyroid cancer (PTC) TPC-1 cells; IHH-4 cells Radioiodine (131I) treatment CASC2 increases 131I sensitivity in PTC by sponging miR-155 33134385 172 Human CASC2 lncRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (HPASMCs) hypoxia treatment CASC2 attenuated hypoxia-induced PASMC proliferation and migration by regulating the miR-222/ING5 axis to prevent vascular remodeling and the development of PAH. 32206065 173 Human CASC7 lncRNA corticosteroid corticosteroid resistance Airway smooth muscle cells (ASMCs) corticosteroid treatment CASC7 increased corticosteroid sensitivity by inhibiting the PI3K/AKT signaling pathway via targeting miR-21. 31412983 174 Human CASC7 lncRNA dexamethasone (DEX) corticosteroid resistance Airway smooth muscle cells (ASMCs) dexamethasone (DEX) treatment Overexpression of CASC7 suppressed the PI3K/AKT signaling pathway and promoted the inhibition effects of dexamethasone on cell proliferation and cytokines secretion via targeting miR-21. 31412983 175 Human CASC7 lncRNA NaSH spinal cord ischemia/reperfusion injury (SCII) SH5Y-SY cells NaSH treatment NaSH preprocessing upregulated CasC7 and downregulated miR-30c in OGD/R-induced SH5Y-SY cells. 29571256 176 Human CASC9 lncRNA lipopolysaccharide (LPS) lung injury human small airway epithelial cells (HSAECs) Lipopolysaccharide (LPS) treatment CASC9 protects lung epithelial cells from sepsis-induced injury via regulating miR-195-5p/PDK4 axis. 32221619 177 Human CASC9 lncRNA hypoxia pancreatic cancer (PC) "human pancreatic cancer cell lines (SW1990, PANC-1, BxPC-3, and MiaPaCa-2)" hypoxia treatment "Additionally, our findings showed that hypoxia induced the expression of CASC9 and enhanced the binding of HIF-1¦Á to its promoter." 33520364 178 Human CCAT1 lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK-2 cells lipopolysaccharide (LPS) treatment LPS administration reduced CCAT1 in tubular epithelial cells in vitro. 32243922 179 Human CCAT1 lncRNA radiation breast cancer MCF-7 cells; MDA-MB-231 cells radiation treatment Radiation treatment triggered a significant increase in CCAT1 and an obvious decrease in miR-148b 29024383 180 Human CCAT1 lncRNA X-rays breast cancer human breast cancer cell lines MCF-7 and MDA-MB-231 radiation treatment upregulated 29024383 181 Human CCAT1 lncRNA cisplatin (DDP) cisplatin (DDP) resistance A2780; SKOV3 cisplatin treatment CCAT1/miR-454/survivin axis conferred cisplatin resistance in ovarian cancer cells. 32124583 182 Human CCAT1 lncRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) "HCT 116, SW1417, HT-29, and KM12 cell lines and NCM460 cell line" 5-fluorouracil (5-FU) treatment the expression levels of CCAT1 were high in HCT 116/5-FU and HT-29/5-FU cell lines 31039730 183 Human CCAT1 lncRNA dandelion gastric cancer (GC) human GC cells dandelion treatment downregulated 28724210 184 Human CCAT1 lncRNA solasonine (SS) hepatocellular carcinoma (HCC) "HepG2 cells, QGY-7703 cells" Solasonine (SS) treatment downregulated 31681610 185 Human CCAT1 lncRNA lipopolysaccharide (LPS) inflammation skin keratinocyte HaCaT cells lipopolysaccharide (LPS) treatment upregulated 31356903 186 Human CCAT1 lncRNA Sinomenine (SIN) inflammation skin keratinocyte HaCaT cells sinomenine treatment downregulated 31356903 187 Human CCAT1 lncRNA tumor necrosis factor alpha (TNF-¦Á) inflammatory bowel disease (IBD) Human colorectal cancer cell line Caco-2 tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 30615124 188 Human CCAT1 lncRNA dexmedetomidine (DEX) ischemia/reperfusion (I/R) injury HL7702 cells dexamethasone (DEX) treatment Dex partially reversed the OGD-inhibited expression of lncRNA CCAT1. 29851220 189 Human CCAT1 lncRNA cigarette smoke extract (CSE) lung cancer human bronchial epithelial (HBE) cell cigarette smoke extract (CSE) treatment upregulated 28184029 190 Human CCAT1 lncRNA baicalin (BAI) melanoma A375 and SK-MEL-28 cells baicalin (BAI) treatment downregulated 31778440 191 Human CCAT1 lncRNA oleic acid (OA) nonalcoholic fatty liver disease (NAFLD) L02 cells oleic acid (OA) treatment "CCAT1 increases LXR¦Á transcription by serving as a competing endogenous RNA for miR-613 in an LXRE-dependent manner, thereby promoting lipid droplet formation and NAFLD." 32413192 192 Human CCAT1 lncRNA hyperoside non-small cell lung cancer (NSCLC) H1975 cells hyperoside treatment downregulated 31894285 193 Human CCAT1 lncRNA hyperoside non-small cell lung cancer (NSCLC) The adenocarcinoma lung cancer cell line PC-9 and the T790M-positive NSCLC cell line NCI-H1975 Hyperoside treatment downregulated 31894285 194 Human CCAT1 lncRNA paclitaxel (PTX) paclitaxel (PTX) resistance PC3-TXR cells; DU145-TXR cells Paclitaxel (PTX) treatment Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1 32089062 195 Human CCAT2 lncRNA X-rays esophageal cancer (EC) TE-3 cells; ECA109 cells X-ray radiation treatment lncRNA CCAT2 promotes radiotherapy resistance for human esophageal carcinoma cells via the miR-145/p70S6K1 and p53 pathway 31789385 196 Human CCAT2 lncRNA calcitriol ovarian cancer (OC) SKOV3 cells; A2780 cells calcitriol treatment calcitriol inhibited CCAT2 expression in ovarian cancer cells. 32230936 197 Human CCDC26 lncRNA imatinib gastrointestinal stromal tumor (GIST) GIST-882 cells; GIST- T1 cells imatinib treatment downregulated 29423012 198 Human CCNB1IP1-1:2 lncRNA nigericin pancreatic cancer (PC) PANC-5 cells nigericin treatment upregulated 32850392 199 Human Ccnd1 lncRNA polyunsaturated fatty acids (PUFAs) glioblastoma multiforme (GBM) Glioblastoma cells (U373; GBM2;GBM5) polyunsaturated fatty acids (PUFAs) treatment downregulated 21961478 200 Human CD160 lncRNA hepatitis B virus (HBV) hepatitis B virus (HBV) infection CD8+ T cells hepatitis B virus (HBV) infection lncRNA-CD160 is positively associated with CD160 in CD8+ T cells with HBV infection. 32565950 201 Human CD1D-2:1 lncRNA melanin melanoma Primary melanocytes melanin treatment upregulated 26596215 202 Human CDKN2B-AS lncRNA gemcitabine (GEM) gemcitabine sensitivity T24 cells gemcitabine treatment The expression of CDKN2B-AS gene in Gemcitabine-resistant T24/Gem cells was much higher than that in T24 cells. 29937935 203 Human CDKN2B-AS1 lncRNA IL-1¦Â crohn disease (CD) Caco-2 cells IL-1¦Â treatment downregulated 29361088 204 Human CDKN2B-AS1 lncRNA high glucose (HG) diabetic nephropathy (DN) Human glomerular mesangial cells (HGMC) high glucose (HG) treatment "Knockdown of CDKN2B-AS1 suppressed proliferation, ECM accumulation and PI3K/AKT signaling by increasing miR-424-5p and decreasing HMGA2 in high glucose-treated HMGC cells." 31707340 205 Human CDKN2B-AS1 lncRNA high glucose (HG) diabetic nephropathy (DN) Human glomerular mesangial cells (HGMC) high glucose (HG) treatment upregulated 31707340 206 Human CDKN2B-AS1 lncRNA high glucose (HG) diabetic nephropathy (DN) human mesangial cells (HMCs) high glucose (HG) treatment Long non-coding RNA CDKN2B-AS1 regulates high glucose-induced human mesangial cell injury via regulating the miR-15b-5p/WNT2B axis 33298110 207 Human CDKN2B-AS1 lncRNA ¦Â-Elemene esophageal squamous cell carcinoma (ESCC) ¦Â-Elemene treatment The chemotherapeutic drug ¦Â-elemene suppressed the proliferation of esophageal carcinoma ECA-109 cells by regulating the inhibition of hTERT expression by lncRNA CDKN2B-AS1 25646744 208 Human CDKN2B-AS1 lncRNA human papilloma virus (HPV) head and neck squamous cell carcinoma (HNSCC) primary tumors resected from HNSCC patients human papillomavirus (HPV) infection upregulated 32998396 209 Human CERNA1 lncRNA "annexin A7 inhibitor, ABO (6-amino-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine)" endothelial dysfunction human umbilical vein endothelial cells (HUVECs) "annexin A7 inhibitor, ABO (6-amino-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine) treatment" upregulated 30911960 210 Human CETP-3 lncRNA medroxyprogesterone acetate (MPA) endometrial cancer (EC) Ishikawa cells (PRB+) medroxyprogesterone acetate (MPA) treatment upregulated 31718641 211 Human CF129 lncRNA hypoxia pancreatic cancer (PC) The PANC-1 and BxPC-3 cell lines hypoxia induce downregulated 31367258 212 Human CHCHD4P4 lncRNA glyoxylate kidney damage and kidney stones HK-2 cells glyoxylate upregulated 29160413 213 Human CHRF lncRNA TGF-¦Â1 idiopathic pulmonary fibrosis (IPF) A549 cells TGF-¦Â1 treatment CHRF and L1CAM expression were significantly upregulated and promoted the EMT process in A549 after treatment of TGF-¦Â1 33754922 214 Human CHRF lncRNA cisplatin (DDP) ovarian cancer (OC) ES2 cells cisplatin treatment upregulated 32901049 215 Human CILinc02 lncRNA ibuprofen osteoarthritis (OA) cartilage tissues of osteoarthritis Ibuprofen treatment downregulated 30548658 216 Human CILinc02 lncRNA methylene blue (MB) osteoarthritis (OA) cartilage tissues of osteoarthritis methylene blue treatment downregulated 30548658 217 Human CLDN10-AS1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 28316063 218 Human CMPK2 lncRNA IFN-¦Á chronic hepatitis C virus (HCV) infection primary human hepatocytes IFN-¦Á treatment upregulation 25122750 219 Human COX2 lncRNA polyunsaturated fatty acids (PUFAs) glioblastoma multiforme (GBM) Glioblastoma cells (U373; GBM2;GBM5) polyunsaturated fatty acids (PUFAs) treatment downregulated 21961478 220 Human COX2 lncRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary arterial smooth muscle cells (PASMCs) hypoxia exposure lincRNA-COX2 expression was upregulated in hypoxic PASMCs. 32803651 221 Human COX2 lncRNA lipopolysaccharide (LPS) postoperative peritoneal adhesion (PPA) The human peritoneal mesothelium cells (HPMCs) lipopolysaccharide (LPS) treatment "Suppression of Cox-2 ameliorated LPS induced HMPCs injury as cell viability was promoted, and cell apoptosis and the production of inflammatory factors were inhibited." 31885500 222 Human CPS1-IT1 lncRNA CoCl2 colorectal cancer (CRC) LoVo and HCT116 CoCl2 treatment downregulated 29017924 223 Human CPS1-IT1 lncRNA melatonin hepatocellular carcinoma (HCC) HepG2 cells;Huh7 cells Melatonin treatment downregulated 29137263 224 Human CRAL lncRNA cisplatin (DDP) gastric cancer (GC) BGC823 cells; SGC7901 cells cisplatin treatment downregulated 31885317 225 Human CRART16 lncRNA cetuximab colorectal cancer (CRC) Caco-2 cells cetuximab treatment lncRNA CRART16 was upregulated in Caco-2 CR cells. 32158358 226 Human CRNDE lncRNA lipopolysaccharide (LPS) sepsis THP-1 cell line lipopolysaccharide (LPS) treatment "si-CRNDE-1 and miR-181a-5p mimic were able to reverse the promoting effects of LPS on production of NF-kB, TNF-a, IL-1b and IL-6 by THP-1 cells." 31604377 227 Human CRNDE lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK-2 cells lipopolysaccharide (LPS) treatment upregulated 32399391 228 Human CRNDE lncRNA paclitaxel (PTX) colorectal cancer (CRC) SW480 cells; SW620 cells Paclitaxel (PTX) treatment ?CRNDE Promotes Colorectal Carcinoma Cell Progression and Paclitaxel Resistance by Regulating miR-126-5p/ATAD2 Axis 32581554 229 Human CRNDE lncRNA dextran sodium sulfate (DSS) inflammatory bowel disease (IBD) "human colonic epithelial cell lines (HT-29, LOVO, and Caco-2)" dextran sulfate sodium (DSS) treatment CRNDE in the colonic epithelial cell lines. 31251902 230 Human CRNDE lncRNA lipopolysaccharide (LPS) liver damage L02 cells lipopolysaccharide (LPS) treatment LPS significantly suppressed CRNDE expression in L02 cells. 32031750 231 Human CRNDE lncRNA cisplatin (DDP) medulloblastoma "Medulloblastoma cell lines D283, Daoy, D425, and D341" cisplatin treatment upregulated 31753063 232 Human CRNDE lncRNA cisplatin (DDP) medulloblastoma Daoy; D341 cisplatin (DDP) treatment upregulated 31753063 233 Human CRNDE lncRNA palmitic acid (PA) obesity Human umbilical vein endothelial cells (HUVECs) palmitic acid (PA) treatment upregulated 31863035 234 Human CRNDE lncRNA lipopolysaccharide (LPS) pneumonia WI-38 cells lipopolysaccharide (LPS) treatment LPS exposure induced cell injuries and increased CRNDE expression in WI-38 cells. 29864958 235 Human CRNDE lncRNA lipopolysaccharide (LPS) pneumonia MRC-5 cells lipopolysaccharide (LPS) treatment CRNDE expression was induced in LPS-induced MRC-5 cells. 32317619 236 Human CRNDE lncRNA lipopolysaccharide (LPS) sepsis THP-1 cells lipopolysaccharide (LPS) treatment Linkage of lncRNA CRNDE sponging miR-181a-5p with aggravated inflammation underlying sepsis. 31604377 237 Human CRNDE lncRNA lipopolysaccharide (LPS) sepsis-induced renal injury HK-2 and HEK293 cells lipopolysaccharide (LPS) treatment CRNDE was markedly downregulated in sepsis models. 31877497 238 Human CTA lncRNA doxorubicin (DOX) osteosarcoma (OS) "osteosarcoma cell lines Saos-2, U-2OS and MG-63" doxorubicin treatment upregulated 28415557 239 Human CTB-60E11.4-001 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 240 Human CTBP1-AS2 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aorta vascular smooth muscle cells oxidized low-density lipoprotein (ox-LDL) treatment lncRNA CTBP1-AS2 may serve a role in AS by inhibiting the proliferation and promoting the autophagy of VSMCs through ATG14 modulation via miR-195-5p. 32626936 241 Human CTBP1-AS2 lncRNA high glucose (HG) diabetic nephropathy (DN) human glomerular mesangial cells (HGMCs) high glucose (HG) treatment "CTBP1-AS2 attenuated HG-induced HGMC proliferation, oxidative stress, ECM accumulation, and inflammation through miR-155-5p/FOXO1 signaling." 32868076 242 Human CTBP1-AS2 lncRNA microwave ablation (MWA) hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) tissues; HCC cell lines microwave ablation (MWA) treatment upregulated 32988587 243 Human CTC-276P9.1 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" esophageal squamous cell carcinoma (ESCC) "Human esophageal cancer cell lines TE1, TE13, T.Tn, YES2, Eca109, and Kyse170" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 29524086 244 Human CTC-276P9.1 lncRNA histone deacetylase inhibitor trichostatin A (TSA) esophageal squamous cell carcinoma (ESCC) "Human esophageal cancer cell lines TE1, TE13, T.Tn, YES2, Eca109, and Kyse170" histone deacetylase (HDAC) inhibitor TSA treatment upregulated 29524086 245 Human CTC-459I6.1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 28316063 246 Human CTD1-2003C8 lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment upregulated 32714991 247 Human CTD-2201E18 lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment upregulated 32714991 248 Human CTD-2215E18.3 lncRNA ginsenoside Rh2 hepatocellular carcinoma (HCC) HepG2 cells ginsenoside Rh2 treatment upregulated 30394104 249 Human CTD-2639E6.9 lncRNA influenza A virus (IAV) influenza A virus (IAV) infection human lung epithelial A549 cells influenza A/Puerto Rico/8/34 infection upregulated 30669933 250 Human CUST_40243 lncRNA benzene benzene-induced hematotoxicity peripheral lymphocytes benzene treatment upregulated 32730034 251 Human CYTOR lncRNA tamoxifen (TAM) breast cancer tamoxifen resistant MCF7 cell lines (MCF7/TAM1 and MCF7/TAM2) tamoxifen treatment upregulated 31894257 252 Human CYTOR lncRNA tamoxifen (TAM) breast cancer MCF7 / TAM2; MCF7 / TAM1 tamoxifen treatment lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR-125a-5p 31894257 253 Human D63785 lncRNA doxorubicin (DOX) gastric cancer (GC) BGC823 cells doxorubicin (DOX) treatment lncR-D63785 was downregulated in BGC823 cells treated by DOX. 30195778 254 Human D63785 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) neuron apoptosis SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 32999283 255 Human DANCR lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK2 cells Lipopolysaccharide (LPS) treatment DANCR Suppressed Lipopolysaccharide-Induced Septic Acute Kidney Injury by Regulating miR-214 in HK-2 Cells 32222722 256 Human DANCR lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment downregulated 32714991 257 Human DANCR lncRNA compression force (CF) cell differentiation root resorption tissues orthodontic tooth movement (OTM) upregulated 31213122 258 Human DANCR lncRNA cisplatin (DDP) colorectal cancer (CRC) SW480 cells cisplatin treatment upregulated 32766131 259 Human DANCR lncRNA doxorubicin (DOX) colorectal cancer (CRC) HCT116 and RKO cells doxorubicin (DOX) treatment we found DANCR was suppressed by Doxorubicin and it acted as an important repressor of apoptosis in colorectal cancer. 33414433 260 Human DANCR lncRNA cisplatin (DDP) gastric cancer (GC) "GC cell lines (SGC7901, BGC823) and cisplatin (DDP)-resistant cell lines (SGC7901/DDP, BGC823/DDP)" cisplatin treatment upregulated 31002130 261 Human DANCR lncRNA cisplatin (DDP) glioblastoma multiforme (GBM) U87 cells; U251 cells cisplatin treatment DANCR highly expressed LN18 and U138MG cells were less sensitive to cisplatin than DANCR lowly expressed U87MG and U251MG cells. 29572052 262 Human DANCR lncRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HEK-293T; Huh7; Hep3B cells sorafenib treatment LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells 32103983 263 Human DANCR lncRNA resveratrol nasopharyngeal carcinoma (NPC) SUNE-1 cells; 5-8F cells resveratrol (RS) treatment Resveratrol downregulated the expression of DANCR 32683392 264 Human DANCR lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) human primary chondrocytes lipopolysaccharide (LPS) treatment "Expression of DANCR was upregulated, and miR-19a was downregulated in human OA cartilage and LPS-treated primary chondrocytes in vitro." 33283483 265 Human DANCR lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) primary chondrocytes lipopolysaccharide (LPS)? treatment "Expression of DANCR was upregulated, and miR-19a was downregulated in human OA cartilage and LPS-treated primary chondrocytes in vitro." 33283483 266 Human DANCR lncRNA TGF-¦Â ovarian cancer (OC) A2780 cells; SKOV3 cells TGF-¦Â treatment Knockdown of DANCR Suppressed the Biological Behaviors of Ovarian Cancer Cells Treated with Transforming Growth Factor-¦Â (TGF-¦Â) by Sponging MiR-214 32417846 267 Human DANCR lncRNA paclitaxel (PTX) prostate cancer "Human prostate cancer cells (PC3, C4-2 and DU145)" Paclitaxel treatment downregulated of DANCR increased paclitaxel sensitivity in prostate cancer cells by negatively regulating the expression of miR-135a 31486484 268 Human DARS-AS1 lncRNA hypoxia myeloma "RPMI 8226, LP-1, U266, H929 cells" hypoxia induce upregulated 31289203 269 Human DDIT4-AS1 lncRNA hypoxia and TGF¦Â1 idiopathic pulmonary fibrosis (IPF) human pulmonary fibroblasts (HPFs) hypoxia and TGF¦Â1 treatment upregulated 31925944 270 Human DGCR5 lncRNA aurora kinase inhibitor (CCT137690) breast cancer MCF-7 cells aurora kinase inhibitor (CCT137690) treatment upregulated 31319040 271 Human DGCR5 lncRNA hypoxia spinal cord injury (SCI) AGE1.HN cells hypoxia treatment DGCR5 was downregulated in AGE1.HN cells treated with hypoxia. 30146926 272 Human DICER1-AS1 lncRNA pterostilbene breast cancer MCF 7 cells pterostilbene treatment upregulated 30619763 273 Human DICER1-AS1 lncRNA arsenite cell proliferation A549 cells arsenite exposure we found that the expression of lncRNA DICER1-AS1 was significantly inhibited by sodium arsenite in a dose-dependent manner. 33609750 274 Human DILC lncRNA lipopolysaccharide (LPS) sepsis THP-1 cells lipopolysaccharide (LPS) treatment downregulated 30365067 275 Human DIO3OS lncRNA resveratrol benign prostatic hyperplasia (BPH) Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1 resveratrol (RS) treatment downregulated 33718067 276 Human DIO3OS lncRNA TGF-¦Â1 benign prostatic hyperplasia (BPH) Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1 TGF-¦Â1 treatment upregulated 33718067 277 Human DKK3-1 lncRNA hypoxia and TGF¦Â1 idiopathic pulmonary fibrosis (IPF) human pulmonary fibroblasts (HPFs) hypoxia and TGF¦Â1 treatment upregulated 31925944 278 Human DLX6-AS1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemia/reperfusion (I/R) injury SH-SY5Ycells; N2a cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 33216728 279 Human DLX6-AS1 lncRNA lipopolysaccharide (LPS) sepsis-induced acute kidney injury HK-2 cells lipopolysaccharide (LPS) treatment LPS induced DLX6-AS1 expression in HK-2 cells 32666494 280 Human DNM3OS lncRNA palmitic acid (PA) diabetes mellitus (DM) THP1 macrophages (TMC) and human primary macrophages palmitic acid (PA) treatment upregulated 29930005 281 Human DNM3OS lncRNA TGF-¦Â1 prostatic hyperplasia (BPH) prostate stromal cells (PrSCs) were primary cultured from BPH tissue TGF¦Â1 treatment "DNM3OS expression was the most upregulated lncRNA in PrSCs induced by TGF¦Â1, DNM3OS silencing decreases the protein level of COL3A1 upon TGF¦Â1 stimulation" 31694982 282 Human DPP10-AS1 lncRNA tetramethylpyrazine (TMP) prostate cancer PC3 cells; DU145 cells Tetramethylpyrazine (TMP) treatment upregulated 32319592 283 Human DYNLRB2-2 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 macrophages oxidized low-density lipoprotein (ox-LDL) treatment upregulated 24493833 284 Human DYN-LRB2-2 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment upregulated 28815701 285 Human DYN-LRB2-2 lncRNA oxidized low density lipoprotein (ox-LDL) cholesterol efflux THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment LincRNA DYN-LRB2-2 was upregulated in oxLDL-treated THP-1 cells. 28815701 286 Human EBF3-AS lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment Ab25¨C35 induced the upregulation of EBF3-AS. 29298096 287 Human EBLN3P lncRNA enterovirus 71 (EV71) hand-foot-mouth disease (HFMD) human rhabdomyosarcoma (RD) cells Enterovirus 71 (EV71) treatment upregulated 30314355 288 Human EFNA3 lncRNA hypoxia breast cancer MDA-MB231-EphrinA3-Luc cells;MDA-MB231-Luc cells "cells were placed in a 1% O2, 5% CO2?and 94% N2?gas mixture treatment" upregulated 25023702 289 Human EGFR-AS1 lncRNA gemcitabine and cisplatin non small cell lung cancer (NSCLC) plasma gemcitabine and cisplatin treatment "the plasma levels of EGFR-AS1 were increased in patients with NSCLC, particularly in GP-resistant patient plasma." 30431074 290 Human EGFR-AS1 lncRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) "The human NLCLC cell lines, A549, NCI-H460, NCI-H1299 and NCI-H358" cisplatin (DPP) treatment upregulated 30431074 291 Human EGOT lncRNA hypoxia autophagy HK-2 cells hypoxia treatment The lncRNA EGOT expression was significantly downregulated in renal tubular cells during hypoxia-induced autophagy. 32030803 292 Human ELIT-1 lncRNA TGF-¦Â epithelial-mesenchymal transition (EMT) "Huh7, A549, HepG2, HaCaT cells" TGF¦Â treatment upregulated 30952633 293 Human LINC01480 lncRNA hydroquinone (HQ) leukemia TK6 cells HQ dysregulated 29221148 294 Human DSCAM-AS1 lncRNA doxorubicin (DOX) breast cancer MCF-7 cells doxorubicin (ADR) treatment upregulated 32547604 295 Human LINC00843 lncRNA high glucose (HG) hyperglycemia-induced vascular endothelial cell damage human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment downregulated 32689997 296 Human ANKRD20A8P lncRNA cadmium (Cd) cadmium-induced toxicity 16HBE cells cadmium (Cd) treatment upregulated 33447366 297 Human NALT1 lncRNA sub-lethal heat hepatocellular carcinoma (HCC) "human SMMC-7721, HepG2, and MHCC97-H HCC cells" treat with sub-lethal heat treatment upregulated 28732507 298 Human lncRNA 74.1 lncRNA TGF-¦Â renal fibrosis HK2 cells TGF-¦Â treatment LncRNA ENST000004537741 was significantly downregulated in the TGF-¦Â-induced HK-2 cell fibrosis 30317629 299 Human lncRNA 74.1 lncRNA TGF-¦Â renal fibrosis human HK-2 cell TGF-¦Â treatment The expression of LncRNA 741 was significantly downregulated in the TGF-¦Â-induced HK-2 cell fibrosis and clinical renal fibrosis specimens 30317629 300 Human DSCAM-AS1 lncRNA doxorubicin (DOX) breast cancer MCF-7 cells doxorubicin (ADR) treatment downregulated 32547604 301 Human ANKRD18DP lncRNA doxorubicin (DOX) breast cancer MCF-7 cells doxorubicin (ADR) treatment downregulated 32547604 302 Human LINC02577 lncRNA X-rays hypopharyngeal cancer RS-FaDu cells 4 Gy radiation upregulated 28487500 303 Human BG772796.1 lncRNA paclitaxel (PTX) lung cancer A549 human lung cancer cells paclitaxel (PTX) treatment downregulated 31516584 304 Human BE779106.1 lncRNA coal tar pitch (CTP) lung cancer human bronchial epithelial cells (BAES-2B) coal tar pitch (CTP) treatment LncRNA-ENST00000501520 could promote the proliferation in malignant-transformed BEAS-2B cells induced with CTP extract which may be mediated by target genes. 31033183 305 Human BE779106.1 lncRNA coal tar pitch extracts (CTPE) lung cancer malignant-transformed Human bronchial epithelial (BEAS-2B) cells coal tar pitch extracts (CTPE) treatment upregulated 32470693 306 Human uc063pbz.2 lncRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 307 Human C1RL-AS1 lncRNA coal tar pitch extracts (CTPE) lung cancer malignant-transformed Human bronchial epithelial (BEAS-2B) cells coal tar pitch extracts (CTPE) treatment upregulated 32470693 308 Human uc058qvk.1 lncRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) HCT116 cells; LoVo cells 5-fluorouracil (5-FU) treatment ENST00000547547 was downregulated in 5-FU-resistant CRC cells in comparison with the parental cells. 29115526 309 Human CB852161.1 lncRNA coal tar pitch extracts (CTPE) lung cancer malignant-transformed Human bronchial epithelial (BEAS-2B) cells coal tar pitch extracts (CTPE) treatment upregulated 32470693 310 Human ENST00000567668.1 lncRNA sub-lethal heat hepatocellular carcinoma (HCC) "human SMMC-7721, HepG2, and MHCC97-H HCC cells" treat with sub-lethal heat treatment upregulated 28732507 311 Human BX116192.1 lncRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 312 Human ENST00000570843.1 lncRNA sub-lethal heat hepatocellular carcinoma (HCC) "human SMMC-7721, HepG2, and MHCC97-H HCC cells" treat with sub-lethal heat treatment upregulated 28732507 313 Human ENST00000574654.1 lncRNA hypoxia renal cell carcinoma (RCC) SW839 cells; OSRC cells hypoxia treatment hypoxia promoted RCC cell invasion through HIF-1¦Á/lncRNA (ENST00000574654.1)/hnRNP/VEGF-A pathway. 32774742 314 Human NARF-AS1 lncRNA sub-lethal heat hepatocellular carcinoma (HCC) "human SMMC-7721, HepG2, and MHCC97-H HCC cells" treat with sub-lethal heat treatment upregulated 28732507 315 Human ZNF667-AS1 lncRNA doxorubicin (DOX) breast cancer MCF-7 cells doxorubicin (ADR) treatment upregulated 32547604 316 Human ZNF528-AS1 lncRNA high glucose (HG) hyperglycemia-induced vascular endothelial cell damage human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment upregulated 32689997 317 Human ENST00000602478.1 lncRNA sub-lethal heat hepatocellular carcinoma (HCC) "human SMMC-7721, HepG2, and MHCC97-H HCC cells" treat with sub-lethal heat treatment upregulated 28732507 318 Human ZNF658B lncRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 319 Human BC028413.1 lncRNA ¦Á-melanocyte-stimulating hormone (¦Á-MSH) skin pigmentation disorders human skin primary melanocytes (MCs) ¦Á-MSH treatment upregulated 33318297 320 Human BF244201.1 lncRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 321 Human BF244201.1 lncRNA dexamethasone (DEX) steatosis ?HepG2 cell lines dexamethasone (DEX) treatment "ENST00000608794 plays an important role in dexamethasone induced steatosis, which was partly mediated by derepressing of PDK4 through competitively binding to miR-15b-5p." 31330194 322 Human BF244201.1 lncRNA dexamethasone (DEX) steatosis hepatocytes dexamethasone (DEX) treatment upregulated 31330194 323 Human BC017676.1 lncRNA high glucose (HG) hyperglycemia-induced vascular endothelial cell damage human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment upregulated 32689997 324 Human AK123910.1 lncRNA high glucose (HG) hyperglycemia-induced vascular endothelial cell damage human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment downregulated 32689997 325 Human EPB41L4A-AS1 lncRNA gemcitabine (GEM) ancreatic cancer (PC) SW1990 cells gemcitabine (GEM) treatment downregulated 30113217 326 Human EPB41L4A-AS2 lncRNA docetaxel (DTX) breast cancer MCF7 cells; MDA cells docetaxel (DTX) treatment downregulated 29683761 327 Human EPEL lncRNA carboplatin (CBP) ovarian endometrioid adenocarcinoma human ovarian endometrioid adenocarcinoma cell line SNU-251 carboplatin (CBP) treatment "EPEL overexpression increased, whereas small interfering RNA (siRNA) silencing reduced the viability of SNU-251 cells under carboplatin treatment." 31621389 328 Human EPIC1 lncRNA dexamethasone (DEX) osteoblast injury OB-6 osteoblastic cells; primary human osteoblasts dexamethasone (Dex) treatment "In OB-6 osteoblastic cells and primary human osteoblasts, treatment with Dex increased expression of Lnc-EPIC1." 29959919 329 Human EPIC1 lncRNA H2O2 neuronal cell injury SH-SY5Y neuronal cells and primary human neuron cultures hydrogen peroxide (H2O2) treatment downregulated 31812951 330 Human EPR lncRNA TGF-¦Â cell proliferation human mammary gland adenocarcinoma cells MDAMB-231 TGF-¦Â treatment TGF-¦Â induced a small increase in EPR levels followed by rapid downregulated 31036808 331 Human ERLR lncRNA TGF-¦Â1 cell proliferation ARPE-19 cells; phRPE cells TGF-¦Â1 treatment ERLR was upregulated in RPE cells stimulated with transforming growth factor (TGF)-¦Â1 as detected by lncRNA microarray and RT-PCR 33664479 332 Human ES3 lncRNA high glucose (HG) calcification/senescence human aortic vascular smooth muscle cells (HA-VSMCs) high glucose (HG) treatment upregulated 32483833 333 Human ES3 lncRNA high glucose (HG) vascular calcification (VC) human aorta vascular smooth muscle cells (HA-VSMCs) high glucose treatment lncRNA-ES3 inhibited miR-34c-5p expression by direct interaction and its knockdown suppressed the calcification/senescence of HA-VSMCs. 30654331 334 Human F11-AS1 lncRNA hepatitis B virus X protein (HBx) HBV-associated hepatocellular carcinoma (HCC) HepG2.2.15 cells HBx-induce downregulated 31880390 335 Human F11-AS1 lncRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HepG2.2.15 cells hepatitis B virus (HBV) infection downregulated 31880390 336 Human FA2H-2 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) "human umbilical vein endothelial cells (ECs; ATCC CRL-1730), and human aorta vascular smooth muscle cells (SMCs; ATCC CRL-1999)" oxidized low-density lipoprotein (OX-LDL) treatment downregulated 30683918 337 Human FAL1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) brain endothelial cell damage human primary brain microvascular endothelial cells (HBMVECs) oxygen-glucose deprivation and reoxygenation (OGD/R) treatment The lncRNA FAL1 protects against hypoxia-reoxygenation- induced brain endothelial damages through regulating PAK1 31927658 338 Human FAL1 lncRNA tumor necrosis factor alpha (TNF-¦Á) diabetic atherosclerosis HUVECs tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 30338819 339 Human FAM133B-2 lncRNA X-rays nasopharyngeal carcinoma (NPC) CNE-2 cells; 6-10B cells X-ray radiation treatment FAM133B-2 is highly expressed in the radio-resistant nasopharyngeal carcinoma cells. 32889799 340 Human FAM225A lncRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HepG2 cells sorafenib treatment FAM225A expression is dramatically upregulated in sorafenib-resistant HepG2/SOR cells 33245102 341 Human FAM83H-AS1 lncRNA TGF-¦Â oesophageal squamous cell carcinoma (ESCC) Eca109 cells TGF-¦Â treatment upregulated 32583631 342 Human FAM83H-AS1 lncRNA staphylococcal protein A (SpA) osteomyelitis Human bone mesenchymal stem cells (hBMSCs) staphylococcal protein A (SpA) treatment FAM83H-AS1/miR-541-3p/WNT3A ameliorated SpA-mediated inhibition of the osteogenic differentiation of hBMSCs 31871129 343 Human FANCI-2 lncRNA human papilloma virus (HPV) cervical cancer (CC) human foreskin keratinocytes (HFK)K-derived organotypic raft cultures HPV infectionn upregulated 33436409 344 Human FAS-AS1 lncRNA hydroquinone (HQ) benzene-induced carcinogenesis TK6 cells Hydroquinone (HQ) treatment downregulated 32088430 345 Human FBXL19-AS1 lncRNA sophorae Fructus hepatocellular carcinoma (HCC) Huh7 cells sophorae Fructus treatment "Flavonoids of Sophorae Fructus could inhibite the proliferation, migration and invasion of hepatoma cells by regulating LncRNA FBXL19-AS1/miR-342-3p pathway" 33164374 346 Human FENDRR lncRNA adriamycin (ADR) chronic lymphocytic leukemia (CLL) human chronic myeloid leukemia cell line K562 and KCL22 adriamycin (ADR) treatment downregulated 31180580 347 Human FENDRR lncRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (HRECs) high glucose (HG) treatment upregulated 30700211 348 Human FENDRR lncRNA hypoxia and TGF¦Â1 idiopathic pulmonary fibrosis (IPF) human pulmonary fibroblasts (HPFs) hypoxia and TGF¦Â1 treatment downregulated 31925944 349 Human FENDRR lncRNA gonadotropin-releasing hormone agonist (GnRHa; Buserelin) infertility Infertility patients testicular biopsies treat with GnRHa for 6 months upregulated 28505621 350 Human FER1L4 lncRNA compression force (CF) orthodontic tooth movement human periodontal ligament stem cells (PDLSCs) compressive force treatment "After the application of compressive force, lncRNA FER1L4 was strongly upregulated." 33604341 351 Human FER1L4 lncRNA paclitaxel (PTX) ovarian cancer (OC) SKOV3 cells paclitaxel (PTX) treatment downregulated 30444026 352 Human FEZF1-AS1 lncRNA hypoxia pancreatic cancer (PC) human PC cell lines PANC©\1;SW1990 hypoxic condition induce "In PC cell lines, FEZF1-AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR-142/HIF-1¦Á axis under hypoxic condition." 30693518 353 Human FEZF1-AS1 lncRNA normoxia pancreatic cancer (PC) "human PC cell lines PANC©\1, SW1990" normoxia condition induce upregulated 30693518 354 Human FEZF1-AS1 lncRNA TGF-¦Â2 posterior capsular opacification (PCO) Human Lens Epithelial Cells SRA01/04 ?TGF-¦Â2 treatment upregulated 31281667 355 Human FGD5-AS1 lncRNA cisplatin (DDP) lung adenocarcinoma (LUAD) A549 cells; Hcc827 cells; lung adenocarcinoma (LAD) tissues cisplatin treatment FGD5-AS1 was highly expressed in DDP-resistant LAD tissues and cells. 33416094 356 Human FGD5-AS1 lncRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells; H1299 cells; Non-small cell lung cancer (NSCLC) tissues cisplatin treatment FGD5-AS1 was upregulated in DDP-resistant tumors and cells compared with DDP-sensitive ones. 32534055 357 Human FGD5-AS1 lncRNA lipopolysaccharide (LPS) periodontitis primary human periodontal ligament cells (PDLC lipopolysaccharide (LPS) treatment upregulated of lncRNA FGD5-AS1 could protect against periodontitis via regulating the miR-142-3p/SOCS6/NF-¦ÊB signals. 31144533 358 Human FLJ46906 lncRNA etoposide (VP-16) DNA damage human HepG2 cells etoposide treatment upregulated 31889167 359 Human FLJ46906 lncRNA helicobacter pylori (H. pylori) gastric cancer (GC) AGS cells Helicobacter pylori (H. pylori) infection upregulated 32457731 360 Human FLJ46906 lncRNA mercury II chloride heavy metal stress human HepG2 cells mercury II chloride treatment upregulated 31889167 361 Human FLJ46906 lncRNA H2O2 oxidative stress human HepG2 cells H2O2 treatment upregulated 31889167 362 Human FOXD2-AS1 lncRNA cisplatin (DDP) cisplatin (DDP) resistance TE-1/DDP cisplatin treatment Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis 31558183 363 Human FOXD2-AS1 lncRNA cisplatin (DDP) esophageal squamous cell carcinoma (ESCC) The human ESCC cell line TE-1 cisplatin treatment upregulated 31558183 364 Human FoxD2-AS1 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) The human glioma cell lines U251 and A172 temozolomide (TMZ) treatment "Knockdown of FoxD2-AS1 decreased the proliferation, metastatic ability of glioma cells and promote the sensitivity to TMZ in glioma cells" 31680769 365 Human FOXD2-AS1 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) "human glioma cell lines (U87, U251, LN229, A172)" temozolomide (TMZ) treatment "downregulated FOXD2-AS1 repressed invasion, proliferation, migration and drug resistance of drug-resistant glioma cells while stimulating their apoptosis via increasing miR-98-5p and inhibiting CPEB4 expression." 31770107 366 Human FOXD2-AS1 lncRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HepG2 and HUH7 cells sorafenib treatment downregulated 31210410 367 Human FOXD2-AS1 lncRNA IL-1¦Â and/or TNF-¦Á osteoarthritis (OA) Human cartilage C28/I2 cells IL-1¦Â and/or TNF-¦Á treatment "IL-1¦Â and/or TNF-¦Á treatment could increase FOXD2-AS1 expression in chondrocytes. FOXD2-AS1 overexpression induced cell proliferation, inflammation and extracellular matrix (ECM) degradation in chondrocytes." 30945573 368 Human FOXD2-AS1 lncRNA hypoxia-inducible factor 1¦Á (HIF-1¦Á) osteosarcoma (OS) "Normal osteoblastic cell line (hFOB); osteosarcoma cell lines (MG63, Saos-2, 143B, U2-OS)" HIF-1¦Á overexpression upregulated 31228799 369 Human FOXD3-AS1 lncRNA hypoxia hypoxia-induced cardiac dysfunctions AC16 cells hypoxia treatment Hypoxia exposure caused an upregulation of FOXD3-AS1 in AC16 cells. 32973515 370 Human FOXD3-AS1 lncRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells; H1299 cells cisplatin treatment FOXD3-AS1 was upregulated in cisplatin-resistant NSCLC cells (A549/DDP and H1299/DDP cells) in comparison with their parental cell lines. 32742197 371 Human FR075921 lncRNA progesterone (P4) lung cancer A549 cells progesterone (P4) treatment downregulated 32391956 372 Human FR324124 lncRNA progesterone (P4) lung cancer A549 cells progesterone (P4) treatment downregulated 32391956 373 Human FTH1P3 lncRNA paclitaxel (PTX) breast cancer MCF-7 cells; MDA-MB-231 cells paclitaxel (PTX) treatment lncRNA FTH1P3 was upregulated in paclitaxel-resistant breast cancer tissue and cells (MCF-7/PTX and MDA-MB-231/PTX cells) 29971911 374 Human GABPB1-AS1 lncRNA human papilloma viruses 16 (HPV16) E6 cervical cancer (CC) C33A cells; SiHa cells; CaSki cells human papillomaviruses 16 (HPV16) E6 infection upregulated 32844486 375 Human GABPB1-AS1 lncRNA etoposide (VP-16) DNA damage human HepG2 cells etoposide treatment upregulated 31889167 376 Human GABPB1-AS1 lncRNA erastin ferroptosis HepG2 hepatocellular carcinoma cells erastin treatment upregulated 31700067 377 Human GABPB1-AS1 lncRNA mercury II chloride heavy metal stress human HepG2 cells mercury II chloride treatment upregulated 31889167 378 Human GABPB1-AS1 lncRNA H2O2 oxidative stress human HepG2 cells H2O2 treatment upregulated 31889167 379 Human GABPB1-AS1 lncRNA N-retinylidene-N-retinylethanolamine (A2E) retinitis pigmentosa human retinal pigment epithelium cells N-retinylidene-N-retinylethanolamine (A2E) treatment downregulated 32326576 380 Human GACAT3 lncRNA IL-6 gastric cancer (GC) gastric cancer SGC-7901 cells IL-6 treatment upregulated 27644247 381 Human GAEA lncRNA connective tissue growth factor (CTGF) epithelial-mesenchymal transition (EMT) MDA-MB-231 cells CTGF treatment upregulated 30631154 382 Human GAEA lncRNA high glucose (HG) epithelial-mesenchymal transition (EMT) MDA-MB-231 cells high glucose treatment upregulated 30631154 383 Human GAEA lncRNA IL-6 epithelial-mesenchymal transition (EMT) MDA-MB-231 cells IL-6 treatment upregulated 30631154 384 Human GAEA lncRNA sonic hedgehog(SHH) epithelial-mesenchymal transition (EMT) MDA-MB-231 cells SHH treatment upregulated 30631154 385 Human GAEA lncRNA TGF-¦Â epithelial-mesenchymal transition (EMT) MDA-MB-231 cells TGF-¦Â treatment upregulated 30631154 386 Human GAPLINC lncRNA hypoxia angiogenesis human umbilical vein endothelial cells (HUVEC) hypoxia induce upregulated 31589383 387 Human GAPLINC lncRNA hypoxia-inducible factor 1¦Á (HIF-1¦Á) angiogenesis human umbilical vein endothelial cells (HUVEC) hypoxia-inducible factor 1¦Á (HIF-1¦Á) treatment upregulated 31589383 388 Human GAS5 lncRNA C-terminal Hsp90 inhibitor KU758 adrenocortical carcinoma NCI-H295R and SW13 cells C-terminal Hsp90 inhibitor KU758 treatment upregulated 31561992 389 Human GAS5 lncRNA ovalbumin (OVA) allergic rhinitis (AR) nasal epithelial cells secreted exosomes ovalbumin (OVA) treatment upregulated 31841965 390 Human GAS5 lncRNA amygdalin anti-cancer therapy "human cancer cells (A549, MCF7, AGS)" amygdalin treatment upregulated 30725348 391 Human GAS5 lncRNA 2-o-methylmagnolol (MM1) apoptosis A375 (melanoma) and A431 (squamous cell carcinoma) cells 2-O-methylmagnolol (MM1) treatment upregulated 28252643 392 Human GAS5 lncRNA TGF-¦Â1 asthma human bronchial epithelial cells BEAS-2B TGF-¦Â1 treatment "TGF-¦Â1, GAS5, HDAC4 were upregulated, while miR-217 was downregulated in bronchial mucosal tissues of asthmatic children and TGF-¦Â1-treated BEAS-2B cells" 33864612 393 Human GAS5 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment GAS5 was enriched in atherosclerotic plaques and THP-1 macrophage exposed to oxidized low-density lipoprotein (ox-LDL). 29859752 394 Human GAS5 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment "We found that the abundance of GAS5 was markedly increased, and miR-135a was decreased in AS patient serums and ox-LDL-induced human THP-1 cells dose and time dependently. Interference of GAS5 suppressed inflammation and oxidative stress induced by ox-LDL in THP-1 cells." 33128668 395 Human GAS5 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment GAS5 knockdown suppresses inflammation and oxidative stress induced by oxidized low-density lipoprotein in macrophages by sponging miR-135a 33128668 396 Human GAS5 lncRNA adriamycin (ADR) breast cancer MCF-7 cells adriamycin (ADR) treatment downregulated 32160712 397 Human GAS5 lncRNA bharangin breast cancer MCF 7 cells bharangin treatment upregulated 30251663 398 Human GAS5 lncRNA chemotherapeutic agents£¨rapamycin; temsirolimus and everolimus; BEZ235 and AZD8055; and imatinib £© breast cancer breast cancer cell chemotherapeutic agents treatment downregulated 24789445 399 Human GAS5 lncRNA dendrosomal curcumin (DNC) breast cancer MCF7 cells; MDA-MB231 cells; SKBR3 cells dendrosomal curcumin (DNC) treatment "GAS5 was upregulated in DNC treatment of MCF7, MDA-MB231, and SKBR3 cells." 29655698 400 Human GAS5 lncRNA tamoxifen (TAM) breast cancer MCF-7?cells tamoxifen treatment lncRNA GAS5 was downregulated in MCF-7R cells 29969658 401 Human GAS5 lncRNA high glucose (HG) cell damage human renal tubular epithelial HK-2 high glucose (HG) treatment HG enhances the expression of GAS5 in HK-2 cells; Silence of GAS5 alleviates the HG-caused HK-2 cell toxicity. 31159592 402 Human GAS5 lncRNA cisplatin (DDP) cervical cancer (CC) Human cervical adenocarcinoma cell Hela and human cervical squamous cancer cell line Siha cisplatin treatment upregulated 30352127 403 Human GAS5 lncRNA radiation cervical cancer (CC) SiHa cells radiation treatment GAS5 was low expressed in the radio-resistant SiHa cells 30579899 404 Human GAS5 lncRNA X-rays cervical cancer (CC) CC tissues and cell lines (SiHa and ME180) 6 MV X-ray irradiation downregulated 30579899 405 Human GAS5 lncRNA lipopolysaccharide (LPS) chronic nonbacterial prostatitis (CNP) Human prostate epithelial cell line RWPE-1 lipopolysaccharide (LPS) treatment downregulated 30892130 406 Human GAS5 lncRNA high glucose (HG) diabetes mellitus (DM) human lymphatic endothelial cells (LECs) high glucose (HG) treatment "GAS5 was significantly downregulated whereas miR-217 was obviously upregulated in diabetic skin, HG-induced lymphatic endothelial cells (LECs) and diabetic mouse model." 33865922 407 Human GAS5 lncRNA glucocorticoid (GC) diabetes mellitus (DM) EndoC-¦ÂH1 cells glucocorticoid (GC) treatment Glucocorticoid induces human beta cell dysfunction by involving riborepressor GAS5 LincRNA 32029226 408 Human GAS5 lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) AC16 cardiomyocytes high glucose (HG) treatment GAS5 expression was upregulated in HG-treated AC16 cardiomyocytes and the rat diabetic myocardial injury model 33682891 409 Human GAS5 lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) AC16 cells high glucose (HG) treatment HG increased GAS5 expression in AC16 cells and knockdown of GAS5 protected AC16 cells from HG-induced injury. 31865425 410 Human GAS5 lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) human cardiomyocyte-like AC16 cells high glucose (HG) treatment upregulated 31865425 411 Human GAS5 lncRNA mevastatin (MEV) diabetic foot ulcer (DFU) skin samples were used to generate acute wounds "treat daily with 50 ¦Ìm ZGA, 10 ¦Ìm MEV, or both ZGA and MEV treatment" upregulated 29158265 412 Human GAS5 lncRNA zaragozic acid (ZGA) diabetic foot ulcer (DFU) skin samples were used to generate acute wounds "treat daily with 50 ¦Ìm ZGA, 10 ¦Ìm MEV, or both ZGA and MEV treatment" upregulated 29158265 413 Human GAS5 lncRNA high fat diet (HFD) diabetic nephropathy (DN) kidney tissues high fat diet (HFD) feed LncRNA Gas5 (GAS5) expression was increased in kidneys of the DKD mouse model. 31810140 414 Human GAS5 lncRNA TGF-¦Â1 diabetic nephropathy (DN) HK-2 cells TGF-¦Â1 treatment LncRNA Gas5(GAS5) expression was increased in TGF-¦Â1-induced HK-2 cells 31810140 415 Human GAS5 lncRNA high glucose (HG) diabetic nephropathy (DN) human renal tubular epithelial HK-2 high glucose (HG) treatment HG enhances the expression of GAS5 in HK-2 cells; Silence of GAS5 alleviates the HG-caused HK-2 cell toxicity. 31159592 416 Human GAS5 lncRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose treatment downregulated 31849505 417 Human GAS5 lncRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment downregulated 32467994 418 Human GAS5 lncRNA high glucose (HG) endometrial cancer (EC) "Human endometrial carcinoma cell lines (HEC1-B, HEC1-A and Ishikawa)" high glucose (HG) treatment downregulated 31105847 419 Human GAS5 lncRNA thapsigargin (Tg) endoplasmic reticulum stress (ERS) "human osteosarcoma cells U2OS, 143B, MG63, Saos-2" thapsigargin (Tg) treatment downregulated 30753838 420 Human GAS5 lncRNA tunicamycin (TM) endoplasmic reticulum stress (ERS) "human osteosarcoma cells U2OS, 143B, MG63, Saos-2" tunicamycin (TM)? treatment downregulated 30753838 421 Human GAS5 lncRNA oxidized low density lipoprotein (ox-LDL) endothelial cells injury and autophagy dysfunction human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment GAS5 expression was upregulated and miR-26a was downregulated in the plasma samples of patients with atherosclerosis and ox-LDL-treated HAECs. 30468731 422 Human GAS5 lncRNA oxidized low density lipoprotein (ox-LDL) endothelial dysfunction human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment "GAS5 knockdown inhibited cell apoptosis and activated autophagy flux, whereas inhibition of miR-26a reversed the effect of GAS5 in HAECs." 30468731 423 Human GAS5 lncRNA radiation esophageal squamous cell carcinoma (ESCC) TE-1 cells; esophageal squamous cell carcinoma (ESCC) tissues radiation treatment GAS5 expression is far higher in radiation sensitive ESCC tissues/cells than radiation resistant tissues/cells 31866421 424 Human GAS5 lncRNA X-rays esophageal squamous cell carcinoma (ESCC) ESCC tissues and TE-1 celss 2 Gy X-ray treatment upregulated 31866421 425 Human GAS5 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) SGC-7901 and SGC-7901/ADM cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 27466992 426 Human GAS5 lncRNA combination of rapamycin plus MP gastric cancer (GC) peripheral blood mononuclear cells (PBMCs) combination of rapamycin plus MP treatment downregulated 27001230 427 Human GAS5 lncRNA steroids glucocorticoids effects HeLa cells; LoVo cells steroids treatment GAS5 was upregulated in GC-resistant cells 28722800 428 Human GAS5 lncRNA dexamethasone (DEX) glucocorticoid (GC)-mediated beta cell dysfunction Human pancreatic islets and the human beta cell line EndoC-¦ÂH1 dexamethasone (DEX) treatment Increasing GAS5 levels using GAS5 HREM alleviated the inhibitory effects of dexamethasone on insulin secretion. 32029226 429 Human GAS5 lncRNA corylin hepatocellular carcinoma (HCC) Huh7 and HepG2 cells Corylin treatment upregulated 29382035 430 Human GAS5 lncRNA lipopolysaccharide (LPS) hepatocellular carcinoma (HCC) HepG2 cells lipopolysaccharide (LPS) treatment LPS stimulation promotes GNAS expression in HCC cells through increasing m6A methylation of GNAS mRNA. 32123532 431 Human GAS5 lncRNA platelet derived growth factor-BB (PDGF-BB) hypertension vascular smooth muscle cells (VSMCs) PDGF©\bb treatment "?GAS5 inhibits PDGF-bb-induced VSMC proliferation and migration, partly through acting as a competing endogenous RNA of miR-21" 31069831 432 Human GAS5 lncRNA hypoxic/ischemic hypoxic/ischemic brain damage (HIBD) neonatal brain tissues;hippocampal neurons tissues hypoxic/ischemic treatment GAS5 expression was significantly upregulated in hypoxic/ischemic-injured neonatal brain and hippocampal neurons. 29428721 433 Human GAS5 lncRNA X-rays improved radiosensitivity NSCLC cell lines (A549 and H1975) X-ray irradiation treatment upregulated 28117028 434 Human GAS5 lncRNA ionizing radiation (IR) non-small cell lung cancer (NSCLC) NCI-H460 cells; A549 cells ionizing radiation (IR) treatment IR enhanced the interaction between lncRNA GAS5 and the miR-21/PTEN/Akt axis. 32020207 435 Human GAS5 lncRNA propofol (PPF) oral squamous cell carcinoma (OSCC) UM-SCC6 and SCC090 cells Propofol treatment upregulated 31583913 436 Human GAS5 lncRNA cisplatin (DDP) ovarian cancer (OC) ES2 cells cisplatin treatment downregulated 32901049 437 Human GAS5 lncRNA androgen prostate cancer "LNCaP, 22RV1, DU145, PC3" androgen treatment downregulated 28771526 438 Human GAS5 lncRNA ¦Á-solanine prostate cancer Human normal prostate epithelial cell line RWPE-1 and PCa cell lines DU145 and PC-3 ¦Á-Solanine treatment upregulated 30970507 439 Human GAS5 lncRNA sorafenib (SOR) renal cell carcinoma (RCC) "Human RCC cell lines, OS-RC-2, Caki-2, Caki-1, A498, 786-O, ACHN, 769-P" sorafenib treatment GAS5 was responsible for sorafenib resistance in RCC cells and GAS5 exerted its function through the miR-21/ SOX5 axis 29895198 440 Human GAS5 lncRNA TGF-¦Â1 renal fibrosis HK-2 cells TGF-¦Â1 treatment lncRNA GAS5 was upregulated in TGF-¦Â1-treated HK-2 cells 31810140 441 Human GAS5 lncRNA hypoxia renal ischemia/reperfusion (I/R) injury HK2 cells hypoxia induce upregulated 30129267 442 Human GAS5 lncRNA tanshinone IIA (Tan IIA) rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) tanshinone IIA (Tan IIA) treatment "Long non-coding RNA (lncRNA) GAS5 expression was significantly decreased in the synovial tissues and RAFLS, while Tan IIA treatment resulted in an upregulated of GAS5" 30232236 443 Human GAS5 lncRNA ribavirin ribavirin-induced cardiac developmental toxicity human induced pluripotent stem cells (hiPSCs) ribavirin treatment Exposuring to ribavirin (5 and 10 ¦ÌM) markedly upregulated the expression of lncRNAs Gas5 in both mid-phase and late phase of differentiation and HBL1 in the mid-phase 32112805 444 Human GAS5 lncRNA dexamethasone (DEX) severe asthma (SA) Human bronchial epithelial cells (HBECs) dexamethasone (DEX) treatment downregulated 32642099 445 Human GAS5 lncRNA IL-2 and IL-4 severe asthma (SA) Human bronchial epithelial cells (HBECs) IL-2 and IL-4 treatment upregulated 32642099 446 Human GAS5 lncRNA cisplatin (DDP) triple negative breast cancer (TNBC) The TNBC cell lines MDA©\MB©\231 and BT549 cisplatin treatment "the expression of lncRNA GAS5 was significantly downregulated in TNBC cells treated with paclitaxel (PTX) or cisplatin (CIS). More interestingly, the expression level of lncRNA GAS5 in TNBC patients was associated with tumor resistance to PTX and CIS." 31692053 447 Human GAS5 lncRNA paclitaxel (PTX) triple negative breast cancer (TNBC) The TNBC cell lines MDA©\MB©\231 and BT549 paclitaxel (PTX) treatment "the expression of lncRNA GAS5 was significantly downregulated in TNBC cells treated with paclitaxel (PTX) or cisplatin (CIS) More interestingly, the expression level of lncRNA GAS5 in TNBC patients was associated with tumor resistance to PTX and CIS" 31692053 448 Human GAS5 lncRNA phosphorus (Pi) vascular calcification (VC) human aortic vascular smooth muscle cells (HASMCs) phosphorus treatment downregulated 32347320 449 Human GAS5-AS1 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" non-small cell lung cancer (NSCLC) non-small cell lung cancer (NSCLC) cells "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 27489122 450 Human GAS6-AS1 lncRNA ultraviolet (UV) irradiation DNA damage CD4 cells ultraviolet-C (UVC) treatment upregulated 32258156 451 Human GAS6-AS2 lncRNA heat stress hepatocellular carcinoma (HCC) Huh7 cells; MHCC97 cells heating treatment GAS6-AS2 was upregulated in Huh7-H and MHCC97-H cells relative to Huh7 and MHCC97 cells. 32799553 452 Human GATA6-AS lncRNA hypoxia oxidative stress human umbilical vein endothelial cells (HUVECs) hypoxia induce upregulated 29339785 453 Human GBCDRlnc1 lncRNA doxorubicin (DOX) gallbladder cancer (GBC) The NOZ and GBC-SD human gallbladder cancer cell lines doxorubicin (Dox) treatment upregulated 30953511 454 Human GHET1 lncRNA hypoxia triple negative breast cancer (TNBC) MDA-MB-468 cells; HCC1937 cells hypoxia treatment Highly expressed lncRNA GHET1 in TNBC tissues and cells and induction of lncRNA GHET1 by hypoxia were proved. 33869194 455 Human GIHCG lncRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) LoVo cells 5-fluorouracil (5-FU) treatment upregulated 30799935 456 Human GIHCG lncRNA oxaliplatin colorectal cancer (CRC) LoVo cells Oxaliplatin (Oxa) treatment upregulated 30799935 457 Human GIRGL lncRNA glutamine starvation glutamine metabolism (HEK) 293T cells glutamine starvation treatment "Here, we characterize a long noncoding RNA, GIRGL (glutamine insufficiency regulator of glutaminase lncRNA), that is induced upon glutamine starvation." 33762340 458 Human GKN2-1:1 lncRNA melanin melanoma Primary melanocytes melanin treatment upregulated 26596215 459 Human Gm15834 lncRNA angiotensin II (Ang II) cardiac hypertrophy human AC-16 cell lines angiotensin II (Ang II) treatment upregulated 33130312 460 Human Gm15834 lncRNA angiotensin II (Ang II) cardiac hypertrophy AC16 cells angiotensin II (Ang II) treatment upregulated 33130312 461 Human Gm22 lncRNA enterovirus 71 (EV71) hand-foot-mouth disease (HFMD) human rhabdomyosarcoma (RD) cells Enterovirus 71 (EV71) treatment downregulated 30314355 462 Human Gm26945 lncRNA enterovirus 71 (EV71) hand-foot-mouth disease (HFMD) human rhabdomyosarcoma (RD) cells Enterovirus 71 (EV71) treatment upregulated 30314355 463 Human GNAS-AS1 lncRNA IL-4 macrophage polarization peripheral blood mononuclear cells (PBMCs) IL-4 treatment upregulated 31267263 464 Human GNAT1-1 lncRNA helicobacter pylori (H. pylori) gastric cancer (GC) SGC-7901 and MNK45 cells Helicobacter (H.) pylori infection downregulated 30132541 465 Human GOLGA2P10 lncRNA actinomycin D (actD) endoplasmic reticulum stress (ERS) MHCC-97H cells actinomycin D (actD) treatment Treatment with actinomycin D abrogated tunicamycin-induced GOLGA2P10 expression. 32332695 466 Human GPX3-AS lncRNA H2O2 age-related cataract (ARC) SRA01/04 cells H2O2 treatment "GPX3-AS downregulated the apoptosis of LECs via promoting GPX3 expression, implying a novel therapeutic target for ARCs." 31814699 467 Human GS1-600G8.5 lncRNA ultraviolet (UV) irradiation ultraviolet radiation (UV) effects primary human skin fibroblasts; keratinocytes; fresh human explant whole skin ultraviolet radiation (UVA) treatment upregulated 29496359 468 Human H19 lncRNA curcumin (Cur) breast cancer tamoxifen-resistant breast cancer cells MCF-7/TAMR curcumin treatment "In addition, following treatment with curcumin for 48 h, H19 expression was decreased in a dose-dependent manner." 33179087 469 Human H19 lncRNA hesperetin breast cancer MDA-MB-231 and MCF-7 cells hesperetin treatment "?Hesperetin restored the expression of miR-486-5p, inhibited H19 lncRNA and ICAM-1 expression and selectively regressed mBC cell aggressiveness." 33882812 470 Human H19 lncRNA high glucose (HG) inflammation HUVECs high glucose (HG) treatment positive modulation of miR29b and inhibition of H19 and VEGFA significantly attenuates high glucose-induced endothelial inflammation and oxidative stress. 31737629 471 Human H19 lncRNA dexamethasone (DEX) pulmonary inflammatory response IL-1¦Â-treated A549 cells dexamethasone (Dex) treatment upregulated 33413425 472 Human H19 lncRNA IL-1¦Â pulmonary inflammatory response A549 cells IL-1¦Â treatment downregulated 33413425 473 Human H19 lncRNA hypoxia/reoxygenation (H/R) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 hypoxia/reoxygenation (H/R) treatment upregulated 33716779 474 Human H19 lncRNA all-trans retinoic acid (ATRA) acute promyelocytic leukemia (APL) NB4- LR1 cells all-trans retinoic acid (ATRA) treatment upregulated 29703210 475 Human H19 lncRNA levonorgestrel (LNG) adenomyosis endometrial stromal cells (ESCs) levonorgestrel (LNG) treatment LNG ameliorates adenomyosis via lncRNA H19/miR-17/TLR4 pathway. 32921982 476 Human H19 lncRNA ultraviolet (UV) irradiation age-related cataract (ARC) Human lens epithelial cells (HLECs) ultraviolet irradiation treatment "the interaction among lncRNA H19, miR-29a and TDG is involved in early ARC lncRNA H19 could be a useful marker of early ARC and oxidative damage repair pathway of lncRNA H19/miR-29a/TDG may be a promising target for the treatment of ARC" 31282110 477 Human H19 lncRNA ¦Â-glycerophosphate (¦Â-GP) arterial calcification vascular smooth muscle cells (VSMCs) ¦Â-glycerophosphate treatment upregulated 32355545 478 Human H19 lncRNA astragaloside IV (AS-IV) atherosclerosis (AS) ¦Â-Glycerophosphate-treated human vascular smooth muscle cells (VSMCs) astragaloside (AS-IV) treatment upregulated 30529164 479 Human H19 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aorta vascular smooth muscle cells (HA-VSMCs). oxidized low-density lipoprotein (ox-LDL) treatment The level of H19 was increased and miR-148b expression was decreased in human AS patient serums and oxidized low-density lipoprotein (ox-LDL)-stimulated human aorta vascular smooth muscle cells (HA-VSMCs). 29415742 480 Human H19 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment "the expression of H19 in the serum of patients with AS and in the ox-LDL-treated human umbilical vein endothelial cells (HUVECs) was significantly upregulated. H19 knockdown by transfection with H19 siRNAs in ox-LDL-treated HUVECs remarkably promoted cell viability, suppressed the secretion of interleukin (IL)-1¦Â, IL-6, and tumour necrosis factor (TNF)-¦Á, decreased the expression of vascular cell adhesion molecule 1 (VCAM1), intercellular adhesion molecule 1 (ICAM1) and E-selectin, reduced levels of reactive oxygen species (ROS) and malondialdehyde (MDA), increased superoxide dismutase (SOD) levels, and reduced cell apoptosis." 31054453 481 Human H19 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human THP-1 macrophages oxidized low-density lipoprotein (ox-LDL) treatment dysregulated 31804889 482 Human H19 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic vascular smooth muscle cells (HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment Our results showed that H19 expression was elevated in serum samples of patients with AS and ox-LDL-treated HA-VSMC. 33235026 483 Human H19 lncRNA ¦Â-glycerophosphate (¦Â-GP) atherosclerosis (AS) human vascular smooth muscle cells (VSMCs) ¦Â-Glycerophosphate treatment downregulated 30529164 484 Human H19 lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment upregulated 32714991 485 Human H19 lncRNA bharangin breast cancer MCF 7 cells bharangin treatment downregulated 30251663 486 Human H19 lncRNA doxorubicin (DOX) breast cancer MCF-7 cells doxorubicin treatment Quantitative real-time PCR (qRT-PCR) analyzed H19 expression in chemotherapy-resistant and sensitive breast cancer tissues. 32345117 487 Human H19 lncRNA huaier extract breast cancer "breast cancer cell lines MDA-MB-231, MDA-MB-468 and MCF7" upregulated 29145193 488 Human H19 lncRNA pterostilbene breast cancer MCF 7 cells pterostilbene treatment upregulated 30619763 489 Human H19 lncRNA tamoxifen (TAM) breast cancer MCF-7 cells; SK-BR-3 cells tamoxifen treatment lncRNA H19 in tamoxifen-resistance cells (MCF-7-R and SK-BR-3-R) was much higher than normal breast cancer cells (MCF-7 and SK-BR-3) 30519041 490 Human H19 lncRNA valproic acid (VPA) apoptosis A549 cells VPA treatment downregulated 28328238 491 Human H19 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia injury (CII) SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment H19 was upregulated whereas miR-19a-3p was downregulated in I/R tissues and OGD/R induced cells 32335212 492 Human H19 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 28203482 493 Human H19 lncRNA platelet lysate (PL) chondrogenesis human umbilical cord-derived mesenchymal stem cells (hUCMSCs) Platelet lysate (PL) treatment PL induced chondrogenic differentiation of hUCMSCs by regulating the H19/miR-29b-3p/SOX9 axis 33058414 494 Human H19 lncRNA 5-fluorouracil (5-Fu) chondrosarcoma human CC cell line JEG-3 5-fluorouracil (5-FU) treatment upregulated 31020694 495 Human H19 lncRNA methotrexate (MTX) chondrosarcoma human CC cell line JEG-3 Methotrexate (MTX) treatment upregulated 31020694 496 Human H19 lncRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) SW1116 cells; HCT8Fu cells 5-fluorouracil (5-FU) treatment H19 expression was obviously upregulated both in primary 5-Fu resistant SW1116 cell line and acquired 5-Fu resistant HCT8Fu cell line. 30451820 497 Human H19 lncRNA hypoxia colorectal cancer (CRC) SW620 cells; HCT116 cells hypoxia treatment "During hypoxic stimulation, colorectal cancer cell lines upregulated the levels of both the lncH19 and its intragenic miR-675-5p." 32481626 498 Human H19 lncRNA high glucose (HG) diabetes mellitus (DM) human umbilical vein endothelial cells (HUVECs) high glucose treatment downregulated 31362245 499 Human H19 lncRNA ¦Á-Mangostin diabetes mellitus (DM) human umbilical vein endothelial cells (HUVECs) ¦Á-Mangostin treatment ¦Á-Mangostin restored the high glucose-induced inhibition of H19 31362245 500 Human H19 lncRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" diabetic nephropathy (DN) CIHP©\1 and HEK 293 cells "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" upregulated 30815865 501 Human H19 lncRNA early growth response protein 1 (EGR1) diabetic nephropathy (DN) CIHP©\1 and HEK 293 cells early growth response protein 1 (EGR1) treatment upregulated 30815865 502 Human H19 lncRNA TGF-¦Â2 diabetic nephropathy (DN) human dermal microvascular endothelial cells (HMVECs) TGF-¦Â2 treatment Knockdown of LncRNA-H19 Ameliorates Kidney Fibrosis in Diabetic Mice by Suppressing miR-29a-Mediated EndMT 32346618 503 Human H19 lncRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment H19 played an important role in regulating inflammatory processes in retinal endothelial cells under high-glucose condition through modulating miR-93/XBP1s axis. 31953562 504 Human H19 lncRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment LncRNA H19 inhibits high glucose-induced inflammatory responses of human retinal epithelial cells by targeting miR-19b to increase SIRT1 expression. 33022863 505 Human H19 lncRNA high glucose (HG) diabetic retinopathy (DR) retinal pigment epithelial cells (ARPE-19) high glucose (HG) treatment "Our results showed that lncRNA H19 and SIRT1 were reduced, while miR-19b was increased in ARPE-19 cells with HG condition." 33022863 506 Human H19 lncRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells high glucose conditions (25 mmol/l) treatment downregulated 30612136 507 Human H19 lncRNA human MSC Growth Medium cell differentiation human adipose-derived stem cells (ASCs) human MSC Growth Medium containing 10% MSCs-Qualified Fetal Bovine Serum (FBS) upregulated 28662497 508 Human H19 lncRNA synthetic preimplantation factor (sPIF) duchenne muscular dystrophy (DMD) myoblast Synthetic preimplantation factor (sPIF) treatment upregulated 30692507 509 Human H19 lncRNA TGF-¦Â epithelial-mesenchymal transition (EMT) SKOV-3 cells; OVCAR3 cells TGF-¦Â treatment TGF-¦Â treatment upregulated H19 and downregulated miR-370-3p 29403287 510 Human H19 lncRNA epstein-barr virus (EBV) Epstein-Barr virus (EBV) infection human peripheral blood monocular cells infecting with Epstein-Barr Virus upregulated 27956246 511 Human H19 lncRNA cigarette smoke extract (CSE) esophageal squamous cell carcinoma (ESCC) SHEE cells cigarette smoke?extract?(CSE) treatment upregulated 32739445 512 Human H19 lncRNA helicobacter pylori (H. pylori) gastric cancer (GC) GC tissues and cells Helicobacter pylori (H. pylori) infection upregulated 31787851 513 Human H19 lncRNA metformin (Met) gastric cancer (GC) AGS and SGC7901 cell lines metformin treatment downregulated 30192003 514 Human H19 lncRNA metformin (Met) gastric cancer (GC) SGC7901 cells metformin treatment downregulated 30192003 515 Human H19 lncRNA benzo(a)pyrene (BaP) gene-methylation alterations by carcinogen BaP 16HBE cells; BEAS-2B cells; VA13 cells benzo(a)pyrene (BaP) exposure BaP-treated cells H19 expressions were increased in a dose- and time-dependent manner. 29772428 516 Human H19 lncRNA TGF-¦Â glaucoma filtration surgery (GFS) primary human Tenon's capsule fibroblasts (HTFs) TGF-¦Â treatment TGF-¦Â promoted the expression of H19 in HTFs and that suppression of H19 inhibited the effect of TGF-¦Â on HTFs 31877306 517 Human H19 lncRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" glioblastoma multiforme (GBM) SH©\SY5Y and SNB©\19 cells "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" downregulated 31468534 518 Human H19 lncRNA curcumin (Cur) glioblastoma multiforme (GBM) SH©\SY5Y and SNB©\19 cells curcumin (CUR) treatment downregulated 31468534 519 Human H19 lncRNA hypoxia glioblastoma multiforme (GBM) "human glioma cell lines U87, U251, Ln229, U373 and U118" hypoxia treatment upregulated 28327666 520 Human H19 lncRNA TGF-¦Â1 glioblastoma multiforme (GBM) glioblastoma cells TGF-¦Â1 treatment ?We identified and characterized 2 lncRNAs (H19 and HOXD-AS2) that were upregulated by TGF-¦Â1 through Smad signaling 32813021 521 Human H19 lncRNA "1,25-dihydroxyvitamin D 3 (calcitriol)" glioblastoma multiforme (GBM) SH-SY5Y cells; SNB-19 cells "1,25-dihydroxyvitamin D 3 (calcitriol) treatment" "1,25(OH) 2 D3 downregulated the expression of H19." 31468534 522 Human H19 lncRNA curcumin (Cur) glioblastoma multiforme (GBM) SH-SY5Y cells; SNB-19 cells curcumin (CUR) treatment CUR downregulated the expression of H19. 31468534 523 Human H19 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U-251 cells; M059 cells Temozolomide (TMZ) treatment H19 was significantly increased in U-251TMZ and M059JTMZ cells 29391808 524 Human H19 lncRNA human papilloma virus (HPV) head and neck squamous cell carcinoma (HNSCC) primary tumors resected from HNSCC patients human papillomavirus (HPV) infection downregulated 32998396 525 Human H19 lncRNA hepatitis B virus (HBV) hepatoblastoma HepG2 cells hepatitis B virus (HBV) infection upregulated 30367502 526 Human H19 lncRNA apigenin hepatocellular carcinoma (HCC) HepG2 cells; SMMC-7721 cells apigenin treatment H19 was downregulated by API. 33345859 527 Human H19 lncRNA hypoxia hepatocellular carcinoma (HCC) hepatoma carcinoma cells (Hep G2 and HCCLM3 cells) hypoxia induce upregulated 31196153 528 Human H19 lncRNA sorafenib (SOR) hepatocellular carcinoma (HCC) Huh7; Hep3B; SNU©\449; SNU©\387 sorafenib treatment Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675 32627034 529 Human H19 lncRNA sorafenib or doxorubicin hepatocellular carcinoma (HCC) "human hepatoma cell lines (HepG2, Plc/Prf5, and Huh7)" sorafenib or doxorubicin treatment upregulated 31225433 530 Human H19 lncRNA hypoxia hypoxia-induced injury human hepatic sinusoidal endothelial cells (HHSEC) hypoxia induce upregulated 31082428 531 Human H19 lncRNA TGF-¦Â idiopathic pulmonary fibrosis (IPF) MRC-5 cells TGF-¦Â treatment the level of lncRNA H19 was significantly increased in activated fibroblasts compared with untreated cells 29411215 532 Human H19 lncRNA H2O2 intervertebral disc degeneration (IDD) nucleus pulposus cells (NPCs) H2O2 treatment "In response to H2O2 treatment, H19 expression was dramatically increased." 29520849 533 Human H19 lncRNA cisplatin (DDP) laryngeal squamous cell carcinoma (LSCC) TU-177 cells; AMC-HN-8 cells cisplatin treatment H19/miR-107/HMGB1 axis sensitizes laryngeal squamous cell carcinoma to cisplatin by suppressing autophagy in vitro and in vivo. 33314408 534 Human H19 lncRNA carbon tetrachloride (CCl4) liver fibrosis hepatic stellate cells carbon tetrachloride (CCl4) treatment upregulated 32445757 535 Human H19 lncRNA hepatitis B virus X protein (HBx) liver damage L02 cells hepatitis B X protein (HBx) treatment "the expression of lncRNA H19 and miR-675 was upregulated in patients with chronic hepatitis B. Inhibition of lncRNA H19 or miR-675 in L02 cells increased cell viability, suppressed hepatitis B X protein (HBx)-induced cell apoptosis, inflammatory cytokine production, and oxidative stress, and remodelled energy metabolism." 31574452 536 Human H19 lncRNA first-generation EGFR tyrosine kinase inhibitors (TKIs) lung cancer HCC827 cells; PC9 cells First-generation EGFR tyrosine kinase inhibitors (TKIs) treatment downregulated 32439420 537 Human H19 lncRNA lipopolysaccharide (LPS) lung injury MRC-5 cells lipopolysaccharide (LPS) treatment upregulated 29315794 538 Human H19 lncRNA cisplatin (DDP) melanoma A375/DDP; M8/DDP cells cisplatin treatment lncRNA H19 could influence DDP-resistance by modulating the miR-18b/IGF axis in melanoma cells. 32265386 539 Human H19 lncRNA bortezomib multiple myeloma (MM) "Human MM cell lines H929, U266" bortezomib? treatment "H19 reduced cell sensitivity to the chemotherapeutic drug BTZ by working as a miRNA sponge to inhibit the expression of miR-29b-3p, enhance MCL-1 transcriptional translation and inhibit apoptosis." 30728351 540 Human H19 lncRNA hypoxia multiple myeloma (MM) MM cell lines (RPMI and MM1.S) hypoxia induce upregulated 30781795 541 Human H19 lncRNA hypoxia myocardial infarction (MI) peripheral blood hypoxia treatment Downregulated H19 and upregulated CYP1B1 were observed in MI patients. 33389498 542 Human H19 lncRNA angelica polysaccharide (AP) neuroblastoma (NB) SH-SY5Y cells angelica polysaccharide (AP) treatment downregulated 29465760 543 Human H19 lncRNA gefitinib non-small cell lung cancer (NSCLC) HCC827 cells; HCC4006 cells gefitinib treatment H19 was increased in gefitinib-resistant cells when compared to sensitive parent cells. 30542738 544 Human H19 lncRNA ghrelin obesity-induced myocardial injury human cardiac myocytes ghrelin treatment Ghrelin protects against PA-induced injury in cardiomyocytes via upregulating the expression of lncRNA H19. 32084395 545 Human H19 lncRNA IL-1¦Â osteoarthritis (OA) chondrocytes IL-1¦Â treatment upregulated 31894109 546 Human H19 lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) C28/I2 cells lipopolysaccharide (LPS) treatment A notably dose-dependent elevation of H19 levels was observed in LPS-treated C28/I2 cells. 30900425 547 Human H19 lncRNA mechanical stimulation osteochondral activity primary umbilical cord mesenchymal stem cells (U-MSCs) mechanical stimulation Exosomes derived from umbilical cord mesenchymal stem cells in mechanical environment show improved osteochondral activity via upregulation of LncRNA H19 33437630 548 Human H19 lncRNA "mechanical tension (10%, 0.5Hz)" osteogenesis human BMMSCs (hBMMSCs) "mechanical tension (10%, 0.5Hz)" upregulated 29253550 549 Human H19 lncRNA tension osteogenic capability Bone marrow mesenchymal stem cells (BMMSCs) tension treatment mechanical tension could enhance osteogenic differentiation and increase H19 expression 29253550 550 Human H19 lncRNA valproic acid (VPA) ovarian cancer (OC) A2780 cells valproic acid (VPA) treatment downregulated 29468525 551 Human H19 lncRNA high glucose (HG) oxidative stress HUVECs high glucose (HG) treatment positive modulation of miR29b and inhibition of H19 and VEGFA significantly attenuates high glucose-induced endothelial inflammation and oxidative stress. 31737629 552 Human H19 lncRNA sulforaphane (SFN) pancreatic ductal adenocarcinoma (PDAC) "human PDAC cell lines BxPc-3, AsPC-1, PANC-1, and MIA-PaCa2" sulforaphane treatment "Sulforaphane regulated the expression of all of five examined lncRNAs, but basal expression, biological function and inhibition of H19 were of highest significance" 33669381 553 Human H19 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y Cells 1-methyl-4-phenylpyridinium (MPP+) treatment H19 was downregulated in MPP+ treated SH-SY5Y cells. 32356199 554 Human H19 lncRNA perfluorooctane sulfonic acid (PFOS) perfluorooctane sulfonic acid (PFOS)-induced placenta cell toxicity HTR-8/SVneo cells Perfluorooctane sulfonic acid (PFOS) treatment upregulated 32738709 555 Human H19 lncRNA estrogen (ES) postmenopausal osteoporosis (PMOP) human bone marrow mesenchymal stem cells (BMSCs) estrogen treatment upregulated 33577975 556 Human H19 lncRNA metformin (Met) preeclampsia (PE) Trophoblast and HUVEC cells Metformin (Met) treatment downregulated 31203154 557 Human H19 lncRNA H2O2 premature senescence C-kit(+) cardiac progenitor cells (CPCs) H2 O2 treatment downregulated 27062045 558 Human H19 lncRNA ginsenoside Rh2 cell proliferation MC3T3-E1 cells treat with Rh2 upregulated 28886306 559 Human H19 lncRNA dihydrotestosterone (DHT) prostate cancer LNCaP cells dihydrotestosterone (DHT) treatment downregulated 32356434 560 Human H19 lncRNA enzalutamide (Enz) prostate cancer LNCaP cells enzalutamide treatment upregulated 32356434 561 Human H19 lncRNA estradiol-17¦Â (E2) prostate cancer prostate epithelial luminal cancer (PCa) cell lines (C27IM and C38IM) estradiol-17¦Â (E2) treatment upregulated 31426484 562 Human H19 lncRNA estradiol-17¦Â (E2) prostate cancer prostate epithelial luminal cancer (PCa) cell lines (C27IM and C38IM) estradiol-17¦Â (E2) treatment downregulated 31426484 563 Human H19 lncRNA hypoxia prostate cancer prostate epithelial luminal cancer (PCa) cell lines (C27IM and C38IM) hypoxia induce upregulated 31426484 564 Human H19 lncRNA arsenite lung fibrosis THP-1 cells arsenic (As) exposure downregulated of H19 or upregulated of let-7a reversed the arsenite-induced M2 polarization of macrophages. 33162208 565 Human H19 lncRNA arsenite lung fibrosis THP-1 cells arsenite exposure upregulated 33162208 566 Human H19 lncRNA phorbol-12-myristate-13-acetate(PMA) rheumatoid arthritis (RA) peripheral blood mononuclear cells (PBMCs) PMA treatment The level of lncRNA H19 was higher in RA patients than in healthy volunteers 33540246 567 Human H19 lncRNA tumor necrosis factor alpha (TNF-¦Á) rheumatoid arthritis (RA) MH7A cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 32525617 568 Human H19 lncRNA lipopolysaccharide (LPS) spinal cord injury (SCI) human astrocyte (NHA) lipopolysaccharide (LPS) treatment lncRNA H19 expression was increased by LPS in NHAs. 32371379 569 Human H19 lncRNA melatonin subarachnoid hemorrhage (SAH) U87 cells; U251 cells melatonin (MT) treatment Melatonin increased H19 expression level by enhancing H19 transcriptional efficiency in a concentration-dependent manner. 29367587 570 Human H19 lncRNA estradiol thyroid cancer (TC) TPC-1cells; K-1 cells estradiol (E2) treatment upregulated 30389909 571 Human H19 lncRNA metformin (Met) type 2 diabetes mellitus (T2DM) ARK2 and MCF-7 cells metformin treatment downregulated 27775072 572 Human H19 lncRNA deoxyelephantopin (DOE) uterine leiomyoma (UL) UL cells deoxyelephantopin (DOE) treatment downregulated 33152917 573 Human H19 lncRNA vincristine (VCR) vincristine (VCR) resistance RPMI 8226/VCR vincristine (VCR) treatment "The lnc-RNA H19/Akt pathway is closely related to the occurrence of VCR resistance in MM cells, and the downregulated of H19 can significantly improve the sensitivity of VCR in MM." 33040789 574 Human H19 lncRNA ginsenoside 20(S)-Rg3 warburg effect SKOV3 cells; A2780 cells ginsenoside 20(S)-Rg3 treatment H19 was found to be decreased by 50% in 20(S)-Rg3-treated cells compared to control cells. 30481782 575 Human H19 lncRNA TGF-¦Â1 lung fibrosis HBE and A549 cells TGF-¦Â1 treatment H19 knockdown attenuated pulmonary fibrosis via the regulatory network of lncRNA H19-miR-140-TGF-¦Â/Smad3 signaling 30988156 576 Human H19 lncRNA cigarette smoke extract (CSE) smoke-induced lung injury (SILI) A549 cells; H460 cells cigarette smoke extract (CSE) treatment upregulated 33523607 577 Human H19 lncRNA Rb3 smoke-induced lung injury (SILI) A549 cells; H460 cells Rb3 treatment downregulated 33523607 578 Human H19X lncRNA TGF-¦Â fibrosis primary dermal fibroblasts TGF-¦Â treatment upregulated 32603313 579 Human HABON lncRNA hypoxia hepatocellular carcinoma (HCC) human hepatocarcinoma cell SMMC-7721; Huh-7;MHCC-97 h;MHCC-97 L;Hep-G2; Hep-3B hypoxia? treatment "Among them, a hypoxia-activated lncRNA that we identified and termed Hypoxia-Activated BNIP3 Overlapping Non-coding RNA (HABON), was not only regulated by hypoxic-induced factor-1¦Á (HIF-1¦Á) but its expression increased significantly under hypoxia in tumour cells." 33478328 580 Human HAGLR lncRNA lipopolysaccharide (LPS) neuropathic pain (NP) SH-SY5Y cells lipopolysaccharide (LPS) treatment HAGLR displayed high levels in spinal cords of CCI rats and in LPS treated SH-SY5Y cells. 33626373 581 Human HAGLROS lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cell 1-methyl-4-phenylpyridinium (MPP+) treatment upregulated 31298038 582 Human HAGLROS lncRNA lipopolysaccharide (LPS) pneumonia WI-38?cells lipopolysaccharide (LPS) treatment LPS caused WI-38?cell injury and increased HAGLROS levels. 29673591 583 Human HAND2-AS1 lncRNA low glucose (LG) osteosarcoma (OS) MG-63 cells; SAOS- 2 cells; U-2OS cells; HOS cells; SW1353 cells 1mM glucose treatment lncRNA HAND2-AS1 was significantly upregulated in glucose starved-cells 29637006 584 Human HAS2-AS1 lncRNA resveratrol hyaluronan (HA) accumulation human aortic smooth muscle cells (AoSMCs) resveratrol (RS) treatment downregulated 31932306 585 Human HAS2-AS1 lncRNA SIRT1 activators (SRT1720) hyaluronan (HA) accumulation human aortic smooth muscle cells (AoSMCs) SIRT1 activators (SRT1720) treatment downregulated 31932306 586 Human HAS2-AS1 lncRNA hypoxia oral squamous cell carcinoma (OSCC) "human OSCC cell lines, SCC-9 and CAL-27" treat with hypoxia upregulated 28485478 587 Human HBBP1 lncRNA hydroquinone (HQ) leukemia TK6 cells HQ dysregulated 29221148 588 Human HCCL5 lncRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) "Human HCC cell lines HepG2, SMMC-7721 and HCCLM3" TGF-¦Â1 treatment upregulated 30482773 589 Human HCG11 lncRNA "oxidized low-density lipoprotein (ox-LDL), IL-6 and TNF-¦Á)" atherosclerosis (AS) human vascular smooth muscle cells (VSMCs) "oxidation Low Lipoprotein (Ox-LDL), interleukin-6 (IL-6) and tumor necrosis factor ¦Á (TNF ¦Á) radiation" LncRNA HCG11 regulates proliferation and apoptosis of vascular smooth muscle cell through targeting miR-144-3p/FOXF1 axis. 33008472 590 Human HCG11 lncRNA high glucose (HG) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment LncRNA HCG11/miR-26b-5p/QKI5 feedback loop reversed high glucose-induced proliferation and angiogenesis inhibition of HUVECs. 33128346 591 Human HCG18 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment upregulated 29947995 592 Human HCP5 lncRNA cisplatin (DDP) breast cancer MDA-MB-231 cells cisplatin treatment upregulated 31028999 593 Human HCP5 lncRNA geniposide (GEN) diffuse large B-cell lymphoma (DLBCL) OCI-LY7; OCI-LY3 cells geniposide treatment Geniposide inhibits proliferation and induces apoptosis of diffuse large B-cell lymphoma cells by inactivating the HCP5/miR-27b-3p/MET axis 33162801 594 Human HCP5 lncRNA 5-fluorouracil (5-FU) gastric cancer (GC) AGS cell; MKN45 cells 5-fluorouracil (5-FU) treatment upregulated 32300102 595 Human HCP5 lncRNA oxaliplatin gastric cancer (GC) AGS cell; MKN45 cells oxaliplatin (OXA) treatment upregulated 32300102 596 Human HCP5 lncRNA TGF-¦Â lung adenocarcinoma (LUAD) A549 cell TGF¦Â treatment upregulated 31131047 597 Human HCP5 lncRNA gemcitabine (GEM) pancreatic cancer (PC) PANC-1 and SW 1990 cells gemcitabine (GEM) treatment upregulated 31632071 598 Human HEAL lncRNA human immunodeficiency virus (HIV)-1 acquired immune deficiency syndrome (AIDS) "MT4, H9, E4 Jurkat, MDMs were prepared by culture of PBMCs cells" ?Human immunodeficiency virus (HIV)-1 infection treatment upregulated 31551335 599 Human HEIH lncRNA hepatitis C virus (HCV) chronic hepatitis C virus (HCV) infection serum; exosomes hepatitis C virus (HCV) infection "In patients with HCV-related HCC, lncRNA-HEIH expression in serum and exosomes was increased, but the ratio of lncRNA-HEIH expression in serum versus exosomes was decreased compared to patients with CHC." 29286922 600 Human HEIH lncRNA paclitaxel (PTX) endometrial cancer (EC) "Human endometrial cancer cell lines (Ishikawa, HHUA) and hESC (Human endometrial stromal cells)" paclitaxel (PTX) treatment "LncRNA HEIH, the dysregulation of which involved in production of drug-resistance, was overexpressed in PTX-resistant endometrial cancer cells" 31650338 601 Human HEIH lncRNA paclitaxel (PTX) endometrial cancer (EC) Ishikawa cells; HHUA cells paclitaxel (PTX) treatment Down-regulating lncRNA HEIH expression reversed the PTX-resistance of endometrial cancer cells through MAPK signaling pathway 31650338 602 Human HEIH lncRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HCCLM3 cells; Huh7 cells sorafenib treatment HEIH was upregulated in sorafenib-resistant HCC tissues and cell lines 32821157 603 Human HEIPP lncRNA hypoxia preeclampsia (PE) HTR-8 / Svneo cellsHTR-8/SVneo human trophoblast cells hypoxia treatment upregulated 33424915 604 Human HIF1A-AS1 lncRNA TGF-¦Â1 activation of hepatic stellate cells (HSCs) HSCs LX-2 TGF-¦Â1 treatment downregulated 25550811 605 Human HIF1A-AS1 lncRNA clopidogrel cardiovascular disease (CVD) HUVECs clopidogrel treatment clopidogrel rescues apoptosis and promotes proliferation of PA-induced damage model of HUVECs through inhibiting the mediator LncRNA HIF1A-AS1 25761653 606 Human HIF1A-AS1 lncRNA arecoline oral submucous fibrosis (OSF) fibrotic buccal mucosal fibroblasts (fBMFs) arecoline treatment Administration of arecoline induced the elevation of HIF1A-AS1 in BMFs. 31959495 607 Human HIF1A-AS2 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human coronary artery endothelial cells (HCAECs) oxidized low-density lipoprotein (ox-LDL) treatment Inhibition of long noncoding RNA HIF1A-AS2 confers protection against atherosclerosis via ATF2 downregulated. 33133688 608 Human HIF1A-AS2 lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment upregulated 32714991 609 Human HIF1A-AS2 lncRNA cisplatin (DDP) bladder cancer T24 cells; 5937 cells; SW780 cells cisplatin treatment "hypoxia inducible factor 1¦Á-antisense RNA 2 (HIF1A-AS2), as a subtype-specific hypoxia inducible lncRNA, is upregulated in bladder cancer cells." 30216500 610 Human HIF1A-AS2 lncRNA cisplatin (DDP) bladder cancer "Bladder cancer cell lines, T24, 5637, and SW780" cisplatin (DPP) treatment upregulated 30216500 611 Human HIF1A-AS2 lncRNA hypoxia ischemic stroke (IS) HUVECs hypoxia treatment upregulated 28985553 612 Human HIF1A-AS2 lncRNA hypoxia myocardial infarction (MI) human cardiomyocytes (HMCs) hypoxia treatment HIF1A-AS2 is upregulated in hypoxia-treated human cardiomyocytes (HMCs) compared with normal cardiomyocytes. 32222118 613 Human HIFCAR lncRNA hypoxia oral cancer Hela cells; HEK293T cells hypoxia conditions (1% oxygen) upregulated 28639619 614 Human HIPK1-AS lncRNA Sipi soup (SPS) cervical cancer (CC) HeLa Sipi soup (SPS) treatment "HIPK1-AS expression levels were upregulated in response to HeLa CM, but were decreased under SPS treatment" 29901171 615 Human HITT lncRNA hypoxia colorectal cancer (CRC) HCT116 cells hypoxia treatment "The enrichment of HITT was significantly decreased, while that of the 5¡ä-UTR was increased in response to the hypoxic switch." 31700144 616 Human HITT lncRNA Hypoxia hypoxia-induced injury HCT116 cells;HeLa cells hypoxia induce downregulated 31784651 617 Human HITT lncRNA hypoxia hypoxia-induced injury HCT116 cells; Hela cells hypoxia treatment downregulated 31784651 618 Human HMGCR lncRNA epigallocatechin-3-gallate (EGCG) cholesterol metabolism "human hepatoblastoma cell line, HepG2" epigallocatechin-3-gallate (EGCG) treatment downregulated 25563320 619 Human HMGN1-1:12 lncRNA nigericin pancreatic cancer (PC) PANC-2 cells nigericin treatment upregulated 32850392 620 Human HOATIR lncRNA oestrogen (E2) osteoporosis HFOB and MG63 cells oestrogen (E2) treatment a dose-dependent upregulated of HOTAIR was observed in cells treated with oestrogen 33733597 621 Human HORAS5 lncRNA cabazitaxel prostate cancer LNCaP cells; DU145 cells cabazitaxel treatment HORAS5 stimulates the expression of BCL2A1 thereby decreasing apoptosis and enhancing cabazitaxel resistance in CRPC cells. 32618200 622 Human HOST2 lncRNA sinomenine hydrochloride (SH) ovarian cancer (OC) "Human ovarian epithelial cell line (HOEpiC), Caov3 and SKOV3 cells" sinomenine hydrochloride (SH) treatment downregulated 31701766 623 Human HOST2 lncRNA gemcitabine (GEM) pancreatic cancer (PC) Hs766T cells; AsPC-1 cells gemcitabine (GEM) treatment upregulated 30406400 624 Human HOST2 lncRNA gemcitabine (GEM) pancreatic neoplasms Hs766T; AsPC-1 cells gemcitabine treatment down- expression of HOST2 observably enhanced sensibility of pancreatic cancer cell lines to gemcitabine. 30406400 625 Human HOTAIR lncRNA metformin (Met) breast cancer MDA-MB-231 breast cancer cells ?metformin treatment "Reduction in the expression of vimentin, ¦Â-catenin, and HOTAIR was detected as the result of metformin treatment" 33164274 626 Human HOTAIR lncRNA tanshinone IIA (Tan IIA) acetaminophen (APAP)-induced liver injury (AILI) L02 cells Tanshinone IIA (Tan IIA) treatment Tan IIA induced the expression of Nrf2-MRP2/4 pathway by downregulating HOTAIR 32777703 627 Human HOTAIR lncRNA all-trans retinoic acid (ATRA) acute myeloid leukemia (AML) HL-60 cells all-trans retinoic acid (ATRA) treatment upregulated 33241756 628 Human HOTAIR lncRNA ethanol (EtOH) alcohol-induced tumor angiogenesis HUVECs endothelial extracellular vesicles (EVs) ethanol treatment upregulated in endothelial extracellular vesicles (EVs) 29062004 629 Human HOTAIR lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment HOTAIR was significantly increased in THP-1 cells treated with ox-LDL. 29698635 630 Human HOTAIR lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human macrophages THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment HOTAIR was significantly increased in THP-1 cells treated with ox-LDL. 30187491 631 Human HOTAIR lncRNA sunitinib (SU) autophagy 786-O-R cells; ACHN-R cells sunitinib treatment HOTAIR expression in sunitinib-resistant cells is higher than that in parental cells 32760216 632 Human HOTAIR lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment upregulated 32714991 633 Human HOTAIR lncRNA aurora kinase inhibitor (CCT137690) breast cancer MDA-MB-231 cells aurora kinase inhibitor (CCT137690) treatment downregulated 31319040 634 Human HOTAIR lncRNA bisphenol-A (BPA) and diethylstilbestrol (DES) breast cancer human breast cancer cells (MCF7) BPA and DES treatment upregulation 24533973 635 Human HOTAIR lncRNA delphinidin breast cancer "Breast cancer cells MDA©\MB©\231, MCF©\7, and MDA©\MB©\453 w" delphinidin treatment downregulated 31325197 636 Human HOTAIR lncRNA estradiol breast cancer breast cancer cells estradiol treatment HOTAIR is crucial for cell growth and viability and its knockdown induced apoptosis in breast cancer cells 23375982 637 Human HOTAIR lncRNA hypoxia breast cancer MDA-MB-231 cells hypoxia treatment HOTAIR levels was upregulated after 48 h hypoxia relative to normoxia in breast cancer cell lines. 32466537 638 Human HOTAIR lncRNA ionizing radiation (IR) breast cancer breast cancer cells and tissues ionizing radiation treatment upregulated 30429228 639 Human HOTAIR lncRNA pterostilbene breast cancer MCF 7 cells pterostilbene treatment downregulated 30619763 640 Human HOTAIR lncRNA hypoxia tumorigenesis "colon adenocarcinoma,cervical cancer,breast cancer,neuroblastoma" hypoxia treatment downregulated 28756022 641 Human HOTAIR lncRNA polyphyllin I (PPI) castration-resistant prostate cancer (CRPC) castration-resistant prostate cancer (CRPC) cells Polyphyllin I (PPI) treatment downregulated 29221985 642 Human HOTAIR lncRNA polyphyllin I (PPI) castration-resistant prostate cancer (CRPC) DU145 cells; PC3 cells polyphyllin I (PPI) treatment PPI also decreased HOTAIR expression 29807357 643 Human HOTAIR lncRNA LiCl cervical cancer (CC) radioresistant HeLa cells LiCl treatment "the short interfering ribonucleic acid (siRNA)-mediated knockdown of HOTAIR disturbed the Wnt signaling pathway, reduced autophagy, inhibited EMT, decreased cell proliferation, and induced apoptosis in radioresistant HeLa cells." 30367473 644 Human HOTAIR lncRNA direct-acting antivirals (DAAs) chronic hepatitis C virus (HCV) infection polymorphonuclear leucocytes (PMNLs) direct-acting antivirals (DAAs) treatment upregulated 33074585 645 Human HOTAIR lncRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) human bronchial epithelial (HBE) cells cigarette smoke extract (CSE) treatment upregulated 31128153 646 Human HOTAIR lncRNA propofol (PPF) colorectal cancer (CRC) LOVO cells; SW480 cells propofol treatment Effects of propofol on colon cancer metastasis through STAT3/HOTAIR axis by activating WIF-1 and suppressing Wnt pathway 31953926 647 Human HOTAIR lncRNA ionizing radiation (IR) colorectal cancer (CRC) SW480 cells; HCT116 cells ionizing radiation (IR) treatment HOTAIR expression was markedly upregulated in plasma from CRC patients after radiotherapy and CRC cells after irradiation. 32144238 648 Human HOTAIR lncRNA lipopolysaccharide (LPS) cytokines expression "C3A, HepG2, and SMMC-7721" lipopolysaccharide (LPS) treatment HOTAIR exerted a crucial role in cytokines expression by activating JAK/STAT and NF-¦ÊB. 31621909 649 Human HOTAIR lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) AC16 cells high glucose (HG) treatment downregulated 30542437 650 Human HOTAIR lncRNA cisplatin (DDP) endometrial cancer (EC) arental Ishikawa cells cisplatin treatment downregulated 28721581 651 Human HOTAIR lncRNA TGF-¦Â1 endometrial fibrosis endometrial stromal cells (ESCs) TGF-¦Â1 treatment HOTAIR was significantly elevated in ESCs that had been treated with TGF-¦Â1 33313721 652 Human HOTAIR lncRNA metformin (Met) epithelial-mesenchymal transition (EMT) MDA-MB-231 cells metformin (Met) treatment downregulated 33164274 653 Human HOTAIR lncRNA 5-fluorouracil (5-Fu) esophageal cancer (EC) TE-1 cells 5-fluorouracil (5-FU) treatment LncRNA HOTAIR-mediated MTHFR methylation inhibits 5-fluorouracil sensitivity in esophageal cancer cells. 32653028 654 Human HOTAIR lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U-87 cells; A172 cells temozolomide (TMZ) treatment upregulated 32279420 655 Human HOTAIR lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) A172 ; LN229 temozolomide (TMZ) treatment Exosomal lncRNA HOTAIR mediated TMZ resistance through miR-519a-3p/RRM1 axis in GB 32721218 656 Human HOTAIR lncRNA polyphyllin I (PPI) growth of CRPC cells castration-resistant prostate cancer cells Polyphyllin I (PPI) treatment downregulated 29221985 657 Human HOTAIR lncRNA tumor necrosis factor alpha (TNF-¦Á) hepatic insulin resistance HepG2 cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 30536334 658 Human HOTAIR lncRNA hypoxia hepatocellular carcinoma (HCC) HepG2; Huh7 hypoxia treatment knockdown of HOTAIR suppressed glycolysis by regulating miR-130a-3p and HIF1A in HCC cells treated by hypoxia 32062551 659 Human HOTAIR lncRNA orafenib hepatocellular carcinoma (HCC) Huh7; Hep3B; SNU-387; SNU-449 orafenib treatment Lnc HOTAIR could increase sorafenib resistance in HCC by inhibiting miR-217. 32462038 660 Human HOTAIR lncRNA taxol hepatocellular carcinoma (HCC) HepG2/Taxol; SMMC7721/Taxol Taxol treatment LncRNA HOTAIR contributes Taxol-resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down-regulating miR-34a 32700738 661 Human HOTAIR lncRNA gonadotropin-releasing hormone agonist (GnRHa; Buserelin) infertility Infertility patients testicular biopsies treat with GnRHa for 6 months upregulated 28505621 662 Human HOTAIR lncRNA cigarette smoke extract (CSE) inflammation human bronchial epithelial (HBE) cells cigarette smoke extract (CSE) treatment upregulated 25447409 663 Human HOTAIR lncRNA lipopolysaccharide (LPS) inflammation "L02, C3A, HepG2, and SMMC-7721 cells." lipopolysaccharide (LPS) treatment "LPS induced the overexpression of HOTAIR in L02, C3A, HepG2, and SMMC-7721 cells." 31621909 664 Human HOTAIR lncRNA lipopolysaccharide (LPS) kidney damage HK-2 cells lipopolysaccharide (LPS) treatment HOTAIR was also upregulated in LPS-induced human renal tubular epithelial cells (HK-2). 30130540 665 Human HOTAIR lncRNA X-rays laryngeal cancer "Laryngeal cancer cell lines TU212, LLN and TU686" X-ray radiation treatment HOTAIR overexpression reduced laryngeal cancer cell radiosensitivity 31849488 666 Human HOTAIR lncRNA TGF-¦Â1 multidrug resistance (MDR) The HepG2 cells transforming growth factor-¦Â1 (TGF-¦Â1) treatment upregulated 30698830 667 Human HOTAIR lncRNA doxorubicin (DOX) multidrug resistance (MDR) K562/A02 cells doxorubicin treatment Overexpression of LncRNA-HOTAIR promotes chemoresistance in acute leukemia cells. 33425105 668 Human HOTAIR lncRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) NCI-H1299 cells criplatin treatment upregulated 29805510 669 Human HOTAIR lncRNA crizotinib non-small cell lung cancer (NSCLC) A549?cells crizotinib treatment upregulated 29470986 670 Human HOTAIR lncRNA type I collagen (Col-1) non-small cell lung cancer (NSCLC) NSCLC cells type I collagen (Col-1) treatment upregulated 23668363 671 Human HOTAIR lncRNA xiaoji decoction (XJD) non-small cell lung cancer (NSCLC) A549 and H1650 cells Xiaoji decoction (XJD) treatment downregulated 30910577 672 Human HOTAIR lncRNA tumor necrosis factor alpha (TNF-¦Á) apoptosis nucleus pulposus cell (NPC) tumor necrosis factor alpha (TNF-¦Á) treatment 31 HOTAIR is downregulated in NPCs induced by TNF-¦Á 30138895 673 Human HOTAIR lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) human articular chondrocyte C28/I2 cells lipopolysaccharide (LPS) treatment upregulated 31966787 674 Human HOTAIR lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) CHON-001 chondrocytes lipopolysaccharide (LPS) treatment "HOTAIR and SGTB were upregulated, while miR-1277-5p was downregulated in OA cartilages and LPS-stimulated CHON-001 chondrocytes." 33721916 675 Human HOTAIR lncRNA lipopolysaccharide (LPS) osteosarcoma (OS) The cell lines MG63 and Saos-2 lipopolysaccharides (LPS) treatment upregulated 30240881 676 Human HOTAIR lncRNA lipopolysaccharide (LPS) osteosarcoma (OS) MG63 and Saos-2 cells lipopolysaccharides (LPS) treatment upregulated 30240881 677 Human HOTAIR lncRNA cisplatin (DDP) ovarian cancer (OC) SKOV3 cells; A2780 cells cisplatin treatment HOTAIR was upregulated in DDP-resistant cells. 32349783 678 Human HOTAIR lncRNA gemcitabine (GEM) pancreatic cancer (PC) pancreatic cancer stem-like cells (CSCs) gemcitabine treatment upregulated 29201179 679 Human HOTAIR lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells N-methyl-4-phenylpyridinium (MPP +) treatment upregulated 28445933 680 Human HOTAIR lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SK-N-SH cells 1-methyl-4-phenylpyridinium (MPP+) treatment HOTAIR promoted MPP+-induced neuronal injury via modulating the miR-874-5p/ATG10 axis in SK-N-SH cells. 33013268 681 Human HOTAIR lncRNA TGF-¦Â2 posterior capsular opacification (PCO) SRA01/04 cells transforming growth factor ¦Â2 (TGF-¦Â2) treatment TGF-¦Â2 induces EMT in SRA01/04 cells via the upregulated of the long non-coding RNA (lncRNA) HOTAIR 30239553 682 Human HOTAIR lncRNA androgen prostate cancer prostate cancer cell low androgen treatment upregulated 26411689 683 Human HOTAIR lncRNA bufalin prostate cancer prostate cancer DU145 and PC3 cells bufalin treatment downregulated 31028291 684 Human HOTAIR lncRNA radiation radiation resistance of breast cancer (BRCA) MCF©\7; T47D; LM©\MCF©\7; BT©\474;SKBR©\3; MDA©\MB©\231 radiation treatment LncRNA HOTAIR facilitates the expression of HSPA1A by sequestering miR-449b-5p post-transcriptionally and thereby endows BRCA with radiation resistance 32374522 685 Human HOTAIR lncRNA TGF-¦Â1 renal fibrosis HK2 cells TGF-¦Â1 treatment upregulated 29717517 686 Human HOTAIR lncRNA arsenite toxicity of arsenic A549 cells arsenic (As) exposure upregulated 32816178 687 Human HOTAIR lncRNA deoxyelephantopin (DOE) uterine leiomyoma (UL) UL cells deoxyelephantopin (DOE) treatment downregulated 33152917 688 Human HOTAIR lncRNA ultraviolet (UV) irradiation UVB-induced apoptosis and inflammatory HaCaT cells UVB treatment UVB also promoted the expression of HOTAIR 29898032 689 Human HOTTIP lncRNA platelet derived growth factor-BB (PDGF-BB) atherosclerosis (AS) human umbilical vein endothelial cells (HUVEC) platelet derived growth factor-BB (PDGF-BB) treatment The expression level of HOTTIP was upregulated in the proliferating endothelial cells induced by TNF-¦Á or PDGF-BB 29058802 690 Human HOTTIP lncRNA tumor necrosis factor alpha (TNF-¦Á) atherosclerosis (AS) human umbilical vein endothelial cells (HUVEC) tumor necrosis factor alpha (TNF-¦Á) treatment The expression level of HOTTIP was upregulated in the proliferating endothelial cells induced by TNF-¦Á or PDGF-BB 29058802 691 Human HOTTIP lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment upregulated 32714991 692 Human HOTTIP lncRNA "TNF-¦Á,PDGF-BB" coronary artery disease (CAD) HU-VECs TNF-¦Á or PDGF-BB treatment upregulated 29058802 693 Human HOTTIP lncRNA hypoxia epithelial-mesenchymal transition (EMT) U87 and U251 cell lines hypoxia treatment upregulated 28886531 694 Human HOTTIP lncRNA salinomycin gastric cancer (GC) SGC7901/cisplatin (CDDP) gastric cancer cell salinomycin treatment downregulated 30882398 695 Human HOTTIP lncRNA hypoxia non-small cell lung cancer (NSCLC) two NSCLC cell lines (A549 and H1299) hypoxia induce upregulated 31422060 696 Human HOTTIP lncRNA IL-1¦Â osteoarthritis (OA) cultured chondrocytes interleukin-1¦Â (IL-1¦Â) treatment upregulated 31508417 697 Human HOTTIP lncRNA IL-1¦Â osteoarthritis (OA) OA cartilage tissues IL-1¦Â treatment "The expression of HOTTIP and FRK were upregulated, while miR-663a was downregulated in OA cartilage tissues." 33435956 698 Human HOTTIP lncRNA cisplatin (DDP) ovarian cancer (OC) ES2 cells cisplatin treatment upregulated 32901049 699 Human HOTTIP lncRNA cisplatin (DDP) pancreatic cancer (PC) PANC-1 cells; HS766T cells; AsPC-1 cells cisplatin treatment upregulated 32280243 700 Human HOX lncRNA TGF-¦Â1 liver fibrosis hepatic stellate cells (HSCs) TGF-¦Â1 treatment upregulated 27979710 701 Human HOXA11-AS lncRNA aurora kinase inhibitor (CCT137690) breast cancer MCF-7 cells; MDA-MB-231 cells aurora kinase inhibitor (CCT137690) treatment downregulated 31319040 702 Human HOXA11-AS lncRNA calcium oxalate (CaOx) calcium oxalate (CaOx) nephrolithiasis HK-2 cell calcium oxalate (CaOx) treatment HOXA11-AS mediated CaOx crystal-induced renal inflammation via the miR-124-3p/MCP-1 axis. 31878844 703 Human HOXA11-AS lncRNA calcium oxalate monohydrate (COM) calcium oxalate (CaOx) nephrolithiasis calcium oxalate monohydrate (COM)-treated HK-2 cells calcium oxalate monohydrate (COM)-treatment HOXA11-AS was significantly upregulated in calcium oxalate monohydrate (COM)-treated HK-2 cells. 31680444 704 Human HOXA11-AS lncRNA propofol (PPF) colorectal cancer (CRC) Colo205; SW620 cells "Propofol (2,6-diisopropylphenol) treatment" Propofol suppresses colorectal cancer tumorigenesis by modulating the HOXA11-AS-let-7i-ABCC10 regulatory network 31013434 705 Human HOXA11-AS lncRNA propofol (PPF) hepatocellular carcinoma (HCC) Huh7 cells; Hep3B cells propofol treatment Propofol suppressed the expression of HOXA11-AS in HCC cells 32705160 706 Human HOXA11-AS lncRNA cisplatin (DDP) lung adenocarcinoma (LUAD) A549 cells; H157 cells cisplatin treatment The expression of HOXA11-AS was much stronger in cisplatin-resistant LUAD cells. 30099826 707 Human HOXA11-AS lncRNA cisplatin (DDP) lung cancer A549 cell line cisplatin treatment upregulated 31144606 708 Human HOXA11-AS lncRNA cisplatin (DDP) nasopharyngeal carcinoma (NPC) C666-1 cells; HNE1 cells cisplatin treatment elevated HOXA11-AS and reduced miR-454-3p were found in NPC tissue and cisplatin-resistant NPC cells. 33115978 709 Human HOXA11-AS lncRNA cisplatin (DDP) oral squamous cell carcinoma (OSCC) "The normal human oral keratinocyte (NHOK) and OSCC cell lines, including TSCCA, CAL-27, SCC-9, and Tca8113" cisplatin treatment upregulated 31275988 710 Human HOXA6-AS lncRNA radiation head and neck squamous cell carcinoma (HNSCC) HNSCC cell lines radiation treatment downregulated 30441874 711 Human HOXA-AS2 lncRNA prednisone acute lymphoblastic leukemia (ALL) Jurkat cells; CEM/C1 cells prednisone treatment lncRNA HOXA-AS2 was highly expressed both in prednisone insensitive ALL cell lines. 30551418 712 Human HOXA-AS2 lncRNA adriamycin (ADR) acute myeloid leukemia (AML) U937 cells; THP-1 cells adriamycin (ADR) treatment upregulated 30466095 713 Human HOXA-AS2 lncRNA adriamycin (ADR) breast cancer T47D cells adriamycin (ADR) treatment upregulated 32163894 714 Human HOXA-AS2 lncRNA oxidized low density lipoprotein (ox-LDL) human aortic vascular smooth muscle cells (HA-VSMCs) injury human aortic vascular smooth muscle cells (HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31957850 715 Human HOXA-AS3 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human vascular endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 32982172 716 Human HOXD10-35 lncRNA X-rays hypopharyngeal cancer RS-FaDu cells 4 Gy radiation upregulated 28487500 717 Human HOXD-AS2 lncRNA TGF-¦Â1 glioblastoma multiforme (GBM) glioblastoma cells TGF-¦Â1 treatment ?We identified and characterized 2 lncRNAs (H19 and HOXD-AS2) that were upregulated by TGF-¦Â1 through Smad signaling 32813021 718 Human HSRL lncRNA tanshinone IIA (Tan IIA) hypertrophic scars (HS) human skin fibroblast (HSF) tanshinone IIA (TSIIA) treatment TSIIA treatment for 24h inhibited HSRL and SNX9 gene transcription in comparison with TGF-¦Â1 group 33049375 719 Human HTR2A-AS1 lncRNA patrinia herba aqueous extract hepatocellular carcinoma (HCC) MHCC97-H cells P. herba aqueous extract treatment "P herba aqueous extract may inhibit the proliferation, invasion and migration of hepatocellular carcinoma cells by up-regulating the expression of HTR2A-AS1 in hepatocellular carcinoma cells and induce apoptosis" 32538757 720 Human HULC lncRNA aurora kinase inhibitor (CCT137690) breast cancer MDA-MB-231 cells aurora kinase inhibitor (CCT137690) treatment downregulated 31319040 721 Human HULC lncRNA prostaglandin E1 (PGE1) contrast-induced nephropathy (CIN) THP-1 cells; peripheral blood samples PGE1 treatment HULC was positively correlated with the expression of PTGS1 and PGE1 32678165 722 Human HULC lncRNA ¦Â-Elemene diffuse large B-cell lymphoma (DLBCL) SU-DHL-8; SU-DHL-10 ¦Â-Elemene treatment ¦Â-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway 32010942 723 Human HULC lncRNA "oxaliplatin, 5-fluorouracil and pirarubicin (THP)" hepatocellular carcinoma (HCC) "human HCC cell lines including HepG2, Hep3B, PLC, Huh7, smmc7721 and hepatic cell line L02 w" THP treatment upregulated 28166203 724 Human HULC lncRNA ultraviolet (UV) irradiation hepatocellular carcinoma (HCC) HaCaT cells Ultraviolet radiation b (UVB) treatment upregulated 29803927 725 Human HULC lncRNA ionizing radiation (IR) prostate cancer PC3 cells; LNCaP cells ionizing radiation (IR) treatment upregulated 29694502 726 Human HULC lncRNA lipopolysaccharide (LPS) sepsis human dermal microvascular endothelial cells (HMECs) lipopolysaccharide (LPS) treatment upregulated 31231228 727 Human HULC lncRNA lipopolysaccharide (LPS) sepsis human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment "LPS impaired cell viability, and promoted cell apoptosis, inflammatory response and oxidative stress in HUVECs by regulating HULC/miR-204-5p/TRPM7 axis." 32484206 728 Human HUR1 lncRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HepG2 cells hepatitis B virus (HBV) infection upregulated 29790592 729 Human HZ02 lncRNA "benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide (BPDE)" miscarriage trophoblast Swan 71 and HTR-8/SVneo cells "BPDE (benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide) treatment" "If trophoblast cells are exposed to BPDE, both miR-hz02 and lnc-HZ02 are upregulated" 33851497 730 Human HZ08 lncRNA "benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide (BPDE)" recurrent miscarriage (RM) Swan 71 and HTR-8/SVneo cell lines "benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide (BPDE) treatment" upregulated 33864160 731 Human IGF2AS lncRNA aurora kinase inhibitor (CCT137690) breast cancer MCF-7 cells aurora kinase inhibitor (CCT137690) treatment upregulated 31319040 732 Human IGF2AS lncRNA high glucose (HG) type 1 diabetes mellitus (T1DM) CD4+ MOLT4 Tregs high glucose (HG) treatment upregulated 33572095 733 Human IGF2-AS lncRNA high glucose (HG) apoptosis "human retinal pigment epithelial cell line, ARPE-19" high glucose (HG) treatment "High-glucose induced apoptosis in ARPE-19 cells, and upregulated IGF-2AS in a dose-dependent manner. SiRNA-mediated IGF2-AS downregulated ameliorated apoptosis, upregulated IGF2/AKT and decreased Casp-9, in high-glucose-treated ARPE-19 cells." 31317640 734 Human IGF2-AS lncRNA high glucose (HG) diabetic retinopathy (DR) "human retinal pigment epithelial cell line, ARPE-19" high glucose (HG) treatment "High-glucose induced apoptosis in ARPE-19 cells, and upregulated IGF-2AS in a dose-dependent manner. SiRNA-mediated IGF2-AS downregulated ameliorated apoptosis, upregulated IGF2/AKT and decreased Casp-9, in high-glucose-treated ARPE-19 cells." 31317640 735 Human IHAT lncRNA hypoxia breast cancer MDA-MB-231 cells hypoxia treatment LncIHAT Is Induced by Hypoxia-Inducible Factor 1 and Promotes Breast Cancer Progression 33380467 736 Human IL7AS lncRNA IL-1¦Â inflammation human lung fibroblasts IL-1¦Â treatment upregulated 30619270 737 Human lnc-IL7R lncRNA lipopolysaccharide (LPS) inflammation human monocytic cell line lipopolysaccharide (LPS) treatment upregulated 24723426 738 Human INXS lncRNA three apoptosis apoptosis 786-O kidney tumor cell line three apoptosis treatment upregulation 24992962 739 Human IPAN lncRNA influenza A virus (IAV) influenza A virus (IAV) infection A549 cells influenza A virus (IAV) infection upregulated 31189112 740 Human IRAK3-3 lncRNA enterovirus 71 (EV71) apoptosis Human rhabdomyosarcoma cells (RD) EV71 infection downregulated 31099182 741 Human IRF1-AS lncRNA IFNs oesophageal squamous cell carcinoma (ESCC) The ESCC cell lines Interferons (IFNs) treatment upregulated 31173852 742 Human ISG20 lncRNA influenza A virus (IAV) antiviral immune response A549 and HEK293T cells influenza A virus (IAV) infection upregulated 29899085 743 Human ISR lncRNA influenza A virus (IAV) influenza A virus (IAV) infection A549 cells influenza A virus (IAV) infection upregulated 31623059 744 Human IUR lncRNA imatinib leukemia Abl-transformed primary bone marrow cells imatinib treatment Increased expression of lncRNA-IUR was detected in both human and mouse Abl-transformed cells upon imatinib treatment. 30961617 745 Human JHDMD1 lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment upregulated 32714991 746 Human KAT14 lncRNA "DAPT (N-[(3,5-Difluorophenyl)-acetyl]-L-al- anyl-2-phenyl]-glycine-1,1-dimethylethylester)" tongue squamous cell carcinoma (TSCC) CAL-27 cell; SCC-9 cells "DAPT (N-[(3,5-Difluorophenyl)-acetyl]-L-al- anyl-2-phenyl]-glycine-1,1-dimethylethylester) treatment" "Proliferation was inhibited after treatment with DAPT, and the expression of lncRNA-KAT14 was upregulated." 31957832 747 Human KB-1980E6.3 lncRNA hypoxia breast cancer BT549 cells hypoxia induce "We identified a hypoxia-induced long noncoding RNA (lncRNA) KB-1980E6.3, which is aberrantly upregulated in clinical breast cancer tissues and closely correlated with poor prognosis of breast cancer patients." 33469161 748 Human KCNK15-AS1 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) "BGC-823 cells, SCG7901 cells" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 31572012 749 Human KCNK15-AS1 lncRNA chidamide gastric cancer (GC) "BGC-823 cells, SCG7901 cells" chidamide treatment upregulated 31572012 750 Human KCNQ1OT1 lncRNA acetaminophen (APAP) acetaminophen (APAP)-induced liver injury (AILI) HepaRG cells acetaminophen (APAP) treatment downregulated 32779042 751 Human KCNQ1OT1 lncRNA TGF-¦Â2 age-related cataract (ARC) SRA01/04 cells TGF-¦Â2 traetment treatment "miR-29c-3p regulated FOS to repress EMT, cell proliferation and facilitate apoptosis in TGF-¦Â2-treated SRA01/04 cells mediated by KCNQ1OT1" 32534225 752 Human KCNQ1OT1 lncRNA phenytoin antiepileptic drug (AED) resistance human brain microvascular endothelial cells (HBMECs) phenytoin treatment upregulated 31920517 753 Human KCNQ1OT1 lncRNA H2O2 cataract SRA01/04 cell lines H2O2 treatment upregulated 28535504 754 Human KCNQ1OT1 lncRNA H2O2 cataract lens epithelial cells (SRA01/04) H2O2 treatment We found that KCNQ1OT1 was upregulated in cataract anterior lens capsule samples and H2O2-induced SRA01/04 cells. 33744257 755 Human KCNQ1OT1 lncRNA TGF-¦Â2 cataract SRA01/04 cells TGF-¦Â2 treatment KCNQ1OT1 was upregulated in transforming growth factor (TGF)-¦Â2-treated SRA01/04 cells 29749509 756 Human KCNQ1OT1 lncRNA cisplatin (DDP) colorectal cancer (CRC) HCT8 cells cisplatin treatment "Compared with CRC cell line HCT8, the cisplatin-resistant CRC cell line HCT8/DDP exhibited a higher expression level of KCNQ1OT1." 32757174 757 Human KCNQ1OT1 lncRNA methotrexate (MTX) colorectal cancer (CRC) The human CRC cell line HT29 and Caco2 cells methotrexate (MTX) treatment KCNQ1OT1 enhanced the MTX resistance of CRC cells by regulating miR-760-mediated PPP1R1B expression via the cAMP signalling pathway 30997746 758 Human KCNQ1OT1 lncRNA oxaliplatin colorectal cancer (CRC) HCT116 ; SW480 cells oxaliplatin (L-OHP) treatment upregulated 31040703 759 Human KCNQ1OT1 lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) cardiac tissues high glucose (HG) treatment Kcnq1ot1 expression was dramatically elevated in cardiac tissue of the diabetic mice. 30250027 760 Human KCNQ1OT1 lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) AC16 cells high glucose (HG) treatment upregulated 30355944 761 Human KCNQ1OT1 lncRNA high glucose (HG) diabetic cataract (DC) SRA01/04 cells high glucose treatment upregulated 32950535 762 Human KCNQ1OT1 lncRNA high glucose (HG) diabetic corneal endothelial keratopathy HCEC-B4G12 cells high glucose (HG) treatment upregulated 31693400 763 Human KCNQ1OT1 lncRNA high glucose (HG) diabetic nephropathy (DN) Human glomerular mesangial cells (HGMCs) cells; human renal glomerular endothelial cells (HRGECs) high glucose (HG) treatment KCNQ1OT1 was upregulated in DN patients and high glucose-induced HGMCs and HRGECs. 32905431 764 Human KCNQ1OT1 lncRNA high glucose (HG) diabetic nephropathy (DN) human mesangial cells (HMCs) high glucose (HG) treatment KCNQ1OT1 expression was increased and miR-18b expression was decreased in DN patients and HG-challenged HMCs. 32989627 765 Human KCNQ1OT1 lncRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells high glucose treatment upregulated 30784065 766 Human KCNQ1OT1 lncRNA sevoflurane (SEV) glioblastoma multiforme (GBM) A172 cells; U251 cells sevoflurane (Sev) treatment "KCNQ1OT1 knockdown mediated the role of Sev in glioma cell proliferation, apoptosis, migration, and invasion both in vitro and in vivo through miR-146b-5p/STC1 pathway" 32996777 767 Human KCNQ1OT1 lncRNA cisplatin (DDP) hepatocellular carcinoma (HCC) SK-HEP-1 cells cisplatin treatment LncRNA KCNQ1OT1 targets miR-338-3p to regulate the survival rate and autophagy of SK-HEP-1/DDP cells and improve the cisplatin sensitivity of SK-HEP-1/DDP cells. 32538770 768 Human KCNQ1OT1 lncRNA sorafenib (SOR) hepatocellular carcinoma (HCC) SK-HEP-1 cells; Huh-7 cells; HCC tissues sorafenib treatment KCNQ1OT1 was found to be upregulated in sorafenib-resistant HCC tissues and cells 33000204 769 Human KCNQ1OT1 lncRNA ¦Â-glycerophosphate + ascorbic acid + dexamethasone osteogenesis human Bone marrow mesenchymal stem cells (BMSCs) "10 mM ¦Â-glycerophosphate (Sigma-Aldrich, USA), 200 ¦ÌM ascorbic acid (Sigma-Aldrich, USA) and 100 nM dexamethasone (Sigma-Aldrich, USA) treatment" KCNQ1OT1 was significantly upregulated during the process of osteogenic induction while miR-214 was contrarily downregulated 30703347 770 Human KCNQ1OT1 lncRNA high glucose (HG) oxidative stress HK-2 cells high glucose (HG) treatment "downregulated of KCNQ1OT1 inhibited the inflammation, oxidative stress and pyroptosis of HG-induced HK-2 cells by up-regulating the expression of miR-506-3p." 32104033 771 Human KRAL lncRNA 5-fluorouracil (5-Fu) hepatocellular carcinoma (HCC) HepG2 cells; SMMC-7721 cells 5-fluorouracil (5-FU) treatment KRAL was significantly decreased in HepG2/5-FU and SMMC-7721/5-FU cells. 30119680 772 Human LASI lncRNA lipopolysaccharide (LPS) allergic asthma (AA) human airway epithelial cells (HAECs) lipopolysaccharides (LPS) treatment upregulated 33122732 773 Human LCPAT1 lncRNA cigarette smoke extract (CSE) DNA damage Beas-2B cells cigarette smoke extract (CSE) treatment upregulated 30509493 774 Human LCPAT1 lncRNA cigarette smoke extract (CSE) lung cancer Beas-2B cells cigarette smoke extract (CSE) treatment "With increased concentration of exposure to CSE, there was higher expression of LCPAT1." 30509493 775 Human LCPAT1 lncRNA cigarette smoke extract (CSE) and particulate matter (PM2.5) lung cancer H1299 cells; H520 cells cigarette smoke extract (CSE) and PM2.5 exposure LCPAT1 was upregulated after the treatment of CSE and PM2.5. 29913439 776 Human LET lncRNA gemcitabine (GEM) urinary bladder cancers (UBCs) "human UBC cell lines, T24, 5637, J82, SW780, BIU87, ScaBER and UMUC3" treat with gemcitabine downregulated 28839463 777 Human LGALS9 lncRNA hydroquinone (HQ) leukemia TK6 cells HQ dysregulated 29221148 778 Human LIFR-AS1 lncRNA photodynamic therapy (PDT) colorectal cancer (CRC) HCT116 cells PDT treatment upregulated 29807108 779 Human LILRP2 lncRNA hydroquinone (HQ) leukemia TK6 cells HQ dysregulated 29221148 780 Human LIN28B-AS1 lncRNA lipopolysaccharide (LPS) inflammatory response ?THP-1 macrophages lipopolysaccharide (LPS) treatment upregulated 31537384 781 Human LINC00114 lncRNA X-rays nasopharyngeal carcinoma (NPC) 5-8F; SUNE-1 cells X-ray treatment LINC00114 contributed to NPC development and radioresistance through the regulation of ERK/JNK signaling pathway and the mediation of miR-203 32196600 782 Human LINC00115 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 783 Human LINC00115 lncRNA TGF-¦Â tumorigenicity glioma stem-like cell (GSC) TGF-¦Â treatment upregulated 31599491 784 Human LINC00115-201 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment upregulated 29947995 785 Human LINC00152 lncRNA oxidized low density lipoprotein (ox-LDL) cardiovascular disease (CVD) human umbilical vein VECs (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 29156700 786 Human LINC00152 lncRNA cigarette smoke extract (CSE) lung cancer human bronchial epithelial cells 16HBE cigarette smoke extract (CSE) exposure upregulated 30289508 787 Human LINC00160 lncRNA paclitaxel (PTX) breast cancer breast cancer (BC) tissues paclitaxel (PTX) treatment downregulated 32652877 788 Human LINC00162 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) ?gastric cancer cell lines "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" "LINC00162, as highly and frequently expressed in gastric cancer cell lines sensitive to 5-aza-2'-deoxycytidine (5-aza-dC)." 30914798 789 Human LINC00173 lncRNA gemcitabine (GEM) ancreatic cancer (PC) SW1990 cells gemcitabine (GEM) treatment upregulated 30113217 790 Human LINC00173 lncRNA cisplatin (DDP) small-cell lung cancer (SCLC) NCI-H69 cells cisplatin treatment Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression 31477834 791 Human LINC00174 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U251 cells; U87 cells temozolomide (TMZ) treatment LINC00174 downregulated decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis 31713817 792 Human LINC00261 lncRNA lipopolysaccharide (LPS) sepsis-induced acute kidney injury HK-2 cells lipopolysaccharide (LPS) treatment downregulated 33481135 793 Human LINC00273 lncRNA TGF-¦Â lung cancer A549 Transforming growth factor ¦Â (TGF¦Â) treatment LINC00273 promoted TGF¦Â-induced lung cancer EMT through miR-200a-3p/ZEB1 feedback loop 32017082 794 Human LINC00294 lncRNA bakkenolide-IIIa (Bak-IIIa) inflammation human umbilical vein endothelial cells (HUVECs) bakkenolide-IIIa (Bak-IIIa) treatment Bak-IIIa ameliorated LPS-induced inflammatory damage in HUVECs by upregulating LINC00294. 33760129 795 Human LINC00294 lncRNA lipopolysaccharide (LPS) inflammation human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment downregulated 33760129 796 Human LINC00299 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human aortic vascular smooth muscle cells (T/G HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment LINC00299 regulated ox-LDL-induced T/G HA-VSMCs injury through the miR-135a-5p/XBP1 axis. 32700888 797 Human LINC00305 lncRNA hypoxia VECs apoptosis human umbilical vein endothelial cells (HUVECs) hypoxia (1% O2) treatment upregulated 28763747 798 Human LINC00324 lncRNA 6-thioguanine (6-TG) breast cancer MCF-7 cells 6-thioguanine (6-TG) treatment upregulated 33376537 799 Human LINC00338-008 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 800 Human LINC00339 lncRNA calcium oxalate monohydrate (COM) kidney stone disease human renal proximal tubular epithelial (HK-2) cells ?calcium oxalate monohydrate (COM)?treatment treatment lncRNA LINC00339 promotes cell pyroptosis by sponging miR-22-3p to regulate NLRP3 expression in COM-treated HK-2 cells 30614043 801 Human LINC00339 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment upregulated 29947995 802 Human LINC00341 lncRNA particulate matter (PM2.5) cell cycle arrest 16HBE cell treated with PM2.5 treatment upregulated 28366736 803 Human LINC00346 lncRNA cisplatin (DDP) nasopharyngeal carcinoma (NPC) HNE1cells; CNE2 cells cisplatin treatment LINC00346 regulates the cisplatin resistance of NPC cells by inhibiting miR-342-5p. 32397872 804 Human LINC00460 lncRNA oxaliplatin advanced colorectal cancer (CRC) SW480 cells oxaliplatin (OXA) treatment LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer 33251049 805 Human LINC00460 lncRNA nicotine lung cancer The NSCLC cell lines A549 and H1299 nicotine treatment upregulated 31123168 806 Human LINC00461 lncRNA IL-6 and TNF-¦Á osteoarthritis (OA) chondrocytes IL-6 and TNF-¦Á treatment LINC00461 may modulate the development of OA by suppressing miR-30a-5p expression in chondrocytes. 32155130 807 Human LINC00461 lncRNA cisplatin (DDP) rectal cancer SW837 cells; HR8348 cells cisplatin treatment "LINC00461 mediates cisplatin resistance of rectal cancer by targeting miR-593-5p/CCND1 axis, shedding new light on the treatment of rectal cancer." 31972361 808 Human LINC00467 lncRNA signal transducers and activators of transcription 1 (STAT1) lung adenocarcinoma (LUAD) "Four acknowledged human LUAD cell lines (H1299, Calu, SPCA1, and A549)" STAT1 overexpression LINC00467 was activated by STAT1 in LUAD. 31027730 809 Human LINC00472 lncRNA lipopolysaccharide (LPS) sepsis-induced acute lung injury THLE-3 cells Lipopolysaccharide (LPS) treatment downregulated of long noncoding RNA LINC00472 alleviates sepsis-induced acute hepatic injury by regulating miR-373-3p/TRIM8 axis. 33129786 810 Human LINC00473 lncRNA H2O2 abdominal aortic aneurysm (AAA) human vascular smooth muscle cells (VSMCs) H2O2 treatment LINC00473 inhibits vascular smooth muscle cell viability to promote aneurysm formation via miR-212-5p/BASP1 axis. 31954705 811 Human LINC00473 lncRNA taxol colorectal cancer (CRC) HCT116 cells taxol treatment upregulated 30126852 812 Human LINC00473 lncRNA X-rays radiosensitivity "KYSE-30, KYSE-180, KYSE-150 and TE-5" X-ray radiation treatment LINC00473 reduces the radiosensitivity of ESCC cells by modulating the miR-497-5p/CDC25A axis 32468021 813 Human LINC00475 lncRNA hypoxia glioblastoma multiforme (GBM) LN229 cells hypoxia treatment LINC00475 was upregulated in hypoxic glioma samples. 32849915 814 Human LINC00511 lncRNA epigallocatechin-3-gallate (EGCG) anti-cancer therapy AGS and SGC7901 GC cells Epigallocatechin gallate (EGCG) treatment Epigallocatechin gallate reverses gastric cancer by regulating the long noncoding RNA LINC00511/miR-29b/KDM2A axis 32512188 815 Human LINC00511 lncRNA paclitaxel (PTX) breast cancer "The breast cancer cell lines (MDA-MB-231, MCF-7, Hs-578T, and T47D) and the immortalized breast epithelial cell line MCF-10A" paclitaxel treatment LINC00511 knockdown enhanced paclitaxel cytotoxicity in breast cancer cells by upregulating miR-29c 31047896 816 Human LINC00511 lncRNA paclitaxel (PTX) cervical cancer (CC) PTX-resistant Hela/PTX cells paclitaxel (PTX) treatment "silencing of LINC00511 could suppress cell resistance to PTX, cell viability, cell proliferation, migration and invasion yet promoted cell apoptosis in PTX-resistant Hela/PTX cells" 31180057 817 Human LINC00511 lncRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) SPCA1 cells; H1975 cells TGF-¦Â1 treatment upregulated 32092827 818 Human LINC00518 lncRNA adriamycin (ADR) breast cancer MCF-7 cells adriamycin (ADR) treatment linc00518 level was almost 2.5 fold higher and MRP1 level was about 2 fold increased in ADR-resistant MCF-7 cells. 30001527 819 Human LINC00574 lncRNA toxic acetaminophen (APAP) drug metabolizing enzymes (DMEs) expression HepaRG cells toxic acetaminophen (APAP) treatment The expression of lncRNA LINC00574 was decreased in APAP-treated HepaRG cells 32273307 820 Human LINC00595 lncRNA Vitamins A and D bacterial infection human monocytes during A.fumigatus infections Vitamins A and D treatment dysregulated 28094339 821 Human LINC00618 lncRNA vincristine (VCR) acute myeloid leukemia (AML) K562 cells; MV4-11 cells vincristine (VCR) treatment upregulated 33002417 822 Human LINC00618 lncRNA vincristine (VCR) leukemia human leukemia vincristine (VCR) treatment "Here, we show that the expression of a nuclear long non-coding RNA (lncRNA), LINC00618, is reduced in human leukemia and strongly increased by vincristine (VCR) treatment" 33002417 823 Human LINC00623 lncRNA IL-1¦Â osteoarthritis (OA) primary OA chondrocytes IL-1¦Â treatment "LINC00623/miR-101/HRAS axis modulates OA chondrocyte apoptosis, senescence and ECM degradation through MAPK signaling" 32062610 824 Human LINC00632 lncRNA IL-13 allergic rhinitis (AR) nasal epithelial cells (NECs) IL-13 treatment downregulated 31315126 825 Human LINC00632 lncRNA IL-13 allergic rhinitis (AR) nasal epithelial cells (NECs) IL-13 treatment "Linc00632 inhibited IL-13-induced GM-CSF, eotaxin, and MUAC5AC production in IL-13-treated NECs by targeting miR-498" 31315126 826 Human LINC00641 lncRNA nutritional stress intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells low nutritional (LN) condition induce Upregulation of LINC00641 and downregulated of miR-153-3p are detected in NP cells under nutritional stress. 30378116 827 Human LINC00645 lncRNA TGF-¦Â glioblastoma multiforme (GBM) glioma cell lines TGF-¦Â treatment upregulated 31558707 828 Human LINC00657 lncRNA oxidized low density lipoprotein (ox-LDL) angiogenesis human umbilical vein endothelial cells (HUVEC) oxidized low-density lipoprotein (ox-LDL) treatment oxLDL also upregulated LINC00657 expression. 29436491 829 Human LINC00657 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVEC) oxidized low-density lipoprotein (ox-LDL) treatment "Silence of LINC00657 repressed ox-LDL-induced injury via inhibiting EndMT, inflammatory response, and apoptosis in HUVEC cells by regulating miR-30c-5p/Wnt7b/¦Â-catenin." 32577947 830 Human LINC00659 lncRNA peiminine colorectal cancer (CRC) SW620 and HT29 cells peiminine treatment "Peiminine notably downregulated the expression of LINC00659, while the expression of miR-760 was upregulated by peiminine treatment" 32740014 831 Human LINC00665 lncRNA gefitinib non-small cell lung cancer (NSCLC) lung cancer tissues and cells (Human LAD cell line PC9) gefitinib treatment upregulated 30889481 832 Human LINC00665 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment upregulated 29947995 833 Human LINC00667 lncRNA yin yang 1 (YY1) cholangiocarcinoma (CCA) CCLP-1 and QBC939 cells yin yang 1 (YY1) treatment "Our data indicated that LINC00667 was highly expressed in CCA tissues and cells, and transcription factor Yin Yang 1 (YY1) induced LINC00667 expression in CCA cells" 33040228 834 Human LINC00667:6 lncRNA nigericin pancreatic cancer (PC) PANC-1 cells nigericin treatment upregulated 32850392 835 Human LINC00668 lncRNA sodium new houttuyfonate (SNH) non-small cell lung cancer (NSCLC) A549 and NCI-H1299 cells sodium new houttuyfonate (SNH) treatment downregulated 30971296 836 Human LINC00673 lncRNA benzo(a)pyrene (BaP) non-small cell lung cancer (NSCLC) A549 cells benzo(a)pyrene (BaP) exposure upregulated 31778776 837 Human LINC00673 lncRNA benzo(a)pyrene (BaP) non-small cell lung cancer (NSCLC) A549 cells benzo(a)pyrene (BaP) exposure BaP significantly elevated the expression level of linc00673. 31778776 838 Human LINC00707 lncRNA acetyl-11-keto-¦Â-boswellic acid (AKBA) breast cancer MCF-10AT cells Acetyl-11-keto-¦Â-boswellic acid (AKBA) treatment AKBA could induce cell apoptosis and G1-phase arrest and inhibit ER-¦Á expression via LINC00707/miR-206 in MCF-10AT cells. 32013235 839 Human LINC00707 lncRNA osteogenic differentiation medium osteogenesis human bone marrow-derived mesenchymal stem cells (HBMSCs) "osteogenic differentiation medium with 100 mmol/L dexamethasone, 0.05 mmol/L ascorbic acid, and 10 mmol/L ¦Â-glycerophosphate treatment" upregulated 30795799 840 Human LINC00707 lncRNA lipopolysaccharide (LPS) pneumonia MRC-5 cells lipopolysaccharide (LPS) treatment "?LINC00707 was increased, and miR-223-5p was decreased in LPS-treated MRC-5 cells." 33604647 841 Human LINC00844 lncRNA acetaminophen (APAP) drug-induced liver injury (DILI) HepaRG cells acetaminophen (APAP) treatment "In HepaRG cells, LINC00844 was significantly downregulated by 5 and 10 mM APAP in a concentration-dependent manner." 31904498 842 Human LINC00847 lncRNA enterovirus 71 (EV71) hand-foot-mouth disease (HFMD) human rhabdomyosarcoma (RD) cells Enterovirus 71 (EV71) treatment downregulated 30314355 843 Human LINC00847 lncRNA microcystin-leucine arginine (MC-LR) MC-LR-induced hepatotoxicity HL7702 cells microcystin-LR(MC-LR) treatment upregulated 30430930 844 Human LINC00882 lncRNA "corticosteroid, dexamethasone, and fetal calf serum (FCS)." airway diseases primary ASM cells "corticosteroid, dexamethasone, and fetal calf serum (FCS) treatment" dysregulated 24886442 845 Human LINC00882 lncRNA platelet-derived growth factor (PDGF) asthma Human fetal airway smooth muscle (ASM) cells platelet-derived growth factor (PDGF) treatment upregulated 31014672 846 Human LINC00883 lncRNA "corticosteroid, dexamethasone, and fetal calf serum (FCS)." airway diseases primary ASM cells "corticosteroid, dexamethasone, and fetal calf serum (FCS) treatment" dysregulated 24886442 847 Human LINC00894-002 lncRNA tamoxifen (TAM) breast cancer MCF-7 cells Tamoxifen treatment downregulated 29738694 848 Human LINC00941 lncRNA TGF-¦Â1 papillary thyroid cancer (PTC) "B-CPAP, TPC1, Cal62 and 8505c cells" TGF-¦Â1 treatment ?Linc00941 was identified as transcribed starting from one of the TGF¦Â-induced ENHs Linc00941 expression was significantly higher in aggressive cancer both in the TCGA dataset and in a separate validation cohort from our institution 32495722 849 Human LINC00943 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SK-N-SH cells 1-methyl-4-phenylpyridinium (MPP+) treatment LINC00943 abundance was upregulated in MPP+-challenged SK-N-SH cells. 33208053 850 Human LINC00943 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SK-N-SH cells 1-methyl-4-phenylpyridinium (MPP+) treatment LINC00943 abundance was upregulated in MPP+-challenged SK-N-SH cells. 33208053 851 Human LINC00958 lncRNA X-rays cervical cancer (CC) Hela cells irradiated with 6?Gy of X-ray treatment upregulated 31169309 852 Human LINC00958 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 853 Human LINC00961 lncRNA c-reactive protein (CRP) atherosclerosis (AS) Human vascular smooth muscle cell line HA-VSMC CRP treatment downregulated 31646586 854 Human LINC00961 lncRNA hypoxia atherosclerosis (AS) Human vascular smooth muscle cell line HA-VSMC hypoxia induce downregulated 31646586 855 Human LINC00968 lncRNA oxidized low density lipoprotein (ox-LDL) coronary artery disease (CAD) endothelial cells oxidized low-density lipoprotein (ox-LDL) treatment LINC00968 was upregulated by oxidized low-density lipoprotein (oxLDL) treatment in endothelial cell. 30485507 856 Human LINC00968 lncRNA N-retinylidene-N-retinylethanolamine (A2E) retinitis pigmentosa human retinal pigment epithelium cells N-retinylidene-N-retinylethanolamine (A2E) treatment downregulated 32326576 857 Human LINC00987 lncRNA lipopolysaccharide (LPS) chronic obstructive pulmonary disease (COPD) BEAS-2B cells lipopolysaccharide (LPS) treatment "LINC00987 Ameliorates COPD by Regulating LPS-Induced Cell Apoptosis, Oxidative Stress, Inflammation and Autophagy Through Let-7b-5p/SIRT1 Axis." 33311978 858 Human LINC01116 lncRNA cisplatin (DDP) lung adenocarcinoma (LUAD) A549 cells cisplatin treatment upregulated 33061421 859 Human LINC01116 lncRNA sulforaphane (SFN) prostate cancer normal human prostate epithelial cells and prostate cancer cells treated with 15 ¦ÌM SFN treatment downregulated 28131897 860 Human LINC01121 lncRNA pterostilbene breast cancer MCF 7 cells pterostilbene treatment downregulated 30619763 861 Human LINC01125 lncRNA LXR-623 (WAY-252623) breast cancer MDA-MB-231 cells LXR-623 (WAY-252623) treatment upregulated 30867411 862 Human LINC01125 lncRNA cisplatin (DDP) ovarian cancer (OC) OC lines (SKOV-3 and A2780) cisplatin treatment downregulated 31865363 863 Human LINC01126 lncRNA hypoxia periodontitis human periodontal ligament cells (hPDLCs) hypoxia treatment "We selected LINC01126, which was the most highly expressed lncRNA, to further verify its functions in periodontitis-induced hypoxia." 33231338 864 Human LINC01133 lncRNA periostin pancreatic ductal adenocarcinoma (PDAC) human PSCs cells periostin treatment upregulated 33824474 865 Human LINC01137 lncRNA etoposide (VP-16) DNA damage human HepG2 cells etoposide treatment upregulated 31889167 866 Human LINC01137 lncRNA mercury II chloride heavy metal stress human HepG2 cells mercury II chloride treatment upregulated 31889167 867 Human LINC01137 lncRNA H2O2 oxidative stress human HepG2 cells H2O2 treatment upregulated 31889167 868 Human LINC01140 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP1 cells oxidized low-density lipoprotein (ox-LDL) treatment "LINC01140 was downregulated, while p53 and miR-23b were upregulated in oxLDL-induced inflammatory response of macrophages." 31748847 869 Human LINC01186 lncRNA TGF-¦Â1 lung cancer A549 cells treat with TGF-¦Â1 treatment downregulated 28119085 870 Human LINC01234 lncRNA cisplatin (DDP) hepatocellular carcinoma (HCC) HepG2 cells and Huh7 cells cisplatin treatment "When miR-31-5p was downregulated, the proliferation and invasion of HepG2 cells and Huh7 cells were enhanced and the cisplatin-induced apoptosis was inhibited, while LINC01234 knockdown could diminish the effects caused by miR-31-5p depletion." 31838274 871 Human LINC01297 lncRNA enterovirus 71 (EV71) hand-foot-mouth disease (HFMD) human rhabdomyosarcoma (RD) cells Enterovirus 71 (EV71) treatment downregulated 30314355 872 Human LINC01311 lncRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) SH-SY5Y cells amyloid ¦Â1-42?(A¦Â) treatment LINC01311 was downregulated whereas hsa-miR-146a-5p upregulated in AB1-42 treated SH-SY5Y cells. 33830627 873 Human LINC01391 lncRNA piplartine hepatocellular carcinoma (HCC) HepG2 and SMMC-7721?cells piplartine treatment upregulated 31207322 874 Human LINC01541 lncRNA estradiol-17¦Â (E2) endometriosis Human endometrial stromal cells (ESCs) estradiol-17¦Â (E2) treatment downregulated 30608887 875 Human LINC01541 lncRNA estradiol-17¦Â (E2) endometriosis ectopic endometrial tissue estradiol-17¦Â (E2) treatment LINC01541 functions as a ceRNA that modulates the Wnt/¦Â-catenin pathway by decoying miR-506-5p. 32833189 876 Human LINC01572 lncRNA cisplatin (DDP) gastric cancer (GC) BGC823 cells; SGC7901 cisplatin treatment upregulated 33149605 877 Human LINC01667 lncRNA bruceine D (BD) gastric cancer (GC) HGC27 cells; MKN45 cells bruceine D (BD) treatment LINC01667 was significantly downregulated after BD treatment. 33390953 878 Human linc-p21 lncRNA ginkgo biloba extract EGb 761 colorectal cancer (CRC) "The human colorectal cancer cell lines SW480, SW620" Ginkgo biloba extract EGb 761 treatment upregulated 29207671 879 Human linc-p21 lncRNA hypoxia warburg effect HeLa cells;MCF7 ccells; H1299 cells;IMR90 cells culture under hypoxic conditions for 24 hr treatment upregulated 24316222 880 Human linc-p21 lncRNA hypoxia warburg effect HeLa cells hypoxia treatment LincRNA-p21 is Induced by Hypoxia and Is Essential for Hypoxia-Enhanced Glycolysis 24316222 881 Human LINP1 lncRNA doxorubicin- and 5-fluorouracil breast cancer MDA-MB-468 cells doxorubicin- and 5-fluorouracil treatment LINP1 was upregulated in doxorubicin- and 5-fluorouracil-resistant cells and induced chemoresistance. 29293402 882 Human LINP1 lncRNA tamoxifen (TAM) breast cancer MCF-7 cells; T47D cells Tamoxifen (TAM) treatment upregulated 31927036 883 Human LINP1 lncRNA TGF-¦Â epithelial-mesenchymal transition (EMT) A549 cells; H1299 cells; H358 cells TGF-¦Â treatment "In three lung cancer cell lines A549, H1299, and H358, TGF-¦Â1 significantly inhibited LINP1 expression" 30416386 884 Human LMCD1-AS1 lncRNA aspirin hepatocellular carcinoma (HCC) HepG2 and Huh-7 cell lines aspirin treatment downregulated 31278071 885 Human lnc949 lncRNA TGF-¦Â1 lung fibrosis L929 cells TGF-¦Â1 treatment Engeletin ameliorates pulmonary fibrosis through endoplasmic reticulum stress depending on lnc949-mediated TGF-¦Â1-Smad2/3 and JNK signalling pathways 33181025 886 Human LncDC lncRNA hepatitis B virus (HBV) immune response DC cells induced by isolated peripheral blood mononuclear cells hepatitis B virus (HBV) infection upregulated 30202418 887 Human lncIHAT lncRNA hypoxia triple negative breast cancer (TNBC) MDA-MB-231 cells hypoxia treatment Hypoxia-inducible factor 1 (HIF1) but not HIF2 bound to the hypoxia response element at the promoter of lncIHAT to activate its transcription in hypoxic TNBC cells. LncIHAT promoted TNBC cell survival?in vitro?and tumor growth and lung metastasis in mice. 33380467 888 Human linc-p21 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) HCAECs oxidized low-density lipoprotein (ox-LDL) treatment upregulated 28983628 889 Human linc-p21 lncRNA oligo-fucoidan hepatocellular carcinoma (HCC) HepG2 cells oligo-fucoidan treatment apoptosis and cell cycle pathways could also contribute to the induction of lncRNA-Saf and lncRNA-p21 by oligo-fucoidan. 30632031 890 Human linc-p21 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) ?human neuroblastoma SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment lnc-p21 was highly expressed in human neuroblastoma SH-SY5Y cells treated with MPP+. 31004593 891 Human lncRNA00364 lncRNA IFN-¦Ã hepatocellular carcinoma (HCC) HCC cells IFN¦Ã treatment upregulated 29254221 892 Human lncRNA01126 lncRNA lipopolysaccharide (LPS) periodontitis human periodontal ligament cells (hPDLCs) lipopolysaccharide of Porphyromonas Gingivalis (LPS-PG) treatment upregulated 32240552 893 Human lncRNA1403 lncRNA 7.5% hypertonic saline (HS) traumatic brain injury (TBI) peripheral blood mononuclear cells 7.5% hypertonic saline (HS) treatment downregulated 30569101 894 Human lncRNA155 lncRNA influenza A virus (IAV) innate immune response "Human lung epithelial cells (A549), human embryonic kidney cells (HEK293T/293T), human acute monocytic leukemia cells (THP-1), mouse embryonic fibroblasts (NIH/3T3), mouse Lewis lung carcinoma cells (LLC), mouse Abelson murine leukemia virus transformed macrophages (RAW 264.7)and madin-darby canine kidney cells (MDCK)" influenza A virus (IAV) infection expression of lncRNA-155 was markedly upregulated during influenza A virus (IAV) infection both in vitro (several cell lines) and in vivo (mouse model) 31045320 895 Human lncRNA2448-11 lncRNA 7.5% hypertonic saline (HS) traumatic brain injury (TBI) peripheral blood mononuclear cells 7.5% hypertonic saline (HS) treatment downregulated 30569101 896 Human lncRNA51663 lncRNA helicobacter pylori (H. pylori) gastric cancer (GC) AGS cells Helicobacter pylori (H. pylori) infection upregulated 32457731 897 Human lncRNA8 lncRNA hepatitis C virus (HCV) chronic hepatitis C virus (HCV) infection Huh-7.5 hepatoma cells hepatitis C virus (HCV) infection upregulated 31200545 898 Human lncRNA91H lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" esophageal squamous cell carcinoma (ESCC) cell line TE-1 and Eca-109 "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated 24706416 899 Human lncRNA-p19461 lncRNA diet weight loss fasting venous blood diet treatment upregulated 27767123 900 Human LOC101927497 lncRNA N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) gastric cancer (GC) human gastric epithelial cells treat with MNNG upregulated 29223541 901 Human LOC101927497 lncRNA N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) gastric cancer (GC) MKN28 cells; MGC-803 cells N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) treatment downregulated 29223541 902 Human LOC101927514 lncRNA particulate matter (PM2.5) respiratory inflammation 16HBE cells fine particulate matter (PM2.5) exposure treatment upregulated 31682869 903 Human LOC101927514 lncRNA particulate matter (PM2.5) respiratory inflammation human normal bronchial 16HBE cells particulate matter (PM2.5) treatment "Inhibiting LncRNA LOC101927514 expression by RNAi, reflected in a reduction in inflammation, is driven by PM25" 31682869 904 Human LOC102724017 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 905 Human LOC105374902 lncRNA tumor necrosis factor alpha (TNF-¦Á) cervical cancer (CC) HeLa cells tumor necrosis factor alpha (TNF-¦Á) treatment "TNF-¦Á-induced lncRNA LOC105374902 may function as a ceRNA for miR-1285-3p to promote the expression of RPL14, promoting the migration, invasion and EMT of CC cells." 30935691 906 Human loc105377478 lncRNA neodymium oxide nanoparticles (NPs-Nd2O3) airway inflammation human bronchial epithelial cells (16HBE) neodymium oxide nanoparticles (NPs-Nd2O3) exposure upregulated 33396129 907 Human loc105377478 lncRNA neodymium oxide nanoparticles (NPs-Nd2O3) cytotoxicity human bronchial epithelial cells (16HBE) neodymium oxide nanoparticles (NPs-Nd2O3) treatment upregulated 33396129 908 Human loc107985872 lncRNA traffic-originated PM2.5 organic component (tPo) toxicity of PM2.5 A549 cells; H1299 cells Traffic-originated PM2.5 organic component (tPo) treatment tPo treatment upregulated the expression of loc107985872 32829169 909 Human loc146880 lncRNA particulate matter (PM2.5) cytotoxicity A549 cells treated with PM2.5 treatment upregulated 27836757 910 Human LOC285194 lncRNA propofol (PPF) pancreatic cancer (PC) PANC-1 cells propofol treatment "Propofol upregulated miR-34a expression, which, in turn, upregulated LOC285194 expression" 32303144 911 Human LOC286367 lncRNA propofol (PPF) inflammation THP-1 macrophages propofol treatment downregulated 30647536 912 Human LOC338799 lncRNA ultraviolet (UV) irradiation DNA damage CD4 cells ultraviolet-C (UVC) treatment upregulated 32258156 913 Human LOC344887 lncRNA hydroquinone (HQ) leukemia TK6 cells HQ dysregulated 29221148 914 Human LOC645166 lncRNA adriamycin (ADR) adriamycin (ADR) treatment in breast cancer MCF-7 cells adriamycin (ADR) treatment lncRNA LOC645166 mediated adriamycin chemoresistance in breast cancer by regulating GATA3 via NF-¦ÊB. 32461377 915 Human LOC728228 lncRNA "anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)" bronchial epithelial cell cancer human bronchial epithelial cell line (16HBE-T cells) "anti-benzo(a) pyrene-7,8-diol-9,10-epoxide (anti-BPDE) treatment" upregulated 25820656 916 Human LOC729178 lncRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) 16HBE cells cigarette smoke extract (CSE) treatment Our data indicated that LOC729178 was underexpressed in COPD tissues and CSE-treated 16HBE cells. 33847879 917 Human LOXL1-AS1 lncRNA doxorubicin (DOX) prostate cancer prostate cancer DU-145 cells doxorubicin (DOX) treatment downregulated 31188543 918 Human LRRC24-2:1 lncRNA nigericin pancreatic cancer (PC) PANC-3 cells nigericin treatment downregulated 32850392 919 Human LSINCT5 lncRNA B-type-natriuretic peptide (BNP) chronic heart failure (CHF) HCM human myocardial cells B-type-natriuretic peptide (BNP) treatment "lncRNA LSINCT5, upregulated by BNP, is able to regulate myocardial cell apoptosis via the activation of the caspase-1/interleukin (IL)-1¦Â signaling pathway." 26323562 920 Human LUADT1 lncRNA lipopolysaccharide (LPS) sepsis primary cardiac endothelial cells lipopolysaccharide (LPS) treatment LPS treatment downregulated the expression of LUADT1 in primary cardiac endothelial cells. 33225891 921 Human LUCAT1 lncRNA hypoxia colorectal cancer (CRC) HCT-116;RKO cells hypoxia treatment Hypoxia induced LUCAT1/PTBP1 axis modulates cancer cell viability and chemotherapy response. 31964396 922 Human LUCAT1 lncRNA methotrexate (MTX) osteosarcoma (OS) MG63 cells; HOS cells methotrexate (MTX) treatment "LUCAT1 was upregulated in MTX-resistant cells (MG63/MTX, HOS/MTX) compared to that in parental cells." 29170124 923 Human LUCAT1 lncRNA methotrexate (MTX) osteosarcoma (OS) "osteosarcoma cell lines (MG-63, U2OS, HOS and SAOS-2)" methotrexate treatment upregulated 29170124 924 Human LUCAT1 lncRNA particulate matter (PM2.5) PM2.5 exposure BEAS-2B cells PM2.5 treatment lncLUCAT1 was increased in PM25 treated BEAS-2B cells 30231965 925 Human LUCAT1 lncRNA high glucose (HG) renal fibrosis HK-2 cells high glucose (HG) treatment LUCAT1 likely promotes HG-induced EMT through ZEB1 by sponging miR-199a-5p. 33426083 926 Human MACC1-AS1 lncRNA TGF-¦Â1 gastric cancer (GC) AGS and MKN45 cancer cells transforming growth factor ¦Â1 (TGF-¦Â1) secretion by MSCs treatment upregulated 30742067 927 Human MACC1-AS1 lncRNA hypoxia ischemic stroke (IS) human brain microvascular endothelial cells (HBMECs) hypoxia treatment downregulated 32793720 928 Human MAF-4 lncRNA brucella.suis brucellosis blood samples brucellosis infection Linc-MAF-4 was significantly increased in the acute group in comparison to control and relapse groups. 32417631 929 Human MAGI2-AS3 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment "The expression of MAGI2-AS3 was increased, and miR-374b-5p was decreased in both SH-SY5Y and BV2 cells exposed to A¦Â25-35." 33279663 930 Human MAGI2-AS3 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment MAGI2-AS3/miR-374b-5p axis regulates A¦Â-induced neurotoxicity in SH-SY5Y cells and neuroinflammation in BV2 cells. 33279663 931 Human MALAT1 lncRNA IL-6 abdominal aortic aneurysm (AAA) human aortic endothelial cells (HAOECs) IL-6 treatment upregulated 29441928 932 Human MALAT1 lncRNA arsenite accelerated glycolysis "L-02 cells, a normal human liver cell line" arsenite exposure arsenite-increased MALAT1 enhances the disassociation of Von Hippel-Lindau (VHL) tumor suppressor from HIF-1¦Á 27287256 933 Human MALAT1 lncRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment LPS treatment upregulated MALAT1 expression and suppressed the proliferation of A549 cells. 31257497 934 Human MALAT1 lncRNA lipopolysaccharide (LPS) acute lung injury (ALI) human pulmonary alveolar epithelial cells (HPAEpiC) lipopolysaccharide (LPS) treatment MALAT1 knockdown alleviated HPAEpiC apoptosis by competitively binding to miR-194-5p and then elevating the inhibitory effect on its target FOXP2. 33117815 935 Human MALAT1 lncRNA lipopolysaccharide (LPS) acute lung injury (ALI) human pulmonary microvascular endothelial cells (HPMECs) lipopolysaccharide (LPS) treatment downregulated 33197806 936 Human MALAT1 lncRNA cytarabine (Ara-C) acute myeloid leukemia (AML) human AML cell lines HL60 and THP-1 cytarabine (Ara-C) treatment "Knockdown of MALAT1 inhibited the proliferation, induced apoptosis, and enhanced Ara-C sensitivity of AML cells." 30970520 937 Human MALAT1 lncRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) human pulmonary microvascular endothelial cells (HPMECs) lipopolysaccharide (LPS) treatment MALAT1 silencing can potentially suppress HPMEC apoptosis and alleviate lung injury in ARDS via miR-150-5p-targeted ICAM-1. 32315984 938 Human MALAT1 lncRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) human pulmonary microvascular endothelial cells (HPMECs) lipopolysaccharide (LPS) treatment upregulated 33197806 939 Human MALAT1 lncRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) Human pulmonary microvascular endothelial cells (HPMECs) lipopolysaccharide (LPS) treatment upregulated 33407436 940 Human MALAT1 lncRNA ethanol (EtOH) alcohol-induced tumor angiogenesis HUVECs endothelial extracellular vesicles (EVs) ethanol treatment upregulated in endothelial extracellular vesicles (EVs) 29062004 941 Human MALAT1 lncRNA tubercidin alternative splicing HeLa cells tubercidin treatment downregulated 24569078 942 Human MALAT1 lncRNA dual MEK/Aurora kinase inhibitor BI-847325 anaplastic thyroid carcinoma (ATC) ATC cell lines (C643 and SW1736) dual MEK/Aurora kinase inhibitor BI-847325 treatment downregulated 31077090 943 Human MALAT1 lncRNA hyperbaric oxygen (HBO) angiogenesis human coronary artery endothelial cells (HCAECs) Hyperbaric oxygen (HBO) treatment upregulated 30301563 944 Human MALAT1 lncRNA amygdalin anti-cancer therapy "human cancer cells (A549, MCF7, AGS)" amygdalin treatment downregulated 30725348 945 Human MALAT1 lncRNA bone morphogenetic protein 7 (BMP7) apoptosis HA-VSMCs bone morphogenetic protein 7 (BMP7) treatment upregulated 29435112 946 Human MALAT1 lncRNA high glucose (HG) apoptosis human vascular endothelial cells (HUVECs) high glucose (HG) treatment "MALAT1 is upregulated in HG-induced HUVECs, and inhibition of MALAT1 inhibits HG-induced apoptosis and inflammation in HUVECs by suppression of the NF-¦ÊB signaling pathway." 32502356 947 Human MALAT1 lncRNA platelet derived growth factor-BB (PDGF-BB) asthma airway smooth muscle cells (ASMCs) platelet-derived growth factor BB (PDGF-BB) treatment upregulated 31695627 948 Human MALAT1 lncRNA high glucose (HG) atherosclerosis (AS) EA.hy926?cells high glucose (HG) treatment lncRNA MALAT1 expression and found that it was upregulated in high glucose-treated EA.hy926?cells. 30591217 949 Human MALAT1 lncRNA high glucose (HG) atherosclerosis (AS) EA.hy926 human endothelial cells (EA.hy926?cells) high glucose treatment Long?noncoding?RNA?MALAT1 promotes high glucose-induced?human endothelial cells pyroptosis by affecting NLRP3 expression through competitively binding miR-22. 30591217 950 Human MALAT1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) "VSMCs were treated with different doses of ox-LDL (0, 25, 50, and 100 mg/L) and for different time points (0, 12, 24, and 48 h) to mimic an in vitro environment of hyperlipidemia." MALAT1 were dose-dependently downregulated in ox-LDL-treated VSMCs. 31696492 951 Human MALAT1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29258822 952 Human MALAT1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29258822 953 Human MALAT1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human Coronary Artery Endothelial Cells (HCAECs) oxidized low-density lipoprotein (ox-LDL) treatment MALAT1 expression was upregulated under oxidative low-density lipoprotein (ox-LDL) treatment. 30314869 954 Human MALAT1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31029709 955 Human MALAT1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) exosomes from Human umbilical VECs (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31305205 956 Human MALAT1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human umbilical vein endothelial cells (HUVEC) oxidized low-density lipoprotein (ox-LDL) treatment MALAT1 suppression protects the endothelium from oxLDL-induced inflammation and oxidative stress in endothelial cells by upregulation of miR-181b and downregulated of TOX. 31949884 957 Human MALAT1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment LncRNA MALAT1 Enhances ox-LDL-Induced Autophagy through the SIRT1/MAPK/NF-¦ÊB Pathway in Macrophages 32183682 958 Human MALAT1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein ECs (HUVECs); human coronary artery ECs (HCAECs) oxidized low-density lipoprotein (ox-LDL) treatment MALAT1 was upregulated in ECs treated with ox-LDL. 33022677 959 Human MALAT1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells oxidized low-density lipoprotein (ox-LDL) treatment MALAT1 was increased in oxLDL-treated human umbilical vein endothelial cells. 29750307 960 Human MALAT1 lncRNA IL-1¦Â autoimmune thyroiditis (AIT) Nthy-ori 3-1 cells IL-1¦Â treatment upregulated 33452572 961 Human MALAT1 lncRNA ursolic acid (UA) autoimmune thyroiditis (AIT) IL-1¦Â-treated Nthy-ori 3-1 cells ursolic acid (UA) treatment downregulated 33452572 962 Human MALAT1 lncRNA oxidized low density lipoprotein (ox-LDL) autophagy human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment MALAT1 expression was markedly increased in HUVECs treated with ox-LDL. 30485490 963 Human MALAT1 lncRNA oxidized low density lipoprotein (ox-LDL) autophagy human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment autophagy was upregulated and MALAT1 expression was markedly increased in HUVECs treated with ox-LDL. 30485490 964 Human MALAT1 lncRNA dexamethasone (DEX) avascular necrosis of the femoral head (ANFH) human bone marrow stromal cells (BMSC) dexamethasone (DEX) treatment upregulated 31678133 965 Human MALAT1 lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment downregulated 32714991 966 Human MALAT1 lncRNA cisplatin (DDP) bladder cancer The 5637 and EJ-M3 cells cisplatin treatment suppression of MALAT1 enhanced the chemotherapeutic drug sensitivity and inhibited the cisplatin resistance of the BC cells. 31650173 967 Human MALAT1 lncRNA TGF-¦Â bladder cancer bladder cancer cells TGF-¦Â treatment upregulation 24449823 968 Human MALAT1 lncRNA receptor activator of nuclear factor-¦ÊB ligand (RANKL) bone metabolism RANKL inhibited hFOB 1.19 cells Receptor activator of NF—κB ligand (RANKL) treatment upregulated 25817340 969 Human MALAT1 lncRNA paclitaxel (PTX) breast cancer SK-BR-3 cells paclitaxel (PTX) treatment upregulated 32897218 970 Human MALAT1 lncRNA cadmium (Cd) cadmium-induced toxicity 16HBE cells cadmium (Cd) treatment upregulated 30090505 971 Human MALAT1 lncRNA TGF-¦Â1 cardiovascular disease (CVD) HUVECs TGF-¦Â1 treatment upregulated 27144026 972 Human MALAT1 lncRNA androgen deprivation therapies (ADT) castration-resistant prostate cancer (CRPC) patients with CRPC androgen deprivation therapies (ADT) treatment upregulated 25189356 973 Human MALAT1 lncRNA high glucose (HG) cell function Human umbilical vein endothelial cells (HUVECs) high glucose treatment upregulated 31646587 974 Human MALAT1 lncRNA high glucose (HG) cell pyroptosis EA.hy926 human endothelial cells (EA.hy926?cells) high glucose treatment Long?noncoding?RNA?MALAT1 promotes high glucose-induced?human endothelial cells pyroptosis by affecting NLRP3 expression through competitively binding miR-22. 30591217 975 Human MALAT1 lncRNA platelet derived growth factor-BB (PDGF-BB) cell proliferation HA-VSMCs platelet-derived growth factor-BB (PDGF-BB) treatment upregulated 29435112 976 Human MALAT1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury cerebrovascular endothelial cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment "Under the normal culture condition, MALAT1 reached 15 times after reoxygenation treatment for 9 h, and the expression level decreased to 027 times significantly after reoxygenation treatment for 36h" 29575939 977 Human MALAT1 lncRNA casiopeina II-gly (Cas-II-gly) cervical cancer (CC) HeLa and CaSki cells Casiopeina II-gly (Cas-II-gly) treatment downregulated 31524268 978 Human MALAT1 lncRNA radiation cervical cancer (CC) CaSki cells radiation treatment "Comparing to radiotherapy sensitive tissues, the MALAT1 level was significantly elevated in radiotherapy resistant tissues" 30178834 979 Human MALAT1 lncRNA oxaliplatin colorectal cancer (CRC) CRC tissues; HCT116 cells; HCT8 cells oxaliplatin (OXA) treatment MALAT1 was upregulated in Ox-resistant CRC tissues and cells 33005106 980 Human MALAT1 lncRNA oxymatrine colorectal cancer (CRC) HT29 cells oxymatrine treatment lncRNA MALAT1 was significantly upregulated in the oxymatrine resistant cells 29328404 981 Human MALAT1 lncRNA radiation colorectal cancer (CRC) CCL244 cells radiation treatment upregulated 32380053 982 Human MALAT1 lncRNA radiation colorectal cancer (CRC) LOVO cells radiation treatment downregulated 32380053 983 Human MALAT1 lncRNA dihydromyricetin (DHM) cutaneous squamous cell carcinoma (CSCC) A431 cells Dihydromyricetin (DHM) treatment downregulated 31413743 984 Human MALAT1 lncRNA lipopolysaccharide (LPS) delayed union of femoral neck fracture MG-63 cells lipopolysaccharide (LPS) treatment MALAT1 expression was upregulated in serum of patients with delayed union of femoral neck fracture. 33725277 985 Human MALAT1 lncRNA dexamethasone (DEX) dexamethasone (DEX)-induced injuries B-6 cells; hFOB1.19 cells; necrotic femoral head tissues dexamethasone (Dex) treatment Lnc-MALAT1 expression was downregulated by Dex treatment. 30439702 986 Human MALAT1 lncRNA high glucose (HG) diabetic cataract (DC) human lens epithelial cells (HLECs) high glucose (HG) treatment MALAT1 not only was aberrantly expressed in DC anterior lens capsule tissues and high glucose (HG)-treated HLECs. 29936249 987 Human MALAT1 lncRNA high glucose (HG) diabetic gastroparesis (DGP) human gastric SMCs high glucose (HG) treatment upregulated 29317209 988 Human MALAT1 lncRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high-glucose upregulated 27964927 989 Human MALAT1 lncRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells streptozotocin treatment upregulated 27964927 990 Human MALAT1 lncRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment hyperglycemia significantly increased the level of MALAT1 but decreased miR-145 expression in a time-dependent manner in HK-2 cells. 31081103 991 Human MALAT1 lncRNA high glucose (HG) diabetic nephropathy (DN) human proximal tubular cells (HK-2 cells) high glucose (HG) treatment upregulated 31388927 992 Human MALAT1 lncRNA high glucose (HG) diabetic retinopathy (DR) retinal endothelial cells high glucose (HG) treatment Glucose increased LncRNA?MALAT1?levels by increasing Sp1 transcription factor binding at its promoter. 33051272 993 Human MALAT1 lncRNA high glucose (HG) diabetic retinopathy (DR) human retina microvascular endothelial cells (hRMECs) high glucose (HG) treatment upregulated 30988072 994 Human MALAT1 lncRNA high glucose (HG) diabetic retinopathy (DR) human retinal microvascular endothelial cells (HRMECs) high glucose (HG) treatment MALAT1 affect angiogenesis by sponging miR-203a-3p in DR. 31689123 995 Human MALAT1 lncRNA high glucose (HG) diabetic retinopathy (DR) human retinal microvascular endothelial cells (HRMECs) high glucose (HG) treatment upregulated 31689123 996 Human MALAT1 lncRNA high glucose (HG) diabetic retinopathy (DR) human retinal vascular endothelial cells (RVECs) high glucose (HG) treatment upregulated 31986419 997 Human MALAT1 lncRNA hypoxia doxorubicin (DOX)-induced cardiotoxicity human adipose-derived mesenchymal stem cells hypoxia treatment Treatment of the human adipose-derived mesenchymal stem cells with hypoxia induced lncRNA-MALAT1 accumulation in the secreted exosomes. 32384281 998 Human MALAT1 lncRNA estradiol-17¦Â (E2) endometriosis Human primary endometrial glandular epithelial cells (EECs) and Ishikawa cells estradiol-17¦Â (E2) treatment upregulated 30500775 999 Human MALAT1 lncRNA hypoxia endometriosis ectopic endometrium and cultured human endometrial stromal cells hypoxia induce upregulated 30324652 1000 Human MALAT1 lncRNA hypoxia endometriosis primary human endometrial stromal cells hypoxia treatment lncRNA-MALAT1 and autophagy were induced by hypoxia in a time-dependent manner and lncRNA-MALAT1 upregulated was dependent on HIF-1¦Á signalling. 30324652 1001 Human MALAT1 lncRNA hypoxia endothelial cell injury human umbilical vein endothelial cells (HUVECs) hypoxia treatment upregulated 31933110 1002 Human MALAT1 lncRNA high glucose (HG) endothelial dysfunction human renal glomerular endothelial cells (HRGECs) high glucose (HG) treatment upregulated 30762931 1003 Human MALAT1 lncRNA estradiol-17¦Â (E2) epithelial-mesenchymal transition (EMT) Human primary endometrial glandular epithelial cells (EECs) and Ishikawa cells estradiol-17¦Â (E2) treatment upregulated 30500775 1004 Human MALAT1 lncRNA oxidized low density lipoprotein (ox-LDL) epithelial-mesenchymal transition (EMT) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 30871555 1005 Human MALAT1 lncRNA particulate matter (PM2.5) epithelial-mesenchymal transition (EMT) human bronchial epithelial cell lines (HBE and BEAS-2B) Organic extracts of PM2.5 treatment "NF-¦ÊB transcriptionally regulates MALAT1, which, by binding with miR-204 and releasing ZEB1, promotes the EMT" 31042084 1006 Human MALAT1 lncRNA TGF-¦Â2 epithelial-mesenchymal transition (EMT) Primary human lens epithelial cells (LECs) TGF-¦Â2 treatment upregulated 31143769 1007 Human MALAT1 lncRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) endothelial progenitor cells (EPCs) treat with TGF-¦Â1 treatment upregulated 28535533 1008 Human MALAT1 lncRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) ARPE-19 cells TGF-¦Â1 treatment upregulated 27019196 1009 Human MALAT1 lncRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) TPC-1 cells TGF-¦Â1 treatment upregulated 29967342 1010 Human MALAT1 lncRNA TGF-¦Â2 epithelial-mesenchymal transition (EMT) human lens epithelial cells (LECs) TGF-¦Â2 treatment upregulated 33327804 1011 Human MALAT1 lncRNA TGF-¦Â1 esophageal squamous cell carcinoma (ESCC) KYSE30 cells; KYSE150 cells; KYSE450 cells TGF-¦Â1 treatment upregulated 33123280 1012 Human MALAT1 lncRNA ¦Ã-rays esophageal squamous cell carcinoma (ESCC) mice xenografted with KYSE150 cells 10 Gy dose of ¦Ã-ray irradiation by the 137Cesium irradiator at 2 Gy/1f/day for 5 days treatment downregulated 27935117 1013 Human MALAT1 lncRNA cisplatin (DDP) gastric cancer (GC) The human GC cell line AGS;HGC-27 cells cisplatin treatment upregulated 30365113 1014 Human MALAT1 lncRNA cisplatin (DDP) gastric cancer (GC) AGS cells; HGC-27 cells cisplatin treatment MALAT1 was found to be highly expressed in CDDP-resistant AGS(AGS/CDDP) cells and CDDP-resistant HGC-27 (HGC-27/CDDP) cells. 30365113 1015 Human MALAT1 lncRNA hydrogen gas (H2) gastric cancer (GC) MGC-803 cells;and BGC-823 cells ?hydrogen treatment "H2?gas significantly inhibited gastric tumor growth in vivo and the proliferation, migration, and lncRNA MALAT1 and EZH2 expression of gastric cancer cells while upregulated miR-124-3p expression" 33482814 1016 Human MALAT1 lncRNA oxaliplatin gastric cancer (GC) "GC tissues;Normal cells (GES-1); GC cells (SGC-7901, BGC-823); GC/OXA cells (SGC-7901/OXA; BCG-823/OXA" oxaliplatin (OXA) treatment MALAT1 modulates ZFP91 to promote GC cells OXA resistance via sponging miR-22-3p 32104001 1017 Human MALAT1 lncRNA propofol (PPF) gastric cancer (GC) SGC7901/CDDP propofol treatment lncRNA MALAT1/miR-30e/ATG5 mediated autophagy-related chemoresistance in GC 32302291 1018 Human MALAT1 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) GBM patients tissues and serum TMZ treatment downregulated 28187000 1019 Human MALAT1 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U251 cells temozolomide (TMZ) treatment MALAT1 was significantly upregulated in TMZ-resistant GBM cells 29479863 1020 Human MALAT1 lncRNA all-trans retinoic acid (ATRA) glioblastoma multiforme (GBM) U87 glioblastoma cells all-trans retinoic acid (ATRA) treatment downregulated 31186810 1021 Human MALAT1 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87 cells temozolomide (TMZ) treatment upregulated 30940658 1022 Human MALAT1 lncRNA hepatitis B virus X protein (HBx) HBV-associated hepatocellular carcinoma (HCC) HepG2 cells Hepatitis B virus X protein (HBx) infection HBx upregulated lncRNA-MALAT1 expression while downregulating miR-124 expression in HepG2-X cells. 30500989 1023 Human MALAT1 lncRNA hepatitis B virus X protein (HBx) HBV-associated hepatocellular carcinoma (HCC) HepG2-X cell line was induced by transfect HBx into HepG2 cells. HBx-induce HBx upregulated lncRNA-MALAT1 expression in HepG2-X cells. 30500989 1024 Human MALAT1 lncRNA hypoxia hepatic ischemia/reperfusion injury (HIRI) human hepatocytes hypoxia induce upregulated 31075559 1025 Human MALAT1 lncRNA betulinic acid (BA) hepatocellular carcinoma (HCC) PLC/PRF/5; MHCC97L betulinic acid (BA) treatment lncRNA MALAT1 functioned as a ceRNA (competing endogenous RNA) to contribute to BA-mediated degradation of IAPs by sponging miR-22-3p. 33135336 1026 Human MALAT1 lncRNA doxorubicin (DOX) hepatocellular carcinoma (HCC) Huh-7 cell; Hep3B cells doxorubicin treatment upregulated 32965597 1027 Human MALAT1 lncRNA hypoxia hepatocellular carcinoma (HCC) Hep3B cells hypoxia induce "LncRNA MALAT1 was involved in proliferation, migration, invasion, and apoptosis by interacting with miR-200a in hypoxic Hep3B cells, revealing a new mechanism of MALAT1 involved in hypoxic HCC progression." 31347327 1028 Human MALAT1 lncRNA hypoxia-inducible factor 2¦Á (HIF-2¦Á) hepatocellular carcinoma (HCC) hepatocellular carcinoma (HCC) cells HIF-2¦Á treatment upregulated 27524242 1029 Human MALAT1 lncRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HepG2 cells; SMMC cells sorafenib treatment upregulated 32220970 1030 Human MALAT1 lncRNA human immunodeficiency virus (HIV)-1 human immunodeficiency virus (HIV)-1 infection CD4+ T cells human immunodeficiency virus (HIV)-1 infection upregulated 30788509 1031 Human MALAT1 lncRNA high glucose (HG) diabetes mellitus (DM) human umbilical vein endothelial cell (HUVEC) high glucose (HG) treatment Knockdown of MALAT1 inhibits HG-induced vascular endothelial injury through regulating miR-361-3p/SOCS3 axis. 32509100 1032 Human MALAT1 lncRNA hypoxia/reoxygenation (H/R) hypoxia/reoxygenation (H/R) injury human umbilical vein endothelial cell (HUVEC) hypoxia/reoxygenation (H/R) treatment MALAT1 represses H/R-stimulated HUVEC injury by targeting the miR-320a/RAC1 axis. 31408432 1033 Human MALAT1 lncRNA lipopolysaccharide (LPS) inflammation human microvascular endothelial cells (HMECs) lipopolysaccharides (LPS) treatment downregulated 31291804 1034 Human MALAT1 lncRNA lipopolysaccharide (LPS) inflammation human lung fibroblasts WI-38 lipopolysaccharides (LPS) treatment upregulated 31633220 1035 Human MALAT1 lncRNA lipopolysaccharide (LPS) innate immune response macrophages lipopolysaccharide (LPS) treatment upregulated 27434861 1036 Human MALAT1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemia/reperfusion (I/R) injury human brain microvascular endothelial cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment downregulated 28413461 1037 Human MALAT1 lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) brain microvascular endothelial cells (BMECs) oxygen glucose deprivation (OGD) treatment OGD induced upregulation of MALAT1 in HBMECs. 32591985 1038 Human MALAT1 lncRNA arsenite liver fibrosis lihuman hepatic (L-02) cells arsenite exposure Co-cultures with arsenite-treated L-02 cells induced the activation of LX-2 cells and overexpression of MALAT1. 31513886 1039 Human MALAT1 lncRNA E2F transcription factor 3 (E2F3) lung adenocarcinoma (LUAD) "SPC-A1/docetaxel (DTX), H1299/docetaxel (DTX), and A549/docetaxel (DTX) cells" E2F transcription factor 3 (E2F3) overexpression upregulated 30771618 1040 Human MALAT1 lncRNA ZEB1 lung adenocarcinoma (LUAD) "SPC-A1/docetaxel (DTX), H1299/docetaxel (DTX), and A549/docetaxel (DTX) cells" ZEB1 overexpression treatment upregulated 30771618 1041 Human MALAT1 lncRNA cigarette smoke extract (CSE) lung cancer human bronchial epithelial (HBE) cells cigarette smoke extract (CSE) treatment upregulated 26415832 1042 Human MALAT1 lncRNA gefitinib lung cancer A549 cells gefitinib treatment "MALAT1 promoted the proliferation and gefitinib resistance of lung cancer cells by sponging miR-200a, which regulates expression of ZEB1 in the A549 cells." 31133357 1043 Human MALAT1 lncRNA hypoxia lung cancer A549 lung adenocarcinoma cells hypoxia induce upregulated 29928414 1044 Human MALAT1 lncRNA IL-4 macrophage polarization human PBMC-derived macrophages and THP-1-derived macrophages. IL-4 treatment downregulated 30676324 1045 Human MALAT1 lncRNA lipopolysaccharide (LPS) macrophage polarization human PBMC-derived macrophages and THP-1-derived macrophages. lipopolysaccharide (LPS) treatment upregulated 30676324 1046 Human MALAT1 lncRNA hypoxia multiple myeloma (MM) "multiple myeloma (MM) cell lines MM1S, 8226, KMS12BM, KMS11, U266" hypoxia induce upregulated 29444873 1047 Human MALAT1 lncRNA palmitic acid (PA) myocardial lipotoxic injury human cardiomyocytes (AC16 cells) palmitic acid (PA) treatment upregulated 31123414 1048 Human MALAT1 lncRNA hyperbaric oxygen (HBO) neovascularization human coronary artery endothelial cells (HCAECs) hyperbaric oxygen (HBO) treatment HBO at 2.5?ATA significantly increased MALAT1 expression in HCAECs and HCAECs-derived exosomes. 30301563 1049 Human MALAT1 lncRNA hypoxia neuroblastoma (NB) human neuroblastoma cell lines hypoxia treatment upregulated 26848616 1050 Human MALAT1 lncRNA bupivacaine neurotoxicity The human neuroblastoma cell line SH-SY5Y bupivacaine treatment "The expression of lncRNA MALAT1 was upregulated upon exposure to bupivacaine. Knockdown of lncRNA MALAT1 significantly increased the cell death rates, and Caspase3 activity assays revealed that the apoptosis rates were manifestly increased in the MALAT1 downregulated group." 31254586 1051 Human MALAT1 lncRNA cisplatin (DDP) oral squamous cell carcinoma (OSCC) CAL-27 cells; SCC-9 cells cisplatin treatment DDP-resistant cells showed higher expression level of MALAT1 compared to cisplatin-na?ve cells. 32494159 1052 Human MALAT1 lncRNA IL-1¦Â osteoarthritis (OA) primary cultured chondrocytes IL-1¦Â treatment upregulated 31637891 1053 Human MALAT1 lncRNA osteogenic differentiation medium osteogenesis Adipose-derived mesenchymal stem cells (ADSCs) osteogenic differentiation media induce upregulated 30511267 1054 Human MALAT1 lncRNA estradiol-17¦Â (E2) osteosarcoma (OS) U2OS cells estradiol-17¦Â (E2) treatment upregulated 28098894 1055 Human MALAT1 lncRNA IL-17A otitis media (OM) human middle ear epithelial cells (HMEECs) IL-17A treatment RT-qPCR analysis revealed that long noncoding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was verified to be upregulated in LPS- or IL-17A-stimulated HMEECs 33506040 1056 Human MALAT1 lncRNA lipopolysaccharide (LPS) otitis media (OM) human middle ear epithelial cells (HMEECs) lipopolysaccharide (LPS) treatment RT-qPCR analysis revealed that long noncoding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was verified to be upregulated in LPS- or IL-17A-stimulated HMEECs 33506040 1057 Human MALAT1 lncRNA cisplatin (DDP) ovarian cancer (OC) ES2 cells cisplatin treatment upregulated 32901049 1058 Human MALAT1 lncRNA cisplatin (DDP) ovarian cancer cell stemness SKOV3 cells cisplatin treatment upregulated 32433460 1059 Human MALAT1 lncRNA high glucose (HG) oxidative stress retinal microvessels high glucose (HG) treatment upregulated 33051272 1060 Human MALAT1 lncRNA "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)" parkinson's disease (PD) SH-SY5Y cells "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment" upregulated 30260025 1061 Human MALAT1 lncRNA resveratrol parkinson's disease (PD) MPTP-treated human neuroblastoma cell line SH©\SY5Y resveratrol (RS) treatment downregulated 30260025 1062 Human MALAT1 lncRNA lipopolysaccharide (LPS) periodontal inflammation Primary human gingival fibroblasts (HGFs) lipopolysaccharide (LPS) treatment upregulated 31552681 1063 Human MALAT1 lncRNA androgen prostate cancer Human prostate cancer cell lines DU145 androgen stimulation lung adenocarcinoma transcript 1 (MALAT1) was increased in prostate cancer cells after androgen stimulation 30642743 1064 Human MALAT1 lncRNA docetaxel (DTX) prostate cancer DU-145 cells; PC-3 cells docetaxel (DTX) treatment LncRNA MALAT1 was overexpressed in human DTX-resistant PCa. 29633510 1065 Human MALAT1 lncRNA enzalutamide (Enz) prostate cancer Pca patients enzalutamide (Enz) treatment upregulated 28528814 1066 Human MALAT1 lncRNA Paris forrestii (PCT3) prostate cancer PC-3 cells Paris forrestii (PCT3) treatment upregulated 31810132 1067 Human MALAT1 lncRNA quercetin prostate cancer PC-3 cells Quercetin (Quer) treatment MALAT1 expression was significantly downregulated in quercetin-treated PC cells in a dose- and time-dependent manner 32210615 1068 Human MALAT1 lncRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (hPASMCs) hypoxia treatment lncRNA MALAT1 promotes the proliferation and migration of hPASMCs and inhibits their apoptosis by inhibiting the miR-503/TLR4 signal axis. 32712618 1069 Human MALAT1 lncRNA X-rays radiation-induced injury human lymphoblast cell line TK6 irradiat a RAD Source 2000 X-ray Biological irradiator treatment upregulated 24502193 1070 Human MALAT1 lncRNA ionizing radiation (IR) radiation-induced acute and chronic complications EA.hy926 cells ionizing radiation (IR) treatment radiation-induced DNA damage triggers cGAS signaling and subsequently increases the expression of MALAT1. 32532422 1071 Human MALAT1 lncRNA sunitinib (SU) renal cell carcinoma (RCC) 769P cells; 786O cells sunitinib (SU) treatment MALAT1 expression was dramatically upregulated in SU-resistance RCC tissues and cell lines. 32663095 1072 Human MALAT1 lncRNA TGF-¦Â1 renal fibrosis human renal proximal tubular epithelial (HK2) cells TGF-¦Â1 treatment TGF-¦Â1 induced fibrosis via upregulating MALAT1 expression in HK2 cells 32203053 1073 Human MALAT1 lncRNA CoCl2 renal ischemia/reperfusion (I/R) injury HK-2 cells cobalt chloride (CoCl 2) treatment upregulated 30277425 1074 Human MALAT1 lncRNA lipopolysaccharide (LPS) sepsis THP-1 cell line lipopolysaccharide (LPS) treatment upregulated 30896848 1075 Human MALAT1 lncRNA lipopolysaccharide (LPS) sepsis g human skeletal muscle cells (HSMKMC 3500) lipopolysaccharide (LPS) treatment upregulated 31830649 1076 Human MALAT1 lncRNA lipopolysaccharide (LPS) sepsis HSMKMC 3500 cells lipopolysaccharide (LPS) treatment upregulated 32882524 1077 Human MALAT1 lncRNA hypoxia spinal cord ischemia/reperfusion injury (SCII) AGE1.HN cells; P12 cells hypoxia treatment "The expression of MALAT1 and Bcl-2 was decreased, while miRNA-204 (miR-204) was upregulated in rats SCIRI model and neurocyte lines under hypoxic conditions." 29998804 1078 Human MALAT1 lncRNA dexamethasone (DEX) steroid-induced avascular necrosis of femoral head (SANFH) human bone marrow stromal cells (BMSC) dexamethasone (DEX) treatment downregulated 31678133 1079 Human MALAT1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) stroke human brain microvascular endothelial cells (HBMECs) oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 32217110 1080 Human MALAT1 lncRNA liposomal spherical nucleic acid (LSNA) therapeutic potential of a LSNA A549 (lung carcinoma) cells liposomal spherical nucleic acid (LSNA) downregulated 28026123 1081 Human MALAT1 lncRNA particulate matter (PM2.5) toxicity of PM2.5 human bronchial epithelial cell lines (BEAS-2B and A549). PM2.5 treatment upregulated 28839203 1082 Human MALAT1 lncRNA high glucose (HG) tubular injury HK-2?cells high glucose (HG) treatment LncRNA MALAT1 was upregulated in HK-2?cells treated with high glucose. 29928873 1083 Human MALAT1 lncRNA rapamycin vascular endothelial dysfunction human umbilical vein endothelial cells (HUVECs) rapamycin (RPM) treatment RPM treatment downregulates the endogenous expression of lncRNAs MALAT1 and SENCR in HUVECs 29845247 1084 Human MALAT1 lncRNA hypoxia vascular growth HUVECs exposed to hypoxia (0.2% O2) treatment upregulated 24602777 1085 Human MALAT1 lncRNA hypoxia vascular remodeling human pulmonary artery smooth muscle cells hypoxia treatment upregulated 28056547 1086 Human MALAT-1 lncRNA estradiol-17¦Â (E2) breast cancer "MCF10a, MCF7 and MB231 cells" estradiol-17¦Â (E2) treatment downregulated 24525122 1087 Human MALAT-1 lncRNA rosmarinic acid (RA) ovarian cancer (OC) OVCAR-3 human ovarian cancer cells rosmarinic acid treatment Rosmarinic acid induced upregulation of lncRNA MALAT-1 expression 30003749 1088 Human MALAT-1 lncRNA androgen prostate cancer human prostate cancer tissues and male nude mice androgen treatment MALAT-1 was upregulated in human prostate cancer tissues and cell lines. 23845456 1089 Human MALAT-1 lncRNA lipopolysaccharide (LPS) sepsis human dermal microvascular endothelial cells (HMECs) lipopolysaccharide (LPS) treatment upregulated 31231228 1090 Human MALAT1 lncRNA lipopolysaccharide (LPS) sepsis human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment MiR-150 was downregulated in LPS-induced HUVECs. 33181172 1091 Human MANTIS lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment upregulated 32714991 1092 Human MANTIS lncRNA HSA-bound P-cresol chronic kidney disease (CKD) and end-stage renal disease (ESRD) human umbilical vein endothelial cells (HUVECs) HSA-bound P-cresol treatment HSA-bound P-cresol induced HUVECs injury and decreased MANTIS expression. 31949698 1093 Human MATR3 lncRNA X-rays radiation-induced injury human lymphoblast cell line TK6 irradiat a RAD Source 2000 X-ray Biological irradiator treatment upregulated 24502193 1094 Human MCM3AP-AS1 lncRNA doxorubicin (DOX) chemoresistance of lymphoma Daudi and Namalwa cells doxorubicin treatment MCM3AP-AS1/miR-15a/EIF4E axis plays a role in the chemoresistance of Burkitt lymphoma 32765087 1095 Human MCM3AP-AS1 lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) human chondrocytes lipopolysaccharide (LPS) treatment upregulated 31836002 1096 Human MEG3 lncRNA CoCl2 acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 CoCl2 treatment upregulated 33175458 1097 Human MEG3 lncRNA hypoxia/reoxygenation (H/R) acute kidney injury (AKI) HK-2 cells hypoxia/reoxygenation (H/R) treatment upregulated 33175458 1098 Human MEG3 lncRNA hypoxia/reoxygenation (H/R) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 hypoxia/reoxygenation (H/R) treatment upregulated 33602903 1099 Human MEG3 lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) TKPTS cells lipopolysaccharide (LPS) treatment MEG3 was significantly increased in TKPTS cells induced by lipopolysaccharide (LPS). 29923218 1100 Human MEG3 lncRNA lipopolysaccharide (LPS) acute lung injury (ALI) human lung fibroblast WI-38 cells and human PMVECs lipopolysaccharide (LPS) treatment MEG3 was downregulated by LPS and its knockdown aggravated LPS-induced injury of human lung cells through miR-4262-mediated downregulated of KLF4. 31184231 1101 Human MEG3 lncRNA adriamycin (ADR) acute myeloid leukemia (AML) U937 cells; THP-1 cells adriamycin (ADR) treatment downregulated 32359033 1102 Human MEG3 lncRNA caerulein (Cae) acute pancreatitis (AP) Human pancreatic duct epithelial cells (HPDE) caerulein (Cae) treatment "As a result, the expression of MEG3 and FGFR2 was decreased in caerulein-induced HPDE cells, while the expression of miR-195-5p was increased." 32856219 1103 Human MEG3 lncRNA H2O2 age-related cataract (ARC) SRA01/04 cells H2O2 treatment MEG3 promoted ARC progression by up-regulating TP53INP1 expression through suppressing miR-223 and promoting P53 expression. 32841649 1104 Human MEG3 lncRNA arsenite apoptosis A549 cells arsenic (As) exposure "Our results demonstrated that MEG3 expression was positively correlated with the concentration of three arsenic species (inorganic arsenic (iAs), monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA)" 33033900 1105 Human MEG3 lncRNA CoCl2 apoptosis HK-2 cells CoCl2 treatment upregulated 33175458 1106 Human MEG3 lncRNA arsenite arsenic-induced apoptosis A549 arsenic (As) exposure upregulated 33033900 1107 Human MEG3 lncRNA baicalin (BAI) atherosclerosis (AS) ox-LDL-induced human aorta vascular smooth muscle cells (HA-VSMCs) baicalin (BAI) treatment upregulated 30535498 1108 Human MEG3 lncRNA baicalin (BAI) atherosclerosis (AS) ox-LDL-treated human aorta vascular smooth muscle cells (HA-VSMCs) baicalin (BAI) treatment upregulated 30535498 1109 Human MEG3 lncRNA melatonin atherosclerosis (AS) human aortic endothelial cells (HAECs) melatonin treatment downregulated 29024030 1110 Human MEG3 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29024030 1111 Human MEG3 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aorta vascular smooth muscle cells (HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 30535498 1112 Human MEG3 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aorta vascular smooth muscle cells (HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 30535498 1113 Human MEG3 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31312370 1114 Human MEG3 lncRNA bharangin breast cancer MCF 7 cells bharangin treatment upregulated 30251663 1115 Human MEG3 lncRNA pterostilbene breast cancer MCF 7 cells pterostilbene treatment upregulated 30619763 1116 Human MEG3 lncRNA angiotensin II (Ang II) cardiovascular disease (CVD) human umbilical vein endothelial cell (HUVECs) angiotensin II (Ang II) treatment downregulated 30838022 1117 Human MEG3 lncRNA etoposide (VP-16) cell senescence A549 and MCF-7 cells etoposide treatment ?the expression of lncRNA MEG3 and VGLL4 was significantly upregulated in senescent cells. 33141998 1118 Human MEG3 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SK-N-SH; SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment MEG3/miR-485/AIM2 axis contributes to pyroptosis via activating caspase1 signaling during cerebral I/R 31794744 1119 Human MEG3 lncRNA lidocaine cervical cancer (CC) HeLa cells lidocaine treatment "Long noncoding RNA maternally expressed gene 3 (lncRNA-MEG3) was significantly downregulated in cervical cancer cells, and lidocaine increased the expression of lncRNA-MEG3 in HeLa cells." 31632519 1120 Human MEG3 lncRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) 16HBE cells cigarette smoke extract (CSE) treatment MEG3 was upregulated in (CSE)-treated 16HBE cells. 31668807 1121 Human MEG3 lncRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) human pulmonary microvascular endothelial cell (HPMEC) cigarette smoke extract (CSE) treatment upregulated 32201430 1122 Human MEG3 lncRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) 16HBE cells cigarette smoke extract (CSE) treatment MEG3 expression was enhanced while miR-181a-2-3p abundance was reduced in the serum of patients with COPD and CSE-treated 16HBE cells. 33262837 1123 Human MEG3 lncRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) HBE135-E6E7 cells cigarette smoke extract (CSE) treatment MEG3 promoted proliferation and inhibited apoptosis by regulating the NF-¦ÊB signal pathway via miR-149-3p in CSE-treated HBE cells. 33365060 1124 Human MEG3 lncRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) CSE-treated 16HBE cells cigarette smoke extract (CSE) treatment "MEG3 was upregulated in COPD tissues and CSE-treated 16HBE cells, and knockdown of MEG3 mitigated CSE-repressed proliferation and CSE-triggered apoptosis or inflammation" 31668807 1125 Human MEG3 lncRNA particulate matter (PM2.5) chronic obstructive pulmonary disease (COPD) human bronchial epithelial cells (HBECs) PM2.5 treatment LncRNA maternally expressed gene 3 ( MEG3) was significantly upregulated in HBECs after PM25 treatment 29899163 1126 Human MEG3 lncRNA smoking chronic obstructive pulmonary disease (COPD) lung tissues smoking treatment MEG3 was upregulated in COPD tissues 31668807 1127 Human MEG3 lncRNA lipopolysaccharide (LPS) cirrhosis liver sinusoidal endothelial cells (LSECs) lipopolysaccharide (LPS) treatment upregulated 32269710 1128 Human MEG3 lncRNA tumor necrosis factor alpha (TNF-¦Á) coronary artery disease (CAD) human endothelial cell from umbilical vein (HU-VECs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 28804550 1129 Human MEG3 lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) human AC16 cardiomyocytes high glucose (HG) treatment "MEG3 was overexpressed in HG-treated AC16 cells, and MEG3 knockdown suppressed the HG-induced apoptosis in AC16 cells" 31085717 1130 Human MEG3 lncRNA high glucose (HG) diabetic nephropathy (DN) Human mesangial cells (HMCs) high glucose treatment upregulated 31737219 1131 Human MEG3 lncRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment High glucose (HG) inhibited MEG3 and SIRT1 expression and enhanced miR-34a expression. 30529346 1132 Human MEG3 lncRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose (HG) treatment High glucose (HG) inhibited MEG3 and SIRT1 expression and enhanced miR-34a expression. 30529346 1133 Human MEG3 lncRNA high glucose (HG) diabetic retinopathy (DR) Primary human retinal pigment epithelium (RPE) cells and ARPE-19 cells high glucose (HG) treatment "lncRNA MEG3 depresses HG-induced apoptosis and inflammation of RPE via miR-93/Nrf2 axis, providing a novel perspective on the genesis and development of DR." 32473920 1134 Human MEG3 lncRNA melatonin diabetic retinopathy (DR) MIO-M1 cells melatonin (MEL) treatment "MEG3 level was lower in HG-treated MIO-M1 cells, and melatonin (MEL) reversed the HG-induced decrease of MEG3." 32324260 1135 Human MEG3 lncRNA advanced glycation end product modified bovine serum albumin (AGE-BSA) diabetic vasculopathy human umbilical vein endothelial cells (HUVECs) advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment upregulated 30544204 1136 Human MEG3 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" epithelial ovarian cancer (EOC) "OVCAR3, SKOV3, HP8910 and ES-2 cells" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 24859196 1137 Human MEG3 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" esophageal squamous cell carcinoma (ESCC) KYSE-410 "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 27778235 1138 Human MEG3 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" esophageal squamous cell carcinoma (ESCC) "human esophageal cancer cell lines TE1, TE13, Eca109, YES2, and T.Tn" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28539329 1139 Human MEG3 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" gastric cancer (GC) "human gastric cancer cell lines MKN45, SGC7901, BGC823, and AGS" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 28345805 1140 Human MEG3 lncRNA TGF-¦Â1 glaucoma Glaucoma Tenon's capsule fibroblasts (GTFs) from patients with glaucoma filtration surgery TGF-¦Â2 (5ng/mL) treatment downregulated 28081465 1141 Human MEG3 lncRNA cisplatin (DDP) glioblastoma multiforme (GBM) U87 cells cisplatin treatment upregulated 28677749 1142 Human MEG3 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" glioblastoma multiforme (GBM) "U251, U87 and A172 human glioma cell lines" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" 5-Aza-2'-deoxycytidine (5-AzadC) decreased aberrant hypermethylation of the MEG3 promoter and prevented the loss of MEG3 expression. 26676363 1143 Human MEG3 lncRNA human papilloma virus (HPV) head and neck squamous cell carcinoma (HNSCC) primary tumors resected from HNSCC patients human papillomavirus (HPV) infection downregulated 32998396 1144 Human MEG3 lncRNA hypoxia/reoxygenation (H/R) hepatic ischemia/reperfusion injury (HIRI) HL7702 cells hypoxia re-oxygenation (H/R) treatment downregulated 28708282 1145 Human MEG3 lncRNA hypoxia/reoxygenation (H/R) hepatic ischemia/reperfusion injury (HIRI) HL7702 cells hypoxia re-oxygenation (H/R) treatment upregulated 28708282 1146 Human MEG3 lncRNA adenosine hepatocellular carcinoma (HCC) HepG2 cells adenosine treatment upregulated 31144362 1147 Human MEG3 lncRNA arsenic trioxide (ATO) hepatocellular carcinoma (HCC) "Four human hepatocellular carcinoma cell lines, SMMC-7721, Huh7, MHCC97H, and HCCLM3, and one human liver cell line L02" arsenic trioxide (ATO) treatment upregulated 31003765 1148 Human MEG3 lncRNA high glucose (HG) high glucose-induced endothelial dysfunction human umbilical vein endothelial cells (HUVEC) high glucose (HG) treatment MEG3 is significantly downregulated in an endothelial cell model of hyperglycemia. 31938204 1149 Human MEG3 lncRNA hypoxia hypoxia-induced injury HK-2 cells hypoxia induce upregulated 30860638 1150 Human MEG3 lncRNA hypoxia hypoxic pulmonary hypertension (HPH) human pulmonary artery smooth muscle cells hypoxia treatment lncRNA MEG3 was downregulated in human pulmonary artery smooth muscle cell in hypoxia. 29198701 1151 Human MEG3 lncRNA dexamethasone (DEX) immune thrombocytopenic purpura (ITP) peripheral blood dexamethasone (DEX) treatment downregulated 27522004 1152 Human MEG3 lncRNA palmitate insulin resistance (IR) Human HepG2 cells and primary hepatocytes "To establish an insulin-resistant hepatocyte cell model, hepatocytes were stimulated by palmitate (0.25 mM, Sigma-Aldrich, St. Louis, MO, USA) for 24 h, and treated with insulin (100 nM) for 20 min before harvest. treatment" MEG3 were upregulated in palmitate-treated insulin resistance hepatocytes and HFD mice 31298399 1153 Human MEG3 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic stroke (IS) human neuroblastoma cell lines SK-N-SH and SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 31794744 1154 Human MEG3 lncRNA etoposide (VP-16) lung adenocarcinoma (LUAD) human senescent cells etoposide treatment ?the expression of lncRNA MEG3 and VGLL4 was significantly upregulated in senescent cells. 33141998 1155 Human MEG3 lncRNA curcumin (Cur) lung cancer lung cancer cell lines A549 and H520 curcumin treatment Curcumin upregulated the expression of lncRNA-MEG3 and PTEN 33566305 1156 Human MEG3 lncRNA TGF-¦Â lung cancer human lung cancer cell lines TGF-¦Â treatment upregulated 27852821 1157 Human MEG3 lncRNA vincristine (VCR) lung cancer A549 cells; H292 cells vincristine treatment downregulated 29509250 1158 Human MEG3 lncRNA nickel lung tumorigenesis human bronchial epithelial cells nickel treatment downregulated 28263966 1159 Human MEG3 lncRNA respiratory syncytial virus (RSV) nasopharyngeal carcinoma (NPC) BEAS-2B cells respiratory syncytial virus (RSV) infection treatment downregulated 29257348 1160 Human MEG3 lncRNA all-trans retinoic acid (ATRA) neurogenesis amniotic epithelial cells (AECs) all-trans retinoic acid (ATRA) treatment "lncRNA MEG3 is upregulated by the ATRA/cAMP/CREB pathway, and it, in turn, is directly downregulated by miR-128-3p to increase the amount of neuron differentiation." 31921854 1161 Human MEG3 lncRNA paclitaxel (PTX) non-small cell lung cancer (NSCLC) A549 cells paclitaxel (PTX) treatment upregulated 30173893 1162 Human MEG3 lncRNA mineralizing solution osteogenesis human periodontal ligament cells (hPDLCs) mineralizing solution treatment downregulated 30256394 1163 Human MEG3 lncRNA mineralizing solution osteogenesis human periodontal ligament cells (hPDLCs) mineralizing solution treatment MEG3 was downregulated in osteogenic differentiation hPDLCs induced by mineralizing solution. 30256394 1164 Human MEG3 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" ovarian cancer (OC) cisplatin-resistant A2780cp cells treated with curcumin "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated 28175963 1165 Human MEG3 lncRNA curcumin (Cur) ovarian cancer (OC) cisplatin-resistant A2780cp cells curcumin treatment upregulated 28175963 1166 Human MEG3 lncRNA lipopolysaccharide (LPS) periodontitis periodontal ligament cells (PDLCs) lipopolysaccharide (LPS) treatment MEG3 level was decreased in LPS-treated PDLCs. 32520926 1167 Human MEG3 lncRNA high glucose (HG) podocyte injury human podocytes high glucose (HG) treatment upregulated 33061608 1168 Human MEG3 lncRNA tumor necrosis factor alpha (TNF-¦Á) psoriasis HaCaT and NHEKs cell lines tumor necrosis factor alpha (TNF-¦Á) treatment "MEG3/miR-21 axis may regulate the expression of caspase-8, and further influence the proliferation and apoptosis of psoriasis keratinocyte, Act-HaCaT and Act- HHEK" 31660855 1169 Human MEG3 lncRNA nickel oxide nanoparticles (NiO NPs) lung fibrosis A549 cells Nickel oxide nanoparticles (NiO NPs) treatment NiO NPs also evoked EMT and decreased MEG3 expression in a dose-dependent manner in A549 cells. 33547861 1170 Human MEG3 lncRNA hypoxia pulmonary hypertension (PH) human pulmonary artery smooth muscle cell hypoxia treatment downregulated 29198701 1171 Human MEG3 lncRNA lipopolysaccharide (LPS) pulpitis human dental pulp cells (hDPCs) lipopolysaccharide (LPS) treatment "Here, we performed high-throughput sequencing to identify dysregulated lncRNAs between human normal and inflamed pulp and concluded that lncMEG3 (lncRNA maternally expressed gene 3, MEG3) was signi?cantly upregulated in both inflamed pulp and LPS-treated hDPCs." 33524362 1172 Human MEG3 lncRNA TGF-¦Â1 renal fibrosis HK2 cells TGF-¦Â1 treatment downregulated 30095214 1173 Human MEG3 lncRNA respiratory syncytial virus (RSV) respiratory syndrome virus (PRRSV) infection BEAS-2B cells respiratory syncytial virus (RSV) infection treatment lncRNA MEG3 was reduced in the NPA samples of RSV-infected patients and in BEAS-2B cells infected with RSV 29257348 1174 Human MEG3 lncRNA etoposide (VP-16) cell senescence A549; MCF-7 cells etoposide treatment upregulated 33141998 1175 Human MEG3 lncRNA lipopolysaccharide (LPS) sepsis Human primary renal mixed epithelial cells lipopolysaccharide (LPS) treatment "lncRNA MEG3 overexpression and silencing using siRNA promoted and inhibited renal epithelial cell and cardiomyocyte apoptosis induced by lipopolysaccharide, respectively." 31641380 1176 Human MEG3 lncRNA lipopolysaccharide (LPS) sepsis U937 cells lipopolysaccharide (LPS) treatment downregulated 33040826 1177 Human MEG3 lncRNA iodine-131 (131I) thyroid cancer (TC) FTC-133 cells; TPC-1 cells iodine-131 (131I) treatment MEG3 expression appeared a decline and miR-182 expression displayed an increase in 131I-resistant FTC-133 (res-FTC-133) and TPC-1 (res-TPC-1) cells. 30021359 1178 Human MEG3 lncRNA high glucose (HG) type 1 diabetes mellitus (T1DM) CD4+ MOLT4 Tregs high glucose (HG) treatment upregulated 33572095 1179 Human MEG3 lncRNA H2O2 ulcerative colitis (UC) Caco-2 cells H2O2 treatment downregulated 33394187 1180 Human MEG3 lncRNA dNK/IFN-¦Á uterovascular transformation vascular smooth muscle cell (VSMC) dNK/IFN-¦Á treatment upregulated 28161059 1181 Human MEG3 lncRNA dNK/IFN-¦Ã spiral artery remodeling human aorta VSMC (HA-VSMC) line dNK/IFN-¦Ã treatment upregulated 28161059 1182 Human MEG4 lncRNA carbon tetrachloride (CCl4) liver fibrosis human hepatic stellate cell lines LX-2 cells CCl4 treatment downregulated 25201081 1183 Human MEG5 lncRNA TGF-¦Â1 liver fibrosis human hepatic stellate cell lines LX-3 cells in response to transforming growth factor-¦Â1 (TGF-¦Â1) treatment downregulated 25201082 1184 Human MEG8 lncRNA TGF-¦Â epithelial-mesenchymal transition (EMT) A549 cells; LC2/ad cells; Panc1 cells TGF-¦Â treatment MEG8 lncRNA expression was immediately induced during TGF-¦Â-mediated EMT of A549 and LC2/ad lung cancer and Panc1 pancreatic cancer cell lines 30262664 1185 Human MER11C lncRNA aurora kinase inhibitor (CCT137690) breast cancer MDA-MB-231 cells aurora kinase inhibitor (CCT137690) treatment downregulated 31319040 1186 Human METTL8 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 1187 Human MFI2-AS1 lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) C28/I2 cells lipopolysaccharide (LPS) treatment MFI2-AS1 expression was increased in osteoarthritis tissues and LPS-treated C28/I2 cells. 31678554 1188 Human MHRT lncRNA bharangin breast cancer MCF 7 cells bharangin treatment upregulated 30251663 1189 Human MHRT lncRNA H2O2 chronic heart failure (CHF) human cardiomyocyte cell line AC16 H2O2 treatment downregulated 31853247 1190 Human MIAT lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aorta vascular smooth muscle cells (HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 29136944 1191 Human MIAT lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aorta vascular smooth muscle cells (HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment Proliferation and migration were modified by MIAT/miR-148b/PAPPA axis in ox-LDL induced AS cell model. 32470448 1192 Human MIAT lncRNA diethylstilbestrol (DES) breast cancer MCF-7?cells diethylstilbestrol (DES) treatment Activating estrogen signaling by diethylstilbestrol (DES) led to a dose- and time-dependent upregulated of MIAT in MCF-7?cells. 29792859 1193 Human MIAT lncRNA high glucose (HG) diabetic nephropathy (DN) human mesangial cells (HMCs) high glucose (HG) treatment upregulated 33009725 1194 Human MIAT lncRNA advanced glycation end product modified bovine serum albumin (AGE-BSA) diabetic retinopathy (DR) human retinal pericytes (HRPCs) advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment "MIAT and CASP1 expression were substantially increased, while that of miR-342-3p was decreased in AGE-BSA-treated HRPCs." 33065089 1195 Human MIAT lncRNA advanced glycation end product modified bovine serum albumin (AGE-BSA) diabetic retinopathy (DR) primary human retinal pericytes (HRPCs) advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment Long noncoding RNA MIAT regulates primary human retinal pericyte pyroptosis by mdulating miR-342-3p targeting of CASP1 in diabetic retinopathy. 33065089 1196 Human MIAT lncRNA high glucose (HG) angiogenesis diabetic retinas and endothelial cells high glucose treatment upregulated 25587098 1197 Human MIAT lncRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) human renal proximal tubular epithelial (HK-2) cells TGF-¦Â1 treatment "MIAT knockdown reduced cell viability, proliferation, migration, and the EMT in HK-2 cells" 31863776 1198 Human MIAT lncRNA hypoxia hepatocellular carcinoma (HCC) HepG2 cells hypoxia treatment upregulated 32468055 1199 Human MIAT lncRNA hypoxia hypoxic pulmonary hypertension (HPH) human pulmonary alveolar epithelial cells (HPAECS) hypoxia treatment "MIAT was upregulated in both in vivo and in vitro HPH models, while miR-29a-5p was downregulated." 32964992 1200 Human MIAT lncRNA tumor necrosis factor alpha (TNF-¦Á) inflammation human adipose-derived stem cells (hASCs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 27797128 1201 Human MIAT lncRNA bortezomib multiple myeloma (MM) Bone marrow bortezomib? treatment upregulated 30967527 1202 Human MIAT lncRNA TGF-¦Â1 renal interstitial fibrosis (RIF) HK-2 cells TGF-¦Â1 treatment upregulated 31863776 1203 Human MIAT lncRNA high glucose (HG) renal tubules injury human renal tubular epithelial cell line (HK-2) high glucose treatment downregulated 26551455 1204 Human MIAT2 lncRNA lipopolysaccharide (LPS) inflammation Human WI©\38 cells lipopolysaccharide (LPS) treatment ?MIAT2 was negatively regulated by LPS and it alleviated LPS-induced damage. 31566734 1205 Human MIAT2 lncRNA lipopolysaccharide (LPS) neonatal pneumonia WI-38 cells lipopolysaccharide (LPS) treatment MIAT2 was negatively regulated by LPS and it alleviated LPS-induced damage. 31566734 1206 Human MINCR lncRNA radiation nasopharyngeal carcinoma (NPC) NP460; CNE2; CNE2R cells radiation treatment "MINCR diminished NPC cell radiosensitivity by sponging miR-223, increasing ZEB1 and activating the AKT/PI3K axis" 33290841 1207 Human MIR100HG lncRNA hypoxia and TGF¦Â1 idiopathic pulmonary fibrosis (IPF) human pulmonary fibroblasts (HPFs) hypoxia and TGF¦Â1 treatment upregulated 31925944 1208 Human MIR100HG lncRNA CoCl2 pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (HPASMCs) CoCl2 treatment upregulated 32391042 1209 Human MIR155HG lncRNA doxorubicin (DOX) cellular defense against genotoxic agents human glioma cell lines doxorubicin (DOX) treatment downregulated 25645334 1210 Human MIR155HG lncRNA resveratrol cellular defense against genotoxic agents human glioma cell lines resveratrol (Res) treatment upregulated 25645334 1211 Human MIR155HG lncRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) human pulmonary microvascular endothelial cell (HPMECs) cigarette smoke extract (CSE) treatment upregulated 32129458 1212 Human MIR155HG lncRNA TGF-¦Â1 lung fibrosis normal human primary lung fibroblasts (NHLFs) TGF-¦Â1 treatment The lncRNA MIR155 host gene (MIR155HG) was found to be abnormally upregulated in pulmonary fibrosis tissues and TGF¦Â1-stimulated normal human primary lung fibroblasts (NHLFs) 33482190 1213 Human MIR181A2HG lncRNA high glucose (HG) diabetic vasculopathy Human umbilical vein endothelial cells (HUVECs) high-glucose (HG) treatment "he persistent exposure of HUVECs to HG resulted in MIR181A2HG downregulated and thus reduced its ability to sponge miR-6832-5p, miR-6842-5p and miR-8056, subsequently leading to an increase in miR-6832-5p, miR-6842-5p and miR-8056 levels." 33537821 1214 Human MIR210HG lncRNA gemcitabine (GEM) ancreatic cancer (PC) SW1990 cells gemcitabine (GEM) treatment upregulated 30113217 1215 Human MIR210HG lncRNA Hypoxia warburg effect MCF7; T47D; ZR-75-1 cells hypoxia treatment upregulated 33392077 1216 Human MIR22 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 1217 Human MIR22HG lncRNA 6-thioguanine (6-TG) breast cancer MCF-7 cells 6-thioguanine (6-TG) treatment upregulated 33376537 1218 Human MIR22HG lncRNA microcystin-leucine arginine (MC-LR) MC-LR-induced hepatotoxicity HL7702 cells microcystin-LR(MC-LR) treatment upregulated 30430930 1219 Human MIR22HG lncRNA hypoxia myocardial infarction (MI) AC16 cardiomyocytes hypoxia treatment Results showed that hypoxia treatment decreased viability and increased MIR22HG expression in AC16 cardiomyocytes. 33631962 1220 Human MIR3142HG lncRNA IL-1¦Â inflammation human lung fibroblasts IL-1¦Â treatment upregulated 30619270 1221 Human MIR31HG lncRNA gefitinib non-small cell lung cancer (NSCLC) gefitinib-resistant PC9 (PC9-R) cell lines gefitinib upregulated 28529576 1222 Human MIR4435-2HG lncRNA Fusobacterium nucleatum (F. nucleatum) oral squamous cell carcinoma (OSCC) human immortalized oral epithelial cells (HIOECs); SCC-9 cells; HSC-4 cells F. nucleatum infection upregulated 31997506 1223 Human MIR497HG lncRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (HRECs) high glucose (HG) treatment High-level glucose (HG) treatment significantly downregulated MIR497HG in HRECs. 32572899 1224 Human MIR503HG lncRNA high glucose (HG) proximal tubular cell apoptosis Human proximal tubular (HK-2) cells high glucose (HG) treatment MIR503HG indirectly regulates Bcl-2 by promoting the co-transcription of miRNA-503 to participate high-glucose-induced proximal tubular cell apoptosis. 33262626 1225 Human MIR503HG lncRNA XAV939 non-small cell lung cancer (NSCLC) "The NSCLC cell line, NCI-H1299" 10 ?M XAV939 for 12 h treatment The downregulated of lncRNA?MIR503HG?induced by XAV939 may serve an important role in NSCLC suppression via sponging?miR-1273c?and regulating?SOX4?expression 31186710 1226 Human MIR6516 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment upregulated 29947995 1227 Human Mirt2 lncRNA lipopolysaccharide (LPS) cell damage HK-2 cells lipopolysaccharide (LPS) treatment LncRNA?Mirt2 prohibits lipopolysaccharide-evoked HK-2 cell injury via modulation of?microRNA-126. 31889348 1228 Human Mirt2 lncRNA lipopolysaccharide (LPS) IgA nephropathy (IgAN) HK-2 cells lipopolysaccharide (LPS) treatment LPS inhibited Mirt2 expression in HK-2 cells. 31889348 1229 Human Mirt2 lncRNA tumor necrosis factor alpha (TNF-¦Á) inflammation SH-Sy5y cells tumor necrosis factor alpha (TNF-¦Á) treatment "Mirt2 overexpression moderated TNF-¦Á-caused apoptosis associated with inflammation and oxidative stress Mirt2 suppressed TNF-¦Á-induced accumulation of miR-101, and based on this Mirt2 exhibited anti-inflammatory roles" 31513985 1230 Human Mirt2 lncRNA tumor necrosis factor alpha (TNF-¦Á) parkinson's disease (PD) SH-Sy5y cells tumor necrosis factor alpha (TNF-¦Á) treatment "Mirt2 overexpression moderated TNF-¦Á-caused apoptosis associated with inflammation and oxidative stress Mirt2 suppressed TNF-¦Á-induced accumulation of miR-101, and based on this Mirt2 exhibited anti-inflammatory roles" 31513985 1231 Human Mirt2 lncRNA lipopolysaccharide (LPS) ulcerative colitis (UC) colonic epithelial cells lipopolysaccharide (LPS) treatment downregulated 31687015 1232 Human MKI67IP-3 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) HUVECs oxidized low-density lipoprotein (ox-LDL) treatment downregulated 28195197 1233 Human MM2P lncRNA lipopolysaccharide- and MSU acute gouty arthritis (AGA) THP-1 cells lipopolysaccharide-and MSU treatment downregulated 32705194 1234 Human Morrbid lncRNA lymphocytic choriomeningitis virus (LCMV) lymphocytic choriomeningitis virus (LCMV) infection CD8 T cell lymphocytic choriomeningitis virus (LCMV) infection upregulated 31138702 1235 Human MPRL lncRNA cisplatin (DDP) tongue squamous cell carcinoma (TSCC) "human TSCC cell lines, CAL-27, SCC-9 and SCC-25" cisplatin treatment MPRL expression was significantly upregulated in TSCC cell lines treated with cisplatin and transactivated by E2F1. 30885939 1236 Human MSC-AS1 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) LN229 cells; SHG-44 cells temozolomide (TMZ) treatment MSC-AS1 was upregulated in TMZ-resistant glioma tissues and cells 33106913 1237 Human MSC-AS1 lncRNA gemcitabine (GEM) pancreatic ductal adenocarcinoma (PDAC) Human pancreatic cancer cell lines PANC-1 and BxPC-3 gemcitabine treatment MSC-AS1/miR-29b-3p axis modulates the cell proliferation and GEM-induced cell apoptosis in PDAC cell lines through CDK14. 30915884 1238 Human MST1P2 lncRNA cisplatin (DDP) cisplatin (DDP) resistance SW 780 cells cisplatin treatment MST1P2 serves as a competing endogenous RNA for miR-133b to counteract miR-133b-induced suppression on Sirt1. 32052927 1239 Human MSTRG.292666.16 lncRNA osimertinib non-small cell lung cancer (NSCLC) plasma; H1975R cells; H1975R cells-derived exosomes osimertinib treatment "lncRNA MSTRG.292666.16 was significantly upregulated in osimertinib-resistant plasma, osimertinib-resistant H1975R cells and their derived exosomes, compared with those in osimertinib-sensitive plasma, H1975 cells and exosomes." 32375124 1240 Human MSX2P1 lncRNA IL-22 psoriasis HaCaT cells IL-22 treatment upregulated 29339075 1241 Human MT1DP lncRNA cadmium (Cd) cadmium (Cd)-induced hepatoxicity HepG2 cells cadmium (Cd) treatment upregulated 30027041 1242 Human MT1DP lncRNA cadmium (Cd) cadmium-induced toxicity blood; blood exosomes; liver cells cadmium (Cd) treatment upregulated 31864927 1243 Human MTA2TR lncRNA hypoxia pancreatic cancer (PC) PANC-1;BxPC-3;SW1990 cell; hypoxia induce upregulated 31410216 1244 Human MTMR9LP lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment upregulated 32714991 1245 Human MUDENG lncRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) nasopharyngeal carcinoma (NPC) cells curcumin treatment dysregulated 24379026 1246 Human MUDENG lncRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) nasopharyngeal carcinoma (NPC) cells curcumin treatment upregulated 24379026 1247 Human MX1-215 lncRNA IFN-¦Á head and neck squamous cell carcinoma (HNSCC) Cal27 cells; HN30 cells IFN-¦Á treatment upregulated 31907020 1248 Human n335586 lncRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HCC tissues; HepG2.2.15cells hepatitis B virus (HBV) infection n335586 was significantly increased in HBV positive HCC tissues and cells. 29753758 1249 Human n336098 lncRNA radiation and microgravity astronaut health human lymphoblastoid TK6 cells radiation and microgravity treatment upregulated 31987473 1250 Human n337041 lncRNA radiation and microgravity astronaut health human lymphoblastoid TK6 cells radiation and microgravity treatment upregulated 31987473 1251 Human n344988 lncRNA radiation and microgravity astronaut health human lymphoblastoid TK6 cells radiation and microgravity treatment upregulated 31987473 1252 Human n345751 lncRNA radiation and microgravity astronaut health human lymphoblastoid TK6 cells radiation and microgravity treatment upregulated 31987473 1253 Human NBR2 lncRNA curcumin (Cur) colorectal cancer (CRC) "4 human CRC cell lines, including HCT116, HCT8, SW480, and SW620" curcumin treatment "when colorectal cancer cells were treated with curcumin, the expression of NBR2 was significantly increased." 31888414 1254 Human NBR2 lncRNA glucose colorectal cancer (CRC) "4 human CRC cell lines, including HCT116, HCT8, SW480, and SW620" glucose starvation "glucose deficiency increased the expression of NBR2 in colorectal cancer cells, and NBR2 knockdown affected the progression of colorectal cancer cells under glucose starvation conditions." 31888414 1255 Human nc886 lncRNA doxorubicin (DOX) cytotoxicity "HCT116 cells, Nthy-ori 3-1 cells" doxorubicin treatment downregulated 30948645 1256 Human nc886 lncRNA ultraviolet (UV) irradiation inflammation ?human keratinocytes HaCaT cells ultraviolet B (UVB) radiation treatment downregulated 30685091 1257 Human nc886 lncRNA TGF-¦Â ovarian cancer (OC) SKOV3 cells transforming growth factor-¦Â (TGF-¦Â) treatment upregulated 29563500 1258 Human nc886 lncRNA ultraviolet (UV) irradiation photoaging human keratinocyte (HaCaT) cells UVB irradiation treatment "UVB irradiation accelerates the methylation of the nc886 gene, therefore, reducing its expression" 32630038 1259 Human NCK1-AS1 lncRNA cisplatin (DDP) cervical cancer (CC) Cervical cancer HeLa cells cisplatin treatment si-NCK1-AS1 and miR-134-5p mimic both reduced MSH2 activity and increased cisplatin-induced apoptosis in cervical cancer cells. 30221354 1260 Human NCK1-AS1 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U251 and A172 cells temozolomide (TMZ) treatment upregulated 31750728 1261 Human NCK1-AS1 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U251; A172 cells temozolomide (TMZ) treatment NCK1-AS1 could increase drug resistance of glioma cells to TMZ by modulating miR-137/TRIM24 pathway 31750728 1262 Human NCRMS lncRNA aurora kinase inhibitor (CCT137690) breast cancer MCF-7 cells; MDA-MB-231 cells aurora kinase inhibitor (CCT137690) treatment downregulated 31319040 1263 Human NEAT1 lncRNA lipopolysaccharide (LPS) inflammation "The human osteosarcoma cell line, MG63" lipopolysaccharide (LPS) treatment "?There were 427 dysregulated genes in the LPS-stimulated MG63 cells, in which NEAT1 was significantly downregulated" 33416115 1264 Human NEAT1 lncRNA IL-1¦Â intervertebral disc degeneration (IDD) human nucleus pulposus cells IL-1¦Â treatment TNF-¦Á/IL-1¦Â induced a time- and dose-dependent increase in the mRNA expression of lncRNA NEAT1 in the nucleus pulposus cells 33478594 1265 Human NEAT1 lncRNA tumor necrosis factor alpha (TNF-¦Á) intervertebral disc degeneration (IDD) human nucleus pulposus cells tumor necrosis factor alpha (TNF-¦Á) treatment TNF-¦Á/IL-1¦Â induced a time- and dose-dependent increase in the mRNA expression of lncRNA NEAT1 in the nucleus pulposus cells 33478594 1266 Human NEAT1 lncRNA Iodine-131 (131I) papillary thyroid cancer (PTC) thyroid papillary cell line TPC-1 (BNCC337912) and B-CPAP (BNCC338685) 131I treatment NEAT1 suppression could inhibit 131I resistance of PTC by upregulating miR-101-3p/FN1 expression and inactivated PI3K/AKT signaling pathway both in vitro and in vivo. 30596336 1267 Human NEAT1 lncRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) HCT8; SW480 cells 5-fluorouracil (5-FU) treatment LncRNA NEAT1 could target miR-34a and promote autophagy to facilitate 5-FU chemoresistance in CRC. 31802650 1268 Human NEAT1 lncRNA CoCl2 acute kidney injury (AKI) human kidney tubular cells (HK-2) CoCl2?-stimulated HK-2 cells NEAT1 was upregulated in AKI patients compared with healthy control. 31090110 1269 Human NEAT1 lncRNA ischemia acute kidney injury (AKI) serum from AKI patients ischemia©\induced AKI The level of NEAT1 in HK©\2 cells treated with CoCl2 was higher in a dose©\dependent manner. 31090110 1270 Human NEAT1 lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK-2 cells lipopolysaccharide (LPS) treatment NEAT1 was upregulated in LPS-stimulated HK-2 cells. 33335994 1271 Human NEAT1 lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 lipopolysaccharide (LPS) treatment NEAT1 was upregulated in serum of sepsis patients and LPS-induced HK2 cells. 33885954 1272 Human NEAT1 lncRNA all-trans retinoic acid (ATRA) acute promyelocytic leukemia (APL) NB4 cells all-trans retinoic acid (ATRA) treatment upregulated 29111326 1273 Human NEAT1 lncRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) SH-SY5Y and SK-N-SH cells amyloid ¦Â1-42?(A¦Â) treatment "NEAT1 expression was enhanced in A¦Â-treated SH-SY5Y and SK-N-SH cells, miR-107 abundance was reduced in A¦Â-treated cells, and its overexpression reversed A¦Â-induced injury. Moreover, interference of miR-107 abated silencing of NEAT1-mediated inhibition of neuronal damage in A¦Â-treated SH-SY5Y and SK-N-SH cells." 31250578 1274 Human NEAT1 lncRNA acrolein apoptosis vascular smooth muscle cells (VSMCs) acrolein treatment downregulated 31864078 1275 Human NEAT1 lncRNA acrolein atherosclerosis (AS) vascular smooth muscle cells (VSMCs) Acrolein treatment downregulated 31864078 1276 Human NEAT1 lncRNA asparagus extract (AE) atherosclerosis (AS) Acrolein-treated vascular smooth muscle cells (VSMCs) asparagus extract (AE) treatment upregulated 31864078 1277 Human NEAT1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment NEAT1 was significantly increased in THP-1 cells incubated with ox-LDL and meanwhile miR-342-3p was greatly decreased. 30259979 1278 Human NEAT1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment upregulated 30259979 1279 Human NEAT1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human aortic endothelial cells (HAECs) oxidized low-density lipoprotein (ox-LDL) treatment NEAT1 adjusted the AKT/mTOR signaling pathway via miR-638 in ox-LDL-induced HAECs to accelerate their proliferation and impede their apoptosis. 32377692 1280 Human NEAT1 lncRNA Trimethylamine N-oxide (TMAO) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) Trimethylamine N-oxide (TMAO) exposure treatment upregulated 31173767 1281 Human NEAT1 lncRNA t-butylhydroperoxide (t-BHP) atherosclerotic coronary heart disease (CHD) Primary HUVECs t-butylhydroperoxide (t-BHP) treatment upregulated 31352814 1282 Human NEAT1 lncRNA bharangin breast cancer MCF 7 cells bharangin treatment upregulated 30251663 1283 Human NEAT1 lncRNA hypoxia breast cancer MCF-7 cells 1% O2 treatment upregulated 26289678 1284 Human NEAT1 lncRNA lipopolysaccharide (LPS) bronchopneumonia BEAS-2B cells lipopolysaccharide (LPS) treatment "NEAT1 and MyD88 were upregulated in BEAS-2B cells by LPS, while miR-155-5p was downregulated." 33719773 1285 Human NEAT1 lncRNA macrophage migration inhibitory factor (MIF) cardioprotective therapy human adipose-derived MSCs (ADMSCs); Human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes macrophage migration inhibitory factor (MIF) treatment LncRNA-NEAT1/miR-142-3p/FOXO1 at least partially mediates the cardioprotective roles of exosomeMIF in protecting cardiomyocytes from apoptosis. 31964409 1286 Human NEAT1 lncRNA H2O2 cataract human lens epithelial cells (HLECs) H2O2 treatment upregulated 33490165 1287 Human NEAT1 lncRNA resveratrol cellular defense against genotoxic agents human glioma cell lines resveratrol (Res) treatment upregulated 25645334 1288 Human NEAT1 lncRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) "Human normal colonic epithelial cell line, FHC, and colorectal carcinoma cell lines, HT29, HCT8, HCT116, SW480, SW620" 5-fluorouracil (5-FU) treatment NEAT1 knockdown noticeably inhibited the proliferation of CRC cells and enhanced 5-FU sensitivity. 31802650 1289 Human NEAT1 lncRNA lipopolysaccharide (LPS) corneal neovascularization (CNV) human corneal fibroblasts (HCFs) lipopolysaccharide (LPS) treatment The expression of NEAT1 in HCFs was upregulated by LPS. 30328354 1290 Human NEAT1 lncRNA high glucose (HG) diabetic nephropathy (DN) Human mesangial cells high glucose (HG) treatment Real-time PCR was performed to detect the relative NEAT1 and miR-222-3p expressions and further confirmed the relationship between NEAT1 and miR-222-3p. 33585566 1291 Human NEAT1 lncRNA high glucose (HG) diabetic nephropathy (DN) HK-2 cells high glucose (HG) treatment "Our results showed that NEAT1 and Drp1 levels were upregulated, while miR-150-5p level was downregulated in HK-2 cells in response to HG." 33914383 1292 Human NEAT1 lncRNA fenofibrate drug-inducible neuroprotection from oxidative stress SH-SY5Y cells fenofibrate treatment upregulated 31311324 1293 Human NEAT1 lncRNA paraquat (PQ) drug-inducible neuroprotection from oxidative stress SH-SY5Y cells paraquat (PQ) treatment upregulated 31311324 1294 Human NEAT1 lncRNA simvastatin drug-inducible neuroprotection from oxidative stress SH-SY5Y cells simvastatin treatment upregulated 31311324 1295 Human NEAT1 lncRNA rapamycin dyslipidemia serum rapamycin treatment hsa-miR-372-3p was filtered using RNA sequencing and identified as a key regulator in rapamycin-induced TGs accumulation 33705959 1296 Human NEAT1 lncRNA progesterone (P4) endometrial cancer (EC) human Ishikawa cells Progesterone treatment NEAT1 or LEF1 was overexpressed in endometrial cancer cells while downregulated following post-treatment with progesterone 30452118 1297 Human NEAT1 lncRNA progesterone (P4) endometrial cancer (EC) Ishikawa cells progesterone treatment LncRNA nuclear enriched abundant transcript 1 (NEAT1) was the most significantly downregulated lncRNA in endometrial cancer cells treated with progesterone 30452118 1298 Human NEAT1 lncRNA TGF-¦Â2 epithelial-mesenchymal transition (EMT) Primary human LECs (HLECs) TGF-¦Â2 treatment "TGF-¦Â2 induces NEAT1 overexpression, which in turn suggests that NEAT1 acts as a ceRNA targeting Snail1 or Zeb1 by binding miR-34a or miR-204" 32596382 1299 Human NEAT1 lncRNA adriamycin (ADR) gastric cancer (GC) SGC7901 cells adriamycin (ADR) treatment "NEAT1 was upregulated in GC tissues and cells, especially in in GC adriamycin-resistant cells." 28401449 1300 Human NEAT1 lncRNA oxaliplatin gastric cancer (GC) GC cell lines HGC-27;BGC-823 oxaliplatin treatment upregulated 31617275 1301 Human NEAT1 lncRNA oxaliplatin gastric cancer (GC) HGC-27 cells; BGC-823 cells oxaliplatin (OXA) treatment upregulated 31617275 1302 Human NEAT1 lncRNA radiation gastric cancer (GC) MKN-45 and AGS cells radiation treatment NEAT1 depletion enhanced radio-sensitivity of GC by negatively regulating miR-27b-3p in vitro and in vivo 33292252 1303 Human NEAT1 lncRNA adenovirus (ADV) glioblastoma multiforme (GBM) FMXJ-1 cells adenovirus (ADV) treatment ADV infection upregulated lncRNA NEAT1. 32843056 1304 Human NEAT1 lncRNA estradiol-17¦Â (E2) hepatic steatosis HepG2 cells estradiol-17¦Â (E2) treatment upregulated 31062612 1305 Human NEAT1 lncRNA oleacein (OA) hepatic steatosis HepG2 cells oleic acids treatment upregulated 31062612 1306 Human NEAT1 lncRNA hypoxia hepatocellular carcinoma (HCC) SNU-182 cells; HUH7 cells hypoxia treatment LncRNA-NEAT1 expression was significantly induced by hypoxia in SNU-182 and HUH7 cells. 32670881 1307 Human NEAT1 lncRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HepG2 or Bel7404 sorafenib (Sora) treatment "lncRNA NEAT1 mediates Sora resistance of HCC cells by suppressing miR-335 expression, and disinhibition on c-Met-Akt signaling pathway" 30937906 1308 Human NEAT1 lncRNA histone deacetylase (HDAC) histone deacetylase resistance in nasopharyngeal cancer (NPC) CNE1; CNE2; C666¨C1 Histone deacetylase treatment upregulated 32692721 1309 Human NEAT1 lncRNA herpes simplex virus 1 (HSV-1) herpes simplex virus 1 (HSV-1) infection HeLa cells infect with HSV-1 upregulated 27783096 1310 Human NEAT1 lncRNA lipopolysaccharide (LPS) osteoblasts inflammation MG63 cells lipopolysaccharide (LPS) treatment downregulated 33416115 1311 Human NEAT1 lncRNA Toll-like receptor3-p38 pathway-triggered poly I:C innate immune response HeLa TO cells £¬ A549 cells cells were transfect poly I:C treatment upregulated 24507715 1312 Human NEAT1 lncRNA advanced glycation end product (AGE) intervertebral disc degeneration (IDD) human nucleus pulposus cells (HNPC) advanced glycation end product (AGE) treatment upregulated 32850952 1313 Human NEAT1 lncRNA sepsis liver damage liver tissues sepsis induce treatment The expression of lncRNA NEAT1 in liver tissue of patients with sepsis-induced liver injury was clearly increased 31344555 1314 Human NEAT1 lncRNA particulate matter (PM2.5) lung cancer BEAS-2B and HBE cells particulate matter (PM2.5) treatment Loss of NEAT1 represses the malignant transformation of BEAS-2B and HBE cells induced by PM25 33829382 1315 Human NEAT1 lncRNA lipopolysaccharide (LPS) lupus nephritis (LN) Human renal mesangial cells (HRMCs) lipopolysaccharide (LPS) treatment "NEAT1 accelerated renal mesangial cell injury via directly targeting miR-146b, promoting the expression of TRAF6, and activating the NF-¦ÊB signaling in lupus nephritis." 32710276 1316 Human NEAT1 lncRNA dexamethasone (DEX) multiple myeloma (MM) MM1R cell lines dexamethasone (Dex) treatment NEAT1 was highly expressed in DEX-resistant myeloma cell lines. 29948578 1317 Human NEAT1 lncRNA resveratrol multiple T myeloma U266 cells; LP1 cells resveratrol (RS) treatment "lncRNA NEAT1 was highly expressed in MM cells, which could be significantly inhibited by resveratrol" 30107344 1318 Human NEAT1 lncRNA free fatty acids (FFA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells free fatty acids (FFA) treatment NEAT1 and miR-140 are upregulated in hepacytes under the NAFLD conditions. The NEAT1-miR-140 axis play a crucial role in modulation of NAFLD via inactivation of AMPK/SREBP1 signaling. 31239155 1319 Human NEAT1 lncRNA free fatty acids (FFA) nonalcoholic fatty liver disease (NAFLD) HepG2 cells free fatty acids (FFA) treatment upregulated 31484042 1320 Human NEAT1 lncRNA bone morphogenetic protein 1 (BMP1) osteogenesis human bone marrow-derived mesenchymal stem cells (hBMSCs) BMP1 treatment NEAT1 promotes osteogenic differentiation in hBMSCs by regulating miR-29b-3p/BMP1 axis. 30638953 1321 Human NEAT1 lncRNA radioactivity iodine (RAI) papillary thyroid cancer (PTC) TPC-1 cells; B-CPAP cells radioactivity iodine (RAI) treatment upregulated 30596336 1322 Human NEAT1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) Human neuroblastoma cell line SH-SY5Y 1-methyl-4-phenylpyridinium (MPP+) treatment ?NEAT1 expression was significantly increased in SH-SY5Y cells after MPP+?treatment in dose- and time- dependent manners. 31228597 1323 Human NEAT1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment downregulated of NEAT1 repressed ¦Á-syn-induced activation of NLRP3 inflammasome via inhibiting the expression of GJB1 by targeting miR-1301-3p. 32712773 1324 Human NEAT1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH5Y-SY cells N-methyl-4-phenylpyridinium (MPP +) treatment upregulated 29287722 1325 Human NEAT1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4- phenylpyridinium iodide(MPP +) treatment upregulated 29575151 1326 Human NEAT1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment upregulated 32712773 1327 Human NEAT1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment "Here, the increased lncRNA NEAT1 was discovered in MPP+-induced SH-SY5Y cells." 32712773 1328 Human NEAT1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SK-N-SH cells 1-methyl-4-phenylpyridinium (MMP+) treatment upregulated 33069733 1329 Human NEAT1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment "We demonstrated that, in SH-SY5Y cells treated with MPP+, NEAT1 and PDE4B expression levels were raised, while miR-124-3p expression was repressed" 33522352 1330 Human NEAT1 lncRNA lipopolysaccharide (LPS) pneumonia WI-38 cells lipopolysaccharide (LPS) treatment upregulated 31632562 1331 Human NEAT1 lncRNA H2O2 preeclampsia (PE) HTR-8/SVneo H2O2 treatment upregulated of LncRNA NEAT1 induces apoptosis of human placental trophoblasts 32998583 1332 Human NEAT1 lncRNA docetaxel (DTX) prostate cancer PCa samples; PC3 cells; DU145 cells docetaxel (DTX) treatment NEAT1 was upregulated in docetaxel-resistant PCa clinical samples and cell lines. 31672604 1333 Human NEAT1 lncRNA Paris forrestii (PCT3) prostate cancer PC-3 cells Paris forrestii (PCT3) treatment downregulated 31810132 1334 Human NEAT1 lncRNA TGF-¦Â1 renal fibrosis HK-2 cells TGF-¦Â1 treatment upregulated 32475133 1335 Human NEAT1 lncRNA hypoxia reperfusion injury human iPS-derived cardiomyocytes (iPS-CM) hypoxia treatment downregulated 32826883 1336 Human NEAT1 lncRNA N-retinylidene-N-retinylethanolamine (A2E) retinitis pigmentosa human retinal pigment epithelium cells N-retinylidene-N-retinylethanolamine (A2E) treatment upregulated 32326576 1337 Human NEAT1 lncRNA tumor necrosis factor alpha (TNF-¦Á) rheumatoid arthritis (RA) RA-FLS cells tumor necrosis factor alpha (TNF-¦Á) treatment "We found that NEAT1 was upregulated, and miR-204-5p was downregulated in the RA patients' synovial tissue and TNF-¦Á treated RA-FLSs" 33394349 1338 Human NEAT1 lncRNA anti-microbial peptide LL-37 rosacea skin tissues LL37 treatment ?NEAT1 was upregulated in rosacea skin and in LL37-treated HaCaT cells. 33678493 1339 Human NEAT1 lncRNA lipopolysaccharide (LPS) sepsis THP-1 cells lipopolysaccharide (LPS) treatment upregulated 32099901 1340 Human NEAT1 lncRNA lipopolysaccharide (LPS) sepsis HK-2 cells lipopolysaccharide (LPS) treatment "NEAT1 regulated TRAF6 expression by sponging let-7b-5p in HK-2 cells, which promotes LPS-induced injury and inflammation in HK-2 cells." 32724027 1341 Human NEAT1 lncRNA lipopolysaccharide (LPS) sepsis-induced acute lung injury A549 cells lipopolysaccharide (LPS) treatment upregulated 32089649 1342 Human NEAT1 lncRNA tuberculosis (MTB) tuberculosis (TB) THP-1 cells Mycobacterium tuberculosis (MTB) infection treatment upregulated 33271233 1343 Human NEAT1.1 lncRNA cisplatin (DDP) bladder cancer T24 cells cisplatin (DPP) treatment "the RNA level of NEAT1.1, one RNA variant of NEAT1, was reduced in cisplatin-sensitive T24 cells compared to cisplatin-resistant T24 (T24R) cells after both treated with cisplatin modulated through Wnt/¦Â-catenin signaling pathway using RNA-seq." 31933859 1344 Human NEAT1_2 lncRNA Solamargine gastric cancer (GC) "The GC cell lines AGS, BGC823, SGC7901, HGC27 and MGC803" Solamargine treatment upregulated 30864686 1345 Human NEAT1-1 lncRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) THP-1 cells mycobacterium tuberculosis (Mtb) infection Mycobacterium tuberculosis infection robustly increased the expression of NEAT1-1 and NEAT1-2 in THP-1 macrophages in vitro. 30534569 1346 Human NEAT1-2 lncRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) THP-1 cells mycobacterium tuberculosis (Mtb) infection Mycobacterium tuberculosis infection robustly increased the expression of NEAT1-1 and NEAT1-2 in THP-1 macrophages in vitro. 30534569 1347 Human NFAT5-1 lncRNA hypoxia and TGF¦Â1 idiopathic pulmonary fibrosis (IPF) human pulmonary fibroblasts (HPFs) hypoxia and TGF¦Â1 treatment downregulated 31925944 1348 Human NIFK-AS1 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 1349 Human NKILA lncRNA active fraction of polyrhachis vicina rogers (AFPR) breast cancer MCF-7 cells active fraction of Polyrhachis vicina Rogers (AFPR) treatment upregulated 31881485 1350 Human NKILA lncRNA active fraction of Polyrhachis vicina Rogers (AFPR) breast cancer MCF-7 cells active fraction of Polyrhachis vicina Rogers (AFPR) treatment upregulated 31881485 1351 Human NKILA lncRNA TGF-¦Â epithelial-mesenchymal transition (EMT) MCF 7 cells TGF-¦Â treatment lncRNA NKILA was upregulated by TGF-¦Â 29761481 1352 Human NKILA lncRNA TGF-¦Â1 esophageal squamous cell carcinoma (ESCC) KYSE30 cells TGF-¦Â1 treatment LncRNA NKILA is upregulated by TGF-¦Â1 29379981 1353 Human NKILA lncRNA baicalin (BAI) hepatocellular carcinoma (HCC) SMMC-7721 cells; HepG2 cells baicalin (BAI) treatment downregulated 29481769 1354 Human NKILA lncRNA tumor necrosis factor alpha (TNF-¦Á) infantile pneumonia (IP) MRC5 cells tumor necrosis factor alpha (TNF-¦Á) treatment NKILA weakens TNF-¦Á-induced inflammation of MRC-5 cells by miR-21 upregulated 32013579 1355 Human NKILA lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) ischemic neuronal injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment OGDR induce NKILA upregulation in SH-SY5Y cells 30007440 1356 Human NKILA lncRNA osteogenic differentiation medium osteogenesis Mesenchymal stem cells (MSCs) "osteogenic medium (¦Á-MEM containing 10% FBS, 50 ¦Ìg/ml ascorbic acid, and 5 mM ¦Â-glycerophosphate) treatment" "NKILA is functionally involved in the regulation of RXFP1/PI3K-AKT and NF-¦ÊB signalling. Knockdown of NKILA dramatically down-regulates the expression of RXFP1 and then reduces the activity of AKT, a downstream regulator of RXFP1 signalling which is widely accepted as an activator of osteogenesis." 31657882 1357 Human NKILA lncRNA hypoxia retinal pigment epithelium (RPE) cells injuries ARPE-19 human RPE cells hypoxia treatment "Hypoxia induced NKILA expression, NKILA-I¦ÊB¦Á association and NF¦ÊB activation in ARPE-19?cells and primary human RPE cells." 30144973 1358 Human NKILA lncRNA lipopolysaccharide (LPS) sepsis-induced acute kidney injury HK-2 cells lipopolysaccharide (LPS) treatment upregulated 31599426 1359 Human NKX2-5-4 lncRNA "2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)" nonalcoholic fatty liver disease (NAFLD) L-02 cells "2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156) treatment" upregulated 31514003 1360 Human NMR lncRNA IL-1¦Â and TNF-¦Á esophageal squamous cell carcinoma (ESCC) KYSE70 Cells IL-1¦Â and TNF-¦Á treatment IL-1¦Â and TNF-¦Á stimulation showed that IL-1¦Â and TNF-¦Á could significantly promote the expression of NMR in ESCC cells. 29763634 1361 Human NNT-AS1 lncRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) 16HBE cells cigarette smoke extract (CSE) treatment NNT-AS1 played a promoting role in smoking-induced COPD via modulating miR-582-5p/FBXO11 signaling. 32768929 1362 Human NONHSAG024980 lncRNA progesterone (P4) lung cancer A549 cells progesterone (P4) treatment downregulated 32391956 1363 Human NONHSAG048134.2 lncRNA docetaxel (DTX) breast cancer MCF7 cells; MDA cells docetaxel (DTX) treatment upregulated 29683761 1364 Human NONHSAG048135.2 lncRNA docetaxel (DTX) breast cancer MCF7 cells; MDA cells docetaxel (DTX) treatment upregulated 29683761 1365 Human NONHSAG048143.2 lncRNA docetaxel (DTX) breast cancer MCF7 cells; MDA cells docetaxel (DTX) treatment upregulated 29683761 1366 Human NONHSAG096479.1 lncRNA docetaxel (DTX) breast cancer MCF7 cells; MDA cells docetaxel (DTX) treatment upregulated 29683761 1367 Human NONHSAT000264 lncRNA progesterone (P4) lung cancer A549 cells progesterone (P4) treatment upregulated 32391956 1368 Human NONHSAT057283 lncRNA doxorubicin (DOX) breast cancer MCF-7 cells doxorubicin (ADR) treatment upregulated 32547604 1369 Human NONHSAT076891 lncRNA all-trans retinoic acid (ATRA) acute promyelocytic leukemia (APL) bone marrow (BM) all-trans retinoic acid (ATRA) treatment upregulated 29956795 1370 Human NONHSAT084969.2 lncRNA high inorganic phosphate (Pi) vascular calcification (VC) vascular smooth muscle cells (VSMCs) high-phosphorus (HP) treatment lncRNAs NONHSAT084969.2 was confirmed to increase significantly in the HP group in comparison with than that in the CON group. 32401115 1371 Human NONHSAT089447 lncRNA olanzapine (OLP) schizophrenia (SZ) Human neuroblastoma cell lines (SK-N-SH) olanzapine (OLP) treatment downregulated 31180069 1372 Human NONHSAT097797 lncRNA doxorubicin (DOX) breast cancer MCF-7 cells doxorubicin (ADR) treatment downregulated 32547604 1373 Human NONHSAT105177 lncRNA melittin pancreatic ductal adenocarcinoma (PDAC) PATU8988 cells; Panc1 cells; SW1990 cells melittin treatment melittin treatment increased NONHSAT105177 expression in PDAC cell lines 30237397 1374 Human NONHSAT108582.2 lncRNA high glucose (HG) hyperglycemia-induced vascular endothelial cell damage human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment downregulated 32689997 1375 Human NONHSAT141593.2 lncRNA high glucose (HG) hyperglycemia-induced vascular endothelial cell damage human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment upregulated 32689997 1376 Human NONHSAT143692.2 lncRNA H2O2 age-related cataract (ARC) human lens epithelial cells (LECs) oxidative stress NONHSAT143692.2 is involved in oxidative DNA damage repair in the lens by regulating the miR-4728-5p/OGG1 axis. 33000245 1377 Human NONHSAT161887 lncRNA "2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)" nonalcoholic fatty liver disease (NAFLD) normal human liver cells L-02 PCB 156 treatment dysregulated 31514003 1378 Human NONHSAT172176 lncRNA "2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)" nonalcoholic fatty liver disease (NAFLD) L-02 cells "2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156) treatment" downregulated 31514003 1379 Human NONHSAT174696 lncRNA "2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)" nonalcoholic fatty liver disease (NAFLD) normal human liver cells L-02 PCB 156 treatment dysregulated 31514003 1380 Human NONHSAT177112.1 lncRNA lipopolysaccharide (LPS) inflammation human cardiomyocytes (HCMs) lipopolysaccharide (LPS) treatment NONHSAT177112.1 showed dynamic expression that first increased and then decreased during LPS stimulation. 33641342 1381 Human NONHSAT179219 lncRNA "2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)" nonalcoholic fatty liver disease (NAFLD) normal human liver cells L-02 PCB 156 treatment dysregulated 31514003 1382 Human NONHSAT187744 lncRNA "2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)" nonalcoholic fatty liver disease (NAFLD) L-02 cells "2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156) treatment" upregulated 31514003 1383 Human NONHSAT193411.1 lncRNA high inorganic phosphate (Pi) vascular calcification (VC) vascular smooth muscle cells (VSMCs) high-phosphorus (HP) treatment NONHSAT193411.1 was confirmed to increase significantly in the HP group in comparison with than that in the CON group. 32401115 1384 Human NONHSAT203881 lncRNA "2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)" nonalcoholic fatty liver disease (NAFLD) L-02 cells "2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156) treatment" upregulated 31514003 1385 Human NONHSAT247851.1 lncRNA particulate matter (PM2.5) cerebrovascular disease (CVD) human umbilical vein endothelial cells (HUVECs) PM 2.5 treatment upregulated 32278143 1386 Human NONMMUT008655.2 lncRNA resveratrol hepatic insulin resistance Hepa cells resveratrol (Res) treatment RSV may improve hepatic insulin resistance and control blood glucose levels by downregulating lncRNA NONMMUT0086552 32051733 1387 Human NONSHAT022487 lncRNA toxoplasma gondii (T. gondii) T. gondii infection human foreskin fibroblast (HFF) cells toxoplasma gondii (T. gondii) infection treatment The transcriptional level of NONHSAT022487 was increased by more than 30-fold after T gondii infection 29530077 1388 Human NONT087634 lncRNA lipopolysaccharide (LPS) sepsis human microvascular endothelial cells lipopolysaccharide (LPS) treatment dysregulated 29147069 1389 Human NONT119666 lncRNA lipopolysaccharide (LPS) sepsis human microvascular endothelial cells lipopolysaccharide (LPS) treatment dysregulated 29147069 1390 Human NORAD lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment "lncRNA NORAD attenuates endothelial cell senescence, endothelial cell apoptosis, and atherosclerosis via NF-¦ÊB and p53-p21 signaling pathways and IL-8." 32267831 1391 Human NORAD lncRNA hypoxia coronary artery disease (CAD) human umbilical vein endothelial cells (HUVECs) hypoxia exposure Long non-coding RNA NORAD regulates angiogenesis of human umbilical vein endothelial cells via miR-590-3p under hypoxic conditions. 32323787 1392 Human NORAD lncRNA high glucose (HG) diabetic cardiomyopathy (DCM) AC16 high glucose (HG) treatment Overexpression of NORAD protects DCM development via miRNA-150-5p/ZEB1 axis. 33215445 1393 Human NORAD lncRNA particulate matter (PM10) lung cancer A549 cells Particulate matter of 10 ¦Ìm or less in diameter (PM10) treatment we demonstrated that PM10?treatment increased the expression levels of NORAD 33250223 1394 Human NORAD lncRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) H446 cells; A549 cells cisplatin treatment downregulated 31894841 1395 Human NORAD lncRNA physcion 8-O-¦Â-glucopyranoside (PG) ovarian cancer (OC) SKOV3 cells physcion 8-O-¦Â-glucopyranoside (PG) treatment upregulated 31299866 1396 Human NORAD lncRNA hypoxia pancreatic cancer (PC) "pancreatic cancer cell lines SW1990, Capan-1, PANC-1, AsPC-1, CFPAC-1, MIAPaCa-2, and BxPC-3" 1% O2 upregulated 29121972 1397 Human NORAD lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment "MPP?+?induced cytotoxicity, and downregulated lncRNA NORAD in both dose- and time- dependent manners in SH-SY5Y cells." 31421205 1398 Human NORAD lncRNA dexamethasone (DEX) steroid-induced osteonecrosis of femoral head (ONFH) human bone marrow-derived mesenchymal stem cells (hBMSCs) dexamethasone (DEX) treatment "NORAD expression was downregulated in SONFH tissues, while miR-26a-5p expression was upregulated." 33413642 1399 Human NPSR1-AS1 lncRNA hypoxia-inducible factor 1¦Á (HIF-1¦Á) hepatocellular carcinoma (HCC) Hep3B cells; Huh7 cells hypoxia-inducible factor-1¦Á (HIF-1¦Á) treatment Hypoxia-inducible long noncoding RNA NPSR1-AS1 promotes the proliferation and glycolysis of hepatocellular carcinoma cells by regulating the MAPK/ERK pathway. 33008585 1400 Human NR_002733 lncRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 1401 Human NR_004845 lncRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment downregulated 29409992 1402 Human NR_024118 lncRNA lipopolysaccharide (LPS) sepsis-induced myocardial injury AC16 cells lipopolysaccharide (LPS) treatment downregulated 33846787 1403 Human NR_024351 lncRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 1404 Human NR_026763 lncRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 1405 Human NR_028034 lncRNA lipopolysaccharide (LPS) inflammation human macrophages lipopolysaccharides (LPS) treatment upregulated 28420462 1406 Human NR_029399 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cell differentiation human umbilical cord derived mesenchymal stem cells (hUCMSCs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated 29633064 1407 Human NR_033661 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cell differentiation human umbilical cord derived mesenchymal stem cells (hUCMSCs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated 29633064 1408 Human NR_038323 lncRNA high glucose (HG) diabetic retinopathy (DR) HK-2 cells High Glucose (HG) treatment upregulated 31430717 1409 Human NR_039985 lncRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 1410 Human NR_109779 lncRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 1411 Human NR_110586 lncRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 1412 Human NR_110801 lncRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 1413 Human NR_120420 lncRNA oxygen glucose deprivation (OGD) stroke SH-SY5Y cells oxygen and glucose deprivation (OGD) treatment upregulated 31838253 1414 Human NR_120420 lncRNA oxygen glucose deprivation (OGD) stroke SH-SY5Y cells oxygen and glucose deprivation (OGD) treatment NR_120420 knockdown inhibited apoptosis after cerebral infarction by downregulating the phosphorylation of a subunit of NF-¦ÊB (P65) 31838253 1415 Human NR_122070 lncRNA dexamethasone (DEX) steatosis HepG6 cells dexamethasone (Dex) treatment upregulated 29409992 1416 Human NR2F1-AS1 lncRNA hypoxia hepatocellular carcinoma (HCC) HCC cells hypoxia treatment ?NR2F1-AS1 level was enhanced in HCC tissues and cells. 33488124 1417 Human NR2F1-AS1 lncRNA oxaliplatin hepatocellular carcinoma (HCC) Huh7 cells; HepG2 cells oxaliplatin (OXA) treatment lncRNA NR2F1-AS1 was upregulated in oxaliplatin-resistant HCC tissue and cells 29602203 1418 Human NRAL lncRNA cisplatin (DDP) hepatocellular carcinoma (HCC) HepG2 and HepG2/CDDP cisplatin treatment NRAL was highly expressed in HepG2 cisplatin resistant cell lines compared to their parental counterparts. 30030687 1419 Human NRAL lncRNA cisplatin (DDP) hepatocellular carcinoma (HCC) HepG2 cells cisplatin treatment upregulated 30030687 1420 Human NRAV lncRNA respiratory syncytial virus (RSV) respiratory syndrome virus (PRRSV) infection sputum specimens respiratory syncytial virus (RSV) infection treatment lncRNA negative regulator of antiviral response (NRAV) in RSV-positive patients was significantly lower than that in uninfected patients 32102886 1421 Human NRIR lncRNA lipopolysaccharide (LPS) systemic sclerosis (SSc) human monocytes lipopolysaccharide (LPS) treatment upregulated 30804934 1422 Human NUTF2P3-001 lncRNA CoCl2 pancreatic cancer (PC) pancreatic cancer cell hypoxia£¬CoCl2 treatment upregulated 26755660 1423 Human NUTF2P3-001 lncRNA hypoxia pancreatic cancer (PC) pancreatic cancer cell hypoxia£¬CoCl2 treatment upregulated 26755660 1424 Human NUTM2A-AS1 lncRNA lipopolysaccharide (LPS) pulpitis human dental pulp cells (HDPCs) lipopolysaccharide (LPS) treatment LPS exposure upregulated the expression of NUTM2A-AS1 and High-Mobility Group Box 1 (HMGB1) and downregulated the level of let-7c-5p. 33831808 1425 Human OBFC2A lncRNA "1,4-benzoquinone (1,4-BQ)" benzene-induced hematotoxicity AHH1 cells "1,4-Benzoquinone (1,4-BQ) treatment" upregulated 32087087 1426 Human OBFC2A lncRNA "1,4-benzoquinone (1,4-BQ)" benzene toxicity human normal lymphocyte line (AHH-1) "1,4-Benzoquinone (1,4-BQ) treatment" upregulated 28388563 1427 Human OGRU lncRNA streptozocin (STZ) diabetic retinopathy (DR) M¨¹ller cells streptozotocin (STZ) treatment DR patients exhibited significantly increased expression of serum LncRNA-OGRU compared with normal individuals Streptozotocin (STZ)-challenged rats with DR also had higher OGRU expression in retinas 33762162 1428 Human OIP5-AS1 lncRNA angiotensin II (Ang II) aortic dissection (AD) human aortic endothelial cells (HAECs); human aortic smooth muscle cells (HASMCs) angiotensin II (Ang II) treatment "We found that lnc-OIP5-AS1 was upregulated, whereas miR-143-3p was downregulated in cells treated with angiotensin II (AngII) and AD tissues." 33577845 1429 Human OIP5-AS1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment OIP5-AS1 knockdown modulated cell progression via regulating miR-320a/LOX1 axis in ox-LDL-treated HUVECs. 32072428 1430 Human OIP5-AS1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment Our data showed the significant upregulation of OIP5-AS1 in atherosclerosis serum and ox-LDL-stimulated HUVECs. 33778018 1431 Human OIP5-AS1 lncRNA dermatophagoides pteronyssinus peptidase 1 (Der p1) bronchial asthma BEAS-2B cells Dermatophagoides pteronyssinus peptidase 1 (Der p1) treatment OIP5-AS1 exacerbated Der p1-induced inflammation and apoptosis in BEAS-2B cells by targeting miR-143-3p via HMGB1. 33174035 1432 Human OIP5-AS1 lncRNA osteogenic differentiation medium calcific aortic valve disease (CAVD) valve interstitial cells (VICs) isolated from human calcific aortic valves "a-minimal essential medium (Gibco, Carlsbad, CA, USA) containing 0.1% FBS, bioactive recombinant human bone morphogenetic protein-2 (BMP-2; 50 ng/mL), dexamethasone (100 nmol/L), ascorbic acid (50 mg/mL), and b-glycerophosphate (5 mmol/L) treatment" downregulated 30846207 1433 Human OIP5-AS1 lncRNA radiation colorectal cancer (CRC) LoVo cells; SW480 cells radiation treatment LncRNA OIP5-AS1 and DYRK1A were downregulated in radio-resistant CRC cell lines 29773344 1434 Human OIP5-AS1 lncRNA etoposide (VP-16) DNA damage human HepG2 cells etoposide treatment upregulated 31889167 1435 Human OIP5-AS1 lncRNA oxidized low density lipoprotein (ox-LDL) endothelial cell injury human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment "The expression of OIP5-AS1 was upregulated, while miR-98-5p was downregulated in ox-LDL-induced human umbilical vein endothelial cells (HUVECs)." 32990894 1436 Human OIP5-AS1 lncRNA mercury II chloride heavy metal stress human HepG2 cells mercury II chloride treatment upregulated 31889167 1437 Human OIP5-AS1 lncRNA KSHV-encoded viral interferon regulatory factor 1 (vIRF1) kaposi's sarcoma (KS) endothelial cell KSHV-encoded viral interferon regulatory factor 1 (vIRF1) treatment upregulated 30699189 1438 Human OIP5-AS1 lncRNA IL-1¦Â osteoarthritis (OA) CHON-001 cells IL-1¦Â treatment OIP5-AS1 was downregulated while miR-29b-3p was upregulated in OA models. 32037864 1439 Human OIP5-AS1 lncRNA cisplatin (DDP) osteosarcoma (OS) MG63 cells; Saos-2 cells cisplatin treatment OIP5-AS1 positively modulated FOSL2 expression to decrease CDDP sensitivity in OS by sponging miR-377-3p. 32440152 1440 Human OIP5-AS1 lncRNA doxorubicin (DOX) osteosarcoma (OS) MG63 cells; KHOS cells; U2OS cells doxorubicin treatment upregulated 30204936 1441 Human OIP5-AS1 lncRNA oxaliplatin oxaliplatin (L-OHP) resistance HCT116; W480 cells oxaliplatin (L-OHP) treatment upregulated 32308348 1442 Human OIP5-AS1 lncRNA H2O2 oxidative stress human HepG2 cells H2O2 treatment upregulated 31889167 1443 Human OR13C9 lncRNA high glucose (HG) diabetic nephropathy (DN) GEnCs high glucose (HG) treatment LncOR13C9 could regulate ABCA1 by inhibiting the action of miR-23a-5p in the LXR pathway. 33192550 1444 Human OTUD6B-AS1 lncRNA arsenic trioxide (ATO) bladder cancer T24 cells arsenic trioxide (As2O3) treatment lncRNA OTUD6B-AS1 Exacerbates As 2 O 3-Induced Oxidative Damage in Bladder Cancer via miR-6734-5p-Mediated Functional Inhibition of IDH2 32952848 1445 Human linc-p21 lncRNA lipopolysaccharide (LPS) acute lung injury (ALI) BEAS-2B cells lipopolysaccharide (LPS) treatment LincRNA-p21 was significantly increased in septic model in vivo and in vitro. 32495896 1446 Human linc-p21 lncRNA oleanolic acid (OLA) arteriosclerosis (AS) vascular smooth muscle cells (VSMCs) oleanolic acid (OLA) treatment upregulated 27900030 1447 Human linc-p21 lncRNA ginkgo biloba extract EGb 761 colorectal cancer (CRC) HT29 cells; HCT116 cells Ginkgo biloba extract EGb 761 treatment lincRNA-p21 was upregulated in colon cancer cells after treatment with EGb 761. 30594943 1448 Human linc-p21 lncRNA X-rays colorectal cancer (CRC) CRC cell lines and tissue X-ray treatment upregulation 24573322 1449 Human linc-p21 lncRNA arsenite lung cancer A549 cells arsenic (As) exposure upregulated 32816178 1450 Human linc-p21 lncRNA hypoxia glioblastoma multiforme (GBM) SMMC7721 hepatoma;U251MG glioma cells hypoxia treatment upregulated 28689810 1451 Human linc-p21 lncRNA X-rays glioblastoma multiforme (GBM) "SMMC7721 hepatoma , U251MG glioma cells" X-ray irradiation treatment upregulated 28689810 1452 Human linc-p21 lncRNA TGF-¦Â1 liver fibrosis Human LX-2 cell strain TGF-¦Â1 treatment downregulated 27610008 1453 Human linc-p21 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells N-methyl-4-phenylpyridinium (MPP +) treatment upregulated 30671473 1454 Human linc-p21 lncRNA methotrexate (MTX) rheumatoid arthritis (RA) Human Jurkat T cell;THP-1 monocyte;Peripheral blood mononuclear cells (PBMCs) methotrexate treatment "MTX restored lincRNA-p21 expression, in vivo, in RA" 25077978 1455 Human linc-p21 lncRNA ultraviolet (UV) irradiation skin cancer keratinocytes UV irradiation treatment lincRNA-p21 is highly inducible by UVB 25789975 1456 Human linc-p21 lncRNA arsenite toxicity of arsenic A549 cells arsenic (As) exposure upregulated 32816178 1457 Human PAAN lncRNA influenza A virus (IAV) influenza A virus (IAV) infection HEK293T cells influenza A virus (IAV) infection The level of lncRNA-PAAN increases upon infection of IAV. 29914164 1458 Human PABPC lncRNA androgen deprivation therapies (ADT) castration-resistant prostate cancer (CRPC) patients with CRPC androgen deprivation therapies (ADT) treatment upregulated 25189356 1459 Human PAGBC lncRNA hydrostatic pressure (HP) osteogenesis adipose-derived mesenchymal stem cells (AMSCs) hydrostatic pressure (HP) treatment lncRNA-PAGBC was upregulated during osteogenic differentiation of AMSCs. 32661199 1460 Human PANDAR lncRNA arsenite DNA damage Peripheral blood lymphocytes arsenic (As) exposure arsenic exposure increased PANDAR expression and DNA damage among arsenic smelting plant laborers. 31885278 1461 Human PANDAR lncRNA arsenite DNA damage peripheral blood lymphocytes arsenic (As) exposure Arsenic exposure increased PANDAR expression. 31885278 1462 Human PANDAR lncRNA cisplatin (DDP) ovarian cancer (OC) A2780 cells cisplatin treatment upregulated 30375398 1463 Human PANDAR lncRNA cisplatin (DDP) ovarian cancer (OC) ES2 cells cisplatin treatment upregulated 32901049 1464 Human PART1 lncRNA gefitinib esophageal squamous cell carcinoma (ESCC) TE1 cells; KYSE-450 cells gefitinib treatment lncRNA PART1 was upregulated in gefitinib-resistant cells when compared to parental ESCC cells. 30049286 1465 Human PART1 lncRNA lipopolysaccharide (LPS) intervertebral disc degeneration (IDD) nucleus pulposus (NP) cell lipopolysaccharide (LPS) treatment "Expression levels of lncRNA PART1 in LPS-treated NP cells were found to be higher compared with those in the control groups.? Collectively, these results suggest that PART1 accelerates the progression of IDD." 33376513 1466 Human PART-1 lncRNA IL-1¦Â osteoarthritis (OA) The immortalized human chondrocytes cell lines C20/A4 IL-1¦Â treatment downregulated 31571401 1467 Human PAX8-AS1-N lncRNA baicalin (BAI) breast cancer MCF-7 cells; MDA-MB-231 cells baicalin (BAI) treatment upregulated 29693272 1468 Human PCAT-1 lncRNA aurora kinase inhibitor (CCT137690) breast cancer MDA-MB-231 cells aurora kinase inhibitor (CCT137690) treatment downregulated 31319040 1469 Human PCAT-1 lncRNA Paris forrestii (PCT3) prostate cancer LNCaP cells Paris forrestii (PCT3) treatment upregulated 31810132 1470 Human PCAT6 lncRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) "Seven CRC cell lines: HCT116, HT©\29, SW620, SW480, DLD©\1, RKO, and LoVo, a normal colon fibroblast cell line CCD©\112CoN" 5-fluorouracil (5-FU) treatment PCAT6 knockdown attenuated CRC chemoresistance to 5-FU through miR-204/HMGA2/PI3K; miR-204 inhibition could partially reverse the effect of PCAT6 knockdown. 30938104 1471 Human PCAT6 lncRNA sevoflurane (SEV) lung cancer H446 cells; H1975 cells sevoflurane (Sev) treatment downregulated 33987473 1472 Human PCGEM1 lncRNA montelukast sodium asthma serum montelukast sodium treatment PCGEM1 was highly expressed in cough-variant asthma (CVA) children with response to the treatment. 32520202 1473 Human PCGEM1 lncRNA hypoxia gastric cancer (GC) human gastric cancer cell lines SGC-7901 and BGC-823 hypoxia induce upregulated 30690667 1474 Human PCGEM1 lncRNA doxorubicin (DOX) prostate cancer LNCaP cells doxorubicin (DOX) treatment PCGEM1 overexpression in LNCaP cell culture model results in the inhibition of apoptosis induced by doxorubicin (DOX) 16569192 1475 Human PCK1-2:1 lncRNA C-BaP-Cr-Pb-As inflammation Human Bronchial Epithelial Cells 16HBE C-BaP-Cr-Pb-As treatment downregulated 30913382 1476 Human PCK1-2:1 lncRNA particulate matter (PM2.5) inflammation Human Bronchial Epithelial Cells 16HBE PM2.5-JN particles treatment downregulated 30913382 1477 Human PDIA3P1 lncRNA hypoxia glioblastoma multiforme (GBM) U251 cells; U87MG cells; A172 cells hypoxia treatment Hypoxia-induced lncRNA PDIA3P1 promotes mesenchymal transition via sponging of miR-124-3p in glioma. 32127518 1478 Human PDIA3P1 lncRNA doxorubicin (DOX) hepatocellular carcinoma (HCC) SK-Hep-1 cells doxorubicin (Dox) treatment Dox induced PDIA3P1 expression in a dose-dependent manner. 31509261 1479 Human PDIA3P1 lncRNA etoposide (VP-16) hepatocellular carcinoma (HCC) SK-Hep-1 cells etoposide treatment Etoposide induced PDIA3P1 expression in a dose-dependent manner. 31509261 1480 Human PGM5-AS1 lncRNA p53 esophageal squamous cell carcinoma (ESCC) ESCC cell lines ?p53 overexpression treatment upregulated 31185143 1481 Human PINT lncRNA tumor necrosis factor alpha (TNF-¦Á) rheumatoid arthritis (RA) Fibroblast-like synoviocytes (FLSs) tumor necrosis factor alpha (TNF-¦Á) treatment LncRNA LINC-PINT increases SOCS1 expression by sponging miR-155-5p to inhibit the activation of ERK signaling pathway in rheumatoid arthritis synovial fibroblasts induced by TNF-¦Á 32289665 1482 Human PMS2L2 lncRNA carboplatin (CBP) endometrial cancer (EC) plasma carboplatin treatment LncRNA PMS2L2 in endometrial cancer was downregulated during carboplatin treatment and regulates chemosensitivity. 31632150 1483 Human PNRC2-1 lncRNA TGF-¦Â1 nasopharyngeal carcinoma (NPC) CNE1 nasopharyngeal carcinoma cells TGF-¦Â1 treatment "Sixty lncRNA genes were clustered in a heatmap, and mRNA expression of 14 dysregulated lncRNAs was consistent with RNA sequencing" 33752469 1484 Human POIR lncRNA sorafenib (SOR) hepatocellular carcinoma (HCC) Huh7 cells; Hep3B; SNU©\387; SNU©\449 cells Sorafenib (SOR) treatment lncRNA-POIR promotes EMT progression and suppresses SOR sensitivity simultaneously by sponging miR-182-5p 32951268 1485 Human POTEF-AS1 lncRNA 5¦Á©\dihydrotestosterone (DHT) prostate cancer LNCaP and VCaP cells DHT treatment upregulated 28032932 1486 Human POU5F1P4 lncRNA cetuximab metastatic colorectal cancer (mCRC) NCI-H508 cells; tumor tissues cetuximab treatment POU5F1P4 was also downregulated in acquired cetuximab resistant cells. 29136952 1487 Human PRINS lncRNA aurora kinase inhibitor (CCT137690) breast cancer MCF-7 cells; MDA-MB-231 cells aurora kinase inhibitor (CCT137690) treatment downregulated 31319040 1488 Human PRINS lncRNA human papilloma virus (HPV) head and neck squamous cell carcinoma (HNSCC) primary tumors resected from HNSCC patients human papillomavirus (HPV) infection upregulated 32998396 1489 Human PRLB lncRNA paclitaxel (PTX) ovarian cancer (OC) CAOV3 cells; SKOV3 cells paclitaxel (Tax) treatment upregulated 33156701 1490 Human PRNCR1 lncRNA cisplatin (DDP) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 cisplatin treatment downregulated 33647908 1491 Human PRNCR1 lncRNA lipopolysaccharide (LPS) pulmonary vascular endothelial cell (PVEC) injury Human pulmonary microvascular endothelial cells (HPMECs) lipopolysaccharide (LPS) treatment PRNCR1 was upregulated in LPS-induced PVEC and aggravated its injury via modulating the miR-330-5p/TLR4 axis. 33049095 1492 Human PSMB8-AS1 lncRNA influenza A virus (IAV) influenza A virus (IAV) infection human lung epithelial A549 cells influenza A/Puerto Rico/8/34 infection upregulated 30669933 1493 Human PSMG3-AS1 lncRNA N-retinylidene-N-retinylethanolamine (A2E) retinitis pigmentosa human retinal pigment epithelium cells N-retinylidene-N-retinylethanolamine (A2E) treatment downregulated 32326576 1494 Human PSOR1C3 lncRNA influenza A virus (IAV) influenza A virus (IAV) infection human lung epithelial A549 cells influenza A/Puerto Rico/8/34 infection upregulated 30669933 1495 Human PTENP1 lncRNA radiation head and neck squamous cell carcinoma (HNSCC) HNSCC cell lines radiation treatment upregulated 30441874 1496 Human PTPRG-AS1 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment upregulated 29947995 1497 Human PTTG3P lncRNA pterostilbene breast cancer MCF 7 cells pterostilbene treatment downregulated 30619763 1498 Human PVT lncRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) TPC-1 cells TGF-¦Â1 treatment upregulated 29967342 1499 Human PVT1 lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 lipopolysaccharide (LPS) treatment "PVT1 expression was significantly increased, whereas miR-20a-5p expression was significantly decreased in sepsis model mice and LPS-induced HK-2 cells compared with sham mice and control HK-2 cells" 33576456 1500 Human PVT1 lncRNA gemcitabine (GEM) advanced pancreatic cancer (PC) BxPC-3 cells; PANC-1 cells Gemcitabine treatment "Gemcitabine treatment decreases PVT1 levels and increases its encoded miRNAs, such as the miR-1207 pair (miR-1207-5p/3p)." 30341811 1501 Human PVT1 lncRNA "corticosteroid, dexamethasone, and fetal calf serum (FCS)." airway diseases primary ASM cells "corticosteroid, dexamethasone, and fetal calf serum (FCS) treatment" dysregulated 24886442 1502 Human PVT1 lncRNA platelet derived growth factor-BB (PDGF-BB) aortic dissection (AD) Human aortic smooth muscle cells (HASMCs) platelet derived growth factor-BB (PDGF-BB) treatment "In AD, PVT1 expression was upregulated, yet that of miR-27b-3p was downregulated" 33106979 1503 Human PVT1 lncRNA platelet activating factor (PAF) asthma Human small airway epithelial cells (HSAECs) platelet activating factor (PAF) treatment LncRNA PVT1 exacerbates the inflammation and cell-barrier injury during asthma by regulating miR-149 32830409 1504 Human PVT1 lncRNA platelet derived growth factor-BB (PDGF-BB) asthma human airway smooth muscle cells (ASMCs) platelet derived growth factor-BB (PDGF-BB)?treatment treatment upregulated 33825599 1505 Human PVT1 lncRNA angiotensin II (Ang II) atrial fibrosis human atrial fibroblasts angiotensin II (Ang II) treatment "upregulated, PVT1 knockdown attenuated the Ang-II-induced mouse atrial fibrosis." 30894138 1506 Human PVT1 lncRNA high glucose (HG) diabetic cataract (DC) Human lens epithelial (HLE) B-3 cells ?high glucose (HG) induce treatment lncRNA?PVT1 modulates the proliferation and apoptosis of lens epithelial cells in diabetic cataract via miR-214-3p/MMP2 axis 31755246 1507 Human PVT1 lncRNA high glucose (HG) diabetic cataract (DC) Human lens epithelial (HLE) B-3 cells high glucose (HG) treatment lncRNA PVT1 expression was upregulated in the HG-induced HLE B-3 cells 31755246 1508 Human PVT1 lncRNA high glucose (HG) diabetic nephropathy (DN) human mesangial cells (MCs) high glucose (HG) treatment PVT1 was highly expressed in high glucose (HG)-induced mesangial cells (MCs). 32322310 1509 Human PVT1 lncRNA high glucose (HG) dilated cardiomyopathy (DCM) AC16 cells high glucose (HG) treatment upregulated 33049089 1510 Human PVT1 lncRNA high glucose (HG) dilated cardiomyopathy (DCM) cardiomyocytes high-glucose (HG) treatment We observed that PVT1 and CASP10 were upregulated while miR-23a-3p was downregulated in high glucose-induced cardiomyocytes. 33049089 1511 Human PVT1 lncRNA 5-fluorouracil (5-Fu) gastric cancer (GC) Human GC cell lines SGC-7901 5-fluorouracil (5-FU) treatment PVT1 can regulate the expression of Bcl2 and enhance drug-resistance of gastric cancer to 5-Fu. 31205469 1512 Human PVT1 lncRNA cardamonin gastric cancer (GC) "The human gastric cancer cell lines (AGS, MGC-803, BGC-823)" cardamonin treatment downregulated 31028131 1513 Human PVT1 lncRNA cisplatin (DDP) gastric cancer (GC) AGS/DPP; NUGC-3/DPP cells cisplatin treatment PVT1 silencing attenuated the DPP resistance in GC by downregulating TBL1XR1 via sponging miR-3619-5p. 32407172 1514 Human PVT1 lncRNA paclitaxel (PTX) glioblastoma multiforme (GBM) SHG 44 cells paclitaxel treatment LncRNA PVT1 was overexpressed in glioma cells SHG-44 RE compared with parent SHG-44 cells 30347597 1515 Human PVT1 lncRNA IFN-¦Á hepatocellular carcinoma (HCC) SMMC-7721 cells IFN-¦Á treatment IFN-¦Á treatment further increases PVT1 expression in HCC cells by enhancing H3K4me3 modification on the promoter. 29715456 1516 Human PVT1 lncRNA hypoxia/reoxygenation (H/R) myocardial ischemia/reperfusion (I/R) injury (MIRI) AC16 cells hypoxia/reoxygenation (H/R) treatment Knockdown of long non-coding RNA PVT1 protects human AC16 cardiomyocytes from hypoxia/reoxygenation-induced apoptosis and autophagy by regulating miR-186/Beclin-1 axis. 32428696 1517 Human PVT1 lncRNA xiaoji decoction (XJD) non-small cell lung cancer (NSCLC) A549 and H1975 cells Xiaoji decoction (XJD) treatment downregulated 31707347 1518 Human PVT1 lncRNA xiaoji decoction (XJD) non-small cell lung cancer (NSCLC) A549 cells; H1975 cells xiaoji decoction (XJD) treatment XJD decreased lncRNA PVT1 expressions. 31707347 1519 Human PVT1 lncRNA high glucose (HG) osteoarthritis (OA) human osteoarthritis (OA) chondrocytes high-glucose (HG) treatment upregulated 31625803 1520 Human PVT1 lncRNA IL-1¦Â osteoarthritis (OA) chondrocytes IL-1¦Â treatment upregulated 30126849 1521 Human PVT1 lncRNA IL-1¦Â osteoarthritis (OA) chondrocytes IL-1¦Â treatment upregulated 31863917 1522 Human PVT1 lncRNA IL-1¦Â osteoarthritis (OA) Human transformed chondrocytes C28/I2 IL-1¦Â treatment upregulated 31863917 1523 Human PVT1 lncRNA pioglitazone osteoarthritis (OA) high-glucose (HG) treated human osteoarthritis (OA) chondrocytes pioglitazone (PGZ) treatment downregulated 31625803 1524 Human PVT1 lncRNA gemcitabine (GEM) osteosarcoma (OS) LncRNA PVT1-overexpressed MG63 cells and LncRNA PVT1 knockdown MG63/DOX cells. gemcitabine treatment "LncRNA PVT1 overexpression promoted cell proliferation and exhibited the anti-apoptotic property in LncRNA PVT1-overexpressing MG63 cells treated with gemcitabine. While, LncRNA PVT1-depleted MG63/DOX cells treated with gemcitabine exhibited significant lower survival rate and high percentage of apoptosis." 30661902 1525 Human PVT1 lncRNA gemcitabine (GEM) osteosarcoma (OS) MG63 cells gemcitabine treatment lncRNA PVT1 level was upregulated about 3.3 folds in MG63/DOX cells compared to MG63 cells. 30661902 1526 Human pvt1 lncRNA carboplatin-docetaxel ovarian cancer (OC) 3AO cells carboplatin-docetaxel treatment carboplatin-docetaxel-induced lncRNA PVT1 which may be a central downstream target of carboplatin plus docetaxel because expression of PVT1 positively correlates with anticancer action of carboplatin plus docetaxel. 26097562 1527 Human PVT1 lncRNA ketamine ovarian cancer (OC) "human ovarian cancer cell lines OVCAR-3, SKOV3, A2780, 3AO, COC1, OV-90" ketamine treatment "We then investigated the effect of ketamine on these lncRNAs, and found that ketamine regulated the expression of lncRNA PVT1." 33763107 1528 Human PVT1 lncRNA radiation radioresistance C666-1; 5¨C8F cells radiation exposure treatment "PVT1 Mediates Cell Proliferation, Apoptosis and Radioresistance in Nasopharyngeal Carcinoma Through Regulating miR-515-5p/PIK3CA Axis" 33116864 1529 Human PVT1 lncRNA TGF-¦Â1 renal fibrosis HK-2 cells TGF-¦Â1 treatment PVT1 was upregulated in TGF-¦Â1-treated HK-2 cells 32921988 1530 Human PVT1 lncRNA lipopolysaccharide (LPS) temporomandibular joint osteoarthritis SW982 cells lipopolysaccharide (LPS) treatment upregulated 32171788 1531 Human R-471B22 lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment upregulated 32714991 1532 Human RAB11B-AS1 lncRNA hypoxia breast cancer MDA-MB-231; MDA-MB-468; SUM159; MCF-7; T47D; BT474; ZR-75-1; HCC1954 cells hypoxia treatment upregulated 31900259 1533 Human RAD51-AS1 lncRNA Corylin hepatocellular carcinoma (HCC) Huh7 and HepG2 cells Corylin treatment upregulated 29749376 1534 Human RAD51-AS1 lncRNA melatonin hepatocellular carcinoma (HCC) Huh7 and HepG2 cells Melatonin treatment upregulated 30201872 1535 Human RAET1K lncRNA hypoxia hepatocellular carcinoma (HCC) HCCLM3 cells; HepG2 cells hypoxia treatment upregulated 32152275 1536 Human RALY-AS1 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 1537 Human RAXIP-AS2 lncRNA Paris forrestii (PCT3) prostate cancer LNCaP cells Paris forrestii (PCT3) treatment downregulated 31810132 1538 Human RDH10-AS1 lncRNA N-retinylidene-N-retinylethanolamine (A2E) retinitis pigmentosa human retinal pigment epithelium cells N-retinylidene-N-retinylethanolamine (A2E) treatment downregulated 32326576 1539 Human RGMB-AS1 lncRNA quercetin chronic high glucose-induced oxidative stress and mitochondrial dysfunction HepG2 cells quercetin treatment Quercetin increased RGMB-AS1 ~35-fold after 6 h in high glucose-treated HepG2 cells 30266680 1540 Human RHPN1-AS1 lncRNA gefitinib non-small cell lung cancer (NSCLC) PC9 cells; HCC827 cells gefitinib treatment RHPN1-AS1 was observed to be downregulated in gefitinib resistant NSCLC cell lines. 30010468 1541 Human RMEL3 lncRNA PD98059 melanoma "five melanoma cell lines: 4 harboring BRAFV600E mutation (WM1617, A375, Skmel19 and UACC-62) and one BRAF-wt/NRAS-mutant (WM1366)" PD98059 treatment downregulated 30457212 1542 Human RMEL3 lncRNA vemurafenib/PLX4032 melanoma "five melanoma cell lines: 4 harboring BRAFV600E mutation (WM1617, A375, Skmel19 and UACC-62) and one BRAF-wt/NRAS-mutant (WM1366)" Vemurafenib/PLX4032 treatment downregulated 30457212 1543 Human RMRP lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 lipopolysaccharide (LPS) treatment RMRP was upregulated in sera from patients with AKI and in LPS-induced cells. 33635017 1544 Human RMRP lncRNA silica lung fibrosis human bronchial epithelial (HBE) cells; BEAS2b cells treatment treatment RMRP is upregulated in human bronchial epithelial (HBE) and BEAS2b cells exposed to silica and activated by p53 33297121 1545 Human RMRP lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) neural ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 30926681 1546 Human RMST lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) HBMEC;bEnd.3 cells oxygen-glucose deprivation (OGD) treatment RMST was upregulated in OGD-treated HBMEC and bEnd3 cells 33607153 1547 Human RMST lncRNA X-rays radiation-induced injury human lymphoblast cell line TK6 irradiat a RAD Source 2000 X-ray Biological irradiator treatment upregulated 24502193 1548 Human RNCR3 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) HUVEC oxidized low-density lipoprotein (ox-LDL) treatment upregulated 27253412 1549 Human ROR lncRNA apatinib breast cancer breast cancer stem cells (BCSCs) were isolated from MDA-MB-231 cells apatinib treatment "Apatinib decreased the viability and colony numbers of BCSCs in a concentration-dependent manner, and it also reduced sphere numbers, suppressed migration, invasion and lncRNA ROR expression, and induced apoptosis of BCSCs." 33845750 1550 Human ROR lncRNA homocysteine (Hcy) atherosclerosis (AS) human aortic smooth muscle cells (HASMCs) homocysteine (HCY) treatment upregulated 31629816 1551 Human ROR lncRNA denovirus type 36 (Ad36) cell differentiation human adipose-derived stem cells (hADSCs) denovirus type 36 (Ad36) treatment Ad36 may promote the differentiation of hADSCs into brown adipocytes by up-regulating LncRNA ROR. 33189825 1552 Human ROR lncRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) TPC-1 cells TGF-¦Â1 treatment upregulated 29967342 1553 Human ROR lncRNA adriamycin (ADR) and vincristine (VCR) gastric cancer (GC) human gastric cancer tissues adriamycin (ADR) and vincristine (VCR) treatment upregulated 32019330 1554 Human ROR lncRNA radiation hepatocellular carcinoma (HCC) HepG2 cells; SMMC-7721 cells radiation treatment linc-ROR was significantly upregulated in radioresistant HCC cells 29559320 1555 Human ROR lncRNA TGF-¦Â hepatocellular carcinoma (HCC) HCC cells TGF-¦Â treatment upregulated 24918061 1556 Human ROR lncRNA hypoxia/reoxygenation (H/R) ischemia/reperfusion (I/R) injury human cardiomyocytes (HCM) hypoxia/reoxygenation (H/R) treatment upregulated 29694511 1557 Human ROR lncRNA arsenic trioxide (ATO) hepatocellular carcinoma (HCC) HepG2 cells arsenic trioxide treatment Long non-coding RNA ROR confers arsenic trioxide resistance to HepG2 cells by inhibiting p53 expression. 32017938 1558 Human ROR lncRNA hypoxia/reoxygenation (H/R) myocardial ischemia/reperfusion (I/R) injury (MIRI) The human cardiac myocyte (HCM) cell line HCMs were exposed to hypoxic conditions for 2?h followed by re-oxygenation (H/R) treatment. lncRNA ROR were upregulated in both MIRI rat model and H/R treated HCMs. 31768721 1559 Human ROR lncRNA polyphyllin I (PPI) nasopharyngeal carcinoma (NPC) "The normal nasopharyngeal cell line NP69 and NPC cell lines (CNE-1, CNE-2, HONE-1, and HNE-1)" Polyphyllin I (PP I) treatment A higher level of lncRNA regulator of reprogramming (ROR) expression was detected in NPC cell lines compared with normal nasopharyngeal cell line and PP I must significantly down-regulate the expression level of lncRNA ROR 30601067 1560 Human ROR lncRNA CoCl2 obstructive sleep apnoea-hypopnoea syndrome (OSAHS) HK-2 cells CoCl2 treatment CoCl2?decreased cell viability and increased apoptosis as well as increased the expression of ROR. 31164009 1561 Human ROR lncRNA cisplatin (DDP) osteosarcoma (OS) "OS tissues, MG63/DDP, and U2OS/DDP cells." cisplatin treatment upregulated 31539112 1562 Human ROR lncRNA curcumin (Cur) prostate cancer HuPCaSCs curcumin treatment downregulated 28843521 1563 Human ROR lncRNA deoxyelephantopin (DOE) uterine leiomyoma (UL) UL cells deoxyelephantopin (DOE) treatment downregulated 33152917 1564 Human RP11 lncRNA artesunate (ART) epithelial-mesenchymal transition (EMT) SK-HEP1 and SM7721 hepatocellular carcinoma cell lines artesunate (ART) treatment RP11 depresses the inhibitory effect of ART on cancer cell EMT. 30335897 1565 Human RP11 lncRNA artesunate (ART) epithelial-mesenchymal transition (EMT) SK-HEP1 cells; SM7721 cells; HepG2 cells; Huh7 cells artesunate (ART) treatment downregulated 30335897 1566 Human RP11 lncRNA artesunate (ART) hepatocellular carcinoma (HCC) SK-HEP1 and SM7721 hepatocellular carcinoma cell lines artesunate (ART) treatment RP11 depresses the inhibitory effect of ART on cancer cell EMT. 30335897 1567 Human RP11 lncRNA radiation radiation-induced lung injury (RILI) HFL-1; WI-38 TGF-¦Â1 and radiation treatment upregulated 33117089 1568 Human RP11-1055B8.4 lncRNA gemcitabine (GEM) ancreatic cancer (PC) SW1990 cells gemcitabine (GEM) treatment upregulated 30113217 1569 Human RP11-120K9.2 lncRNA progesterone (P4) lung cancer A549 cells progesterone (P4) treatment downregulated 32391956 1570 Human RP11-121G22.3 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment upregulated 29956723 1571 Human RP11-132E11.2 lncRNA IL-1¦Â crohn disease (CD) Caco-2 cells IL-1¦Â treatment downregulated 29361088 1572 Human RP11-134F2.2 lncRNA progesterone (P4) lung cancer A549 cells progesterone (P4) treatment downregulated 32391956 1573 Human RP11-135L22.1 lncRNA cisplatin (DDP) ovarian cancer (OC) HO8910 cells cisplatin treatment RP11-135L22.1 level in chemotherapy-sensitive group was significantly lower than that of insensitive group. 29509240 1574 Human RP11-154D6 lncRNA steroids osteonecrosis of femoral head (ONFH) BMSCs of patients steroid treatment ?the expression of lncRNA RP11-154D6 was significantly decreased in BMSCs of patients with ONFH 31190361 1575 Human RP11-218C14.5 lncRNA ginsenoside Rh2 hepatocellular carcinoma (HCC) HepG2 cells ginsenoside Rh2 treatment upregulated 30394104 1576 Human RP11-23P13.6 lncRNA gemcitabine (GEM) ancreatic cancer (PC) SW1990 cells gemcitabine (GEM) treatment upregulated 30113217 1577 Human RP11-2C24.6-001 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 1578 Human RP11-347E10.1 lncRNA IL-1¦Â crohn disease (CD) Caco-2 cells IL-1¦Â treatment downregulated 29361088 1579 Human RP11-354P11.2 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment upregulated 29956723 1580 Human RP11-354P17.15-001 lncRNA T cell acute kidney injury (AKI) kidney biopsies and urine T cell treatment upregulated 26506996 1581 Human RP11-381N20.2 lncRNA paclitaxel (PTX) cervical cancer (CC) SiHa cells paclitaxel treatment The expression of RP11-381N202 was reduced with the increased paclitaxel dose 29863245 1582 Human RP11-381O7.3 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment upregulated 29947995 1583 Human RP11-388M20.9 lncRNA hexavalent chromium [Cr(VI)] DNA damage Cr(VI)-treated 16HBE cells Cr(VI) exposure "dysregulated. RP11-388M20.9 to regulate DNA damage by interacting with the target gene after Cr(VI) exposure, and was likely to be a potential biomarker of DNA damage in Cr(VI)-treated 16HBE cells." 30476843 1584 Human RP11-388M20.9 lncRNA hexavalent chromium [Cr(VI)] DNA damage 16HBE cells hexavalent chromium [Cr(VI)] treatment upregulated 30476843 1585 Human RP11-390F4.3 lncRNA hypoxia tumor metastasis FADU cells; MCF7 cells; U2-OS cells hypoxia treatment upregulated 32353468 1586 Human RP11-394l13.1 lncRNA Vitamins A and D fungal infection human monocytes during C.albicans infections Vitamins A and D treatment dysregulated 28094339 1587 Human RP11-395P13.3-001 lncRNA T cell acute kidney injury (AKI) kidney biopsies and urine T cell treatment upregulated 26506996 1588 Human RP1-140K8.5 lncRNA homocysteine (Hcy) homocysteine (HCY)-induced vascular endothelial injury human umbilical vein endothelial cells (HUVECs) homocysteine (HCY) treatment upregulated 30093949 1589 Human RP11-414H23.3 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment upregulated 29956723 1590 Human RP11-415D17.3 lncRNA homocysteine (Hcy) homocysteine (HCY)-induced vascular endothelial injury human umbilical vein endothelial cells (HUVECs) homocysteine (HCY) treatment downregulated 30093949 1591 Human RP11-426C22.6 lncRNA gemcitabine (GEM) ancreatic cancer (PC) SW1990 cells gemcitabine (GEM) treatment downregulated 30113217 1592 Human RP11-430L16.1 lncRNA ginsenoside Rh2 hepatocellular carcinoma (HCC) HepG2 cells ginsenoside Rh2 treatment upregulated 30394104 1593 Human RP11-442H21.2 lncRNA gemcitabine (GEM) ancreatic cancer (PC) SW1990 cells gemcitabine (GEM) treatment downregulated 30113217 1594 Human RP11-445H22.4 lncRNA lipopolysaccharide (LPS) osteoarthritis (OA) human cartilage ATDC5 cells lipopolysaccharide (LPS) treatment LPS significantly promoted RP11-445H22.4 expression. 29414810 1595 Human RP11-474G23.2-001 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 1596 Human RP11-48O20.4 lncRNA gemcitabine (GEM) ancreatic cancer (PC) SW1990 cells gemcitabine (GEM) treatment downregulated 30113217 1597 Human RP11-497G19.1 lncRNA gemcitabine (GEM) ancreatic cancer (PC) SW1990 cells gemcitabine (GEM) treatment upregulated 30113217 1598 Human RP11-504P24.3 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 1599 Human RP11-504P24.3-005 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment upregulated 29947995 1600 Human RP11-543N12.1 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment upregulated 29956723 1601 Human RP11-553L6.5 lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment upregulated 32714991 1602 Human RP11-566E18.3-201 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 1603 Human RP11-588G21.2 lncRNA Vitamins A and D fungal infection human monocytes during C.albicans infections Vitamins A and D treatment dysregulated 28094339 1604 Human RP11-642d21.1 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment upregulated 29956723 1605 Human RP11-65M17.3 lncRNA calycosin breast cancer MCF-7 and T47D cells calycosin treatment "Here we provide evidence for the presence of a positive feedback loop between ER¦Á and long noncoding RNA RP11-65M17.3 in both normal and cancer cells, and calycosin stimulated this feedback loop in ECs but decreased RP11-65M17.3 expression in BCCs." 33647882 1606 Human RP11-670E13.5 lncRNA influenza A virus (IAV) influenza A virus (IAV) infection human lung epithelial A549 cells influenza A/Puerto Rico/8/34 infection upregulated 30669933 1607 Human RP11-670E13.6 lncRNA ultraviolet (UV) irradiation cell senescence primary human dermal fibroblasts UVB-irradiated treatment RP11-670E136?may facilitate DNA damage repair by increasing ATM and ¦ÃH2AX levels 31444317 1608 Human RP11-670E13.6 lncRNA ultraviolet (UV) irradiation skin photodamage primary human dermal fibroblasts (HDFs) UVB treatment upregulated 29143326 1609 Human RP11-798E3.2 lncRNA IL-1¦Â crohn disease (CD) Caco-2 cells IL-1¦Â treatment downregulated 29361088 1610 Human RP1-179N16.3 lncRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) nasopharyngeal carcinoma (NPC) cells curcumin treatment dysregulated 24379026 1611 Human RP1-179N16.3 lncRNA curcumin (Cur) nasopharyngeal carcinoma (NPC) nasopharyngeal carcinoma (NPC) cells curcumin treatment upregulated 24379026 1612 Human RP11-820 lncRNA H2O2 primary open angle glaucoma (POAG) Human trabecular meshwork cells (HTMCs) H2O2 induced oxidative stress lncRNA-RP11-820 was significantly upregulated under oxidative stress in HTMCs. 31495061 1613 Human RP11-838N2.4 lncRNA erlotinib non-small cell lung cancer (NSCLC) HCC827 cells; HCC4006 cells erlotinib treatment lncRNA RP11-838N2.4 was upregulated in erlotinib-resistant cells when compared to normal NSCLC cells. 29845246 1614 Human RP11-86H7.1 lncRNA traffic-originated PM2.5 organic component (tPo) chronic obstructive pulmonary disease (COPD) human bronchial epithelial cells (HBECs) Traffic-related air pollution particulate matter 2.5 (TRAPM2.5) treatment LncRNA RP11-86H71 promotes airway inflammation induced by TRAPM25 by acting as a ceRNA of miRNA-9-5p to regulate NFKB1 in HBECS 32665564 1615 Human RP1-286D6 lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment upregulated 32714991 1616 Human RP1-43E13 lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment upregulated 32714991 1617 Human RP1-77H15.1 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment upregulated 29956723 1618 Human RP-1-7H24.1 lncRNA influenza A virus (IAV) influenza A virus (IAV) infection human lung epithelial A549 cells influenza A/Puerto Rico/8/34 infection upregulated 30669933 1619 Human RP1-93H18.7 lncRNA progesterone (P4) lung cancer A549 cells progesterone (P4) treatment downregulated 32391956 1620 Human RP6-65G23.1 lncRNA "M5 (IL-17A, TNF-¦Á, IL-1¦Á, IL-22, and Oncostatin-M)" psoriasis HaCaT cells; primary keratinocytes "M5 (IL-17A, TNF-¦Á, IL-1¦Á, IL-22, and Oncostatin-M) treatment" RP6-65G23.1 was significantly upregulated in M5-stimulated keratinocytes. 32065443 1621 Human RPMS1 lncRNA epstein-barr virus (EBV) nasopharyngeal carcinoma (NPC) NPC C666-1 cells Epstein-Barr virus (EBV) infection upregulated 31696060 1622 Human Rpph1 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SK-N-SH cells amyloid-¦Â (A¦Â) 25-35 treatment Both lncRNA Rpph1 and miR-122 were upregulated in AD mouse and Rpph1 activated Wnt/¦Â-catenin signaling to ameliorate amyloid-¦Â induced neuronal apoptosis in SK-N-SH cells via direct targeting miR-122. 31718352 1623 Human RPPH1 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment upregulated 32336203 1624 Human RPPH1 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment A¦Â25-35-induced ERS and apoptosis in SH-SY5Y cells can be attenuated by lncRNA RPPH1 through regulating miR-326/PKM2 axis. 32336203 1625 Human Rpph1 lncRNA amyloid-¦Â (A¦Â) neuronal cell injury SK-N-SH cells amyloid-¦Â (A¦Â) treatment LncRNA Rpph1 protects amyloid-¦Â induced neuronal injury in SK-N-SH cells via miR-122/Wnt1 axis 31718352 1626 Human RPS27L-1 lncRNA hypoxia and TGF¦Â1 idiopathic pulmonary fibrosis (IPF) human pulmonary fibroblasts (HPFs) hypoxia and TGF¦Â1 treatment upregulated 31925944 1627 Human RPSAP52 lncRNA high glucose (HG) diabetic retinopathy (DR) ARPE-19 cells high glucose treatment "High glucose treatment led to downregulated RPSAP52 and Timp3, but upregulated miR-365 in RPE cells." 33178344 1628 Human SAF lncRNA human immunodeficiency virus (HIV)-1 apoptosis human monocyte-derived macrophages (MDM) Human immunodeficiency virus (HIV)-1 infection upregulated 30918127 1629 Human SAF lncRNA oligo-fucoidan hepatocellular carcinoma (HCC) HepG2 cells oligo-fucoidan treatment apoptosis and cell cycle pathways could also contribute to the induction of lncRNA-Saf and lncRNA-p21 by oligo-fucoidan. 30632031 1630 Human SAMD12-AS1 lncRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) HepG2 cells hepatitis B virus (HBV) infection upregulated 31406141 1631 Human SAMD12-AS1 lncRNA N-retinylidene-N-retinylethanolamine (A2E) retinitis pigmentosa human retinal pigment epithelium cells N-retinylidene-N-retinylethanolamine (A2E) treatment downregulated 32326576 1632 Human SARCC lncRNA cisplatin (DDP) osteosarcoma (OS) Sarcoma Osteogenic-2 (Saos-2) cells cisplatin treatment lncRNA-SARCC was significantly downregulated in the cisplatin-resistant OS tissues. 32508321 1633 Human SARCC lncRNA sunitinib (SU) renal cell carcinoma (RCC) renal cell carcinoma (RCC) treat with sunitinib treatment upregulated 28644440 1634 Human SBF2-AS1 lncRNA Vitamins A and D bacterial infection human monocytes during A.fumigatus infections Vitamins A and D treatment dysregulated 28094339 1635 Human SBF2-AS1 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) "Five human GBM cell lines (U87, LN229, A172, T98, U251)" temozolomide (TMZ) treatment "SBF2-AS1 was upregulated in TMZ-resistant GBM cells and tissues, and overexpression of SBF2-AS1 led to the promotion of TMZ resistance, whereas its inhibition sensitized resistant GBM cells to TMZ" 30992025 1636 Human SBF2-AS1 lncRNA radiation non-small cell lung cancer (NSCLC) NCI-H1299 ; NCI-H1299R cells radiation treatment upregulated 31928130 1637 Human SBF2-AS1 lncRNA gemcitabine (GEM) pancreatic cancer (PC) "Pancreatic cancer cell lines including AsPC-1, HPAC, BxPC-3, and PANC-1" gemcitabine treatment knock-down of SBF2-AS1 inhibits the expression of TWF1 by competitively binding with miR-142-3p to induce gemcitabine resistance in pancreatic cancer. 31619579 1638 Human SBF2-AS1 lncRNA IFN-¦Ã and lipopolysaccharide (LPS) pancreatic cancer (PC) THP-1 cells lipopolysaccharide; interferon-¦Ã treatment "lncRNA SBF2-AS1 in M2 macrophage-derived exosomes increases miR-122-5p expression to restrain XIAP expression, which further inhibits PC progression." 32301277 1639 Human SCA8 lncRNA aurora kinase inhibitor (CCT137690) breast cancer MDA-MB-231 cells aurora kinase inhibitor (CCT137690) treatment downregulated 31319040 1640 Human SCAL1 lncRNA high glucose (HG) diabetic lung disease Normal human lung cell line BEAS-2B high (30 mM) glucose treatment upregulated 31410144 1641 Human SCAL1 lncRNA cigarette smoke (CS) lung cancer A549;CL1¨C0; CL1¨C5; H1975; HCC-827; NCI-H292;PC9 cells;Normal human primary bronchial epithelial (NHBE) cells cigarette smoke (CS) treatment a novel long noncoding RNA (lncRNA) that is induced by cigarette smoke extract (CSE) bothin vitroandin vivoand is elevated in numerous lung cancer cell lines. 23672216 1642 Human SCAMP1 lncRNA H2O2 renal cell carcinoma (RCC) ACHN and Caki-1 cells H2O2 treatment upregulated 31550675 1643 Human SCARNA2 lncRNA enterovirus 71 (EV71) hand-foot-mouth disease (HFMD) human rhabdomyosarcoma (RD) cells Enterovirus 71 (EV71) treatment downregulated 30314355 1644 Human SCRG1 lncRNA TGF-¦Â1 liver fibrosis LX2 cells TGF-¦Â1 treatment upregulated 30226813 1645 Human SDHAP1 lncRNA paclitaxel (PTX) ovarian cancer (OC) SKOV3 and Hey-8 Paclitaxel (PTX) treatment SDHAP1 was upregulated in PTX-resistant SKOV3 and Hey-8 ovarian cancer cell lines while the level of miR-4465 was downregulated 32211849 1646 Human SDHAP2 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment upregulated 29947995 1647 Human SENCR lncRNA rapamycin vascular endothelial dysfunction human umbilical vein endothelial cells (HUVECs) rapamycin (RPM) treatment RPM treatment downregulates the endogenous expression of lncRNAs MALAT1 and SENCR in HUVECs 29845247 1648 Human SGCG-5:4 lncRNA melanin melanoma Primary melanocytes melanin treatment upregulated 26596215 1649 Human SIAH1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells N-methyl-4-phenylpyridinium (MPP +) treatment upregulated 29217406 1650 Human SIKIAT1 lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) HK-2 cells lipopolysaccharide (LPS) treatment upregulated 32342116 1651 Human SLC7A11-AS1 lncRNA gemcitabine (GEM) pancreatic ductal adenocarcinoma (PDAC) BxPC-3 cells gemcitabine treatment upregulated 32036249 1652 Human SMILR lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) U937 cells oxidized low-density lipoprotein (ox-LDL) treatment SMILR was upregulated in ox-LDL-induced AS cell models. 32367412 1653 Human SMILR lncRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary arterial smooth muscle cells (hPASMCs) hypoxia treatment SMILR is upregulated in vitro PAH model. 32559140 1654 Human snaR lncRNA human papilloma virus (HPV) human papillomaviruses (HPV)-negative cervical squamous cell carcinoma (CSCC) plasma human papillomaviruses (HPV) infection lncRNA snaR was downregulated in HPV-negative CSCC patients comparing with healthy controls. 30249756 1655 Human SNHG1 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y and human primary neuron (HPN) cells amyloid-¦Â (A¦Â) 25-35 treatment "A¦Â25-35 inhibited cell viability, induced cell apoptosis and increased the expression of SNHG1 in SH-SY5Y and human primary neuron (HPN) cells." 31447119 1656 Human SNHG1 lncRNA resveratrol Alzheimer's disease (AD) SK-N-SH cells; CHP-212 cells resveratrol (Res) treatment SNHG1 expression was positively regulated by A¦Â and negatively regulated by resveratrol 32741808 1657 Human SNHG1 lncRNA gemcitabine (GEM) ancreatic cancer (PC) SW1990 cells gemcitabine (GEM) treatment downregulated 30113217 1658 Human SNHG1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment downregulated 32536864 1659 Human SNHG1 lncRNA tumor necrosis factor alpha (TNF-¦Á) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) tumor necrosis factor alpha (TNF-¦Á) treatment LncRNA SNHG1 regulates vascular endothelial cell proliferation and angiogenesis via miR-196a 32297149 1660 Human SNHG1 lncRNA H2O2 cardiomyocyte apoptosis human cardiomyocytes (HCMs) Hydrogen peroxide (H2O2) treatment Hydrogen peroxide (H2O2) treatment suppressed SNHG1 expression in HCMs. 30355909 1661 Human SNHG1 lncRNA doxorubicin (DOX) cardiotoxicity human AC16 cardiomyocytes Doxorubicin (DOX)? treatment "DOX treatment also reduced the expression of SNHG1 in AC16 cells, and overexpression of SNHG1 alleviated the increased apoptosis in DOX-treated AC16 cells." 31300525 1662 Human SNHG1 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment lncRNA SNHG1 regulates OGD/R-induced cell death through serving as a ceRNA for miR-424 in SH-SY5Y cells 31900069 1663 Human SNHG1 lncRNA sorafenib (SOR) hepatocellular carcinoma (HCC) "Human HCC HepG2 and Huh7 cells, and SR-HCC cells" sorafenib treatment upregulated 31053148 1664 Human SNHG1 lncRNA hypoxia hypoxic brain injury SH-SY5Y cells hypoxia treatment "LncRNA SNHG1-modulated miR-140-5p inhibition regulates Bcl-XL expression, thereby reducing cell apoptosis and recovering cell viability of SH-SY5Y cells." 32186226 1665 Human SNHG1 lncRNA oxygen glucose deprivation (OGD) hypoxic brain injury SH-SY5Y cells Oxygen glucose deprivation (OGD) treatment Oxygen glucose deprivation (OGD) treatment inhibited SNHG1 and Bcl-XL expression and enhanced miR-140-5p expression 32186226 1666 Human SNHG1 lncRNA oxygen glucose deprivation (OGD) ischemic stroke (IS) HCMEC/D3 cells Oxygen-glucose deprivation (OGD) treatment LncRNA SNHG1 depressed apoptosis and inflammation of IS cell model via inhibiting miR-376a and upregulating CBS/H2S signal 32532171 1667 Human SNHG1 lncRNA hypoxia/reoxygenation (H/R) myocardial ischemia/reperfusion (I/R) injury (MIRI) human umbilical vein endothelial cells (HUVECs) hypoxia/reoxygenation (H/R) induce upregulated 31792649 1668 Human SNHG1 lncRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) NSCLC cell lines (A549 and H1299) cisplatin treatment upregulated 31288529 1669 Human SNHG1 lncRNA IL-1¦Â osteoarthritis (OA) human articular chondrocytes-knee cells IL-1¦Â treatment SNHG1 alleviates the inflammation of IL-1¦Â-induced OA through the activation of miR-16-5p-mediated p38MAPK and NF-¦ÊB signaling pathway. 31383786 1670 Human SNHG1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) human SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment upregulated lncRNA SNHG1 promotes MPP+ -induced cytotoxicity and ROS production through the miR-15b-5p/GSK3¦Â axis in human dopaminergic SH-SY5Y cells 30302821 1671 Human SNHG1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment SNHG1 aggravates MPP+-induced cellular toxicity in SH-SY5Y cells by regulating PTEN/AKT/mTOR signaling via sponging miR-153-3p. 31907031 1672 Human SNHG1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells N-methyl-4-phenylpyridinium (MPP +) treatment upregulated 29217406 1673 Human SNHG1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH5Y-SY cells N-methyl-4-phenylpyridinium (MPP +) treatment upregulated 30031125 1674 Human SNHG1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells N-methyl-4-phenylpyridinium (MPP +) treatment Upregulation of SNHG1 enhanced MPP + -induced cellular toxicity in SH-SY5Y cells. 30302821 1675 Human SNHG1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SK-N-SH cells; SK-N- AS cessl 1-methyl-4-phenylpyridinium (MPP+) treatment "We discovered that SNHG1 was significantly elevated, while miR-181a-5p was decreased in N-methyl-4-phenylpyridinium (MPP+)-treated neuroblastoma cells in dose-dependent manners." 33389428 1676 Human SNHG12 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 32339345 1677 Human SNHG12 lncRNA radiation cervical cancer (CC) SiHa cells; Hela cells radiation treatment LncRNA SNHG12 promoted CDK1 expression to regulate the sensitivity of CC cells to radiation through sponging miR-148a 33292254 1678 Human SNHG12 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) Pri GBM; Rec GBM; N3S; N3T3rd; U251; U251T3rd; glioblastoma (GBM) tissues temozolomide (TMZ) treatment SNHG12 was upregulated in TMZ-resistant cells and tissues. 32039732 1679 Human SNHG12 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) vascular endothelial dysfunction SH-SY5Y cell oxygen-glucose deprivation and reoxygenation (OGD/R) treatment upregulated 31056262 1680 Human SNHG12 lncRNA angiotensin II (Ang II) vascular endothelial injury human umbilical vein endothelial cells (HUVECs) angiotensin II (Ang II) treatment "As a result, LncRNA SNHG12 was downregulated in aortic primary ECs isolated from Ang II-induced hypertensive mice and 1 kidney/deoxycorticosterone acetate/salt-induced hypertensive mice." 33464650 1681 Human SNHG14 lncRNA hypoxia/reoxygenation (H/R) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 hypoxia/reoxygenation (H/R) treatment "SNHG14 was boosted in renal tissues of I/R-stimulated rats and H/R-induced HK-2 cells, while miR-124-3p was diminished in H/R-stimulated HK-2 cells." 33490282 1682 Human SNHG14 lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 lipopolysaccharide (LPS) treatment Increased expression of SNHG14 was observed in LPS-induced HK-2 cells. 33505213 1683 Human SNHG14 lncRNA lipopolysaccharide (LPS) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 lipopolysaccharide (LPS) treatment upregulated 33856026 1684 Human SNHG14 lncRNA lipopolysaccharide (LPS) acute lung injury (ALI) A549 cells lipopolysaccharide (LPS) treatment "LPS induced A549 cells apoptosis and inflammation, wherein SNHG14 was upregulated and miR-124-3p was downregulated." 33652176 1685 Human SNHG14 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Vascular smooth muscle cells (VSMCs) and human mononuclear cells (U937) oxidized low-density lipoprotein (ox-LDL) treatment he current study revealed that SNHG14 level was high in the serum of AS patients and oxidized low-density lipoprotein (ox-LDL)-induced AS cell lines. 32735135 1686 Human SNHG14 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Vascular smooth muscle cells (VSMCs); human mononuclear cells (U937) oxidized low-density lipoprotein (ox-LDL) treatment SNHG14 level was high in oxidized low-density lipoprotein (ox-LDL)-induced AS cell lines. 32876518 1687 Human SNHG14 lncRNA trastuzumab breast cancer SKBR-3 cells; BT474 cells trastuzumab treatment lncRNA-small nucleolar RNA host gene 14 (SNHG14) was upregulated in trastuzumab-resistant cells when compared with parental breast cancer cells 30015837 1688 Human SNHG14 lncRNA trastuzumab breast cancer SKBR-3 cells; BT474 cells trastuzumab treatment SNHG14 was upregulated in resistant cell lines in contrast to their parental cell lines 30063126 1689 Human SNHG14 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SK-N-SH cells 1-methyl-4-phenylpyridinium (MPP+) treatment upregulated 33071725 1690 Human SNHG15 lncRNA high glucose (HG) diabetes mellitus (DM) human umbilical vein endothelial cells (HUVECs) high glucose (HG) treatment downregulated 33636173 1691 Human SNHG15 lncRNA hypoxia cardiomyocyte apoptosis AC16 cells hypoxia treatment upregulated 32970504 1692 Human SNHG15 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment SNHG15 knockdown protected against cerebral I/R injury via targeting miR-183-5p/FOXO1 axis 33194027 1693 Human SNHG15 lncRNA high glucose (HG) diabetic nephropathy (DN) human glomerular mesangial cells (HGMCs) high glucose (HG) treatment The results showed that SNHG15 was remarkably upregulated in pediatric DN tissues and HG-induced HGMCs. 33506255 1694 Human SNHG15 lncRNA palbociclib glioblastoma multiforme (GBM) "HMC3 cells, temozolomide-resistant (TMZ-R) cells" palbociclib treatment SNHG15-silenced TMZ-R cells became significantly sensitive towards TMZ treatment and less capable of promoting M2-phenotype in the HMC3 microglial cells 31462285 1695 Human SNHG15 lncRNA IL-1¦Â osteoarthritis (OA) chondrocytes IL-1¦Â treatment Long non-coding RNA SNHG15 is a competing endogenous RNA of miR-141-3p that prevents osteoarthritis progression by upregulating BCL2L13 expression 32247266 1696 Human SNHG16 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 macrophage-derived foam cells oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31646601 1697 Human SNHG16 lncRNA platelet derived growth factor-BB (PDGF-BB) cell proliferation human aortic smooth muscle cell (HASMC) platelet-derived growth factor (PDGF)-BB treatment upregulated 31441592 1698 Human SNHG16 lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment OGD/R itreatment downregulated LncRNA SNHG16 in SH-SY5Y cells 32407850 1699 Human SNHG16 lncRNA H2O2 diabetic retinopathy (DR) human retinal microvascular endothelial cells (HMRECs) H2O2 treatment We confirmed that over-expression of SNGH16 attenuated H2O2-induced angiogenesis by HMRECs. 33530902 1700 Human SNHG16 lncRNA ropivacaine glioblastoma multiforme (GBM) T98G cells; LN229 cells ropivacaine treatment ropivacaine impeded SNHG16 expression in glioma cells. 33817285 1701 Human SNHG16 lncRNA sorafenib (SOR) hepatocellular carcinoma (HCC) HepG2/SOR cell line sorafenib treatment "SNHG16 is upregulated in HepG2/SOR cells, whereas knockdown of SNHG16 increases the sensitivity of HepG2/SOR cells to sorafenib in vitro and in vivo" 30655679 1702 Human SNHG16 lncRNA ketamine ketamine-induced neurotoxicity human embryonic stem cell (hESC) ketamine treatment "48-h in vitro treatment of ketamine induced significant neurotoxicity, and downregulated SNHG16 among hESC-derived neurons." 30171995 1703 Human SNHG16 lncRNA oxidized low density lipoprotein (ox-LDL) myocardial infarction (MI) HUVECs oxidized low-density lipoprotein (ox-LDL) treatment downregulated 31355606 1704 Human SNHG16 lncRNA cisplatin (DDP) neuroblastoma (NB) SK-N-AS cells; SK-N-SH cells cisplatin treatment upregulated 32365562 1705 Human SNHG16 lncRNA liposomal bupivacaine (BUP) neurotoxicity SH-SY5Y cells liposomal bupivacaine (BUP) treatment BUP induced dose-dependent cell death and SNHG16 downregulated in SH-SY5Y cells. 32335807 1706 Human SNHG16 lncRNA IL-1¦Â osteoarthritis (OA) CHON-001 cells IL-1¦Â treatment lncRNA SNHG16 knockdown significantly limited the progression of OA by sponging miR-373-3p in vitro 33300061 1707 Human SNHG16 lncRNA cisplatin (DDP) osteosarcoma (OS) "osteosarcoma cell lines (SAOS2, U2OS)" cisplatin (DPP) treatment SNHG16 enhanced the cisplatin resistance in osteosarcoma cell lines. 31427084 1708 Human SNHG16 lncRNA lipopolysaccharide (LPS) pneumonia human lung fibroblasts cell WI-38 lipopolysaccharide (LPS) treatment SNHG16 regulated LPS-induced inflammation injury in WI-38 cells through competitively binding miR-146a-5p with CCL5 further mediating JNK and NF-¦ÊB pathways 31071307 1709 Human SNHG16 lncRNA lipopolysaccharide (LPS) pneumonia A549 cells LPS treatment "SNHG16 impeded cell viability and promoted apoptosis, inflammatory injury by targeting IGF2 mediated by miR-370-3p in LPS-induced A549 cells." 31841752 1710 Human SNHG16 lncRNA lipopolysaccharide (LPS) pneumonia WI-38 cells lipopolysaccharide (LPS) treatment "SNHG16 and sushi domain containing 2 (SUSD2) were upregulated, and miRNA (miR)-141-3p was downregulated in the serum of acute pneumonia patients and lipopolysaccharide (LPS)-challenged human lung fibroblasts WI-38." 33836533 1711 Human SNHG16 lncRNA lipopolysaccharide (LPS) pneumonia A549 cells lipopolysaccharides (LPS) treatment upregulated 31841752 1712 Human SNHG22 lncRNA cisplatin (DDP) epithelial ovarian cancer (EOC) "Eight EOC cell lines (Hey, OAW28, COV-362, OVCAR-3, CAOV3, SKOV3, A2780, and A2780/CP)" cisplatin treatment Knockdown of SNHG22 expression increased the sensitivity of EOC cells to cisplatin and paclitaxel. 31581131 1713 Human SNHG22 lncRNA paclitaxel (PTX) epithelial ovarian cancer (EOC) "Eight EOC cell lines (Hey, OAW28, COV-362, OVCAR-3, CAOV3, SKOV3, A2780, and A2780/CP)" paclitaxel treatment Knockdown of SNHG22 expression increased the sensitivity of EOC cells to cisplatin and paclitaxel 31581131 1714 Human SNHG29 lncRNA ¦Â-glycerophosphate (¦Â-GP) vascular calcification (VC) human aortic smooth muscle cells (HASMCs) ¦Â-glycerophosphate (¦Â-GP) treatment downregulated 32818704 1715 Human SNHG3 lncRNA sorafenib (SOR) hepatocellular carcinoma (HCC) "Seven HCC cell lines PLC/PRF/5, Hep3B, HepG2, MHCC97L, Huh7, SMMC©\7721, and HCCLM3" sorafenib treatment "forced expression of SNHG3 promoted cell invasion, epithelial-mesenchymal transition (EMT), and sorafenib resistance in HCC" 30132868 1716 Human SNHG4 lncRNA high glucose (HG) diabetic retinopathy (DR) retinal pigment epithelial cells (ARPE-19) high glucose (HG) treatment We found that SNHG4 was downregulated in DR. 33822671 1717 Human SNHG5 lncRNA yin yang 1 (YY1) acute myeloid leukemia (AML) "Human AML cells U937, KG-1, THP-1, and HL-60" yin yang 1 (YY1) treatment upregulated 33318617 1718 Human SNHG5 lncRNA adriamycin (ADR) acute myeloid leukemia (AML) AML cell lines adriamycin (ADR) treatment upregulated 31884339 1719 Human SNHG5 lncRNA lipopolysaccharide (LPS) acute respiratory distress syndrome (ARDS) A549 cells lipopolysaccharide (LPS) treatment "SNHG5 was downregulated, while miR-205 was upregulated in the serum of ARDS patients and lung tissues of LPS-induced mice." 33170429 1720 Human SNHG5 lncRNA gemcitabine (GEM) ancreatic cancer (PC) SW1990 cells gemcitabine (GEM) treatment downregulated 30113217 1721 Human SNHG5 lncRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) 16HBE cells cigarette smoke extract (CSE) treatment LncRNA SNHG5 regulates cell apoptosis and inflammation by miR-132/PTEN axis in COPD 32145584 1722 Human SNHG5 lncRNA lipopolysaccharide (LPS) cirrhosis liver sinusoidal endothelial cells (LSECs) lipopolysaccharide (LPS) treatment upregulated 32269710 1723 Human SNHG5 lncRNA high glucose (HG) and high fat diet (HFD) type 2 diabetes mellitus (T2DM) NCM460 cells; DLD-1 cells high-glucose and high-fat treatment upregulated 32242546 1724 Human SNHG5 lncRNA TGF-¦Â1 intrauterine adhesion (IUA) primary human endometrial stromal cells (HESCs) TGF-¦Â1 treatment upregulated 33176855 1725 Human SNHG5 lncRNA gefitinib lung adenocarcinoma (LUAD) PC9 cells; A549 cells gefitinib treatment downregulated 29592872 1726 Human SNHG5 lncRNA IL-1¦Â osteoarthritis (OA) chondrocytes IL-0¦Â treatment LncRNA SNHG5 promotes chondrocyte proliferation and inhibits apoptosis in osteoarthritis by regulating miR-10a-5p/H3F3B axis 32967481 1727 Human SNHG6 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment The levels of SNHG6 was increased in oxidized low-density lipoprotein (ox-LDL)-treated HUVECs. 31921409 1728 Human SNHG6 lncRNA propofol (PPF) heart failure (HF) Human induced pluripotent stem cell-derived cardiomyocytes (HiPSC-CMs) Propofol (PPF) treatment "PPF induced significant cytotoxicity, as well as SNHG6 upregulation in HiPSC-CMs" 32968636 1729 Human SNHG6 lncRNA 5-fluorouracil (5-Fu) colorectal cancer (CRC) RKO cells 5-fluorouracil (5-FU) treatment SNHG6 enhanced CRC cell resistance to 5-fluorouracil (5-FU). 31516391 1730 Human SNHG7 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) Human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment lncRNA SNHG7 was remarkedly upregulated in ox-LDL exposed HUVECs. 32603818 1731 Human SNHG7 lncRNA high glucose (HG) diabetic retinopathy (DR) human retinal endothelial cells (hRECs) high glucose (HG) treatment SNHG7 was decreased in hRECs under HG stimuli. 31056258 1732 Human SNHG7 lncRNA cisplatin (DDP) neuroblastoma (NB) SK-N-AS; LAN-6 cells cisplatin (DPP) treatment LncRNA SNHG7 enhances chemoresistance in neuroblastoma through cisplatin-induced autophagy by regulating miR-329-3p/MYO10 axis. 32329857 1733 Human SNHG7 lncRNA IL-1¦Â osteoarthritis (OA) primary human chondrocytes IL-1¦Â treatment "SNHG7 sponged miR-34a-5p to affect cell proliferation, apoptosis and autophagy through targeting SYVN1" 32066502 1734 Human SNHG7 lncRNA IL-1¦Â osteoarthritis (OA) human primary chondrocytes IL-1¦Â treatment "The results showed that SNHG7 was distinctly downregulated, while miR-214-5p was significantly upregulated in OA patients and primary chondrocytes treated with IL-1¦Â." 33296783 1735 Human SNHG7 lncRNA IL-1¦Â osteoarthritis (OA) primary chondrocytes IL-1¦Â treatment SNHG7 prevents IL-1¦Â induced OA by inhibiting NLRP3 inflammasome and apoptosis through miR-214-5p/PPARGC1B axis. 33296783 1736 Human SNHG7-003 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment "SNHG7-003 may inhibit the proliferation, migration and invasion of VSMCs via the miR-1306-5p/SIRT7 signaling pathway." 33416100 1737 Human SNHG8 lncRNA human papilloma virus (HPV) cervical cancer (CC) HeLa cells; SiHa cells; MS751 cells; CaSki cells human papillomaviruses (HPVs) treatment SNHG8 was upregulated in HPV-induced CC cells was found compared with HPV-negative CC cells. 31961005 1738 Human SOX21-AS1 lncRNA amyloid-¦Â (A¦Â) 1-42 Alzheimer's disease (AD) SH-SY5Y;SK-N-SH cells amyloid ¦Â1-42?(A¦Â) treatment SOX21-AS1 silencing could attenuate A¦Â1-42-induced neuronal damage by sponging miR-107 32124921 1739 Human SOX2OT lncRNA aurora kinase inhibitor (CCT137690) breast cancer MDA-MB-231 cells aurora kinase inhibitor (CCT137690) treatment downregulated 31319040 1740 Human SOX2OT lncRNA high glucose (HG) diabetic nephropathy (DN) human podocytes cells (HPCs) high glucose (HG) treatment SOX2OT overexpression alleviates the HG-induced podocytes injury through autophagy induction by the miR-9/SIRT1 axis. 31301307 1741 Human SOX2OT lncRNA all-trans retinoic acid (ATRA) glioblastoma multiforme (GBM) U87 glioblastoma cells all-trans retinoic acid (ATRA) treatment downregulated 31186810 1742 Human SOX2OT lncRNA X-rays radiation-induced injury human lymphoblast cell line TK6 irradiat a RAD Source 2000 X-ray Biological irradiator treatment upregulated 24502193 1743 Human SOX2OT lncRNA H2O2 thoracic aortic aneurysm (TAA) mouse aortic smooth muscle cells (SMCs) H2O2 treatment long noncoding RNA (lncRNA) Sox2ot modulates the progression of TAA by regulating miR-330-5p/Myh11 axis. 32578852 1744 Human SOX2OT lncRNA hypoxia myocardial infarction (MI) human cardiomyocyte primary cells (HCM) hypoxia treatment lncRNA SOX2-OT expression was upregulated in hypoxic HCMs. 32528555 1745 Human SOX2OT variant 7 lncRNA epigallocatechin-3-gallate (EGCG) osteosarcoma (OS) U2OS and SaoS2 cell lines epigallocatechin-3-gallate (EGCG) treatment downregulated 29475441 1746 Human SPAG5-AS1 lncRNA high glucose (HG) podocyte injury human podocytes (HPCs) high glucose (HG) treatment upregulated 31957155 1747 Human SPRY4-IT1 lncRNA ketamine neurotoxicity human embryonic stem cells (hESCs) ketamine treatment "Ketamine-induced dose-dependent apoptosis, neurite degeneration, and SPRY4-IT1 upregulation in hESC-induced neurons." 33827085 1748 Human SRA lncRNA resveratrol atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) resveratrol (RSV) treatment RSV suppressed the production of SRA 30272285 1749 Human SRA1 lncRNA X-rays radiation-induced injury human lymphoblast cell line TK6 irradiat a RAD Source 2000 X-ray Biological irradiator treatment upregulated 24502193 1750 Human SRAs lncRNA high glucose (HG) type 1 diabetes mellitus (T1DM) CD4+ MOLT4 Tregs high glucose (HG) treatment upregulated 33572095 1751 Human SRLR lncRNA sorafenib (SOR) renal cell carcinoma (RCC) RCC cells sorafenib treatment upregulated 27841868 1752 Human STAiRs15 lncRNA IL-6 multiple myeloma (MM) human multiple myeloma cell lines INA-6 and JK-6E interleukin-6 (IL-6) treatment upregulated 28801664 1753 Human STAiRs18 lncRNA IL-6 multiple myeloma (MM) human multiple myeloma cell lines INA-6;JK-6E interleukin-6 (IL-6) treatment upregulated 28801664 1754 Human T199678 lncRNA ¦Á-synuclein (¦Á-Syn) parkinson's disease (PD) SH-SY5Y cells ¦Á-synuclein (¦Á-Syn) treatment Xogenous ¦Á-Syn induced the downregulated of lncRNA-T199678 in SH-SY5Y cells 33328976 1755 Human TALC lncRNA temozolomide (TMZ) temozolomide (TMZ) resistance in glioblastoma (GBM) "LN229, U251, 551 W, and HG7 cells" temozolomide (TMZ) treatment Lnc-TALC is highly expressed in TMZ-resistant GBM cells 31053733 1756 Human TapSAKI lncRNA lipopolysaccharide (LPS) sepsis HK-2 cells lipopolysaccharide (LPS) treatment TapSAKI was upregulated and miR-205 was downregulated in LPS-induced HK-2 cells. 33869780 1757 Human TapSAKI lncRNA lipopolysaccharide (LPS) sepsis-induced acute kidney injury HK-2 cells lipopolysaccharide (LPS) treatment "TapSAKI was elevated in urine derived sepsis-induced kidney injury, and promoted HK-2 cell apoptosis and inflammatory response through miR-22/PTEN/TLR4/NF-¦ÊB pathway." 30666657 1758 Human TATDN1 lncRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) NSCLC tissues and cell lines cisplatin treatment "?TATDN1 and TRIM66 was significantly upregulated while miR-451 was downregulated in NSCLC tissues and cell lines, especially in DDP-resistant tumor tissues and cells." 30481109 1759 Human TATDN1 lncRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells; H157 cells cisplatin treatment upregulated 30481109 1760 Human TBILA lncRNA TGF-¦Â1 non-small cell lung cancer (NSCLC) A549 cells; H226 cells TGF-¦Â1 treatment lncRNA TBILA is upregulated in response to TGF-¦Â1 treatment 29908210 1761 Human TBULC lncRNA TGF-¦Â non-small cell lung cancer (NSCLC) NSCLC cell lines (A549 and H226) TGF¦Â treatment upregulated 31921623 1762 Human TBX2-AS1 lncRNA hypoxia and TGF¦Â1 idiopathic pulmonary fibrosis (IPF) human pulmonary fibroblasts (HPFs) hypoxia and TGF¦Â1 treatment downregulated 31925944 1763 Human TC0101441 lncRNA estrogen (ES) epithelial ovarian cancer (EOC) E2 receptor (ER) ¦Á-positive EOC cells Estrogen (E2) treatment dysregulated 24481591 1764 Human TC0101441 lncRNA oestrogen (E2) epithelial ovarian cancer (EOC) The human EOC cell lines SKOV3 and A2780 oestrogen(E2) treatment E2 modulates lncRNA expression in ER?-positive EOC cells and that this regulation is sometimes ER¦Á-mediate 24380700 1765 Human TC0101441 lncRNA oestrogen (E2) ovarian cancer (OC) The human EOC cell lines SKOV3 and A2780 the cells were ed for 24 h with 10-8 M E2 treatment dysregulated 24380700 1766 Human TC0101686 lncRNA estrogen (ES) epithelial ovarian cancer (EOC) E2 receptor (ER) ¦Á-positive EOC cells Estrogen (E2) treatment dysregulated 24481591 1767 Human TC0101686 lncRNA oestrogen (E2) ovarian cancer (OC) The human EOC cell lines SKOV3 and A2780 the cells were ed for 24 h with 10-8 M E2 treatment dysregulated 24380700 1768 Human TCF7 lncRNA platelet derived growth factor-BB (PDGF-BB) asthma airway smooth muscle cells (ASMCs) platelet-derived growth factor (PDGF)-BB treatment PDGF-BB treated ASMCs exhibited elevated levels of lncTCF7 30528236 1769 Human TCONS_00001266 lncRNA sub-lethal heat hepatocellular carcinoma (HCC) "human SMMC-7721, HepG2, and MHCC97-H HCC cells" treat with sub-lethal heat treatment upregulated 28732507 1770 Human TCONS_00006019 lncRNA sorafenib (SOR) hepatocellular carcinoma (HCC) Huh7 cells; HepG2 cells sorafenib treatment upregulated 32149026 1771 Human TCONS_00015544 lncRNA sub-lethal heat hepatocellular carcinoma (HCC) "human SMMC-7721, HepG2, and MHCC97-H HCC cells" treat with sub-lethal heat treatment upregulated 28732507 1772 Human TCONS_00022632-XLOC_010933 lncRNA all-trans retinoic acid (ATRA) acute promyelocytic leukemia (APL) bone marrow (BM) all-trans retinoic acid (ATRA) treatment downregulated 29956795 1773 Human TCONS_00024652 lncRNA tumor necrosis factor alpha (TNF-¦Á) acute coronary syndrome (ACS) human umbilical vein endothelial cells (HUVECs) tumor necrosis factor alpha (TNF-¦Á) treatment TCONS_00024652 is highly expressed in TNF-¦Á-induced HUVECs 30233677 1774 Human TCONS_00284048 lncRNA sorafenib (SOR) hepatocellular carcinoma (HCC) Huh7 cells; HepG2 cells sorafenib treatment upregulated 32149026 1775 Human TCONS-00010875 lncRNA X-rays hypopharyngeal cancer RS-FaDu cells 4 Gy radiation upregulated 28487500 1776 Human TCONS-00018436 lncRNA X-rays hypopharyngeal cancer RS-FaDu cells 4 Gy radiation downregulated 28487500 1777 Human TCTN2 lncRNA oxygen glucose deprivation (OGD) spinal cord injury (SCI) human SY-SH-5Y cells oxygen-glucose deprivation treatment "TCTN2 was downregulated in the spinal cord tissues of a rat model of SCI and in oxygen-glucose deprivation-induced hypoxic SY-SH-5Y cells, while microRNA-216b (miR-216b) was upregulated" 31050183 1778 Human TDRG1 lncRNA hypoxia cervical cancer (CC) HeLa and C-33A cells hypoxia induce We found Lnc-TDRG1 was highly expressed in CC tissues and cells and it was upregulated in response to hypoxia. 33394293 1779 Human TDRG1 lncRNA high glucose (HG) diabetic retinopathy (DR) human retinal microvascular endothelial cells (HRECs) high glucose (HG) treatment upregulated 32082175 1780 Human TERRA lncRNA H2O2 oxidative stress HEK-293T cells H2O2 treatment TERRA levels significantly increased upon incubation of cells with 500 ¦ÌM H2O2. 31917282 1781 Human TERRA lncRNA compound C subtelomeric DNA methylation HeLa and HCT116 cells AMPK inhibitor (compound C) treatment upregulated 31181625 1782 Human TERRAs lncRNA etoposide (VP-16) DNA damage HeLa cells etoposide treatment upregulated 31756221 1783 Human TFDP2-001 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 1784 Human TGFB2-AS1 lncRNA TGF-¦Â epithelial-mesenchymal transition (EMT) Human immortalized male keratinocytes (HaCaT) TGF-¦Â treatment upregulated 31533040 1785 Human TGF¦Â2-AS1 lncRNA H2O2 open-angle glaucoma (OAG) human trabecular meshwork cells (HTMCs) H2O2 treatment lnc-TGF¦Â2-AS1 promotes ECM production via TGF-¦Â2 in HTMC. 32423825 1786 Human TGS-1 lncRNA mycobacterium tuberculosis (Mtb) tuberculosis (TB) whole blood samples Mycobacterium tuberculosis (MTB) infection downregulated 31028876 1787 Human THAP9-AS1 lncRNA helicobacter pylori (H. pylori) gastric cancer (GC) "The human GC cell lines AGS, BGC-823, HGC-27, MGC803 and SGC-7901" H. pylori infection upregulated 32021238 1788 Human THOR lncRNA triptolide (TPL) nasopharyngeal carcinoma (NPC) HONE-1 cells triptolide (TPL) treatment "THOR (¡°Lnc-THOR¡±), was significantly decreased in TN-treated cells" 30503558 1789 Human THOR lncRNA triptolide (TPL) nasopharyngeal carcinoma (NPC) "The established human NPC cell lines, HONE-1, CNE1, CNE-2, 5¨C8F, 6¨C10B and primary culture of human NPC cells" triptolide (TPL) treatment downregulated 30503558 1790 Human THRIL lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment THRIL was upregulated in both?in vitro?and?in vivo?models of brain ischemia-reperfusion injury 33675584 1791 Human THRIL lncRNA lipopolysaccharide (LPS) sepsis human bronchial epithelial cells (HBEpCs) lipopolysaccharide (LPS) treatment "THRIL is upregulated in sepsis and may sponge miR-19a to upregulate TNF-¦Á, thereby promoting lung cell apoptosis." 32944003 1792 Human THRIL lncRNA lipopolysaccharide (LPS) systemic lupus erythematosus (SLE) HK2 cells lipopolysaccharide (LPS) treatment LncRNA THRIL was highly expressed in the LPS-stimulated cells. 30414207 1793 Human THUMPD3-AS1 lncRNA calcium oxalate monohydrate (COM) renal injury HK-2?cells calcium oxalate monohydrate treatment downregulated 29947995 1794 Human TINCR lncRNA trastuzumab breast cancer SKBR-3-TR and BT474-TR cell lines Trastuzumab treatment upregulated 30621694 1795 Human TINCR lncRNA high glucose (HG) cardiac hypertrophy human cardiomyocyte cells high glucose (HG) treatment upregulated 30453794 1796 Human TINCR lncRNA X-rays colorectal cancer (CRC) radioresistant CRC cell line (SW620R) 2 Gy of X-ray irradiation (120 kV and 3.5 mA for 4 min with a 0.5-mm A1 filter) treatment upregulated 31540772 1797 Human TINCR lncRNA photodynamic therapy using 5©\aminolevulinic acid (ALA-PDT) cutaneous squamous cell carcinoma (CSCC) CSCC cell lines A431 ALA©\PDT treatment "ALA-PDT treatment at 32?mmol/L for 120?minutes significantly promoted TINCR expression in CSCC A431 cells, and TINCR promoted ALA-PDT-induced apoptosis and cell autophagy" 30993776 1798 Human TLINC lncRNA TGF-¦Â intrahepatic cholangiocarcinoma (iCCA) HuCCT1 cells; Huh28 cells TGF¦Â treatment upregulated 29916183 1799 Human TM1P3 lncRNA IL-1 osteoarthritis (OA) primary cultured chondrocytes ?IL-1 treatment The lncRNA-TM1P3 significantly upregulated in patients with OA 30887601 1800 Human TMPO-AS1 lncRNA propofol (PPF) esophageal cancer (EC) EC109; KYSE70 cells Propofol treatment "Propofol suppresses hypoxia-induced esophageal cancer cell migration, invasion, and EMT through regulating lncRNA TMPO-AS1/miR-498 axis" 32643321 1801 Human TNK2-AS1 lncRNA oxidized low density lipoprotein (ox-LDL) cell proliferation and migration human aortic smooth muscle cells (HASMCs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31468685 1802 Human TOCN_00011820 lncRNA coal tar pitch extracts (CTPE) lung cancer malignant-transformed Human bronchial epithelial (BEAS-2B) cells coal tar pitch extracts (CTPE) treatment downregulated 32470693 1803 Human tp53inp1 lncRNA polyunsaturated fatty acids (PUFAs) glioblastoma multiforme (GBM) Glioblastoma cells (U373; GBM2;GBM5) polyunsaturated fatty acids (PUFAs) treatment downregulated 21961478 1804 Human TP53TG1 lncRNA glucose deprivation (GD) cell proliferation and migration U87 and LN18 cells glucose deprivation treatment upregulated 28569381 1805 Human TP53TG1 lncRNA ultraviolet (UV) irradiation DNA damage CD4 cells ultraviolet-C (UVC) treatment upregulated 32258156 1806 Human TP53TG1 lncRNA covalent inhibitor of CDK7 (THZ1) nasopharyngeal carcinoma (NPC) "HK1,S18, S26, SUNE1, and SUNE2 cells" THZ1 treatment upregulated 28951465 1807 Human TP73-AS1 lncRNA bisphosphonates (BPs) bisphosphonate-induced osteonecrosis of the jaw (BONJ) lymphomonocytes bisphosphonates (BPs) treatment upregulated 32714991 1808 Human TP73-AS1 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) GBM cancer stem cells (gCSC) temozolomide (TMZ) treatment "Using CRISPRi to downregulate our candidate lncRNA in gCSC, we demonstrate that TP73-AS1 promotes TMZ resistance in gCSC and is linked to regulation of the expression of metabolism- related genes and ALDH1A1, a protein known to be expressed in cancer stem cell markers and protects gCSC from TMZ treatment." 30867410 1809 Human TPTEP1 lncRNA cisplatinum hepatocellular carcinoma (HCC) "The human HCC cell lines, including HepG2, SMMC-7721, QGY-7703, Huh-7, MHCC97h, SNU-449 and Sk-hep1, and L02 human normal liver cell line" cisplatinum treatment upregulated 31072375 1810 Human TRERNA1 lncRNA hepatitis B virus X protein (HBx) hepatocellular carcinoma (HCC) HCC cells ?hepatitis B virus-encoded X (HBx) protein treatment we found that translation regulatory lncRNA 1 (TRERNA1) upregulation by HBx not only promoted HCC cell proliferation by regulating the cell cycle in vitro and in vivo but also correlated positively with poor prognosis in HCC 33839325 1811 Human TRIM58 lncRNA progesterone (P4) lung cancer A549 cells progesterone (P4) treatment downregulated 32391956 1812 Human TRINGS lncRNA glucose starvation glucose homeostasis human tumor cells glucose starvation condition upregulated 29046333 1813 Human TSI lncRNA TGF-¦Â1 renal fibrosis HK2 and HKC8 cells TGF-¦Â1 treatment upregulated 30305452 1814 Human TSPEAR-AS2 lncRNA CoCl2 pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (HPASMCs) CoCl2 treatment upregulated 32391042 1815 Human TSPOAP1-AS1 lncRNA influenza A virus (IAV) influenza A virus (IAV) infection "A549 and THP-1 cell lines, MDCK, A172, Caco-2, and SH-SY5Y cells" influenza A virus (IAV) infection upregulated 30968963 1816 Human TSPOAP1-AS1 lncRNA polyinosinic-polycytidilic acid (Poly(I:C)) influenza A virus (IAV) infection "A549 and THP-1 cell lines, MDCK, A172, Caco-2, and SH-SY5Y cells" poly (I:C) treatment upregulated 30968963 1817 Human TTN-AS1 lncRNA sorafenib (SOR) hepatocellular carcinoma (HCC) Bel7404; HepG2 cells sorafenib treatment LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1 33378944 1818 Human TTN-AS1 lncRNA X-rays large intestine cancer SW620 cells; HT29 cells X-ray radiation treatment upregulated 32749739 1819 Human TTTY14 lncRNA human papilloma virus (HPV) head and neck squamous cell carcinoma (HNSCC) primary tumors resected from HNSCC patients human papillomavirus (HPV) infection upregulated 32998396 1820 Human TTTY15 lncRNA H2O2 acute myocardial infarction (AMI) Human myocardial cell line (AC16) H2O2 treatment upregulated 32888161 1821 Human TTTY15 lncRNA hypoxia acute myocardial infarction (AMI) AC16 hypoxia treatment upregulated 32922590 1822 Human TTTY15 lncRNA hypoxia dysfunction of vascular endothelial cells human umbilical vein endothelial cells (HUVECs) hypoxia treatment downregulated of TTTY15 ameliorated hypoxia-induced cell injury by targeting miR-186-5p in HUVECs. 32271447 1823 Human TTTY15 lncRNA human papilloma virus (HPV) head and neck squamous cell carcinoma (HNSCC) primary tumors resected from HNSCC patients human papillomavirus (HPV) infection upregulated 32998396 1824 Human TTTY15 lncRNA hypoxia myocardial infarction (MI) human cardiomyocyte hypoxia induce Suppression of long noncoding RNA TTTY15 attenuates hypoxia-induced cardiomyocytes injury by targeting miR-455-5p. 30898696 1825 Human TTTY15 lncRNA hypoxia myocardial ischaemic injury AC16 cells hypoxia treatment upregulated 32926961 1826 Human TUC339 lncRNA IL-4 hepatocellular carcinoma (HCC) THP-1 cells IL-4 treatment upregulated 30274167 1827 Human TUG1 lncRNA hypoxia/reoxygenation (H/R) acute kidney injury (AKI) Human renal proximal tubular cell line HK-2 hypoxia/reoxygenation (H/R) treatment lncRNA TUG1 was decreased while miR-494-3p was elevated in vivo and in vitro. 33663500 1828 Human TUG1 lncRNA adriamycin (ADR) acute myeloid leukemia (AML) Human bone marrow stromal cell line HS-5 and human AML cell line HL60 adriamycin (ADR) treatment upregulated 30551433 1829 Human TUG1 lncRNA adriamycin (ADR) acute myeloid leukemia (AML) HL60 cells adriamycin (ADR) treatment TUG1 was upregulated in ADR-resistant AML tissues and cells. 30551433 1830 Human TUG1 lncRNA rapamycin angiogenesis human umbilical vein endothelial cells (HUVECs) rapamycin treatment upregulated 30186415 1831 Human TUG1 lncRNA metformin (Met) atherosclerosis (AS) Blood Samples; HUVECs Metformin treatment Metformin prevent AS by activating the AMPK/mTOR pathway via lncRNA TUG1. 32099330 1832 Human TUG1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human VSMC; human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment TUG1 knockdown attenuated ox-LDL-induced injury through regulating proliferation and apoptosis of VSMC and HUVEC by miR-148b/IGF2 axis 31926240 1833 Human TUG1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) vascular smooth muscle cells (HA-VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment TUG1 enhanced the progression of AS in vitro by regulating the miR-141-3p/ROR2 axis. 32565910 1834 Human TUG1 lncRNA X-rays bladder cancer "SW780,HT1376,BIU87, T24" X-ray treatment upregulated 28376901 1835 Human TUG1 lncRNA pterostilbene breast cancer MCF 7 cells pterostilbene treatment upregulated 30619763 1836 Human TUG1 lncRNA doxorubicin (DOX) cellular defense against genotoxic agents human glioma cell lines doxorubicin (DOX) treatment downregulated 25645334 1837 Human TUG1 lncRNA cigarette smoke extract (CSE) chronic obstructive pulmonary disease (COPD) BEAS-2B cells cigarette smoke extract (CSE) treatment LncRNA TUG1 knockdown mitigates inflammatory injury induced by cigarette smoke extract in chronic obstructive pulmonary disease via miR-34c/BRD4 axis 32812639 1838 Human TUG1 lncRNA lipopolysaccharide (LPS) cirrhosis liver sinusoidal endothelial cells (LSECs) lipopolysaccharide (LPS) treatment LPS treatment enhanced autophagy and promoted EndMT of LSECs by upregulating TUG1. 32269710 1839 Human TUG1 lncRNA methotrexate (MTX) colorectal cancer (CRC) human colorectal cancer cell lines HT-29-P/HT-29-R cell and HCT-8 cells methotrexate treatment upregulated 28805722 1840 Human TUG1 lncRNA high glucose (HG) diabetic atherosclerosis human umbilical vein endothelial cells (HUVECs) high glucose treatment upregulated 30402858 1841 Human TUG1 lncRNA tumor necrosis factor alpha (TNF-¦Á) diabetic atherosclerosis human umbilical vein endothelial cells (HUVECs) tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 30402858 1842 Human TUG1 lncRNA high glucose (HG) diabetic nephropathy (DN) human podocyte cell line (CIHP) cells high glucose (HG) treatment upregulated 30671964 1843 Human TUG1 lncRNA lipopolysaccharide (LPS) dysfunction of vascular endothelial cells human umbilical vein endothelial cells (HUVECs) lipopolysaccharide (LPS) treatment "TUG1 could repress cell apoptosis, autophagy, and inflammatory response in LPS-treated HUVECs by sponging miR-27a-3p to target SLIT2." 32738556 1844 Human TUG1 lncRNA endothelial growth medium©\2 (EGM©\2) plus VEGF endothelial dysfunction Adipose-derived stem cells (ADSCs) endothelial growth medium©\2 (EGM©\2) supplemented with 15 ng/mL VEGF innduce upregulated 31264280 1845 Human TUG1 lncRNA hypoxia hypoxia-induced cardiac dysfunctions AC16 cells hypoxia treatment upregulated 31926162 1846 Human TUG1 lncRNA baicalin (BAI) inflammation LPS stimulated human normal liver L-02 and THLE2 cells baicalin (BAI) treatment upregulated 31396818 1847 Human TUG1 lncRNA lipopolysaccharide (LPS) inflammation human normal liver L-02; THLE2 cells lipopolysaccharide (LPS) treatment downregulated 31396818 1848 Human TUG1 lncRNA tumor necrosis factor alpha (TNF-¦Á) intervertebral disc degeneration (IDD) human nucleus pulposus (NP) cells tumor necrosis factor alpha (TNF-¦Á) treatment upregulated 28756222 1849 Human TUG1 lncRNA TGF-¦Â1 intrauterine adhesion (IUA) human embryonic stem cells (hESCs) TGF-¦Â1 treatment lncRNA TUG1 promotes endometrial fibrosis and inflammation by sponging miR-590-5p to regulate Fasl in intrauterine adhesions 32599321 1850 Human TUG1 lncRNA TGF-¦Â liver fibrosis LX-2 cells TGF-¦Â treatment upregulated 29904430 1851 Human TUG1 lncRNA lipopolysaccharide (LPS) lupus nephritis (LN) HK2 cells lipopolysaccharide (LPS) treatment TUG1 was downregulated and related with LPS-induced HK-2 cell inflammatory response. 29800915 1852 Human TUG1 lncRNA ultraviolet (UV) irradiation melanogenesis PIG1 cells UVB irradiation exposure treatment upregulated 30924963 1853 Human TUG1 lncRNA hypoxia myocardial ischaemic injury AC16 cells hypoxia treatment upregulated 33165134 1854 Human TUG1 lncRNA IL-1¦Â osteoarthritis (OA) Human chondrocytes IL-1¦Â treatment TUG1 was elevated in OA cartilage tissues and interleukin (IL)-1¦Â-induced chondrocytes. 33093892 1855 Human TUG1 lncRNA IL-1¦Â and TNF-¦Á osteoarthritis (OA) primary chondrocytes interleukin-1 beta (IL-1¦Â) and tumor necrosis factor-alpha (TNF-¦Á) treatment "After chondrocytes were induced by IL-1¦Â and TNF-¦Á, the expression of lncRNA-TUG1 increased." 30575896 1856 Human TUG1 lncRNA ionizing radiation (IR) osteogenesis bone marrow mesenchymal stem cells (BM-MSCs) "For the radiation treatment, when cultured cells reached 80 % confluence, they were irradiated with Co-60 for 13min at a rate of 0.69 Gy/min" upregulated 31149038 1857 Human TUG1 lncRNA cisplatin (DDP) osteosarcoma (OS) "osteosarcoma cell lines (Saos-2/DDP, MG-63/DDP)" cisplatin treatment upregulated 31305159 1858 Human TUG1 lncRNA cisplatin (DDP) osteosarcoma (OS) Saos-2 cells; MG-63 cells cisplatin treatment upregulated 31305159 1859 Human TUG1 lncRNA paclitaxel (PTX) ovarian cancer (OC) A2780 cells; SK-OV-3 cells Paclitaxel (PTX) treatment TUG1 Promotes Autophagy-Associated Paclitaxel Resistance by Sponging miR-29b-3p in Ovarian Cancer Cells 32189969 1860 Human TUG1 lncRNA lipopolysaccharide (LPS) periodontitis human periodontal ligament cells (hPDLCs) lipopolysaccharide (LPS) treatment ?TUG1 was downregulated upon LPS stimulation in hPDLCs. 32762066 1861 Human TUG1 lncRNA lipopolysaccharide (LPS) periodontitis human periodontal ligament cells (PDLCs) lipopolysaccharide (LPS) treatment "TUG1 had a decreased expression in both periodontal ligament (PDL) tissues with periodontitis and PDLCs under a LPS-induced inflammatory condition, and TUG1 expression was negatively correlated with miR-132 expression in periodontitis-affected PDL tissues." 31735958 1862 Human TUG1 lncRNA lipopolysaccharide (LPS) pneumonia MRC-5 cells lipopolysaccharide (LPS) treatment TUG1 lightened LPS-evoked pro-inflammatory response in MRC-5 cells. 31017717 1863 Human TUG1 lncRNA X-rays prostate cancer PC-3 cells; DU145 cells X-ray radiation treatment Knockdown of lncRNA TUG1 enhanced radiosensitivity in PCa via the TUG1/miR-139-5p/SMC1A axis 32256083 1864 Human TUG1 lncRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary smooth muscle cell (HPASMC) hypoxia induce upregulated 31679623 1865 Human TUG1 lncRNA IL-6 pulmonary arterial hypertension (PAH) human pulmonary smooth muscle cell (HPASMC) IL-6 treatment upregulated 31679623 1866 Human TUG1 lncRNA TGF-¦Â1 renal interstitial fibrosis (RIF) HK-2 cells transforming growth factor (TGF)-¦Â1 treatment upregulated 33135476 1867 Human TUG1 lncRNA tumor necrosis factor alpha (TNF-¦Á) ulcerative colitis (UC) HT-29 cells tumor necrosis factor alpha (TNF-¦Á) treatment TUG1 negatively regulated inflammation in ulcerative colitis through miR-142-5p/SOCS1 axis 32173492 1868 Human TUSC7 lncRNA temozolomide (TMZ) glioblastoma multiforme (GBM) U87 cells temozolomide (TMZ) treatment low expression of TUSC7 in GBM cells and tissues resistant to TMZ 29397407 1869 Human uc.173 lncRNA lead (Pb) lead-induced nephrotoxicity Human proximal tubular epithelial cell line (HK-2) cells; human kidney proximal tubular epithelial cell line (HKC) lead (Pb) exposure Lead exposure inhibited the expression of lncRNA UC.173 in renal tubular epithelial cells. 29425744 1870 Human uc.173 lncRNA lead (Pb) nerve injury serum lead treatment downregulated 26683706 1871 Human uc.187 lncRNA lipopolysaccharide (LPS) preeclampsia (PE) HTR-8/SVneo cells lipopolysaccharide (LPS) treatment Overexpression of uc.187 could induce PE-like symptoms in a pregnant rat model by affecting the distribution of ¦Â-catenin in the cytoplasm and nucleus. 31950140 1872 Human uc.333 lncRNA IL-6 insulin resistance (IR) HepG2 cells IL-6 treatment downregulated 32303004 1873 Human uc.333 lncRNA tumor necrosis factor alpha (TNF-¦Á) insulin resistance (IR) HepG2 cells tumor necrosis factor alpha (TNF-¦Á) treatment downregulated 32303004 1874 Human uc.477 lncRNA herbal formula HQT rheumatoid arthritis (RA) fibroblast-like synoviocytes herbal formula HQT treatment upregulated 32696503 1875 Human uc.477 lncRNA Tongbi formula (HQT) rheumatoid arthritis (RA) RA-derived human fibroblast-like synoviocytes (HFLS-RA) Tongbi formula (HQT) treatment upregulated 32696503 1876 Human uc001.dgp.1 lncRNA particulate matter (PM2.5) airway inflammation "human bronchial epithelial cell line, BEAS-3B" particulate matter 2.5 (PM2.5) exosure treatment upregulated 31864925 1877 Human uc001.dgp.1 lncRNA particulate matter (PM2.5) airway inflammation "human bronchial epithelial cell line, BEAS-2B" particulate matter 2.5 (PM2.5) exposure treatment upregulated 31864925 1878 Human uc002mbe.2 lncRNA histone deacetylase inhibitor trichostatin A (TSA) hepatocellular carcinoma (HCC) Huh7;Bel7402; Bel7721; HepG2 "histone deacetylase inhibitor (Trichostatin A, TSA) treatment" TSA-induced apoptosis of HCC cells is uc002mbe.2 dependent and reduced expression of uc002mbe.2 may be associated with liver carcinogenesis 23643933 1879 Human uc007keu.1 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cell differentiation human umbilical cord derived mesenchymal stem cells (hUCMSCs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated 29633064 1880 Human uc010vei.1 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cell differentiation human umbilical cord derived mesenchymal stem cells (hUCMSCs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 29633064 1881 Human UCA1 lncRNA 5-fluorouracil (5-Fu) retinoblastoma (RB) retinoblastoma cells 5-fluorouracil (5-Fu) treatment knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs 31264280 1882 Human UCA1 lncRNA carboplatin (CBP) retinoblastoma (RB) retinoblastoma cells carboplatin (CBP) treatment knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs 31264280 1883 Human UCA1 lncRNA cisplatin (DDP) retinoblastoma (RB) retinoblastoma cells cisplatin treatment knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs 31264280 1884 Human UCA1 lncRNA vincristine (VCR) retinoblastoma (RB) retinoblastoma cells vincristine (VCR) treatment knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs 31264280 1885 Human UCA1 lncRNA etoposide (VP-16) retinoblastoma (RB) retinoblastoma cells Etoposide (VP-16) treatment knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs 31264280 1886 Human UCA1 lncRNA adriamycin (ADR) acute myeloid leukemia (AML) HL60 cells adriamycin (ADR) treatment UCA1 expression was upregul.ated following adr-based chemotherapy 29663500 1887 Human UCA1 lncRNA arsenite arsenic (As) toxicities HepG2 cells arsenic (As) exposure lncRNA UCA1 was markedly induced by As treatment in human hepatocytes. 29248574 1888 Human UCA1 lncRNA arsenite arsenic (As) toxicities HepG2 cells arsenic (As) exposure UCA1 facilitates the ubiquitination of EZH2 to upregulate NFATc2 and further antagonizes As-induced cell cycle arrest. 32537408 1889 Human UCA1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cell line oxidized low-density lipoprotein (ox-LDL) treatment ox-LDL increased UCA1 expression greatly in THP-1 cells. 30633352 1890 Human UCA1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human vascular smooth muscle cell line (VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment Dysregulation of the Urothelial Cancer Associated 1 Long Noncoding RNA Promotes Proliferation of Vascular Smooth Muscle Cells by Modulating Expression of P27KIP1/CDK2. 32213082 1891 Human UCA1 lncRNA arsenite autophagy human hepatocytes arsenic (As) exposure upregulated 29248574 1892 Human UCA1 lncRNA cisplatin (DDP) bladder cancer patients with bladder and cancer.cisplatin-resistant bladder cancer cells cisplatin treatment upregulated 24495014 1893 Human UCA1 lncRNA metformin (Met) bladder cancer bladder cancer 5637 cells metformin downregulated 28641488 1894 Human UCA1 lncRNA transcription factor CCAAT/enhancer binding protein ¦Á (C/EBP¦Á) bladder cancer human bladder cancer cell lines 5637 and T24 C/EBP¦Á treatment upregulated 24648007 1895 Human UCA1 lncRNA aurora kinase inhibitor (CCT137690) breast cancer MDA-MB-231 cells aurora kinase inhibitor (CCT137690) treatment downregulated 31319040 1896 Human UCA1 lncRNA paclitaxel (PTX) breast cancer MCF-7 cells paclitaxel (PTX) treatment Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis 32425595 1897 Human UCA1 lncRNA tamoxifen (TAM) breast cancer breast cancer cells (LCC2 and LCC9) tamoxifen treatment upregulated 30628639 1898 Human UCA1 lncRNA TGF-¦Â breast cancer MCF-7 cells TGF-¦Â treatment "TGF-¦Â induced genome-wide changes in lncRNA levels in breast cancer cells, among which AC0269041 and UCA1 were highly expressed in metastatic breast cancer and closely associated with poor prognosis" 29774079 1899 Human UCA1 lncRNA trastuzumab breast cancer SKBR-3 cells trastuzumab treatment upregulated 29408336 1900 Human UCA1 lncRNA ionizing radiation (IR) cervical cancer (CC) SiHa cells; HeLa cells irradiation treatment upregulated 30015920 1901 Human UCA1 lncRNA 5-fluorouracil (5-Fu) chemoresistance of 5-fluorouracil (5-FU) SW480 and SW620 5-fluorouracil (5-FU) treatment UCA1 mediated 5-FU resistance of CRC cells through facilitating autophagy and inhibiting apoptosis via miR-23b-3p/ZNF281 axis in vivo and in vitro. 32801774 1902 Human UCA1 lncRNA X-rays colorectal cancer (CRC) CCL244 cells X-ray irradiation treatment UCA1 was significantly higher in CRC tissues after chemoradiotherapy 30015983 1903 Human UCA1 lncRNA high glucose (HG) diabetic nephropathy (DN) HK2 cells high glucose (HG) treatment downregulated 31608712 1904 Human UCA1 lncRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) "Human tongue cancer cell lines, CAL©\27 and SCC©\9" TGF¦Â1 treatment LncRNA?UCA1/miR-124 axis modulates TGFbeta1-induced?epithelial-mesenchymal transition and invasion of tongue cancer cells through JAG1/Notch signaling 30635938 1905 Human UCA1 lncRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) human umbilical vein endothelial cells (HUVECs) TGF-¦Â1 treatment UCA1 exerted its role via regulating the UCA1/miR-455/ZEB1 regulatory axis in HUVECs treated with TGF-¦Â1 32584608 1906 Human UCA1 lncRNA hypoxia hypoxic pulmonary hypertension (HPH) human pulmonary artery smooth muscle cells (HPASMCs) hypoxia induce upregulated 30353369 1907 Human UCA1 lncRNA curcumin (Cur) lung cancer A549 cells curcumin treatment curcumin inhibited the expression of UCA1. 30001775 1908 Human UCA1 lncRNA cetuximab metastatic colorectal cancer (mCRC) Caco2 cells cetuximab treatment upregulated 30377411 1909 Human UCA1 lncRNA lipopolysaccharide (LPS) neonatal pneumonia WI-38 cells lipopolysaccharide (LPS) treatment UCA1 inhibition protected WI-38 cells against LPS-managed inflammatory injury and apoptosis process via miR-499b-5p/TLR4 crosstalk. 33368965 1910 Human UCA1 lncRNA lipopolysaccharide (LPS) neonatal pneumonia WI-38 cells lipopolysaccharide (LPS) treatment ?We displayed that UCA1 was elevated in LPS-injured WI-38 cells. 33368965 1911 Human UCA1 lncRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells cisplatin treatment upregulated 30652341 1912 Human UCA1 lncRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) A549 cells cisplatin (DPP) treatment The cisplatin-R group exhibited lower levels of UCA1 and NRF2 expression but a higher level of miR-495 expression than the cisplatin-S group. 31583720 1913 Human UCA1 lncRNA gefitinib non-small cell lung cancer (NSCLC) The NSCLC cell lines (HCC827 and PC9) gefitinib treatment UCA1 was increased in both gefitinib-resistant NSCLC cells and their secreted exosomes. 31951852 1914 Human UCA1 lncRNA gefitinib non-small cell lung cancer (NSCLC) HCC827 cells; PC9 cells gefitinib treatment UCA1 was increased in both gefitinib-resistant NSCLC cells and their secreted exosomes. 31951852 1915 Human UCA1 lncRNA cisplatin (DDP) ovarian cancer (OC) Human ovarian cancer cell lines (A2780 and SKOV-3) and normal ovarian epithelial cell line (IOSE-80) cisplatin treatment upregulated 31234009 1916 Human UCA1 lncRNA cisplatin (DDP) ovarian cancer (OC) ES2 cells cisplatin treatment upregulated 32901049 1917 Human UCA1 lncRNA paclitaxel (PTX) ovarian cancer (OC) SKOV3 cells; HeyA8 cells paclitaxel (PTX) treatment UCA1 was markedly upregulated in PTX-resistant OC cells 32016960 1918 Human UCA1 lncRNA hypoxia pancreatic cancer (PC) human umbilical vein endothelial cells (HUVECs) hypoxia exposure hypoxic exosomal UCA1 could promote angiogenesis and tumor growth through the miR-96-5p/AMOTL2/ERK1/2 axis 32942233 1919 Human UCA1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4- phenylpyridinium iodide(MPP +) treatment upregulated 30536337 1920 Human UCA1 lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SK-N-SH cells 1-methyl-4-phenylpyridinium (MPP+) treatment Our data showed that MPP+?induced UCA1 expression in SK-N-SH cells. 33464446 1921 Human UCA1 lncRNA metformin (Met) preeclampsia (PE) HUVEC and HPASMC cells Metformin treatment downregulated 31582211 1922 Human UCA1 lncRNA oxidized low density lipoprotein (ox-LDL) cell proliferation and migration vascular smooth muscle cells (VSMCs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 32346422 1923 Human UCA1 lncRNA artesunate (ART) prostate cancer "DU145,LNCaP cells" artesunate (ART) treatment upregulated 28209917 1924 Human UCA1 lncRNA ¦Ã-rays prostate cancer 22RV1; DU145 cells Gy radiation treatement LncRNA UCA1 deletion suppressed the radioresistance to PCa by suppressing EIF4G1 expression via miR-331-3p. 32943997 1925 Human UCA1 lncRNA hypoxia pulmonary arterial hypertension (PAH) human pulmonary artery smooth muscle cells (HPASMCs) hypoxia treatment UCA1 was confirmed to be highly expressed under hypoxia compared with normoxia. 30353369 1926 Human UCA1 lncRNA carboplatin (CBP) retinoblastoma (RB) SO-RB50 cells carboplatin (CBP) treatment upregulated 31702387 1927 Human UCA1 lncRNA vincristine (VCR) retinoblastoma (RB) SO-RB50 cells vincristine (VCR) treatment upregulated 31702387 1928 Human UCA1 lncRNA lipopolysaccharide (LPS) sepsis human dermal microvascular endothelial cells (HMECs) lipopolysaccharide (LPS) treatment upregulated 31231228 1929 Human UCA1 lncRNA TGF-¦Â1 tongue squamous cell carcinoma (TSCC) "Human tongue cancer cell lines, CAL©\27 and SCC©\9" TGF¦Â1 treatment LncRNA?UCA1/miR-124 axis modulates TGFbeta1-induced?epithelial-mesenchymal transition and invasion of tongue cancer cells through JAG1/Notch signaling 30635938 1930 Human UIHTC lncRNA H2O2 myocardial infarction (MI) AC16 cells H2O2 treatment upregulated 29887450 1931 Human UIHTC lncRNA hypothermia myocardial infarction (MI) AC16 cells hypothermia (28 ¡ãC) treatment upregulated 29887450 1932 Human Unigene56159 lncRNA hepatitis B virus (HBV) hepatocellular carcinoma (HCC) Huh7 cells hepatitis B virus (HBV) infection Unigene56159 significantly promoted cell migration/invasion and epithelial-mesenchymal transition (EMT) in HCC. 27597739 1933 Human UPK1A-AS1 lncRNA hypoxia lung cancer A549 cells;NCI-H460 cells hypoxia treatment upregulated 33273139 1934 Human VCAN-AS1 lncRNA hypoxia and TGF¦Â1 idiopathic pulmonary fibrosis (IPF) human pulmonary fibroblasts (HPFs) hypoxia and TGF¦Â1 treatment upregulated 31925944 1935 Human VIM-AS1 lncRNA high glucose (HG) diabetic retinopathy (DR) human retinal pigment epithelial cells (RPEs) high glucose treatment downregulated 32447557 1936 Human VLDLR lncRNA adriamycin (ADR) esophageal squamous cell carcinoma (ESCC) Eca109 cell line adriamycin (ADR) treatment upregulated 30606658 1937 Human VLDLR lncRNA "anticancer agents£¨sorafenib, camptothecin, and doxorubicin£©" hepatocellular carcinoma (HCC) malignant hepatocytes anticancer agents treatment upregulated 24874432 1938 Human VNN3 lncRNA benzene benzene-induced hematotoxicity serum low-dose benzene exposure upregulated 31541949 1939 Human VPS9D1-AS1 lncRNA histone deacetylase inhibitor chidamide acute myeloid leukemia (AML) SKM-1 cells; THP-1 cells histone deacetylase inhibitor Chidamide treatment Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 downregulated via MEK/ERK Signaling Pathway 33192510 1940 Human WAKMAR2 lncRNA TGF-¦Â chronic wounds cultured keratinocytes TGF-¦Â treatment upregulated 30594489 1941 Human WDR86-AS1 lncRNA hypoxia preeclampsia (PE) human trophoblast HTR-8/SVneo cells hypoxia induce upregulated 30552989 1942 Human WISP1-AS1 lncRNA carcinogenic nephrotoxin ochratoxin A carcinogenic nephrotoxin ochratoxin A. toxicity HK-2 cells carcinogenic nephrotoxin ochratoxin A. treatment upregulated 29282485 1943 Human WT1-AS lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment "Overexpression of WT1-AS can inhibit the miR-375/SIX4 axis, OSI and neuronal apoptosis in AD by inhibiting WT1 expression." 33234729 1944 Human WWC2-AS1 lncRNA ionizing radiation (IR) radiation-induced intestinal fibrosis (RIF) human intestinal CCD-18Co fibroblasts cell lines;subepithelial SEMFs "Ionizing radiation (IR) was done with 6 MV photons, 8 Gy/min by a linear accelerator (Varian, America) at room temperature." upregulated 31262262 1945 Human X72487 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cell differentiation human umbilical cord derived mesenchymal stem cells (hUCMSCs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 29633064 1946 Human X85157 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cell differentiation human umbilical cord derived mesenchymal stem cells (hUCMSCs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" downregulated 29633064 1947 Human XIST lncRNA CoCl2 acute kidney injury (AKI) HK-2 cells CoCl2 treatment downregulated of XIST ameliorates acute kidney injury by sponging miR-142-5p and targeting PDCD4. 32347551 1948 Human XIST lncRNA ethanol (EtOH) alcoholic liver fibrosis (ALF) Human HSC cells (LX-2) ethanol treatment upregulated 31418997 1949 Human XIST lncRNA hypoxia angiogenesis Human Brain Microvascular Endothelial Cells (HBMEC) hypoxia induce upregulated 31737200 1950 Human XIST lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment lncRNA XIST (X-inactive specific transcript) was upregulated in human umbilical vein endothelial cells (HUVECs) stimulated by ox-LDL. 29902461 1951 Human XIST lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human THP-1 macrophages oxidized low-density lipoprotein (ox-LDL) treatment dysregulated 31804889 1952 Human XIST lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment "silence of XIST displayed a protective role in ox-LDL-induced injury in HUVECs by regulating miR-204-5p/TLR4 axis, providing a novel mechanism for understanding the pathogenesis of atherosclerosis." 32345778 1953 Human XIST lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 33542956 1954 Human XIST lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) vascular smooth muscle cells (VSMCs) and human mononuclear cells (U937) oxidized low-density lipoprotein (ox-LDL) treatment "n this research, we uncovered that the XIST level was elevated in the serum of AS patients and ox-LDL-treated AS cell models." 33566259 1955 Human XIST lncRNA platycodin D (PD) bladder cancer T24; RT4 Platycodin D (PD) treatment "PD inhibited LncRNA-XIST expressions, while increased miR-335 expression levels in bladder cancer cells" 32919956 1956 Human XIST lncRNA cyclosporine A (CsA) cell proliferation and invasion HT cells cyclosporine A treatment upregulated 28059474 1957 Human XIST lncRNA oxygen-glucose deprivation and reoxygenation (OGD/R) cerebral ischemia/reperfusion (I/R) injury SH-SY5Y cells oxygen-glucose deprivation and reoxygenation (OGD/R) treatment "XIST and GAB2 were significantly highly expressed, while miR-486-5p was low expressed in SH-SY5Y cells under I/R" 33660813 1958 Human XIST lncRNA IL-1¦Â chondrocyte apoptosis CHON-001 cells IL-1¦Â treatment downregulated 32517436 1959 Human XIST lncRNA high glucose (HG) diabetic nephropathy (DN) ?human renal tubular epithelial HK-2 cells ?high glucose (HG) induce silenced XIST inducing miR-93-5p-dependent CDKN1A inhibition was beneficial for preventing renal interstitial fibrosis in DN 31545928 1960 Human XIST lncRNA high glucose (HG) diabetic nephropathy (DN) podocytes high glucose (HG) treatment HG could inhibit the expression of XIST. 33332155 1961 Human XIST lncRNA high glucose (HG) diabetic retinopathy (DR) human retinal pigment epithelial ARPE-19 cells high-glucose (HG) treatment "XIST, likely through competitive binding of hsa-miR-21-5p, provides protection against hyperglycemia-associated injury in human retinal pigment epithelial cells." 32106367 1962 Human XIST lncRNA TGF-¦Â1 epithelial-mesenchymal transition (EMT) "Five PC cell lines (AsPC-1, MIAPaCa-2, PATU8988T, PANC-1 and SW1990)" transforming growth factor (TGF)-¦Â1 treatment "Silencing XIST reduced the expression of YAP and suppressed transforming growth factor (TGF)-¦Â1-induced EMT, while over-expression of XIST increased the expression of YAP and promoted EMT" 31013436 1963 Human XIST lncRNA cisplatin (DDP) gastric cancer (GC) SGC 7901cells; AGC cells cisplatin treatment upregulated 33009035 1964 Human XIST lncRNA X-rays glioblastoma multiforme (GBM) U251 cells X-ray radiation treatment "XIST accelerates cell proliferation, invasion and inhibits cell apoptosis by repressing radio-sensitivity of glioma via enhancing CREB1 expression through sponging miR-329-3p" 32271437 1965 Human XIST lncRNA gonadotropin-releasing hormone agonist (GnRHa; Buserelin) infertility Infertility patients testicular biopsies treat with GnRHa for 6 months upregulated 28505621 1966 Human XIST lncRNA IL-1¦Â intervertebral disc degeneration (IDD) nucleus pulposus (NP) cell ?IL-1¦Â treatment "XIST expression was upregulated in the NP tissues of patients with IDD, and IL-1¦Â treatment resulted in a degradation of NPCs" 33722663 1967 Human XIST lncRNA estradiol-17¦Â (E2) leiomyoma leiomyoma smooth muscle cells (LSMC) estradiol-17¦Â (E2) treatment "XIST levels was reduced in leiomyoma smooth muscle cells (LSMC) after treatment with 17¦Â-estradiol, progesterone." 33070965 1968 Human XIST lncRNA IL-4 macrophage polarization THP-1-differentiated macrophages IL-4 treatment upregulated 31632059 1969 Human XIST lncRNA angiotensin II (Ang II) membranous nephropathy (MN) Conditionally immortalized human podocyte cell line AB8/13 angiotensin II (Ang II) treatment upregulated 30414341 1970 Human XIST lncRNA ionizing radiation (IR) nasopharyngeal carcinoma (NPC) human NPC cell lines CNE-1 and CNE-2 ionizing radiation downregulated 28985197 1971 Human XIST lncRNA Hypoxia nasopharyngeal carcinoma (NPC) HK-1 and C666-1 hypoxia treatment "XIST knockdown inhibited glycolysis and metastasis in hypoxia-induced NPC cells through regulating miR-381-3p/NEK5 axis, providing new insights into the pathogenesis of NPC." 32196601 1972 Human XIST lncRNA cisplatin (DDP) non-small cell lung cancer (NSCLC) non-small cell lung cancer (NSCLC) tumors; A549 cells; SPC A1 cells; H2279 cells; H1875 cells; HC827 cells cisplatin treatment "XIST is upregulated in human NSCLC specimens, and is especially overexpressed in tumors previously treated with cisplatin (cis-diamminedichloroplatinum(II); DDP)." 32209729 1973 Human XIST lncRNA cisplatin (DDP) oral squamous cell carcinoma (OSCC) oral squamous cell carcinoma (OSCC) cells cisplatin treatment upregulated 33191714 1974 Human XIST lncRNA IL-1¦Â osteoarthritis (OA) chondrocyte IL-1¦Â treatment upregulated 30005876 1975 Human XIST lncRNA IL-1¦Â osteoarthritis (OA) articular chondrocytes (ACs) IL-1¦Â treatment upregulated 31198977 1976 Human XIST lncRNA paclitaxel (PTX) ovarian cancer (OC) SKOV3 cells paclitaxel treatment XIST promoted the sensitivity of ovarian cancer stem cells to paclitaxel in a KMT2C-dependent manner 32943985 1977 Human XIST lncRNA TGF-¦Â1 pancreatic cancer (PC) "Five PC cell lines (AsPC-1, MIAPaCa-2, PATU8988T, PANC-1 and SW1990)" transforming growth factor (TGF)-¦Â1 treatment "Silencing XIST reduced the expression of YAP and suppressed transforming growth factor (TGF)-¦Â1-induced EMT, while over-expression of XIST increased the expression of YAP and promoted EMT" 31013436 1978 Human XIST lncRNA 1-methyl-4-phenylpyridinium (MPP+) parkinson's disease (PD) SH-SY5Y cells 1-methyl-4-phenylpyridinium (MPP+) treatment upregulated 33494069 1979 Human XIST lncRNA lipopolysaccharide (LPS) pneumonia WI-38 human lung fibroblasts cells lipopolysaccharide (LPS) treatment upregulated 31066476 1980 Human XIST lncRNA lipopolysaccharide (LPS) pneumonia WI-38 cells lipopolysaccharide (LPS) treatment "Expression of XIST and CCL16 was upregulated in the serum of patients with pneumonia and LPS-induced WI-38 cells, respectively" 33817304 1981 Human XIST lncRNA oxidized low density lipoprotein (ox-LDL) inflammation HUVEC oxidized low-density lipoprotein (ox-LDL) treatment "PTEN was a target of miR-30c-5p, and its interference led to great inhibition of cell apoptosis and inflammatory response induced by ox-LDL in HUVEC, while this effect was attenuated by miR-30c-5p deficiency or XIST overexpression." 31539155 1982 Human XLOC_000620 lncRNA helicobacter pylori (H. pylori) H. pylori infection gastric epithelial cells H. pylori-infected treatment dysregulated 25420666 1983 Human XLOC_004122 lncRNA helicobacter pylori (H. pylori) H. pylori infection gastric epithelial cells H. pylori-infected treatment dysregulated 25420666 1984 Human XLOC_004562 lncRNA helicobacter pylori (H. pylori) H. pylori infection gastric epithelial cells H. pylori-infected treatment dysregulated 25420666 1985 Human XLOC_005912 lncRNA helicobacter pylori (H. pylori) H. pylori infection gastric epithelial cells H. pylori-infected treatment dysregulated 25420666 1986 Human XLOC_014388 lncRNA helicobacter pylori (H. pylori) H. pylori infection gastric epithelial cells H. pylori-infected treatment dysregulated 25420666 1987 Human XLOC_032768 lncRNA cisplatin (DDP) cisplatin (DDP)-induced nephrotoxicity human renal proximal tubular epithelial cells (HK-2) cisplatin treatment lncRNA XLOC_032768 expression was significantly repressed by cisplatin treatment. 32278129 1988 Human XLOC-006390 lncRNA silver nanoparticles (AgNPs) breast cancer "MCF7, T47D and MDA-MB-231 cells" silver nanoparticles (AgNPs)?treatment treatment "we found that a long noncoding RNA, XLOC_006390, was decreased in AgNPs-treated breast cancer cells" 33613979 1989 Human Z74666 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" cell differentiation human umbilical cord derived mesenchymal stem cells (hUCMSCs) "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 29633064 1990 Human ZBTB20-AS1 lncRNA amyloid-¦Â (A¦Â) 25-35 Alzheimer's disease (AD) SH-SY5Y cells amyloid-¦Â (A¦Â) 25-35 treatment upregulated 29956723 1991 Human ZEB1-AS1 lncRNA oxidized low density lipoprotein (ox-LDL) carotid artery atherosclerosis HCtAEC | Human Carotid Artery Endothelial Cells; THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment LncRNA ZEB1-AS1 contributed to ox-LDL-mediated injury and apoptosis of HCtAEC cells and the oxidative stress and inflammation of THP-1 cells through up-regulating HMGB1 via sponging miR-942. 31962131 1992 Human ZEB1-AS1 lncRNA cisplatin (DDP) cisplatin (DDP) resistance MCF-7 and MDA-MB-231 cells cisplatin treatment lncRNA ZEB1-AS1 silencing protects against drug resistance in breast cancer by promoting miR-129-5p-dependent ZEB1 downregulated. 33430826 1993 Human ZEB1-AS1 lncRNA high glucose (HG) diabetic lung disease BEAS©\2B cells high glucose (HG) treatment ZEB1-AS1 in lung cells was downregulated by high glucose treatment. 33193839 1994 Human ZEB1-AS1 lncRNA high glucose (HG) diabetic nephropathy (DN) HK2 cells high glucose treatment ZEB1-AS1 suppressed HG-induced EMT and fibrogenesis by regulating miR-216a-5p and BMP-7. 32294702 1995 Human ZEB1-AS1 lncRNA oxidized low density lipoprotein (ox-LDL) endothelial dysfunction Human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 31040785 1996 Human ZEB1-AS1 lncRNA high glucose (HG) renal fibrosis HK-2 cells high glucose (HG) treatment The expression of lnc ZEB1-AS1 was significantly suppressed by high glucose. 30121551 1997 Human ZEB2-AS1 lncRNA hepatitis B virus X protein (HBx) hepatocellular carcinoma (HCC) HepG2 ?hepatitis B virus-encoded X (HBx) protein treatment upregulated 29258558 1998 Human ZEB2-AS1 lncRNA IL-6 non-small cell lung cancer (NSCLC) A549 cells IL-6 treatment upregulated 32329850 1999 Human ZFAS1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) THP-1 cells oxidized low-density lipoprotein (ox-LDL) treatment The expression of ZFAS1 was significantly upregulated in in-vitro cell model of atherosclerosis at a dose- and time-dependent manner. 32349937 2000 Human ZFAS1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment upregulated 33278458 2001 Human ZFAS1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment lncRNA ZFAS1 promotes ox-LDL induced EndMT through miR-150-5p/Notch3 signaling axis 33278458 2002 Human ZFAS1 lncRNA cisplatin (DDP) cervical cancer (CC) cervical cancer CaSki;the HeLa cell lines cisplatin treatment "Silencing ZFAS1 may inhibit cell proliferation, migration and invasion and enhance cisplatin chemosensitivity." 30738960 2003 Human ZFAS1 lncRNA cisplatin (DDP) high-grade serous ovarian carcinomas (HGSOC) "A2008, HeyA8, and HeyC2 cell lines" cisplatin treatment upregulated 28154416 2004 Human ZFAS1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment We found that ZFAS1 and Notch3 were upregulated while miR-150-5p was downregulated in atherosclerosis mice and ox-LDL-treated HUVECs. 33278458 2005 Human Zfhx2as lncRNA radiation head and neck squamous cell carcinoma (HNSCC) HNSCC cell lines radiation treatment downregulated 30441874 2006 Human ZNF295-AS1 lncRNA oxidized low density lipoprotein (ox-LDL) atherosclerosis (AS) human umbilical vein endothelial cells (HUVECs) oxidized low-density lipoprotein (ox-LDL) treatment ZNF295-AS1 inhibits autophagy via the ZNF295-AS1/miR-508-5p/ATG7 axis in AS 32633396 2007 Human ZNF593-AS lncRNA phenylephrine (PE) dilated cardiomyopathy (DCM) cardiomyocytes phenylephrine treatment "ZNF593-AS, which mainly localized in the cytoplasm of cardiomyocytes, was robustly decreased in the failing heart of DCM patients, as well as in phenylephrine-treated human cardiomyocytes" 33550812 2008 Human ZNF649-AS1 lncRNA trastuzumab breast cancer SKBR-3 cells; BT474 cells trastuzumab treatment ZNF649-AS1 was more highly expressed in trastuzumab-resistant cells compared to sensitive cells 32735773 2009 Human ZNF667-AS1 lncRNA "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)" esophageal squamous cell carcinoma (ESCC) "Human esophageal cancer cell lines (Kyse170, Eca109, TE1, and TE13)" "5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment" upregulated 31804468 2010 Human ZNF667-AS1 lncRNA histone deacetylase inhibitor trichostatin A (TSA) esophageal squamous cell carcinoma (ESCC) "Human esophageal cancer cell lines (Kyse170, Eca109, TE1, and TE13)" histone deacetylase inhibitor TSA treatment upregulated 31804468 2011 Human ZNRD1-AS1 lncRNA cold atmospheric plasma (CAP) cancer treatment MCF-7 breast cancer cells Cold atmospheric plasma (CAP) treatment ZNRD1 and Its Antisense Long Noncoding RNA ZNRD1-AS1 Are Oppositely Regulated by Cold Atmospheric Plasma in Breast Cancer Cells. 32454947 2012 Human ZXF1 lncRNA cisplatin (DDP) lung cancer A549 cells cisplatin treatment Enhanced expression of lncRNA ZXF1 promotes cisplatin resistance in lung cancer cell via MAPK axis. 32533982